WEST Search History

Hide Items Restore Clear Cancel

DATE: Tuesday, March 16, 2004

END OF SEARCH HISTORY

e b

h

b cg b

chh

e e

Hide?	Set Name DR=PGP	Query B,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YE	Hit Count
	L32	L31 AND 435/325.CCLS.	143
	L31	L30 NOT Ashkenazi-Avi-J.IN.	437
	L30	L29 NOT Rosen-Craig-A.IN.	437
	L29	L28 NOT Baker-Kevin-P.IN.	559
	L28	L26 AND central nervous system	711
	L27	L26 AND central nervous system	711
	L26	L25 AND neuronal	842
	L25	L24 AND neurodegenerative	1092
	L24	(FK506 OR cyclosporin A OR rapamycin)	8236
	L23	L21 AND immunophilin	24
	L22	L21 AND neuronal	46
	L21	L20 NOT Baker-Kevin-P.IN.	248
	L20	L19 NOT Rosen-Craig-A.IN.	248
	L19	L18 AND L12	255
	L18	514/1,2.CCLS.	6720
	L17	L16 NOT Baker-Kevin-P.IN.	57
	L16	L15 NOT Rosen-Craig-A.IN.	124
	L15	L13 NOT Ashkenazi-Avi-J.IN.	127
	L14	L13 AND neuronal cell	150
	L13	L11 AND L12	205
	L12	FK506 OR cyclosporin A OR rapamycin	8236
	L11	L10 AND immunophilin	282
	L10	435/93.1,93.7,325.CCLS.	14340
	L9	Zeevi-A.IN.	4
	L8	Zeevi-Adriana.IN.	0
	L7	Zeevi.IN.	98
	L6	Avramut-M.IN.	0
	L5	Avramut-Mihaela.IN.	0
	L4	Avramut.IN.	0
	L3	Achim-C.IN.	3
	L2	Achim-Cristian.IN.	0
	L1	(Achim.IN.)	4672

e ch

c ch

e



cb

h

h g

e e





OMBM PACC Journals 800 PubMed Nucleotide Protein Genome Structure Entrez Go Clear Search | PubMed for immunophilin AND cell transplantation Clipboard Details Preview/Index Limits History About Entrez Show: |500 Send to Text Display Summary Items 1-8 of 8 One page. **Text Version** Related Articles, Links 1: Jacobsohn DA. Entrez PubMed Emerging therapies for graft-versus-host disease. Overview Expert Opin Emerg Drugs. 2003 Nov;8(2):323-38. Help | FAQ PMID: 14661992 [PubMed - in process] Tutoria! New/Noteworthy 1 2: Junker K, Koehl U, Zimmerman S, Stein S, Schwabe D, Klingebiel Related Articles, Links E-Utilities T, Grez M. Kinetics of cell death in T lymphocytes genetically modified with two novel **PubMed Services** Journals Database suicide fusion genes. MeSH Database Gene Ther. 2003 Jul; 10(14):1189-97. Single Citation Matcher PMID: 12833128 [PubMed - indexed for MEDLINE] **Batch Citation Matcher** Clinical Queries Thomis DC, Marktel S, Bonini C, Traversari C, Gilman M, Related Articles, Links LinkOut Bordignon C, Clackson T. Cubby A Fas-based suicide switch in human T cells for the treatment of graft-Related Resources versus-host disease. Order Documents Blood. 2001 Mar 1;97(5):1249-57. **NLM Gateway** PMID: 11222367 [PubMed - indexed for MEDLINE] TOXNET Consumer Health 4. Jacobson P, Uberti J, Davis W, Ratanatharathorn V. Related Articles, Links Clinical Alerts Tacrolimus: a new agent for the prevention of graft-versus-host disease in ClinicalTrials.gov PubMed Central hematopoietic stem cell transplantation. Bone Marrow Transplant. 1998 Aug;22(3):217-25. Review. Privacy Policy PMID: 9720734 [PubMed - indexed for MEDLINE] Related Articles, Links 5: Yu C, Seidel K, Fitzsimmons WE, Sale G, Storb R. Glucocorticoids fail to enhance the effect of FK506 and methotrexate in prevention of graft-versus-host disease after DLA-nonidentical, unrelated marrow transplantation. Bone Marrow Transplant. 1997 Jul;20(2):137-41. PMID: 9244417 [PubMed - indexed for MEDLINE] 6: Rivera VM, Clackson T, Natesan S, Pollock R, Amara JF, Keenan Related Articles, Links T. Magari SR, Phillips T, Courage NL, Cerasoli F Jr, Holt DA, Gilman M A humanized system for pharmacologic control of gene expression. Nat Med. 1996 Sep;2(9):1028-32. PMID: 8782462 [PubMed - indexed for MEDLINE] Related Articles, Links 7: Hemenway C. FK 506 in bone marrow transplantation. Blood. 1995 Nov 1;86(9):3611-2. No abstract available. PMID: 7579473 [PubMed - indexed for MEDLINE] Related Articles, Links 8: Shibata N, Shimakawa H, Minouchi T, Yamaji A.

Erythrocyte uptake and protein binding of cyclosporin A (CyA) in human

b e

blood: factors affecting CyA concentration in erythrocytes.

e ch

fcg

е

Biol Pharm Bull. 1993 Jul;16(7):702-7. PMID: 8401406 [PubMed - indexed for MEDLINE]

Display Summary Show: 500 Sort Send to Text One page.

Write to the Help Desk
NCB! | NLM | NIH
Department of Health & Human Services
Freedom of Information Act | Disclaimer

Mar 11 2004 06:56:25



cb

h g

e e

h





PMC Book Structure OMBM Journals PubMed Nucleotide Protein Genome Entrez Go Clear Search PubMed for FK506 AND cell transplantation Details Clipboard Preview/Index History Limits About Entrez Show: 500 Sort Send to Text Display Summary One page. Items 1-358 of 358 Text Version 1: Del Toro G, Satwani P, Harrison L. Cheung YK, Brigid Bradley M. Related Articles, Links George D, Yamashiro DJ, Garvin J, Skerrett D, Bessmertny O, Entrez PubMed Wolownik K, Wischhover C, Van De Ven C, Cairo MS. Overview Help | FAQ A pilot study of reduced intensity conditioning and allogeneic stem cell Tutorial transplantation from unrelated cord blood and matched family donors in New/Noteworthy children and adolescent recipients. E-Utilities Bone Marrow Transplant. 2004 Mar;33(6):613-22. PMID: 14730337 [PubMed - in process] **PubMed Services** Journals Database Related Articles, Links 2: Ahn KJ, Lee JW, Hahn ST, Yang DW, Kim PS, Kim HJ, Kim CC. MeSH Database Single Citation Matcher Diffusion-weighted MRI and ADC mapping in FK506 neurotoxicity. **Batch Citation Matcher** Br J Radiol. 2003 Dec;76(912):916-9. **Clinical Queries** PMID: 14711782 [PubMed - indexed for MEDLINE] LinkOut Cubby 3. Khouri IF. Lee MS, Saliba RM, Jun G, Fayad L. Younes A, Pro B, Related Articles, Links Acholonu S. McLaughlin P. Katz RL, Champlin RE. Related Resources Nonablative allogeneic stem-cell transplantation for advanced/recurrent Order Documents **NLM Gateway** mantle-cell lymphoma. TOXNET J Clin Oncol. 2003 Dec 1;21(23):4407-12. Consumer Health PMID: 14645431 [PubMed - indexed for MEDLINE] Clinical Alerts ClinicalTrials.gov Related Articles, Links 4: Azuma T, Narumi H, Kojima K, Nawa Y, Hara M. PubMed Central Hyponatremia during administration of tacrolimus in an allogeneic bone Privacy Policy marrow transplant recipient. Int J Hematol. 2003 Oct;78(3):268-9. No abstract available. PMID: 14604289 [PubMed - indexed for MEDLINE] Toso C, Morel P, Bucher P, Mathe Z, Demuylder-Mischler S, Bosco Related Articles, Links D, Berney T, Oberholzer J, Shapiro J, Oberholzer J, Philippe J. Insulin independence after conversion to tacrolimus and sirolimus-based immunosuppression in islet-kidney recipients. Transplantation. 2003 Oct 15;76(7):1133-4. No abstract available. PMID: 14557767 [PubMed - indexed for MEDLINE] 6: Chohan R, Vij R, Adkins D, Blum W, Brown R, Tomasson M, Related Articles, Links Devine S. Graubert T. Goodnough LT, DiPersio JF, Khoury H. Long-term outcomes of allogeneic stem cell transplant recipients after calcineurin inhibitor-induced neurotoxicity. Br J Haematol. 2003 Oct;123(1):110-3. PMID: 14510951 [PubMed - indexed for MEDLINE] Related Articles, Links 7: Foster RD, Pham S, Li S, Aitouche A. Long-term acceptance of composite tissue allografts through mixed chimerism and CD28 blockade. Transplantation. 2003 Sep 27;76(6):988-94. PMID: 14508367 [PubMed - indexed for MEDLINE] Related Articles, Links


Levay-Young B. Gruessner SE, Shearer JD, Cheol Kim S, Nahkleh

e ch

b e

е


fcg



h cb hg e e e fcg

e ch

Entrez-PubMed Page 3 of 42



h

ch

h g

e e

fcg

e ch

h e

h


ch


h g

e e

e fcg


e ch






	Efficacy of myoblast transplantation in nonhuman primasimple intramuscular cell injections: toward defining str to humans. Exp Neurol. 2002 May;175(1):112-26. PMID: 12009764 [PubMed - indexed for MEDLINE]	
□ 43	Shapiro AM, Suarez-Pinzon WL, Power R, Rabinovitch A.	Related Articles, Links
	Combination therapy with low dose sirolimus and tacro in preventing spontaneous and recurrent autoimmune di diabetic mice. Diabetologia. 2002 Feb;45(2):224-30. PMID: 11935154 [PubMed - indexed for MEDLINE]	
□ 44	Jacobsohn DA, Vogelsang GB.	Related Articles, Links
	Novel pharmacotherapeutic approaches to prevention an GVHD. Drugs. 2002;62(6):879-89. Review. PMID: 11929336 [PubMed - indexed for MEDLINE]	nd treatment of
□ 45	Yang H, McAlister VC, Al-Jazaeri A, Wright JR Jr.	Related Articles, Links
	Liposomal encapsulation significantly enchances the imeffect of tacrolimus in a discordant islet xenotransplant Transplantation. 2002 Mar 15;73(5):710-3. PMID: 11907415 [PubMed - indexed for MEDLINE]	* *
□ 46	Prast I, Carlsson PO, Jansson L, Mattsson G.	Related Articles, Links
	Nerve cells in transplanted pancreatic islets: no effects of tacrolimus on immediate neuronal survival. Ups J Med Sci. 2001;106(2):145-50. PMID: 11888070 [PubMed - indexed for MEDLINE]	of cyclosporin or
□ 47	Okoshi Y, Itoh M, Okimoto Y, Horie H, Takashima S.	Related Articles, Links
`	[A case of FK 506-induced leukoencephalopathy] No To Shinkei. 2002 Jan;54(1):51-5. Japanese. PMID: 11868353 [PubMed - indexed for MEDLINE]	
□ 48	Suehiro A, Sawada A, Hasegawa Y, Takatsuka H, Higasa S, Kakishita E.	Related Articles, Links
	Enhancement by cyclosporine A and tacrolimus of serot formation of small platelet aggregation. Bone Marrow Transplant. 2002 Jan;29(2):107-11. PMID: 11850703 [PubMed - indexed for MEDLINE]	conin-induced
□ 49	Girman P, Kriz J, Dovolilova E, Cihalova E, Saudek F.	Related Articles, Links
	The effect of bone marrow transplantation on survival of pancreatic islets with short-term tacrolimus conditioning Ann Transplant. 2001;6(2):43-5. PMID: 11803619 [PubMed - indexed for MEDLINE]	
□ 50:	Espino G, Denney J, Furlong T, Fitzsimmons W, Nash RA.	Related Articles, Links
	Assessment of myocardial hypertrophy by echocardiograpatients receiving tacrolimus or cyclosporine therapy fo acute GVHD. Bone Marrow Transplant. 2001 Dec;28(12):1097-103. PMID: 11803349 [PubMed - indexed for MEDLINE]	
□ 51:	Menillo SA, Goldberg SL, McKiernan P, Pecora AL.	Related Articles, Links

 $h \hspace{1cm} cb \hspace{1cm} h \hspace{1cm} g \hspace{1cm} e \hspace{1cm} e \hspace{1cm} e \hspace{1cm} ch \hspace{1cm} b \hspace{1cm} e$




h cb hg e e e fcg e ch b e




b e

h cb hg e e e fcg e ch

h



cb hg e e e fcg e ch b e



h cb hg e e e fcg e ch b e

h

cb

h g


e e

fcg

e ch

b e


Transplant Proc. 2001 Feb-Mar;33(1-2):340-1. No abstract available. PMID: 11266851 [PubMed - indexed for MEDLINE] Related Articles, Links 86: Rinsch C, Peduto G, Schneider BL, Aebischer P. Inducing host acceptance to encapsulated xenogeneic myoblasts. Transplantation. 2001 Feb 15;71(3):345-51. PMID: 11233892 [PubMed - indexed for MEDLINE] 87: Thomis DC, Marktel S, Bonini C, Traversari C, Gilman M, Related Articles, Links Bordignon C, Clackson T. A Fas-based suicide switch in human T cells for the treatment of graftversus-host disease. Blood. 2001 Mar 1;97(5):1249-57. PMID: 11222367 [PubMed - indexed for MEDLINE] 88: Boulad F, Gillio A, Small TN, George D, Prasad V, Torok-Related Articles, Links Castanza J, Regan AD, Collins N, Auerbach AD, Kernan NA, O'Reilly RJ. Stem cell transplantation for the treatment of Fanconi anaemia using a fludarabine-based cytoreductive regimen and T-cell-depleted related HLAmismatched peripheral blood stem cell grafts. Br J Haematol. 2000 Dec;111(4):1153-7. PMID: 11167755 [PubMed - indexed for MEDLINE] E 89: Gondo H. Okamura C. Osaki K. Shimoda K. Asano Y. Okamura T. Related Articles, Links Acquired Pelger-Huet anomaly in association with concomitant tacrolimus and fluconazole therapy following allogeneic bone marrow transplantation. Bone Marrow Transplant. 2000 Dec;26(11):1255-7. PMID: 11149744 [PubMed - indexed for MEDLINE] 20: Carnevale-Schianca F, Martin P, Sullivan K, Flowers M, Gooley Related Articles, Links T. Anasetti C. Deeg J. Furlong T. McSweeney P. Storb R. Nash RA. Changing from cyclosporine to tacrolimus as salvage therapy for chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2000;6(6):613-20. PMID: 11128811 [PubMed - indexed for MEDLINE] 91: Arai S, Vogelsang GB. Related Articles, Links Management of graft-versus-host disease. Blood Rev. 2000 Dec;14(4):190-204. Review. PMID: 11124107 [PubMed - indexed for MEDLINE] 12: Watanabe K, Ito K, Otani F, Masaki Y, Maruyama S, Endo T, Sato Related Articles, Links K, Kaneko T, Zhang F. Donor bone marrow cell infusion is effective in inducing tolerance in dogs treated with fractionated lymphoid irradiation and FK506. Transplant Proc. 2000 Nov;32(7):2544-7. No abstract available. PMID: 11120286 [PubMed - indexed for MEDLINE] 1 93: Imamura M, Tao HR, Hashino S, Kobayashi S, Mori A, Kobayashi Related Articles, Links M, Asaka M, Tanaka J. FK 506 inhibits severe graft-versus-host disease without mediating cytokine balance and/or cytotoxic molecules. Transplant Proc. 2000 Nov;32(7):2448-9. No abstract available. PMID: 11120238 [PubMed - indexed for MEDLINE] 7 94. Tashiro H, Shintaku S, Fudaba Y, Yamamoto H, Shibata S. Related Articles, Links Mizunuma K, Okimasa S, Marubayashi S, Fukuda Y, Dohi K, Asahara T.



 $h \hspace{1cm} cb \hspace{1cm} h \hspace{1cm} g \hspace{1cm} e \hspace{1cm} e \hspace{1cm} fcg \hspace{1cm} e \hspace{1cm} ch \hspace{1cm} b \hspace{1cm} e$

□ 103:	Miyake K, Kamimura T, Gondo H, Okamura T, Niho Y.	Related Articles, Links
	[Tacrolimus administration to a patient with cyclosporiencephalopathy after allogeneic bone marrow transplar Rinsho Ketsueki. 2000 Jul;41(7):585-90. Japanese. PMID: 11020982 [PubMed - indexed for MEDLINE]	
□ 104:	Nakao A, Yagi T, Sun DS, Matsukawa H, Endo A, Okada Y, Sadamori H, Inagaki M, Matsuno T, Tanaka N.	Related Articles, Links
	Cytokine mRNA expression on rat small bowel allogratacrolimus and simultaneous bone marrow transplantativein. Transplant Proc. 2000 Sep;32(6):1318-9. No abstract available. PMID: 10995965 [PubMed - indexed for MEDLINE]	
□ 105:	Nash RA, Antin JH, Karanes C, Fay JW, Avalos BR, Yeager AM, Przepiorka D, Davies S, Petersen FB, Bartels P, Buell D, Fitzsimmons W, Anasetti C, Storb R, Ratanatharathorn V.	Related Articles, Links
	Phase 3 study comparing methotrexate and tacrolimus and cyclosporine for prophylaxis of acute graft-versus-marrow transplantation from unrelated donors. Blood. 2000 Sep 15;96(6):2062-8. PMID: 10979948 [PubMed - indexed for MEDLINE]	
□ 106:	Oliverio PJ, Restrepo L, Mitchell SA, Tornatore CS, Frankel SR.	Related Articles, Links
	Reversible tacrolimus-induced neurotoxicity isolated to AJNR Am J Neuroradiol. 2000 Aug;21(7):1251-4. PMID: 10954277 [PubMed - indexed for MEDLINE]	o the brain stem.
E 107.	Uchida N, Taniguchi S, Harada N, Shibuya T.	Onlaine Aminian Links
1: 10/:	ochida iv. Tamguom o, riarada iv. omodya 1.	Related Articles, Links
1 107	Myocardial ischemia following allogeneic bone marro possible implication of tacrolimus overdose. Blood. 2000 Jul 1;96(1):370-2. No abstract available. PMID: 10939803 [PubMed - indexed for MEDLINE]	· ·
	Myocardial ischemia following allogeneic bone marro possible implication of tacrolimus overdose. Blood. 2000 Jul 1;96(1):370-2. No abstract available.	· ·
	Myocardial ischemia following allogeneic bone marro possible implication of tacrolimus overdose. Blood. 2000 Jul 1;96(1):370-2. No abstract available. PMID: 10939803 [PubMed - indexed for MEDLINE] Miki T, Lee YH, Tandin A, Subbotin V, Kuddus R, Rao AS,	w transplantation: Related Articles, Links
□ 108:	Myocardial ischemia following allogeneic bone marror possible implication of tacrolimus overdose. Blood. 2000 Jul 1;96(1):370-2. No abstract available. PMID: 10939803 [PubMed - indexed for MEDLINE] Miki T, Lee YH, Tandin A, Subbotin V, Kuddus R, Rao AS, Fung JJ, Starzl TE, Valdivia LA. Xenogeneic humoral graft-Vs-host disease following humarrow transplantation. Transplant Proc. 2000 Aug;32(5):1036-7. No abstract available.	w transplantation: Related Articles, Links
□ 108:	Myocardial ischemia following allogeneic bone marror possible implication of tacrolimus overdose. Blood. 2000 Jul 1;96(1):370-2. No abstract available. PMID: 10939803 [PubMed - indexed for MEDLINE] Miki T, Lee YH, Tandin A, Subbotin V, Kuddus R, Rao AS, Fung JJ, Starzl TE, Valdivia LA. Xenogeneic humoral graft-Vs-host disease following humarrow transplantation. Transplant Proc. 2000 Aug;32(5):1036-7. No abstract available. PMID: 10936339 [PubMed - indexed for MEDLINE] Song Z, Wennberg L, Zhang J, Sundberg B, Bari S, Groth CG,	w transplantation: Related Articles, Links tamster-to-Rat bone Related Articles, Links
□ 108: □ 109:	Myocardial ischemia following allogeneic bone marror possible implication of tacrolimus overdose. Blood. 2000 Jul 1;96(1):370-2. No abstract available. PMID: 10939803 [PubMed - indexed for MEDLINE] Miki T, Lee YH, Tandin A, Subbotin V, Kuddus R, Rao AS, Fung JJ, Starzl TE, Valdivia LA. Xenogeneic humoral graft-Vs-host disease following hmarrow transplantation. Transplant Proc. 2000 Aug;32(5):1036-7. No abstract available. PMID: 10936339 [PubMed - indexed for MEDLINE] Song Z, Wennberg L, Zhang J, Sundberg B, Bari S, Groth CG, Korsgren O. Protective effect of FK-506 in pig-to-rat islet xenotranabrogated by prednisolone. Transplant Proc. 2000 Aug;32(5):1025. No abstract available.	w transplantation: Related Articles, Links tamster-to-Rat bone Related Articles, Links
□ 108: □ 109:	Myocardial ischemia following allogeneic bone marror possible implication of tacrolimus overdose. Blood. 2000 Jul 1;96(1):370-2. No abstract available. PMID: 10939803 [PubMed - indexed for MEDLINE] Miki T, Lee YH, Tandin A, Subbotin V, Kuddus R, Rao AS, Fung JJ, Starzl TE, Valdivia LA. Xenogeneic humoral graft-Vs-host disease following hmarrow transplantation. Transplant Proc. 2000 Aug;32(5):1036-7. No abstract available. PMID: 10936339 [PubMed - indexed for MEDLINE] Song Z, Wennberg L, Zhang J, Sundberg B, Bari S, Groth CG, Korsgren O. Protective effect of FK-506 in pig-to-rat islet xenotranabrogated by prednisolone. Transplant Proc. 2000 Aug;32(5):1025. No abstract available. PMID: 10936332 [PubMed - indexed for MEDLINE]	w transplantation: Related Articles, Links namster-to-Rat bone Related Articles, Links splantation is
	Myocardial ischemia following allogeneic bone marror possible implication of tacrolimus overdose. Blood. 2000 Jul 1;96(1):370-2. No abstract available. PMID: 10939803 [PubMed - indexed for MEDLINE] Miki T, Lee YH, Tandin A, Subbotin V, Kuddus R, Rao AS, Fung JJ, Starzl TE, Valdivia LA. Xenogeneic humoral graft-Vs-host disease following humarrow transplantation. Transplant Proc. 2000 Aug;32(5):1036-7. No abstract available. PMID: 10936339 [PubMed - indexed for MEDLINE] Song Z, Wennberg L, Zhang J, Sundberg B, Bari S, Groth CG, Korsgren O. Protective effect of FK-506 in pig-to-rat islet xenotran abrogated by prednisolone. Transplant Proc. 2000 Aug;32(5):1025. No abstract available. PMID: 10936332 [PubMed - indexed for MEDLINE] Basara N, Blau IW, Willenbacher W, Kiehl MG, Fauser AA. New strategies in the treatment of graft-versus-host dis Bone Marrow Transplant. 2000 May;25 Suppl 2:S12-5.	w transplantation: Related Articles, Links namster-to-Rat bone Related Articles, Links splantation is

 $h \hspace{1cm} cb \hspace{1cm} h \hspace{1cm} g \hspace{1cm} e \hspace{1cm} e \hspace{1cm} fcg \hspace{1cm} e \hspace{1cm} ch \hspace{1cm} b \hspace{1cm} e$



PMID: 10831083 [PubMed - indexed for MEDLINE] 121: Przepiorka D, Saliba R, Cleary K, Fischer H, Tonai R, Fritsche Related Articles, Links H, Khouri IF, Folloder J, Ueno NT, Mehra R, Ippoliti C, Giralt S, Gajewski J, Donato M, Claxton D, Braunschweig I, van Besien K, Anderlini P, Andersson BS, Champlin R Tacrolimus does not abrogate the increased risk of acute graft-versus-host disease after unrelated-donor marrow transplantation with allelic mismatching at HLA-DRB1 and HLA-DQB1. Biol Blood Marrow Transplant. 2000;6(2A):190-7. PMID: 10816027 [PubMed - indexed for MEDLINE] 122: Forre O, Haugen M, Hassfeld WG. Related Articles, Links New treatment possibilities in rheumatoid arthritis. Scand J Rheumatol. 2000;29(2):73-84. Review. PMID: 10777119 [PubMed - indexed for MEDLINE] 123: Gaziev D, Galimberti M, Lucarelli G, Polchi P. Related Articles, Links Chronic graft-versus-host disease: is there an alternative to the conventional treatment? Bone Marrow Transplant. 2000 Apr;25(7):689-96. Review. PMID: 10745252 [PubMed - indexed for MEDLINE] Related Articles, Links 124: Skuk D, Goulet M, Roy B, Tremblay JP. Myoblast transplantation in whole muscle of nonhuman primates. J Neuropathol Exp Neurol. 2000 Mar; 59(3):197-206. PMID: 10744058 [PubMed - indexed for MEDLINE] 125: Fukuda H, Teshima H, Karasuno T, Hiraoka A, Nakamura H, Related Articles, Links Masaoka T. Differences between lymphocyte subsets, after allogeneic bone marrow transplantation, in patients who received tacrolimus and patients who received cyclosporin A. Int J Hematol. 2000 Jan;71(1):70-4. Erratum in: Int J Hematol 2000 Feb;71(2):192. PMID: 10729997 [PubMed - indexed for MEDLINE] 126: Hale GA, Reece DE, Munn RK, Kniska AB, Phillips GL. Related Articles, Links Blood tacrolimus concentrations in bone marrow transplant patients undergoing plasmapheresis. Bone Marrow Transplant. 2000 Feb;25(4):449-51. PMID: 10723590 [PubMed - indexed for MEDLINE] 127: Morita H, Sugiura K, Nagahama T, Sakakura Y, Tu W, Oda M. Related Articles, Links Inoue T, Inui H, Taketani S, Kamiyama Y, Ikehara S. Acceptance of skin xenografts (from guinea pig to mice) by portal venous and intravenous injections of donor hematolymphoid cells. Transplant Proc. 2000 Mar;32(2):293-4. No abstract available. PMID: 10715422 [PubMed - indexed for MEDLINE] 128: Vasconcelles MJ, Bernardo MV, King C, Weller EA, Antin JH. Related Articles, Links Aerosolized pentamidine as pneumocystis prophylaxis after bone marrow E transplantation is inferior to other regimens and is associated with decreased survival and an increased risk of other infections. Biol Blood Marrow Transplant. 2000;6(1):35-43. PMID: 10707997 [PubMed - indexed for MEDLINE] Related Articles, Links 129: Skuk D. Tremblay JP. Progress in myoblast transplantation: a potential treatment of dystrophies.

h cb hg e e e fcg e ch b e

Microsc Res Tech. 2000 Feb 1-15;48(3-4):213-22. Review.

PMID: 10679968 [PubMed - indexed for MEDLINE] 130: Mehta P, Beltz S, Kedar A, Graham-Pole J, Wingard JR. Related Articles, Links Increased clearance of tacrolimus in children: need for higher doses and \equiv earlier initiation prior to bone marrow transplantation. Bone Marrow Transplant. 1999 Dec;24(12):1323-7. PMID: 10627642 [PubMed - indexed for MEDLINE] 131: Wright DC, Deol HS, Tuch BE. Related Articles, Links A comparison of the sensitivity of pig and human peripheral blood mononuclear cells to the antiproliferative effects of traditional and newer immunosuppressive agents. Transpl Immunol. 1999 Sep;7(3):141-7. PMID: 10608297 [PubMed - indexed for MEDLINE] 132: Przepiorka D, Devine S, Fay J, Uberti J, Wingard J. Related Articles, Links Practical considerations in the use of tacrolimus for allogeneic marrow transplantation. Bone Marrow Transplant. 1999 Nov;24(10):1053-6. Review. PMID: 10578154 [PubMed - indexed for MEDLINE] 133: Mathew JM, Carreno M, Fuller L, Ricordi C, Kenyon N, Tzakis Related Articles, Links AG, Miller J, Esquenazi V. In vitro immunogenicity of cadaver donor bone marrow cells used for the induction of allograft acceptance in clinical transplantation. Transplantation. 1999 Oct 27;68(8):1172-80. PMID: 10551647 [PubMed - indexed for MEDLINE] 134: Okada M, Okamoto T, Yamada S, Yamada S, Itoh T, Mori A. Related Articles, Links Saheki K, Takatsuka H, Wada H, Tamura A Y, Fujimori Y, Takemoto Y, Kakishita E. Successful treatment of chronic graft-versus-host disease with sulfasalazine in allogeneic bone marrow transplantation. Acta Haematol. 1999;102(2):107-9. No abstract available. PMID: 10529517 [PubMed - indexed for MEDLINE] 135: Przepiorka D, Khouri I, Ippoliti C, Ueno NT, Mehra R, Korbling Related Articles, Links M, Giralt S, Gajewski J, Fischer H, Donato M, Cleary K, Claxton D, Chan KW, Braunschweig I, van Besien K, Andersson BS, Anderlini P, Champlin R. Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantation. Bone Marrow Transplant. 1999 Oct;24(7):763-8. PMID: 10516680 [PubMed - indexed for MEDLINE] 136: Pinna AD, Weppler D, Berho M, Masetti M, DeFaria W, Kato T. Related Articles, Links Thompson J, Ricordi C, Tzakis AG. Unusual presentation of graft-versus-host disease in pediatric liver transplant recipients: evidence of late and recurrent disease. Pediatr Transplant. 1999 Aug;3(3):236-42. PMID: 10487286 [PubMed - indexed for MEDLINE] 137: Otsu S, Ichinohe T, Yago K, Kitahara M, Shiomura T, Shimada Related Articles, Links [T cell non-depleted bone marrow transplantation for primary refractory erythroleukemia using a partially HLA-mismatched related donor] Rinsho Ketsueki. 1999 Jul;40(7):581-6. Japanese.

cb hg e e fcg e ch b e


h

PMID: 10483142 [PubMed - indexed for MEDLINE]

□ 138:	Mookerjee B. Altomonte V. Vogelsang G.	Related Articles, Links
	Salvage therapy for refractory chronic graft-versus-hos mycophenolate mofetil and tacrolimus. Bone Marrow Transplant. 1999 Sep;24(5):517-20. PMID: 10482936 [PubMed - indexed for MEDLINE]	t disease with
□ 139:	Perry SS, Kim M, Spangrude GJ	Related Articles, Links
	Direct effects of cyclosporin A on proliferation of hema progenitor cells. Cell Transplant. 1999 Jul-Aug;8(4):339-44. PMID: 10478713 [PubMed - indexed for MEDLINE]	atopoietic stem and
□ 140:	Uchiyama H, Kong Y, Kishihara K, Sugimachi K, Nomoto K.	Related Articles, Links
	Approach to withdrawal from tacrolimus in a fully allograft model. Immunology. 1999 Jun;97(2):294-300. PMID: 10447745 [PubMed - indexed for MEDLINE]	geneic murine skin
□ 141:	Przepiorka D, Smith TL, Folloder J, Khouri I, Ueno NT, Mehra R, Korbling M, Huh YO, Giralt S, Gajewski J, Donato M, Cleary K, Claxton D, Braunschweig I, van Besien K, Andersson BS, Anderlini P, Champlin R.	Related Articles, Links
	Risk factors for acute graft-versus-host disease after all stem cell transplantation. Blood. 1999 Aug 15;94(4):1465-70. PMID: 10438735 [PubMed - indexed for MEDLINE]	ogeneic blood
□ 142:	Przepiorka D, Petropoulos D, Mullen CA, Danielson M, Mattewada V, Chan KW.	Related Articles, Links
	Tacrolimus for prevention of graft-versus-host disease unrelated donor cord blood transplantation. Bone Marrow Transplant. 1999 Jun;23(12):1291-5. PMID: 10414918 [PubMed - indexed for MEDLINE]	after mismatched
□ 143:	Horowitz MM, Przepiorka D, Bartels P, Buell DN, Zhang MJ, Fitzsimmons WE, Erdman J, Huang C, Hodosh E, Maher R, Wingard JR	Related Articles, Links
	Tacrolimus vs. cyclosporine immunosuppression: resultstage disease compared with historical controls treated cyclosporine. Biol Blood Marrow Transplant. 1999;5(3):180-6. PMID: 10392964 [PubMed - indexed for MEDLINE]	
144 :	Przepiorka D, Nash RA, Wingard JR, Zhu J, Maher RM. Fitzsimmons WE, Fay JW.	Related Articles, Links
	Relationship of tacrolimus whole blood levels to efficate outcomes after unrelated donor marrow transplantation Biol Blood Marrow Transplant. 1999;5(2):94-7. PMID: 10371361 [PubMed - indexed for MEDLINE]	
□ 145:	Bakonyi Neto A, Ricordi C, Feo CF, Porcu A, Misiakos EP, Gandia C, Ruiz P, Bertho M, Carreno M, Esquenazi V, Miller J, Tzakis AG.	Related Articles, Links
	Correlation between allograft survival and chimeric stamarrow infusion in rat small bowel transplantation. Pediatr Transplant. 1999 Feb;3(1):67-73. PMID: 10359034 [PubMed - indexed for MEDLINE]	
□ 146:	Murata M, Nishida T, Haneda M, Kanie T, Taji H, Iida H, Suzuki R, Hamaguchi M, Minami S, Kodera Y.	Related Articles, Links

 $h \hspace{1.5cm} cb \hspace{1.5cm} h \hspace{1.5cm} g \hspace{1.5cm} e \hspace{1.5cm} e \hspace{1.5cm} ch$

ch



h cb hg e e e fcg

e ch

h


cb

h g

e e

e fcg

e ch




h

cb

h g

e e



b e


e ch


e fcg


	Lymphoid/nonlymphoid compartmentalization of donor chimerism in rat recipients of heart allografts, with or vibone marrow. Transplantation. 1998 Aug 15;66(3):350-7. PMID: 9721804 [PubMed - indexed for MEDLINE]	
□ 172	· Jacobson P, Uberti J, Davis W, Ratanatharathorn V.	Related Articles, Links
	Tacrolimus: a new agent for the prevention of graft-ve hematopoietic stem cell transplantation. Bone Marrow Transplant. 1998 Aug;22(3):217-25. Review. PMID: 9720734 [PubMed - indexed for MEDLINE]	rsus-host disease in
□ 173	: Tao HR.	Related Articles, Links
	FK506 inhibits severe graft-versus-host disease withou involvement of perforin and granzyme B. Hokkaido Igaku Zasshi. 1998 May;73(3):227-37. PMID: 9719949 [PubMed - indexed for MEDLINE]	t mediating the
□ 174	: Sanada O, Fukuda Y, Sumimoto R, Hoshino S, Nishihara M, Kaneda K, Asahara T, Dohi K.	Related Articles, Links
	Establishment of chimerism in donor liver with recipies marrow cells prior to liver transplantation produces may of allograft rejection in rats. Transpl Int. 1998;11 Suppl 1:S174-8. PMID: 9664973 [PubMed - indexed for MEDLINE]	
□ 175	Potter MA, Hymus S, Stockley T, Chang PL.	Related Articles, Links
	Suppression of immunological response against a transdelivered from microencapsulated cells. Hum Gene Ther. 1998 Jun 10;9(9):1275-82. PMID: 9650612 [PubMed - indexed for MEDLINE]	sgene product
□ 176	: Fitzsimmons WE, Bekersky I, Dressler D, Raye K, Hodosh E, Mekki Q.	Related Articles, Links
200 to 100 to 10	Demographic considerations in tacrolimus pharmacok Transplant Proc. 1998 Jun;30(4):1359-64. No abstract available. PMID: 9636552 [PubMed - indexed for MEDLINE]	inetics.
□ 177	: Li S, Liù K, Yousem SA, Pham SM.	Related Articles, Links
	Intrathymic inoculation of donor bone marrow at the transplantation plus a short course of tacrolimus induc acceptance to rat lung allografts. Transplant Proc. 1998 Jun;30(4):1065-6. No abstract available. PMID: 9636431 [PubMed - indexed for MEDLINE]	
□ 178	Lito H, Vilquin JT, Skuk D, Roy B, Goulet M, Lille S, Dugre FJ, Asselin I, Roy R, Fardeau M, Tremblay JP	Related Articles, Links
	Myoblast transplantation in non-dystrophic dog. Neuromuscul Disord. 1998 Apr;8(2):95-110. PMID: 9608563 [PubMed - indexed for MEDLINE]	
I 179	Tomura N, Kurosawa R, Kato K, Takahashi S, Watarai J, Takeda O, Watanabe A, Takada G.	Related Articles, Links
	Transient neurotoxicity associated with FK506: MR fi J Comput Assist Tomogr. 1998 May-Jun;22(3):505-7. PMID: 9606397 [PubMed - indexed for MEDLINE]	ndings.
18 0	Abu-Elmagd K, Reyes J, Todo S, Rao A, Lee R, Irish W, Furukawa H, Bueno J, McMichael J, Fawzy AT, Murase N, Demetris J, Rakela J, Fung JJ, Starzl TE	Related Articles, Links

h cb hg e e e fcg


e ch








h cb hg e e e fcg e ch b e



h e

h cb hg e e e fcg e ch



е

h cb hg e e e fcg e ch b

h

cb


h g


е

е

e fcg

e ch





b e

h cb hg e e e fcg e ch

(C) -

f W.

\$

h


cb

h g

e e

fcg

e ch




000 000 000 000 000	Prolonged survival of hearts obtained from chimeric do rat xenotransplant model. Transplant Proc. 1996 Apr;28(2):733-4. No abstract available. PMID: 8623371 [PubMed - indexed for MEDLINE]	nors in a mouse to
□ 248:	Anderson JE, Anasetti C, Appelbaum FR, Schoch G, Gooley TA, Hansen JA, Buckner CD, Sanders JE, Sullivan KM, Storb R.	Related Articles, Links
	Unrelated donor marrow transplantation for myelodyspl MDS-related acute myeloid leukaemia. Br J Haematol. 1996 Apr;93(1):59-67. PMID: 8611476 [PubMed - indexed for MEDLINE]	lasia (MDS) and
□ 249:	Vilquin JT, Kinoshita I, Roy B, Goulet M, Engvall E, Tome F, Fardeau M, Tremblay JP.	Related Articles, Links
	Partial laminin alpha2 chain restoration in alpha2 chain mouse by primary muscle cell culture transplantation. J Cell Biol. 1996 Apr;133(1):185-97. PMID: 8601607 [PubMed - indexed for MEDLINE]	-deficient dy/dy
□ 250:	Weppler D, Khan R, Fragulidis GP, Nery JR, Ricordi C, Tzakis AG	Related Articles, Links
	Status of liver and gastrointestinal transplantation at the Miami. Clin Transpl. 1996;:187-201. PMID: 9286568 [PubMed - indexed for MEDLINE]	e University of
□ 251 :	Greeno EW, Perry EH, Ilstrup SJ, Weisdorf DJ.	Related Articles, Links
	Exchange transfusion the hard way: massive hemolysis transplantation of bone marrow with minor ABO incom Transfusion. 1996 Jan;36(1):71-4. PMID: 8607158 [PubMed - indexed for MEDLINE]	
□ 252:	Delaney CP, Murase N, Chen-Woan M, Fung JJ, Starzl TE, Demetris AJ.	Related Articles, Links
	Allogeneic hematolymphoid microchimerism and preveautoimmune disease in the rat. A relationship between autoimmunity. J Clin Invest. 1996 Jan 1;97(1):217-25. PMID: 8550837 [PubMed - indexed for MEDLINE]	
□ 253:	Tai J, Cheung SS, Tsang A, Tze WJ	Related Articles, Links
	In vivo function of pig islet xenografts in immunosupprince. Transplant Proc. 1995 Dec;27(6):3316-7. No abstract available. PMID: 8539968 [PubMed - indexed for MEDLINE]	ressed diabetic
□ 254	Wennberg L, Wallgren AC, Sundberg B, Rafael E, Zhu S, Liu J, Tibell A, Karlsson-Parra A, Groth CG, Korsgren O.	Related Articles, Links
	Immunosuppression with leflunomide and cyclosporine rat islet xenograft rejection. Transplant Proc. 1995 Dec;27(6):3314-5. No abstract available. PMID: 8539967 [PubMed - indexed for MEDLINE]	e prevents pig-to-
□ 255	Gharpure VS, Devine SM, Holland HK, Geller RB, O'Toole K, Wingard JR.	Related Articles, Links
	Thrombotic thrombocytopenic purpura associated with bone marrow transplantation. Bone Marrow Transplant. 1995 Nov;16(5):715-6. PMID: 8547871 [PubMed - indexed for MEDLINE]	FK506 following

e ch

b e

 $h \hspace{1cm} cb \hspace{1cm} h \hspace{1cm} g \hspace{1cm} e \hspace{1cm} e \hspace{1cm} fcg$



h cb hg e e fcg

e ch

h g

e e

cb


h

e fcg


□ 265:	Ito A, Ito T, Kamiike W, Nozaki S, Uchikoshi F, Tanaka T, Kuhara A, Moriguchi A, Miyata M, Nakata S, et al.	Related Articles, Links
	Induction of tolerance in rat cardiac allograft model by injection of donor bone marrow cells. Transplant Proc. 1995 Apr;27(2):1607-8. No abstract available. PMID: 7536974 [PubMed - indexed for MEDLINE]	intrathymic
□ 266	Masaki Y, Kimura H, Oohara T.	Related Articles, Links
	Cellular basis of acquired immunologic tolerance follo transplantation in rats. I. Relation between donor lymp and host-cell-mediated immunity. Transplant Proc. 1995 Apr;27(2):1585-8. No abstract available. PMID: 7536971 [PubMed - indexed for MEDLINE]	
267	Carroll PB, Rilo HL, Alejandro R, Zeng Y, Khan R, Fontes P, Tzakis AG, Carr B, Ricordi C.	Related Articles, Links
	Long-term (> 3-year) insulin independence in a patient islet cell transplantation following upper abdominal ex replacement for fibrolamellar hepatocellular carcinoma Transplantation. 1995 Mar 27;59(6):875-9. PMID: 7701583 [PubMed - indexed for MEDLINE]	enteration and liver
268	: Woo J, Thomson AW, Ildstad ST.	Related Articles, Links
	Effects of FK 506 on chimerism and the induction of dunresponsiveness following fully allogeneic bone marrin mice. Transpl Immunol. 1995 Mar;3(1):86-90. No abstract available. PMID: 7551985 [PubMed - indexed for MEDLINE]	
□ 269	Fukuzaki T, Gotoh M, Monden M, Dono K, Ohta Y, Nishihara M, Hasuike Y, Kanai T, Miyasaka M, Mori T.	Related Articles, Links
	Induction of unresponsiveness to islet allografts with connection followed by a single injection of FK 506. Transplant Proc. 1995 Feb;27(1):354. No abstract available. PMID: 7533407 [PubMed - indexed for MEDLINE]	lonor spleen cell
□ 270	Wennberg L, Wallgren AC, Karlsson-Parra A, Kozlowski T, Sundberg B, Tibell A, Groth CG, Korsgren O	Related Articles, Links
	Efficacy of various immunosuppressive drugs in preveislet xenograft rejection. Transplant Proc. 1995 Feb;27(1):266-7. No abstract available. PMID: 7533391 [PubMed - indexed for MEDLINE]	enting pig-to-rat
□ 271	· Watanabe K, Ito I, Otani F, Obata F, Sato K, Ishida K, Masaki Y Maruyama S, Kashiwagi N.	Related Articles, Links
	Factors influencing long-term operational tolerance in fractionated lymphoid irradiation, donor bone marrow FK 506. Transplant Proc. 1995 Feb;27(1):221-4. No abstract available.	
	PMID: 7533389 [PubMed - indexed for MEDLINE]	
□ 272	: Zeevi A, Pavlick M, Lombardozzi S, Banas R, Rao AS, Fontes P Demetris AJ, Shapiro R, Jordan M, Dodson F, et al.	
	Serial evaluation of immune profiles of simultaneous whole organ transplant recipients. Transplant Proc. 1995 Feb;27(1):213-5. No abstract available. PMID: 7533388 [PubMed - indexed for MEDLINE]	oone marrow and
□ 273	: Murase N, Demetris AJ, Fujisaki S, Tanabe M, Qing Y, Todo S, Starzl TF	Related Articles, Links

 $b \quad e \\$


e ch



h cb hg e e e fcg e ch b e



b e



h cb hg e e e fcg

e ch

b e


PMID: 7547544 [PubMed - indexed for MEDLINE] 301: Abu-Elmagd K, Todo S, Fung J, Demetris J, Rakela J, Rao AS, Related Articles, Links Iwatsuki S, Starzl T. Hepatic transplantation at the University of Pittsburgh: new horizons and paradigms after 30 years of experience. Clin Transpl. 1994;:133-56. No abstract available. PMID: 7547533 [PubMed - indexed for MEDLINE] Related Articles, Links 302: Woo J, Ildstad ST, Thomson AW. FK506 inhibits the differentiation of developing thymocytes but not negative selection of T cell receptor V beta 5+ and V beta 11+ T lymphocytes in vivo. Transpl Immunol. 1994;2(1):11-21. PMID: 7521743 [PubMed - indexed for MEDLINE] 1303: Yasunami Y, Ikeda S. Related Articles, Links Induction of donor specific unresponsiveness in rat islet allografts by intraportal grafting and FK506. Cell Transplant. 1994;3 Suppl 1:S11-2. No abstract available. PMID: 7512877 [PubMed - indexed for MEDLINE] 304: Yasunami Y, Ryu S, Ueki M, Arima T, Kamei T, Tanaka M, Related Articles, Links Ikeda S. Donor-specific unresponsiveness induced by intraportal grafting and FK506 in rat islet allografts: importance of low temperature culture and transplant site on induction and maintenance. Cell Transplant. 1994 Jan-Feb;3(1):75-82. PMID: 7512876 [PubMed - indexed for MEDLINE] 305: Akita K, Ogawa M, Mandel TE. Related Articles, Links Effect of FK506 and anti-CD4 therapy on fetal pig pancreas xenografts and host lymphoid cells in nod/Lt, CBA, and BALB/c mice. Cell Transplant. 1994 Jan-Feb;3(1):61-73. PMID: 7512875 [PubMed - indexed for MEDLINE] 306: Ishizuka J, Gugliuzza KK, Wassmuth Z, Hsieh J, Sato K, Related Articles, Links Tsuchiva T, Townsend CM Jr. Fish JC, Thompson JC. Effects of FK506 and cyclosporine on dynamic insulin secretion from isolated dog pancreatic islets. Transplantation, 1993 Dec;56(6):1486-90. PMID: 7506454 [PubMed - indexed for MEDLINE] 307: Demetris AJ, Murase N, Fujisaki S, Fung JJ, Rao AS, Starzl TE. Related Articles, Links Hematolymphoid cell trafficking, microchimerism, and GVH reactions after liver, bone marrow, and heart transplantation. Transplant Proc. 1993 Dec;25(6):3337-44. No abstract available. PMID: 7505503 [PubMed - indexed for MEDLINE] 308: Akita K, Mandel TE. Related Articles, Links Effect of FK 506 and anti-CD4 monoclonal antibody treatment on xenografts of organ-cultured fetal pig pancreas and host lymphoid populations. Transplant Proc. 1993 Oct;25(5):2924-5. No abstract available. PMID: 7692650 [PubMed - indexed for MEDLINE] 309: Storb R, Raff RF, Appelbaum FR, Deeg HJ, Fitzsimmons W, Related Articles, Links Graham TC, Pepe M, Pettinger M, Sale G, van der Jagt R, et al.

FK-506 and methotrexate prevent graft-versus-host disease in dogs given


b e

e ch

h cb hg e e e fcg




h cb hg e e e fcg e ch b e




□ 328:	Federlin K. Hering B. Bretzel RG.	Related Articles, Links
	Islet transplantation: clinical and experimental. Horm Metab Res Suppl. 1992;26:148-51. Review. PMID: 1490685 [PubMed - indexed for MEDLINE]	
□ 329:	Ito T, Shirakura R, Nakata S, Yamamoto S, Yamaguchi T, Miyata M, Matsuda H.	Related Articles, Links
######################################	Bone marrow cell- and FK 506-induced donor-specific in rat heart allografts. Transplant Proc. 1991 Dec;23(6):3285-7. No abstract available. PMID: 1721437 [PubMed - indexed for MEDLINE]	unresponsiveness
□ 330:	Cooper MH, Markus PM, Cai X, Starzl TE, Fung JJ.	Related Articles, Links
	Prolonged prevention of acute graft-versus-host disease bone marrow transplantation by donor pretreatment usi Transplant Proc. 1991 Dec;23(6):3238-9. No abstract available. PMID: 1721421 [PubMed - indexed for MEDLINE]	
□ 331:	Boggs S, Patrene K, Vecchini F, Markus P, Cooper M, Duquesnoy R, Starzl TE, Bloomer W.	Related Articles, Links
	FK 506 has no short-term effects on endogenous or excreconstitution in irradiated mice. Transplant Proc. 1991 Dec;23(6):3236-7. No abstract available. PMID: 1721420 [PubMed - indexed for MEDLINE]	ogenous myeloid
□ 332:	Cooper MH, Hartman GG, Starzl TE, Fung JJ.	Related Articles, Links
	The induction of pseudo-graft-versus-host disease followone marrow transplantation using FK 506. Transplant Proc. 1991 Dec;23(6):3234-5. No abstract available. PMID: 1721419 [PubMed - indexed for MEDLINE]	owing syngeneic
□ 333:	Markus PM, Cai X, Selvaggi G, Cooper M, Harnaha J, Fung JJ, Starzl TE.	Related Articles, Links
	The effect of cyclosporine, rapamycin and FK 506 the allogeneic bone marrow transplantation. Transplant Proc. 1991 Dec;23(6):3232-3. No abstract available. PMID: 1721418 [PubMed - indexed for MEDLINE]	survival following
□ 334	Masaoka T, Shibata H, Kakishita E, Kanamaru A, Takemoto Y, Moriyama Y.	Related Articles, Links
	Phase II study of FK 506 for allogeneic bone marrow to Transplant Proc. 1991 Dec;23(6):3228-31. No abstract available. PMID: 1721417 [PubMed - indexed for MEDLINE]	ransplantation.
□ 335	Tzakis AG, Abu-Elmagd K, Fung JJ, Bloom EJ, Nour B, Greif F, Starzl TE	. Related Articles, Links
	FK 506 rescue in chronic graft-versus-host-disease after transplantation. Transplant Proc. 1991 Dec;23(6):3225-7. No abstract available. PMID: 1721416 [PubMed - indexed for MEDLINE]	er bone marrow
□ 336	Fukuzaki T, Gotoh M, Monden M, Dono K, Wada H, Tono T, Nagano H, Kanai T, Mori T.	Related Articles, Links
	Induction of tolerance to islet allografts with preoperated cell injection and a short course of FK 506 treatment. Transplant Proc. 1991 Dec;23(6):3221-2. No abstract available. PMID: 1721415 [PubMed - indexed for MEDLINE]	ive donor spleen
□ 337	Ohtsuka S, Hayashi S, Sato E, Tanaka Y, Hachisuka T, Haba T, Taira N, Oribara A, Uchida K, Kano T, et al.	Related Articles, Links

b e



b e

h cb hgeeefcg ech



fcg h cb h g e е е e ch

b e

	Clin Transpl. 1990;:115-21. PMID: 1715740 [PubMed - indexed for MEDLINE]	
□ 357:	Yasunami Y, Ryu S, Kamei T, Konomi K.	Related Articles, Links
	Effects of a novel immunosuppressive agent, FK-506, survival in the rat. Transplant Proc. 1989 Feb;21(1 Pt 3):2720. No abstract available. PMID: 2468234 [PubMed - indexed for MEDLINE]	
□ 358:	Watanabe K, Yuge K, Sato K, Yamagishi K, Sonoda K, Masaki Y, Maruyama S, Takahara H, Matsubayashi T, Yago K, et al.	Related Articles, Links
	Prolongation effect of a small dose of FK506, cyclospon azathioprine on renal allografts in dogs treated with frairradiation and donor bone marrow cell infusion. Transplant Proc. 1989 Feb;21(1 Pt 1):1112-5. No abstract availab PMID: 2468213 [PubMed - indexed for MEDLINE]	ctionated lymphoid
Display	Summary Show: 500 Sort S	end to Text 🔻
	Items 1-358 of 358	One page.

Write to the Help Desk
NCBI | NLM | NIH
Department of Health & Human Services
Freedom of Information Act | Disclaimer

Mar 11 2004 06:56:25







Entrez

PubMed

Nuclectide

Protein

Genome

Structure

OMIM

PMC

Clear

Journals

Boo:

Search PubMed

for FK506 AND cell transplantation AND neuron Limits Preview/Index

History

Clipboard

Go

Details

About Entrez

Text Version

Entrez PubMed Overview Help | FAQ Tutorial New/Noteworthy E-Utilities

PubMed Services Journals Database McSH Database Single Citation Matcher **Batch Citation Matcher Clinical Queries** LinkOut Cubby

Related Resources Order Documents **NLM Gateway** TOXNET Consumer Health Clinical Alerts ClinicalTrials.gov PubMed Central

Privacy Policy

Display Summary 1. Prast I, Carlsson PO, Jansson L, Mattsson G.

▼ Show: 500 ▼ Sort

Send to

Text

Related Articles, Links Nerve cells in transplanted pancreatic islets: no effects of cyclosporin or

tacrolimus on immediate neuronal survival. Ups J Med Sci. 2001;106(2):145-50.

PMID: 11888070 [PubMed - indexed for MEDLINE]

Write to the Help Desk NCBI | NLM | NIH Department of Health & Human Services Freedom of Information Act | Disclaimer

6

Mar 11 2004 06:56:25

е







Ennez

PubMed

Nucleotide

Protein

Genome

Structure

OMIM

FMC

Journals

Boot

Search PubMed

for FK506 AND cell transplantation AND neuronal Limits Preview/Index

History

Go Clear Clipboard

Details

About Entrez

Display Summary

Show: 500 🔻

Nerve cells in transplanted pancreatic islets: no effects of cyclosporin or

Send to

Text

Text Version

Entrez PubMed Overview Help | FAQ Tutorial New/Noteworthy E-Utilities

PubMed Services Journals Database MeSH Database Single Citation Matcher **Batch Citation Matcher** Clinical Queries LinkOut Cubby

Related Resources Order Documents **NLM Gateway** TOXNET Consumer Health Clinical Alerts ClinicalTrials.gov PubMed Central

Privacy Policy

1: Prast I, Carlsson PO, Jansson L, Mattsson G.

Related Articles, Links

tacrolimus on immediate neuronal survival. Ups J Med Sci. 2001;106(2):145-50.

PMID: 11888070 [PubMed - indexed for MEDLINE]

Write to the Help Desk NCBI | NLM | NIH Department of Health & Human Services Freedom of Information Act | Disclaimer

> b е

Mar 11 2004 06:56:25







OMIM PMC Journals Boo! Nucleotide Protein Genome Structure PubMed Entrez Search PubMed Clear for FK506 AND cell transplantation AND neuron Go Details Clipboard Limits Preview/Index History About Entrez Show: |500 ₩ Display Summary Sort Send to Text 1: Prast I, Carlsson PO, Jansson L, Mattsson G. Related Articles, Links **Text Version**

Entrez PubMed Overview Help | FAQ Tutorial New/Noteworthy E-Utilities

PubMed Services Journals Database MeSH Database Single Citation Matcher **Batch Citation Matcher** Clinical Queries **LinkOut** Cubby

Related Resources Order Documents **NLM Gateway** TOXNET Consumer Health Clinical Alerts ClinicalTrials.gov PubMed Central

Privacy Policy

h

cb

Nerve cells in transplanted pancreatic islets: no effects of cyclosporin or tacrolimus on immediate neuronal survival.

Ups J Med Sci. 2001;106(2):145-50.

PMID: 11888070 [PubMed - indexed for MEDLINE]

Write to the Help Desk NCBI | NLM | NIH Department of Health & Human Services Freedom of Information Act | Disclaimer

Mar 11 2004 06:56:25

e ch b е h g



cb

h

e e

h g





OMIM PMC PubMed Nuclectide Protein Genome Structure Journals Boo: Envez Search | PubMed for FK506 AND neuron Clear Go History Details Limits Preview/Index Clipboard About Entrez Show: 500 Display Summary Sort Send to Text Items 1-156 of 156 One page. **Text Version** 1: Birge RB, Wadsworth S, Akakura R, Abeysinghe H, Kanojia R, Related Articles, Links MacIelag M, Desbarats J, Escalante M, Singh K, Sundarababu S, Entrez PubMed Parris K, Childs G, August A, Siekierka J, Weinstein DE. Overview Help I FAQ A role for schwann cells in the neuroregenerative effects of a non-Tutorial immunosuppressive fk506 derivative, jnj460. New/Noteworthy Neuroscience. 2004;124(2):351-66. E-Utilities PMID: 14980385 [PubMed - in process] PubMed Services 2: Khan OH, Enno T, Del Bigio MR. Related Articles, Links Journals Database MeSH Database Tacrolimus and cyclosporine A are of no benefit to young rats with kaolin-Single Citation Matcher induced hydrocephalus. **Batch Citation Matcher** Pediatr Neurosurg. 2003 Dec;39(6):309-13. Clinical Queries PMID: 14734865 [PubMed - indexed for MEDLINE] LinkOut Cubby 1 3. Morot-Gaudry-Talarmain Y. Rezaei H. Guermonprez L. Treguer E. Related Articles, Links Grosclaude J. Related Resources Order Documents Selective prion protein binding to synaptic components is modulated by **NLM Gateway** oxidative and nitrosative changes induced by copper(II) and peroxynitrite in TOXNET cholinergic synaptosomes, unveiling a role for calcineurin B and Consumer Health Clinical Alerts thioredoxin. ClinicalTrials.gov J Neurochem. 2003 Dec;87(6):1456-70. PubMed Central PMID: 14713301 [PubMed - indexed for MEDLINE] Privacy Policy 4: Suen KC, Lin KF, Elyaman W, So KF, Chang RC, Hugon J. Related Articles, Links Reduction of calcium release from the endoplasmic reticulum could only provide partial neuroprotection against beta-amyloid peptide toxicity. J Neurochem. 2003 Dec; 87(6):1413-26. PMID: 14713297 [PubMed - indexed for MEDLINE] 5: Akgun S, Tekeli A, Kurtkaya O, Civelek A, Isbir SC, Ak K, Arsan Related Articles, Links S, Sav A. Neuroprotective effects of FK-506, L-carnitine and azathioprine on spinal cord ischemia-reperfusion injury. Eur J Cardiothorac Surg. 2004 Jan;25(1):105-10. PMID: 14690740 [PubMed - in process] 6: Pan YA, Misgeld T, Lichtman JW, Sanes JR. Related Articles, Links Effects of neurotoxic and neuroprotective agents on peripheral nerve regeneration assayed by time-lapse imaging in vivo. J Neurosci. 2003 Dec 10;23(36):11479-88. PMID: 14673013 [PubMed - indexed for MEDLINE] 7: Colledge M, Snyder EM, Crozier RA, Soderling JA, Jin Y, Related Articles, Links Langeberg LK, Lu H, Bear MF, Scott JD. Ubiquitination regulates PSD-95 degradation and AMPA receptor surface expression. Neuron. 2003 Oct 30;40(3):595-607.


PMID: 14642282 [PubMed - indexed for MEDLINE]

b е

fcg

□ 8:	Gordon T, Sulaiman O, Boyd JG.	Related Articles, Links
	Experimental strategies to promote functional recovery a nerve injuries. J Peripher Nerv Syst. 2003 Dec;8(4):236-50. PMID: 14641648 [PubMed - indexed for MEDLINE]	fter peripheral
□9:	Terada H. Matsushita M. Lu YF. Shirai T. Li ST. Tomizawa K. Moriwaki A. Nishio S. Date I. Ohmoto T. Matsui H.	Related Articles, Links
	Inhibition of excitatory neuronal cell death by cell-perme autoinhibitory peptide. J Neurochem. 2003 Dec;87(5):1145-51. PMID: 14622094 [PubMed - indexed for MEDLINE]	eable calcineurin
□10	Stevens TR, Krueger SR, Fitzsimonds RM, Picciotto MR.	Related Articles, Links
	Neuroprotection by nicotine in mouse primary cortical activation of calcineurin and L-type calcium channel in J Neurosci. 2003 Nov 5;23(31):10093-9. PMID: 14602824 [PubMed - indexed for MEDLINE]	
1.1	: Gillon RS, Cui Q, Dunlop SA, Harvey AR.	Related Articles, Links
	Effects of immunosuppression on regrowth of adult rat axons into peripheral nerve allografts. J Neurosci Res. 2003 Nov 15;74(4):524-32. PMID: 14598296 [PubMed - indexed for MEDLINE]	retinal ganglion cell
1 12	2: Sun F, Li P, Ding Y, Wang L, Bartlam M, Shu C, Shen B, Jiang H Li S, Rao Z.	Related Articles, Links
	Design and structure-based study of new potential FKB Biophys J. 2003 Nov;85(5):3194-201. PMID: 14581219 [PubMed - in process]	SP12 inhibitors.
□ 13	3: Udina E, Ceballos D, Gold BG, Navarro X.	Related Articles, Links
	FK506 enhances reinnervation by regeneration and by of peripheral nerve fibers. Exp Neurol. 2003 Sep;183(1):220-31. PMID: 12957505 [PubMed - indexed for MEDLINE]	collateral sprouting
T. 1	4: Jouvenceau A, Billard JM, Haditsch U, Mansuy IM, Dutar P.	Related Articles, Links
	Different phosphatase-dependent mechanisms mediate depression and depotentiation of long-term potentiation hippocampal CA1 area. Eur J Neurosci. 2003 Sep;18(5):1279-85. PMID: 12956726 [PubMed - indexed for MEDLINE]	
1 1	5: Brecht S, Schwarze K, Waetzig V, Christner C, Heiland S, Fische G, Sartor K, Herdegen T.	Related Articles, Links
	Changes in peptidyl-prolyl cis/trans isomerase activity protein expression following neuroprotection by FK500 brain. Neuroscience. 2003;120(4):1037-48. PMID: 12927209 [PubMed - indexed for MEDLINE]	
□ 10	6: Udina E, Voda J, Gold BG, Navarro X.	Related Articles, Links
	Comparative dose-dependence study of FK506 on transnerve repaired by allograft or xenograft. J Peripher Nerv Syst. 2003 Sep;8(3):145-54. PMID: 12904235 [PubMed - indexed for MEDLINE]	sected mouse sciatic

b e



b e

PMID: 12731731 [PubMed - indexed for MEDLINE] 1 26: Meller R, Schindler CK, Chu XP, Xiong ZG, Cameron JA, Simon Related Articles, Links RP, Henshall DC. Seizure-like activity leads to the release of BAD from 14-3-3 protein and cell death in hippocampal neurons in vitro. Cell Death Differ. 2003 May; 10(5):539-47. PMID: 12728252 [PubMed - indexed for MEDLINE] 27: Katsuta K, Umemura K, Ueyama N, Matsuoka N. Related Articles, Links Pharmacological evidence for a correlation between hippocampal CA1 cell damage and hyperlocomotion following global cerebral ischemia in gerbils. Eur J Pharmacol. 2003 Apr 25;467(1-3):103-9. PMID: 12706462 [PubMed - indexed for MEDLINE] 28: Agostinho P, Oliveira CR. Related Articles, Links Involvement of calcineurin in the neurotoxic effects induced by amyloidbeta and prion peptides. Eur J Neurosci. 2003 Mar; 17(6):1189-96. PMID: 12670307 [PubMed - indexed for MEDLINE] 29: Fumoto N, Nakatsuka H, Ohta S, Kumon Y, Ohnishi T. Related Articles, Links Hippocampal CA1 neuron survival and cytosolic FKBP12, the 12 kDa FK506-binding protein, after ischemia and tacrolimus treatment in gerbils. Neurosci Lett. 2003 Mar 27;339(3):219-22. PMID: 12633892 [PubMed - indexed for MEDLINE] 130: Furuichi Y, Katsuta K, Maeda M, Uevama N, Moriguchi A, Related Articles, Links Matsuoka N, Goto T, Yanagihara T. Neuroprotective action of tacrolimus (FK506) in focal and global cerebral ischemia in rodents: dose dependency, therapeutic time window and longterm efficacy. Brain Res. 2003 Mar 7;965(1-2):137-45. PMID: 12591130 [PubMed - indexed for MEDLINE] 31: Takano H, Fukushi H, Morishima Y, Shirasaki Y. Related Articles, Links Calmodulin and calmodulin-dependent kinase II mediate neuronal cell death induced by depolarization. Brain Res. 2003 Feb 7;962(1-2):41-7. PMID: 12543454 [PubMed - indexed for MEDLINE] ☐ 32: Avramut M, Achim CL. Related Articles, Links Immunophilins and their ligands: insights into survival and growth of human neurons. Physiol Behav. 2002 Dec;77(4-5):463-8. Review. PMID: 12526984 [PubMed - indexed for MEDLINE] 133: Kano Y, Nohno T, Hasegawa T, Takahashi R, Hiragami F, Related Articles, Links Kawamura K, Iwama MK, Motoda H, Miyamoto K Immunosuppressant FK506 induces neurite outgrowth in PC12 mutant cells with impaired NGF-promoted neuritogenesis via a novel MAP kinase signaling pathway. Neurochem Res. 2002 Dec;27(12):1655-61. PMID: 12515319 [PubMed - indexed for MEDLINE] Related Articles, Links 34: Kamsler A, Segal M.

h cb hg e e e fcg

b e

Hydrogen peroxide modulation of synaptic plasticity.


J Neurosci. 2003 Jan 1;23(1):269-76. PMID: 12514224 [PubMed - indexed for MEDLINE] 35: Keswani SC, Chander B, Hasan C, Griffin JW, McArthur JC, Hoke Related Articles, Links FK506 is neuroprotective in a model of antiretroviral toxic neuropathy. = Ann Neurol. 2003 Jan;53(1):57-64. PMID: 12509848 [PubMed - indexed for MEDLINE] 136: Li FQ, Cheng XX, Liang XB, Wang XH, Xue B, He QH, Wang Related Articles, Links XM. Han JS. Neurotrophic and neuroprotective effects of tripchlorolide, an extract of Chinese herb Tripterygium wilfordii Hook F, on dopaminergic neurons. Exp Neurol. 2003 Jan;179(1):28-37. PMID: 12504865 [PubMed - indexed for MEDLINE] T 37: Kano Y, Hiragami F, Kawamura K, Kimata Y, Nakagiri S, Related Articles, Links Poffenberger CK, Akiyama J, Okishima K, Koike Y, Gomita Y. Immunosuppressant FK506 induces sustained activation of MAP kinase and promotes neurite outgrowth in PC12 mutant cells incapable of differentiating. Cell Struct Funct. 2002 Oct;27(5):393-8. PMID: 12502894 [PubMed - indexed for MEDLINE] 38: Fujii H, Hirano T. Related Articles, Links Calcineurin regulates induction of late phase of cerebellar long-term depression in rat cultured Purkinje neurons. Eur J Neurosci. 2002 Nov;16(9):1777-88. PMID: 12431231 [PubMed - indexed for MEDLINE] 139: Iwasaki Y, Ichikawa Y, Igarashi O, Iwamoto K, Kinoshitata M, Related Articles, Links lkeda K. Neuroprotective actions of FK506 and cyclosporin A on motor neuron survival following neonatal axotomy. Neurol Res. 2002 Sep;24(6):573-6. PMID: 12238623 [PubMed - indexed for MEDLINE] 40: Udina E, Ceballos D, Verdu E, Gold BG, Navarro X. Related Articles, Links Bimodal dose-dependence of FK506 on the rate of axonal regeneration in mouse peripheral nerve. Muscle Nerve. 2002 Sep;26(3):348-55. PMID: 12210363 [PubMed - indexed for MEDLINE] 1: Revill WP, Voda J, Reeves CR, Chung L, Schirmer A, Ashley G, Related Articles, Links Carney JR, Fardis M, Carreras CW, Zhou Y, Feng L, Tucker E, Robinson D, Gold BG. Genetically engineered analogs of ascomycin for nerve regeneration. J Pharmacol Exp Ther. 2002 Sep;302(3):1278-85. PMID: 12183690 [PubMed - indexed for MEDLINE] 12: Zuber M, Donnerer J. Related Articles, Links Effect of FK506 on neurotransmitter content and expression of GAP-43 in neurotoxin-lesioned peripheral sensory and sympathetic neurons. Pharmacology. 2002 Sep;66(1):44-50. PMID: 12169765 [PubMed - indexed for MEDLINE] 1 43: Wu YO, Wilkinson DE, Limburg D, Li JH, Sauer H, Ross D, Related Articles, Links Liang S, Spicer D, Valentine H, Fuller M, Guo H, Howorth P, Soni


Synthesis of ketone analogues of prolyl and pipecolyl ester FKBP12

R, Chen Y, Steiner JP, Hamilton GS.

fcg

	ligands. J Med Chem. 2002 Aug 1;45(16):3558-68. PMID: 12139467 [PubMed - indexed for MEDLINE]	
□ 44	Hamilton GS, Wu YQ, Limburg DC, Wilkinson DE, Vaal MJ, Li JH, Thomas C, Huang W, Sauer H, Ross DT, Soni R, Chen Y, Guo H, Howorth P, Valentine H, Liang S, Spicer D, Fuller M, Steiner JP.	Related Articles, Links
	Synthesis of N-glyoxyl prolyl and pipecolyl amides and evaluation of their in vitro and in vivo nerve regenerative J Med Chem. 2002 Aug 1;45(16):3549-57. PMID: 12139466 [PubMed - indexed for MEDLINE]	thioesters and re effects.
— 45	Okajima S, Hojo T, Tamai K, Takai S, Hirasawa Y.	Related Articles, Links
	Histological and electrophysiological analysis of the perallografts using an immunosuppressive agent. Microsc Res Tech. 2002 Jul 1;58(1):52-8. PMID: 12112423 [PubMed - indexed for MEDLINE]	ripheral nerve
 46	Bouret S, Croix D, Mariot M, Loyens A, Prevot V, Jegou S, Vaudry H, Beauvillain JC, Mitchell V.	Related Articles, Links
	Galanin modulates the activity of proopiomelanocortin isolated mediobasal hypothalamus of the male rat. Neuroscience. 2002;112(2):475-85. PMID: 12044465 [PubMed - indexed for MEDLINE]	neurons in the
□ 47	: Sulaiman OA, Voda J, Gold BG, Gordon T.	Related Articles, Links
	FK506 increases peripheral nerve regeneration after chronic after chronic schwann cell denervation. Exp Neurol. 2002 May;175(1):127-37. PMID: 12009765 [PubMed - indexed for MEDLINE]	onic axotomy but
□ 48	: Grand AG, Myckatyn TM, Mackinnon SE, Hunter DA	Related Articles, Links
	Axonal regeneration after cold preservation of nerve all immunosuppression with tacrolimus in mice. J Neurosurg. 2002 May;96(5):924-32. PMID: 12005401 [PubMed - indexed for MEDLINE]	ografts and
I 49	: Wang SJ.	Related Articles, Links
	Interaction between FK 506 and isoproterenol in the moglutamate release from cerebrocortical nerve terminals. Neuroreport. 2002 May 24;13(7):983-6. PMID: 12004204 [PubMed - indexed for MEDLINE]	odulation of
□ 50	: Norris CM, Blalock EM, Chen KC, Porter NM, Landfield PW.	Related Articles, Links
	Calcineurin enhances L-type Ca(2+) channel activity in neurons: increased effect with age in culture. Neuroscience. 2002;110(2):213-25. PMID: 11958864 [PubMed - indexed for MEDLINE]	hippocampal
5 1	: Macleod MR, Butcher SP.	Related Articles, Links
	Nitric-oxide-synthase-mediated cyclic guanosine mono production in neonatal rat cerebellar prisms is resistant inhibition. Neurosci Lett. 2002 Mar 29;322(1):41-4. PMID: 11958839 [PubMed - indexed for MEDLINE]	
□ 52	Panickar KS, Jayakumar AR, Norenberg MD.	Related Articles, Links





cb

PMID: 11166724 [PubMed - indexed for MEDLINE] Related Articles, Links 71: Tanaka K, Fujita N, Yoshioka M, Ogawa N. Immunosuppressive and non-immunosuppressive immunophilin ligands improve H(2)O(2)-induced cell damage by increasing glutathione levels in NG108-15 cells. Brain Res. 2001 Jan 19;889(1-2):225-8. PMID: 11166708 [PubMed - indexed for MEDLINE] Related Articles, Links 72: Freeman EE, Grosskreutz CL. The effects of FK 506 on retinal ganglion cells after optic nerve crush. Invest Ophthalmol Vis Sci. 2000 Apr;41(5):1111-5. PMID: 10752948 [PubMed - indexed for MEDLINE] 73: Shi J, Townsend M, Constantine-Paton M. Related Articles, Links Activity-dependent induction of tonic calcineurin activity mediates a rapid developmental downregulation of NMDA receptor currents. Neuron. 2000 Oct;28(1):103-14. PMID: 11086987 [PubMed - indexed for MEDLINE] 74: Springer JE, Azbill RD, Nottingham SA, Kennedy SE. Related Articles, Links Calcineurin-mediated BAD dephosphorylation activates the caspase-3 apoptotic cascade in traumatic spinal cord injury. J Neurosci. 2000 Oct 1;20(19):7246-51. PMID: 11007881 [PubMed - indexed for MEDLINE] 75: Brogan IJ, Pravica V, Hutchinson IV. Related Articles, Links Genetic conservation of the immunophilin-binding domains of human calcineurin A1 and A2. Transpl Immunol. 2000 Jun;8(2):139-41. PMID: 11005320 [PubMed - indexed for MEDLINE] Related Articles, Links 76: Zhang W, Victor RG. Calcineurin inhibitors cause renal afferent activation in rats: a novel mechanism of cyclosporine-induced hypertension. Am J Hypertens. 2000 Sep; 13(9):999-1004. PMID: 10981550 [PubMed - indexed for MEDLINE] Related Articles, Links 77: Burley JR, Sihra TS. A modulatory role for protein phosphatase 2B (calcineurin) in the regulation of Ca2+ entry. Eur J Neurosci. 2000 Aug;12(8):2881-91. PMID: 10971631 [PubMed - indexed for MEDLINE] 78: Mogi M, Togari A, Tanaka K, Ogawa N, Ichinose H, Nagatsu T. Related Articles, Links Increase in level of tumor necrosis factor-alpha in 6-hydroxydopaminelesioned striatum in rats is suppressed by immunosuppressant FK506. Neurosci Lett. 2000 Aug 11;289(3):165-8. PMID: 10961655 [PubMed - indexed for MEDLINE] 79: Terashima A, Taniguchi T, Nakai M, Yasuda M, Kawamata T, Related Articles, Links Tanaka C. Rapamycin and FK506 induce long-term potentiation by pairing stimulation via an intracellular Ca(2+) signaling mechanism in rat hippocampal CA1 neurons. Neuropharmacology. 2000 Jul 24;39(10):1920-8. PMID: 10884573 [PubMed - indexed for MEDLINE]

hg e e e fcg

b e

cb

cb

h g

e e

h

e fcg

□ 80:	Parker EM, Monopoli A, Ongini E, Lozza G, Babij CM.	Related Articles, Links
	Rapamycin, but not FK506 and GPI-1046, increases neu PC12 cells by inhibiting cell cycle progression. Neuropharmacology. 2000 Jul 24;39(10):1913-9. PMID: 10884572 [PubMed - indexed for MEDLINE]	rite outgrowth in
□ 81:	Castilho RF, Hansson O, Brundin P.	Related Articles, Links
	FK506 and cyclosporin A enhance the survival of culture embryonic dopamine neurons. Exp Neurol. 2000 Jul;164(1):94-101. PMID: 10877919 [PubMed - indexed for MEDLINE]	ed and grafted rat
□ 82:	Costantini LC, Isacson O.	Related Articles, Links
	Immunophilin ligands and GDNF enhance neurite branc from developing dopamine neurons in culture. Exp Neurol. 2000 Jul;164(1):60-70. PMID: 10877916 [PubMed - indexed for MEDLINE]	hing or elongation
□ 83:	Lu YM, Mansuy IM, Kandel ER, Roder J.	Related Articles, Links
	Calcineurin-mediated LTD of GABAergic inhibition unincreased excitability of CA1 neurons associated with L Neuron. 2000 Apr;26(1):197-205. PMID: 10798404 [PubMed - indexed for MEDLINE]	
□ 84:	He L, Poblenz AT, Medrano CJ, Fox DA.	Related Articles, Links
	Lead and calcium produce rod photoreceptor cell apopto mitochondrial permeability transition pore. J Biol Chem. 2000 Apr 21;275(16):12175-84. PMID: 10766853 [PubMed - indexed for MEDLINE]	osis by opening the
□ 85:	Wang MS, Gold BG.	Related Articles, Links
	FK506 increases the regeneration of spinal cord axons in peripheral nerve autograft. J Spinal Cord Med. 1999 Winter;22(4):287-96. PMID: 10751133 [PubMed - indexed for MEDLINE]	n a predegenerated
□ 86:	Li ST. Kato K. Mikoshiba K.	Related Articles, Links
	High Ca(2+)/low Mg(2+) solution induces long-term de pyramidal neurons. Neurosci Lett. 2000 Apr 7;283(2):141-4. PMID: 10739895 [PubMed - indexed for MEDLINE]	pression in rat CA1
□ 87:	Campbell G, Holt JK, Shotton HR, Anderson PN, Bavetta S, Lieberman AR.	Related Articles, Links
	Spontaneous axonal regeneration after optic nerve injury. Neuroreport. 1999 Dec 16;10(18):3955-60. PMID: 10716240 [PubMed - indexed for MEDLINE]	y in adult rat.
□ 88	Dunnett SB.	Related Articles, Links
	The failure of axon regeneration in the CNS is not absol Neuroreport. 1999 Dec 16;10(18):iii-iv. Review. No abstract availa PMID: 10716198 [PubMed - indexed for MEDLINE]	ute. ible.
□ 89	Aronowski J, Grotta JC, Strong R, Waxham MN.	Related Articles, Links
	Interplay between the gamma isoform of PKC and calci of vulnerability to focal cerebral ischemia. J Cereb Blood Flow Metab. 2000 Feb;20(2):343-9.	neurin in regulation

b e

PMID: 10698072 [PubMed - indexed for MEDLINE]

90: Guerini D, Wang X, Li L, Genazzani A, Carafoli E.

Related Articles, Links



Calcineurin controls the expression of isoform 4CII of the plasma membrane Ca(2+) pump in neurons.

J Biol Chem. 2000 Feb 4;275(5):3706-12.

PMID: 10652370 [PubMed - indexed for MEDLINE]

91: Hashii M, Minabe Y, Higashida H.

Related Articles, Links



cADP-ribose potentiates cytosolic Ca2+ elevation and Ca2+ entry via L-type voltage-activated Ca2+ channels in NG108-15 neuronal cells.

Biochem J. 2000 Jan 15;345 Pt 2:207-15.

PMID: 10620496 [PubMed - indexed for MEDLINE]

92: Zeilhofer HU, Blank NM, Neuhuber WL, Swandulla D.

Related Articles, Links



Calcium-dependent inactivation of neuronal calcium channel currents is independent of calcineurin.

Neuroscience. 2000;95(1):235-41.

PMID: 10619480 [PubMed - indexed for MEDLINE]

93: Nusser Z, Sieghart W, Mody I.

Related Articles, Links



Differential regulation of synaptic GABAA receptors by cAMP-dependent protein kinase in mouse cerebellar and olfactory bulb neurones.

J Physiol. 1999 Dec 1;521 Pt 2:421-35.

PMID: 10581313 [PubMed - indexed for MEDLINE]

1. 94: Asai A. Qiu J. Narita Y. Chi S. Saito N. Shinoura N. Hamada H. Related Articles, Links Kuchino Y. Kirino T.



High level calcineurin activity predisposes neuronal cells to apoptosis. J Biol Chem. 1999 Nov 26;274(48):34450-8.

PMID: 10567426 [PubMed - indexed for MEDLINE]

95: Fansa H, Keilhoff G, Hom T, Altmann S, Wolf G, Schneider W. Related Articles, Links



[Stimulation of Schwann cell growth and axon regeneration of peripheral nerves by the immunosuppressive drug FK 506]

Handchir Mikrochir Plast Chir. 1999 Sep;31(5):323-9; discussion 330-2. German. PMID: 10566134 [PubMed - indexed for MEDLINE]

96: Mao Z. Wiedmann M.

Related Articles, Links



Calcineurin enhances MEF2 DNA binding activity in calcium-dependent survival of cerebellar granule neurons.

J Biol Chem. 1999 Oct 22;274(43):31102-7.

PMID: 10521511 [PubMed - indexed for MEDLINE]

97: Shuto H, Kataoka Y, Fujisaki K, Nakao T, Sueyasu M, Miura I, Watanabe Y, Fujiwara M, Oishi R. Releted Articles, Links



Inhibition of GABA system involved in cyclosporine-induced convulsions. Life Sci. 1999;65(9):879-87.

PMID: 10465348 [PubMed - indexed for MEDLINE]

98: Alexanian AR, Bamburg JR.

Related Articles, Links



Neuronal survival activity of s100betabeta is enhanced by calcineurin inhibitors and requires activation of NF-kappaB.

FASEB J. 1999 Sep;13(12):1611-20.

PMID: 10463953 [PubMed - indexed for MEDLINE]

99: Gold BG.


Related Articles, Links

FK506 and the role of the immunophilin FKBP-52 in nerve regeneration.

Drug Metab Rev. 1999 Aug;31(3):649-63. Review. PMID: 10461545 [PubMed - indexed for MEDLINE] 100: Volbracht C, Leist M, Nicotera P. Related Articles, Links ATP controls neuronal apoptosis triggered by microtubule breakdown or potassium deprivation. Mol Med. 1999 Jul;5(7):477-89. PMID: 10449809 [PubMed - indexed for MEDLINE] 101: Bavetta S, Hamlyn PJ, Burnstock G, Lieberman AR, Anderson Related Articles, Links The effects of FK506 on dorsal column axons following spinal cord injury in adult rats: neuroprotection and local regeneration. Exp Neurol. 1999 Aug; 158(2):382-93. PMID: 10415144 [PubMed - indexed for MEDLINE] 102: Gold BG, Gordon HS, Wang MS. Related Articles, Links Efficacy of delayed or discontinuous FK506 administrations on nerve regeneration in the rat sciatic nerve crush model: lack of evidence for a conditioning lesion-like effect. Neurosci Lett. 1999 May 21;267(1):33-6. PMID: 10400242 [PubMed - indexed for MEDLINE] 103: Gold BG, Densmore V, Shou W, Matzuk MM, Gordon HS. Related Articles, Links Immunophilin FK506-binding protein 52 (not FK506-binding protein 12) mediates the neurotrophic action of FK506. J Pharmacol Exp Ther. 1999 Jun;289(3):1202-10. PMID: 10336507 [PubMed - indexed for MEDLINE] 104: Morioka M, Hamada J, Ushio Y, Miyamoto E. Related Articles, Links Potential role of calcineurin for brain ischemia and traumatic injury. Prog Neurobiol. 1999 May;58(1):1-30. Review. PMID: 10321795 [PubMed - indexed for MEDLINE] 105: Martin-Villalba A, Herr I, Jeremias I, Hahne M, Brandt R, Vogel Related Articles, Links J. Schenkel J. Herdegen T. Debatin KM. CD95 ligand (Fas-L/APO-1L) and tumor necrosis factor-related apoptosis-inducing ligand mediate ischemia-induced apoptosis in neurons. J Neurosci. 1999 May 15;19(10):3809-17. PMID: 10234013 [PubMed - indexed for MEDLINE] 106: Herr I, Martin-Villalba A, Kurz E, Roncaioli P, Schenkel J, Related Articles, Links Cifone MG, Debatin KM. FK506 prevents stroke-induced generation of ceramide and apoptosis signaling. Brain Res. 1999 May 1;826(2):210-9. PMID: 10224298 [PubMed - indexed for MEDLINE] 107: Lee JP, Palfrey HC, Bindokas VP, Ghadge GD, Ma L, Miller RJ. Related Articles, Links Roos RP. The role of immunophilins in mutant superoxide dismutase-1linked familial amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):3251-6. PMID: 10077670 [PubMed - indexed for MEDLINE] 108: Harrison S, Reddy S, Page CP, Spina D. Related Articles, Links Stimulation of airway sensory nerves by cyclosporin A and FK506 in

b e

guinea-pig isolated bronchus.



Nature. 1998 Jul 23;394(6691):381-4. PMID: 9690474 [PubMed - indexed for MEDLINE] Related Articles, Links 117: Yardin C, Terro F, Lesort M, Esclaire F, Hugon J. FK506 antagonizes apoptosis and c-jun protein expression in neuronal cultures. Neuroreport. 1998 Jun 22;9(9):2077-80. PMID: 9674596 [PubMed - indexed for MEDLINE] Related Articles, Links 118: Tamura K. [Multiple actions of tacrolimus and cyclosporin A as specific inhibitors of calcineurin] Tanpakushitsu Kakusan Koso. 1998 Jun;43(8 Suppl):1118-30. Review. Japanese. No abstract available. PMID: 9655970 [PubMed - indexed for MEDLINE] 119: Matsui H, Lu YF, Moriwaki A. Related Articles, Links [Physiological role of calcineurin in central nervous system] Tanpakushitsu Kakusan Koso. 1998 Jun;43(8 Suppl):1039-46. Review. Japanese. No abstract available. PMID: 9655961 [PubMed - indexed for MEDLINE] 120: Burnett PE, Blackshaw S, Lai MM, Qureshi IA, Burnett AF, Related Articles, Links Sabatini DM, Snyder SH. Neurabin is a synaptic protein linking p70 S6 kinase and the neuronal cytoskeleton. Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):8351-6. PMID: 9653190 [PubMed - indexed for MEDLINE] 121: Friberg H. Ferrand-Drake M. Bengtsson F. Halestrap AP. Related Articles, Links Wieloch T Cyclosporin A, but not FK 506, protects mitochondria and neurons against hypoglycemic damage and implicates the mitochondrial permeability transition in cell death. J Neurosci. 1998 Jul 15;18(14):5151-9. PMID: 9651198 [PubMed - indexed for MEDLINE] 122: Terashima A, Nakai M, Hashimoto T, Kawamata T, Taniguchi T, Related Articles, Links Yasuda M, Maeda K, Tanaka C. Single-channel activity of the Ca2+-dependent K+ channel is modulated = by FK506 and rapamycin. Brain Res. 1998 Mar 9;786(1-2):255-8. PMID: 9555045 [PubMed - indexed for MEDLINE] 123: Kikuchi M, Kashii S, Mandai M, Yasuyoshi H, Honda Y, Kaneda Related Articles, Links K, Akaike A. Protective effects of FK506 against glutamate-induced neurotoxicity in retinal cell culture. Invest Ophthalmol Vis Sci. 1998 Jun;39(7):1227-32. PMID: 9620083 [PubMed - indexed for MEDLINE] Related Articles, Links 124: Hashimoto T, Kawamata T, Tanaka C. [Involvement of calcineurin A alpha and A beta in neuronal death in a gerbil model of cerebral ischemia Nippon Yakurigaku Zasshi. 1998 Jan;111(1):21-8. Review. Japanese. PMID: 9551469 [PubMed - indexed for MEDLINE] Related Articles, Links 125: Matsuda T, Baba A.

[Response of Na+/Ca2+ antiporter to ischemia and glial/neuronal death]

Nippon Yakurigaku Zasshi. 1998 Jan;111(1):13-9. Review. Japanese. PMID: 9551468 [PubMed - indexed for MEDLINE]

126: Carreau A, Gueugnon J, Benavides J, Vige X.

Related Articles, Links

Comparative effects of FK-506, rapamycin and cyclosporin A, on the in vitro differentiation of dorsal root ganglia explants and septal cholinergic neurons

Neuropharmacology. 1997 Nov-Dec;36(11-12):1755-62. PMID: 9517448 [PubMed - indexed for MEDLINE]

127: Gold BG, Yew JY, Zeleny-Pooley M.

Related Articles, Links



The immunosuppressant FK506 increases GAP-43 mRNA levels in axotomized sensory neurons.

Neurosci Lett. 1998 Jan 23;241(1):25-8.

PMID: 9502207 [PubMed - indexed for MEDLINE]

128: Gold BG.

Related Articles, Links



FK506 and the role of immunophilins in nerve regeneration.

Mol Neurobiol. 1997 Dec; 15(3):285-306. Review. PMID: 9457703 [PubMed - indexed for MEDLINE]

129: Wang JH, Kelly PT.

Related Articles, Links



Attenuation of paired-pulse facilitation associated with synaptic potentiation mediated by postsynaptic mechanisms.

J Neurophysiol. 1997 Nov;78(5):2707-16.

PMID: 9356420 [PubMed - indexed for MEDLINE]

130: Audesirk G, Cabell L, Kern M.

Related Articles, Links



Modulation of neurite branching by protein phosphorylation in cultured rat hippocampal neurons.

Brain Res Dev Brain Res. 1997 Sep 20;102(2):247-60. PMID: 9352107 [PubMed - indexed for MEDLINE]

131: Gold BG, Zeleny-Pooley M, Wang MS, Chaturvedi P, Armistead Related Articles, Links DM.



A nonimmunosuppressant FKBP-12 ligand increases nerve regeneration. Exp Neurol. 1997 Oct;147(2):269-78.

PMID: 9344552 [PubMed - indexed for MEDLINE]

132: Wang MS, Zeleny-Pooley M, Gold BG.

Related Articles, Links



Comparative dose-dependence study of FK506 and cyclosporin A on the rate of axonal regeneration in the rat sciatic nerve.

J Pharmacol Exp Ther. 1997 Aug;282(2):1084-93. PMID: 9262378 [PubMed - indexed for MEDLINE]

133: Wang JH, Kelly PT.

Related Articles, Links



Postsynaptic calcineurin activity downregulates synaptic transmission by weakening intracellular Ca2+ signaling mechanisms in hippocampal CA1 neurons.

J Neurosci. 1997 Jun 15;17(12):4600-11.

PMID: 9169521 [PubMed - indexed for MEDLINE]


Tal: Steiner JP, Connolly MA, Valentine HL, Hamilton GS, Dawson Related Articles, Links TM, Hester L, Snyder SH.



Neurotrophic actions of nonimmunosuppressive analogues of immunosuppressive drugs FK506, rapamycin and cyclosporin A.

Nat Med. 1997 Apr;3(4):421-8.

PMID: 9095176 [PubMed - indexed for MEDLINE]



PMID: 7472502 [PubMed - indexed for MEDLINE]

144: Chang HY, Takei K, Sydor AM, Bom T, Rusnak F, Jay DG. Related

Related Articles, Links

Asymmetric retraction of growth cone filopodia following focal inactivation of calcineurin.

Nature. 1995 Aug 24;376(6542):686-90.

PMID: 7544441 [PubMed - indexed for MEDLINE]

145: Victor RG, Thomas GD, Marban E, O'Rourke B.

Related Articles, Links



Presynaptic modulation of cortical synaptic activity by calcineurin.

Proc Natl Acad Sci U S A. 1995 Jul 3;92(14):6269-73.

PMID: 7541535 [PubMed - indexed for MEDLINE]

146: Perrot-Applanat M, Cibert C, Geraud G, Renoir JM, Baulieu EE. Related Articles, Links



The 59 kDa FK506-binding protein, a 90 kDa heat shock protein binding immunophilin (FKBP59-HBI), is associated with the nucleus, the cytoskeleton and mitotic apparatus.

J Cell Sci. 1995 May; 108 (Pt 5): 2037-51.

147: Lyons WE, Steiner JP, Snyder SH, Dawson TM.

PMID: 7544801 [PubMed - indexed for MEDLINE]

Related Articles, Links



Neuronal regeneration enhances the expression of the immunophilin FKBP-12.

J Neurosci. 1995 Apr; 15(4):2985-94.

PMID: 7536825 [PubMed - indexed for MEDLINE]

148: Coghlan VM, Perrino BA, Howard M, Langeberg LK, Hicks JB. Related Articles, Links Gallatin WM, Scott JD.



Association of protein kinase A and protein phosphatase 2B with a common anchoring protein.

Science. 1995 Jan 6;267(5194):108-11.

PMID: 7528941 [PubMed - indexed for MEDLINE]

149: Yamamoto S, Nagaki Y, Fukuo Y, Hirata H.

Related Articles, Links



Cross-species transplantation of photoreceptors with tacrolimus hydrate (FK506) treatment.

Jpn J Ophthalmol. 1995;39(4):334-9.

PMID: 8926639 [PubMed - indexed for MEDLINE]

150: Dawson VL, Brahmbhatt HP, Mong JA, Dawson TM.

Related Articles, Links



Expression of inducible nitric oxide synthase causes delayed neurotoxicity in primary mixed neuronal-glial cortical cultures.

Neuropharmacology. 1994 Nov;33(11):1425-30. PMID: 7532825 [PubMed - indexed for MEDLINE]

151: Lieberman DN, Mody I.

Related Articles, Links



Regulation of NMDA channel function by endogenous Ca(2+)-dependent phosphatase.

Nature. 1994 May 19;369(6477):235-9.

PMID: 7514273 [PubMed - indexed for MEDLINE]

152: Funauchi M, Haruta H, Tsumoto T.

Related Articles, Links



Effects of an inhibitor for calcium/calmodulin-dependent protein phosphatase, calcineurin, on induction of long-term potentiation in rat visual cortex.

Neurosci Res. 1994 May;19(3):269-78.

PMID: 7520143 [PubMed - indexed for MEDLINE]


Related Articles, Links 153: Lvons WE, George EB, Dawson TM, Steiner JP, Snyder SH. Immunosuppressant FK506 promotes neurite outgrowth in cultures of PC12 cells and sensory ganglia. Proc Natl Acad Sci U S A. 1994 Apr 12;91(8):3191-5. PMID: 7512727 [PubMed - indexed for MEDLINE] 154: Dawson TM, Zhang J, Dawson VL, Snyder SH. Related Articles, Links Nitric oxide: cellular regulation and neuronal injury. Prog Brain Res. 1994;103:365-9. Review. No abstract available. PMID: 7533914 [PubMed - indexed for MEDLINE] 155: Dawson TM, Steiner JP, Dawson VI., Dinerman JL, Uhl GR, Related Articles, Links Snyder SH. Immunosuppressant FK506 enhances phosphorylation of nitric oxide synthase and protects against glutamate neurotoxicity. Proc Natl Acad Sci U S A. 1993 Nov 1;90(21):9808-12. PMID: 7694293 [PubMed - indexed for MEDLINE] 156: Manev H, Favaron M, Candeo P, Fadda E, Lipartiti M, Milani D. Related Articles, Links Macrolide antibiotics protect neurons in culture against the N-methyl-Daspartate (NMDA) receptor-mediated toxicity of glutamate. Brain Res. 1993 Oct 8;624(1-2):331-5. PMID: 7504570 [PubMed - indexed for MEDLINE] Show: 500 Send to Text Display Summary Items 1-156 of 156 One page.

Write to the Help Desk
NCBI | NLM | NIH
Department of Health & Human Services
Freedom of Information Act | Disclaimer

Mar 11 2004 06:56:25







OMIM PMC Journals 800 Structure PubMed Nucleotide Protein Genome Search PubMed for cyclosporin A AND neuron Go Clear Clipboard Details Preview/Index Limits History About Entrez Show: 500 ₩ Sort Send to Text Display Summary Items 1-293 of 293 One page. Text Version 1: Khan OH, Enno T, Del Bigio MR. Related Articles, Links Entrez PubMed Tacrolimus and cyclosporine A are of no benefit to young rats with kaolin-Overview induced hydrocephalus. Help | FAQ Pediatr Neurosurg. 2003 Dec;39(6):309-13. Tutorial New/Noteworthy PMID: 14734865 [PubMed - indexed for MEDLINE] E-Utilities 1 2: Tobias CA, Shumsky JS, Shibata M, Tuszynski MH, Fischer I, Related Articles, Links Tessler A, Murray M. **PubMed Services** Journals Database Delayed grafting of BDNF and NT-3 producing fibroblasts into the injured MeSH Database spinal cord stimulates sprouting, partially rescues axotomized red nucleus Single Citation Matcher neurons from loss and atrophy, and provides limited regeneration. **Batch Citation Matcher** Exp Neurol. 2003 Nov;184(1):97-113. **Clinical Queries** LinkOut PMID: 14637084 [PubMed - indexed for MEDLINE] Cubby 3: Jordan J, Galindo MF, Gonzalez-Garcia C, Cena V. Related Articles, Links Related Resources Role and regulation of p53 in depolarization-induced neuronal death. Order Documents Neuroscience. 2003;122(3):707-15. **NLM Gateway** PMID: 14622914 [PubMed - indexed for MEDLINE] TOXNET Consumer Health Related Articles, Links 4. Mivoshi K, Sakagami K, Orita K. Clinical Alerts ClinicalTrials.gov Ex vivo perfusion of canine pancreaticoduodenal allografts using class-II-PubMed Central specific monoclonal antibody delays the onset of acute rejection. Transpl Int. 1992;5 Suppl 1:S516-20. Privacy Policy PMID: 14621864 [PubMed - indexed for MEDLINE] 5: Gillon RS, Cui Q, Dunlop SA, Harvey AR. Related Articles, Links Effects of immunosuppression on regrowth of adult rat retinal ganglion cell axons into peripheral nerve allografts. J Neurosci Res. 2003 Nov 15;74(4):524-32. PMID: 14598296 [PubMed - indexed for MEDLINE] Related Articles, Links 6: Shin CY, Shin J, Kim BM, Wang MH, Jang JH, Surh YJ, Oh U. Essential role of mitochondrial permeability transition in vanilloid receptor 1-dependent cell death of sensory neurons. Mol Cell Neurosci. 2003 Sep;24(1):57-68. PMID: 14550768 [PubMed - indexed for MEDLINE] 7: Choi D. Raisman G. Related Articles, Links Immune rejection of a facial nerve xenograft does not prevent regeneration and the return of function; an experimental study. Neuroscience. 2003;121(2):501-7. PMID: 14522009 [PubMed - indexed for MEDLINE] 8. Huang HM, Ou HC, Xu H, Chen HL, Fowler C, Gibson GE. Related Articles, Links


Inhibition of alpha-ketoglutarate dehydrogenase complex promotes


e ch

cytochrome c release from mitochondria, caspase-3 activation, and necrotic


b e

cb hg e e fcg







h cb hgeeefcg ech be




h cb hg e e e fcg e ch b e



h cb hg e e e fcg e ch b e



h cb hgeeefcg ech be



e fcg

e e

h g

h

cb

e ch

PMID: 11745615 [PubMed - indexed for MEDLINE] 64: Frantseva MV, Carlen PL, Perez Velazquez JL. Related Articles, Links Dynamics of intracellular calcium and free radical production during ischemia in pyramidal neurons. Free Radic Biol Med. 2001 Nov 15;31(10):1216-27. PMID: 11705700 [PubMed - indexed for MEDLINE] Related Articles, Links 65: Suehiro E, Singleton RH, Stone JR, Povlishock JT. The immunophilin ligand FK506 attenuates the axonal damage associated with rapid rewarming following posttraumatic hypothermia. Exp Neurol. 2001 Nov;172(1):199-210. PMID: 11681852 [PubMed - indexed for MEDLINE] 66: Larsson LC, Frielingsdorf H, Mirza B, Hansson SJ, Anderson P, Related Articles, Links Czech KA, Strandberg M, Widner H. Porcine neural xenografts in rats and mice: donor tissue development and characteristics of rejection. Exp Neurol. 2001 Nov;172(1):100-14. PMID: 11681844 [PubMed - indexed for MEDLINE] 67: Riess P, Bareyre FM, Saatman KE, Cheney JA, Lifshitz J. Related Articles, Links Raghupathi R, Grady MS, Neugebauer E, McIntosh TK. Effects of chronic, post-injury Cyclosporin A administration on motor and sensorimotor function following severe, experimental traumatic brain Restor Neurol Neurosci. 2001;18(1):1-8. PMID: 11673665 [PubMed - indexed for MEDLINE] 68: Liu W, Liu R, Chun JT, Bi R, Hoe W, Schreiber SS, Baudry M. Related Articles, Links Kainate excitotoxicity in organotypic hippocampal slice cultures: evidence for multiple apoptotic pathways. Brain Res. 2001 Oct 19;916(1-2):239-48. PMID: 11597611 [PubMed - indexed for MEDLINE] 69: Jiang D, Sullivan PG, Sensi SL, Steward O, Weiss JH. Related Articles, Links Zn(2+) induces permeability transition pore opening and release of proapoptotic peptides from neuronal mitochondria. J Biol Chem. 2001 Dec 14;276(50):47524-9. Epub 2001 Oct 10. PMID: 11595748 [PubMed - indexed for MEDLINE] 70: van De Borne P, Neubauer J, Rahnama M, Jansens JL, Montano N, Related Articles, Links Porta A, Somers VK, Degaute JP. Differential characteristics of neural circulatory control: early versus late after cardiac transplantation. Circulation. 2001 Oct 9;104(15):1809-13. PMID: 11591619 [PubMed - indexed for MEDLINE] 71: Jovanovic JN, Sihra TS, Nairn AC, Hemmings HC Jr, Greengard Related Articles, Links P, Czemik AJ, Opposing changes in phosphorylation of specific sites in synapsin I during Ca2+-dependent glutamate release in isolated nerve terminals. J Neurosci, 2001 Oct 15;21(20):7944-53. PMID: 11588168 [PubMed - indexed for MEDLINE] Related Articles, Links 72: Smith PM, Franklin RJ The effect of immunosuppressive protocols on spontaneous CNS remyelination following toxin-induced demyelination.

J Neuroimmunol. 2001 Oct 1;119(2):261-8.

e ch

b e

fcg

cb

h

h g

e e

PMID: 11585629 [PubMed - indexed for MEDLINE] 73: Dunn SE, Simard AR, Bassel-Duby R, Williams RS, Michel RN. Related Articles, Links Nerve activity-dependent modulation of calcineurin signaling in adult fast and slow skeletal muscle fibers. J Biol Chem. 2001 Nov 30;276(48):45243-54. Epub 2001 Sep 12. PMID: 11555650 [PubMed - indexed for MEDLINE] 74: Storozhevykh TP, Yuryavichyus AI, Sorokina EG, Pinelis VG. Related Articles, Links Induction of cyclosporin A-sensitive pore in mitochondria of intact neurons = during uncoupling of oxidative phosphorylation. Bull Exp Biol Med. 2001 May;131(5):440-3. PMID: 11550047 [PubMed - indexed for MEDLINE] 75: Huang H, Farley J. Related Articles, Links PP1 inhibitors depolarize Hermissenda photoreceptors and reduce K+ J Neurophysiol. 2001 Sep;86(3):1297-311. PMID: 11535678 [PubMed - indexed for MEDLINE] Related Articles, Links 76: Reichert SA, Kim-Han JS, Dugan LL. The mitochondrial permeability transition pore and nitric oxide synthase mediate early mitochondrial depolarization in astrocytes during oxygenglucose deprivation. J Neurosci. 2001 Sep 1;21(17):6608-16. PMID: 11517250 [PubMed - indexed for MEDLINE] 77: Miyata K, Omori N, Uchino H, Yamaguchi T, Isshiki A, Shibasaki Related Articles, Links Involvement of the brain-derived neurotrophic factor/TrkB pathway in neuroprotecive effect of cyclosporin A in forebrain ischemia. Neuroscience. 2001;105(3):571-8. PMID: 11516824 [PubMed - indexed for MEDLINE] 78: Kaminska B. Figiel I, Pyrzynska B, Czajkowski R, Mosieniak G. Related Articles, Links Treatment of hippocampal neurons with cyclosporin A results in calcium overload and apoptosis which are independent on NMDA receptor activation. Br J Pharmacol. 2001 Aug;133(7):997-1004. PMID: 11487508 [PubMed - indexed for MEDLINE] 79: Graca DL, Bondan EF, Pereira LA, Fernandes CG, Maiorka PC. Related Articles, Links Behaviour of oligodendrocytes and Schwann cells in an experimental model of toxic demyelination of the central nervous system. Arq Neuropsiquiatr. 2001 Jun;59(2-B):358-61. PMID: 11460179 [PubMed - indexed for MEDLINE] 80: Nahreini P, Hovland AR, Kumar B, Andreatta C, Edwards-Prasad Related Articles, Links J. Prasad KN. Effects of altered cyclophilin A expression on growth and differentiation of human and mouse neuronal cells. Cell Mol Neurobiol. 2001 Feb;21(1):65-79. PMID: 11440199 [PubMed - indexed for MEDLINE] 81: Buckman JF, Reynolds IJ. Related Articles, Links

Spontaneous changes in mitochondrial membrane potential in cultured

cb hg e e e fcg e ch b e

h

J Neurosci. 2001 Jul 15;21(14):5054-65.

PMID: 11438581 [PubMed - indexed for MEDLINE] 82: Singleton RH, Stone JR, Okonkwo DO, Pellicane AJ, Povlishock Related Articles, Links The immunophilin ligand FK506 attenuates axonal injury in an impact-= acceleration model of traumatic brain injury. J Neurotrauma. 2001 Jun;18(6):607-14. PMID: 11437083 [PubMed - indexed for MEDLINE] 13: Hagl C, Tatton NA, Weisz DJ, Zhang N, Spielvogel D, Shiang HH, Related Articles, Links Bodian CA, Griepp RB. Cyclosporine A as a potential neuroprotective agent: a study of prolonged hypothermic circulatory arrest in a chronic porcine model. Eur J Cardiothorac Surg. 2001 Jun;19(6):756-64. PMID: 11404127 [PubMed - indexed for MEDLINE] 84: Tatton NA, Hagl C, Nandor S, Insolia S, Spiclvogel D, Griepp RB. Related Articles, Links Apoptotic cell death in the hippocampus due to prolonged hypothermic circulatory arrest: comparison of cyclosporine A and cycloheximide on neuron survival. Eur J Cardiothorac Surg. 2001 Jun;19(6):746-55. PMID: 11404126 [PubMed - indexed for MEDLINE] 85: Mizumoto H, Mizumoto K, Whiteley SJ, Shatos M, Klassen H, Related Articles, Links Young MJ Transplantation of human neural progenitor cells to the vitreous cavity of the Royal College of Surgeons rat. Cell Transplant. 2001 Mar-Apr; 10(2):223-33. PMID: 11332637 [PubMed - indexed for MEDLINE] 86: Yang JH. Gross RL, Basinger SF, Wu SM. Related Articles, Links Apoptotic cell death of cultured salamander photoreceptors induced by cccp: CsA-insensitive mitochondrial permeability transition. J Cell Sci. 2001 May;114(Pt 9):1655-64. PMID: 11309197 [PubMed - indexed for MEDLINE] Related Articles, Links 87: Almeida A, Bolanos JP. A transient inhibition of mitochondrial ATP synthesis by nitric oxide synthase activation triggered apoptosis in primary cortical neurons. J Neurochem. 2001 Apr;77(2):676-90. PMID: 11299330 [PubMed - indexed for MEDLINE] 88: Kristal BS, Conway AD, Brown AM, Jain JC, Ulluci PA, Li SW, Related Articles, Links Burke WJ. Selective dopaminergic vulnerability: 3,4-dihydroxyphenylacetaldehyde targets mitochondria. Free Radic Biol Med. 2001 Apr 15;30(8):924-31. PMID: 11295535 [PubMed - indexed for MEDLINE] Related Articles, Links 89: Kowaltowski AJ, Vercesi AE, Fiskum G. Bcl-2 prevents mitochondrial permeability transition and cytochrome c release via maintenance of reduced pyridine nucleotides. Cell Death Differ. 2000 Oct;7(10):903-10. PMID: 11279535 [PubMed - indexed for MEDLINE] 1 90: Plyte S, Boncristiano M, Fattori E, Galvagni F, Paccani SR, Related Articles, Links Majolini MB, Oliviero S, Ciliberto G, Telford JL, Baldari CT. Identification and characterization of a novel nuclear factor of activated T-

h cb hg e e e fcg


cells-1 isoform expressed in mouse brain.

e ch

J Biol Chem. 2001 Apr 27;276(17):14350-8. Epub 2001 Jan 24. PMID: 11278367 [PubMed - indexed for MEDLINE] Related Articles, Links 91: Keep M. Elmer E, Fong KS, Csiszar K. Intrathecal cyclosporin prolongs survival of late-stage ALS mice. Brain Res. 2001 Mar 16;894(2):327-31. PMID: 11251210 [PubMed - indexed for MEDLINE] 92: Suchiro E, Povlishock JT. Related Articles, Links Exacerbation of traumatically induced axonal injury by rapid posthypothermic rewarming and attenuation of axonal change by cyclosporin A. J Neurosurg. 2001 Mar;94(3):493-8. PMID: 11235956 [PubMed - indexed for MEDLINE] 1 93: Urushitani M, Nakamizo T, Inoue R, Sawada H, Kihara T, Honda Related Articles, Links K, Akaike A, Shimohama S. N-methyl-D-aspartate receptor-mediated mitochondrial Ca(2+) overload in acute excitotoxic motor neuron death: a mechanism distinct from chronic neurotoxicity after Ca(2+) influx. J Neurosci Res. 2001 Mar 1;63(5):377-87. PMID: 11223912 [PubMed - indexed for MEDLINE] Related Articles, Links 94: Kerokoski P, Suuronen T, Salminen A, Soininen H, Pirttila T. The levels of cdk5 and p35 proteins and tau phosphorylation are reduced during neuronal apoptosis. Biochem Biophys Res Commun. 2001 Feb 2;280(4):998-1002. PMID: 11162625 [PubMed - indexed for MEDLINE] 95: Duan WM, Westerman M, Flores T, Low WC. Related Articles, Links Survival of intrastriatal xenografts of ventral mesencephalic dopamine neurons from MHC-deficient mice to adult rats. Exp Neurol. 2001 Jan; 167(1): 108-17. PMID: 11161598 [PubMed - indexed for MEDLINE] 96: Midha R, Nag S, Munro CA, Ang LC. Related Articles, Links Differential response of sensory and motor axons in nerve allografts after withdrawal of immunosuppressive therapy. J Neurosurg. 2001 Jan;94(1):102-10. PMID: 11147877 [PubMed - indexed for MEDLINE] 97: Cousin MA, Tan TC, Robinson PJ. Related Articles, Links Protein phosphorylation is required for endocytosis in nerve terminals: potential role for the dephosphins dynamin I and synaptojanin, but not AP180 or amphiphysin. J Neurochem. 2001 Jan;76(1):105-16. PMID: 11145983 [PubMed - indexed for MEDLINE] Related Articles, Links 98: Paschen W. Role of calcium in neuronal cell injury: which subcellular compartment is involved? Brain Res Bull. 2000 Nov 1;53(4):409-13. Review. PMID: 11136996 [PubMed - indexed for MEDLINE] 99: Jiang Q. Gu Z, Zhang G, Jing G. Related Articles, Links N-methyl-D-aspartate receptor activation results in regulation of

extracellular signal-regulated kinases by protein kinases and phosphatases

h cb hg e e e fcg e ch b e



b e

h cb hg e e e fcg e ch

PMID: 10967684 [PubMed - indexed for MEDLINE]

109: Kowaltowski AJ, Smaili SS, Russell JT, Fiskum G.

Related Articles, Links



Elevation of resting mitochondrial membrane potential of neural cells by cyclosporin A, BAPTA-AM, and bcl-2.

Am J Physiol Cell Physiol. 2000 Sep;279(3):C852-9. PMID: 10942734 [PubMed - indexed for MEDLINE]

1. 110: Zhang W. Li JL, Hosaka M, Janz R, Shelton JM, Albright GM, Related Articles, Links Richardson JA, Sudhof TC, Victor RG.



Cyclosporine A-induced hypertension involves synapsin in renal sensory nerve endings.

Proc Natl Acad Sci U S A. 2000 Aug 15;97(17):9765-70. PMID: 10920204 [PubMed - indexed for MEDLINE]

111: Naciff JM, King KL, Dedman JR.

Related Articles, Links

Targeted neutralization of calcineurin, by expression of an inhibitor peptide under the control of a cholinergic specific promoter in PC12 cells, promotes neurite outgrowth in the presence of NGF.

Metab Brain Dis. 2000 Mar; 15(1):65-81.

PMID: 10885541 [PubMed - indexed for MEDLINE]

112: Terashima A, Taniguchi T, Nakai M, Yasuda M, Kawamata T. Related Articles, Links Tanaka C.

Rapamycin and FK506 induce long-term potentiation by pairing \equiv stimulation via an intracellular Ca(2+) signaling mechanism in rat hippocampal CA1 neurons.

Neuropharmacology. 2000 Jul 24;39(10):1920-8. PMID: 10884573 [PubMed - indexed for MEDLINE]

113: Castilho RF, Hansson O, Brundin P.

Related Articles, Links

FK506 and cyclosporin A enhance the survival of cultured and grafted rat embryonic dopamine neurons.

Exp Neurol. 2000 Jul;164(1):94-101.

PMID: 10877919 [PubMed - indexed for MEDLINE]

114: Costantini LC, Isacson O.

Related Articles, Links

Immunophilin ligands and GDNF enhance neurite branching or = elongation from developing dopamine neurons in culture. Exp Neurol. 2000 Jul;164(1):60-70.

PMID: 10877916 [PubMed - indexed for MEDLINE]

115: Sturgess NC, Rustad A, Fonnum F, Lock EA.

Related Articles, Links

Neurotoxic effect of L-2-chloropropionic acid on primary cultures of rat cerebellar granule cells.

Arch Toxicol. 2000 May;74(3):153-60.

PMID: 10877001 [PubMed - indexed for MEDLINE]

116: Taskinen HS, Roytta M.

Related Articles, Links

Cyclosporin A affects axons and macrophages during Wallerian degeneration.

J Neurotrauma. 2000 May; 17(5):431-40.


PMID: 10833062 [PubMed - indexed for MEDLINE]

117: Steiner MR, Holtsberg FW, Keller JN, Mattson MP, Steiner SM. Related Articles, Links


Lysophosphatidic acid induction of neuronal apoptosis and necrosis. Ann N Y Acad Sci. 2000 Apr;905:132-41.

PMID: 10818449 [PubMed - indexed for MEDLINE]

e ch e e e fcg b e h g h cb



h cb hgeeefcg ech be



h cb hgeeefcg ech be

Related Articles, Links

h

cb

Page 16 of 33 Sakanaka M, Sakaki S Release of cytochrome c from mitochondria to cytosol in gerbil hippocampal CA1 neurons after transient forebrain ischemia. Brain Res. 1999 Dec 4;849(1-2):216-9. PMID: 10592304 [PubMed - indexed for MEDLINE] Related Articles, Links 137: Liu Q. Berg DK. Actin filaments and the opposing actions of CaM kinase II and calcineurin in regulating alpha7-containing nicotinic receptors on chick ciliary ganglion neurons. J Neurosci. 1999 Dec 1;19(23):10280-8. PMID: 10575025 [PubMed - indexed for MEDLINE] 138: Asai A, Qiu J, Narita Y, Chi S, Saito N, Shinoura N, Hamada H. Related Articles, Links Kuchino Y, Kirino T. High level calcineurin activity predisposes neuronal cells to apoptosis. J Biol Chem. 1999 Nov 26;274(48):34450-8. PMID: 10567426 [PubMed - indexed for MEDLINE] 139: Mao X, Moerman AM, Lucas MM, Barger SW. Related Articles, Links Inhibition of the activity of a neuronal kappaB-binding factor by J Neurochem. 1999 Nov;73(5):1851-8. PMID: 10537043 [PubMed - indexed for MEDLINE] 140: Mao Z, Wiedmann M. Related Articles, Links Calcineurin enhances MEF2 DNA binding activity in calcium-dependent survival of cerebellar granule neurons. J Biol Chem. 1999 Oct 22;274(43):31102-7. PMID: 10521511 [PubMed - indexed for MEDLINE] Related Articles, Links 141: Muller M. Somjen GG. Intrinsic optical signals in rat hippocampal slices during hypoxia-induced spreading depression-like depolarization. J Neurophysiol. 1999 Oct;82(4):1818-31. PMID: 10515971 [PubMed - indexed for MEDLINE] Related Articles, Links 142: Vescovi AL, Gritti A, Galli R, Parati EA. Isolation and intracerebral grafting of nontransformed multipotential embryonic human CNS stem cells. J Neurotrauma. 1999 Aug; 16(8):689-93. PMID: 10511241 [PubMed - indexed for MEDLINE] 143: Khaspekov L, Friberg H, Halestrap A, Viktorov I, Wieloch T. Related Articles, Links Cyclosporin A and its nonimmunosuppressive analogue N-Me-Val-4cyclosporin A mitigate glucose/oxygen deprivation-induced damage to rat cultured hippocampal neurons. Eur J Neurosci. 1999 Sep;11(9):3194-8. PMID: 10510183 [PubMed - indexed for MEDLINE] 1144: Shuto H, Kataoka Y, Fujisaki K, Nakao T, Sueyasu M, Miura I, Related Articles, Links Watanabe Y, Fujiwara M, Oishi R. Inhibition of GABA system involved in cyclosporine-induced


e fcg e ch b e h g е е

PMID: 10465348 [PubMed - indexed for MEDLINE]

Life Sci. 1999;65(9):879-87.

convulsions.

145: Alexanian AR, Bamburg JR.



 $h \hspace{1cm} cb \hspace{1cm} h \hspace{1cm} g \hspace{1cm} e \hspace{1cm} e \hspace{1cm} fcg \hspace{1cm} e \hspace{1cm} ch \hspace{1cm} b \hspace{1cm} e$


h

ch

h g

e e

e fcg



e ch



The optically determined size of exo/endo cycling vesicle pool correlates with the quantal content at the neuromuscular junction of Drosophila larvae

J Neurosci. 1999 Mar 1;19(5):1557-65.

PMID: 10024343 [PubMed - indexed for MEDLINE]

165: Kruman II, Mattson MP.

Related Articles, Links

Pivotal role of mitochondrial calcium uptake in neural cell apoptosis and necrosis.

J Neurochem. 1999 Feb;72(2):529-40.

PMID: 9930724 [PubMed - indexed for MEDLINE]

166: Harrison S, Reddy S, Page CP, Spina D.

Related Articles, Links

Stimulation of airway sensory nerves by cyclosporin A and FK506 in guinea-pig isolated bronchus.

Br J Pharmacol. 1998 Dec;125(7):1405-12.

PMID: 9884067 [PubMed - indexed for MEDLINE]

167: Kruman II, Nath A, Mattson MP.

Related Articles, Links

HIV-1 protein Tat induces apoptosis of hippocampal neurons by a mechanism involving caspase activation, calcium overload, and oxidative stress.

Exp Neurol. 1998 Dec; 154(2): 276-88.

PMID: 9878167 [PubMed - indexed for MEDLINE]

168: Scanlon JM, Reynolds IJ.

Related Articles, Links



Effects of oxidants and glutamate receptor activation on mitochondrial membrane potential in rat forebrain neurons.

J Neurochem. 1998 Dec;71(6):2392-400.

PMID: 9832137 [PubMed - indexed for MEDLINE]

169: Zaprianova E, Deleva D, Filchev A.

Related Articles, Links



Ganglioside changes in brain in chronic relapsing experimental allergic encephalomyelitis induced in the Lewis rat.

Neurochem Res. 1998 Nov;23(11):1421-5.

PMID: 9814553 [PubMed - indexed for MEDLINE]

170: Yu GD, Yin QZ, Hu YM, Yin ZW, Gu ZL, Qian ZN, Qian ZM. Related Articles, Links



Effects of Coriolus versicolor polysaccharides peptides on electric activity of mediobasal hypothalamus and on immune function in rats.

Zhongguo Yao Li Xue Bao. 1996 May;17(3):271-4. PMID: 9812756 [PubMed - indexed for MEDLINE]

171: Fall CP, Bennett JP Jr.

Related Articles, Links



MPP+ induced SH-SY5Y apoptosis is potentiated by cyclosporin A and inhibited by aristolochic acid.

Brain Res. 1998 Nov 16;811(1-2):143-6.

PMID: 9804931 [PubMed - indexed for MEDLINE]

172: Toyoda M. Morohashi M.

Related Articles, Links



Morphological assessment of the effects of cyclosporin A on mast cell-nerve relationship in atopic dermatitis.

Acta Derm Venereol. 1998 Sep;78(5):321-5.

PMID: 9779245 [PubMed - indexed for MEDLINE]

173: Power C, Buist R, Johnston JB, Del Bigio MR, Ni W, Dawood MR, Peeling J.

Related Articles, Links

h

cb

hg e e e fcg

e ch



Neurovirulence in feline immunodeficiency virus-infected neonatal cats is viral strain specific and dependent on systemic immune suppression.

J Virol. 1998 Nov;72(11):9109-15.

PMID: 9765456 [PubMed - indexed for MEDLINE]

174: Dubinsky JM, Levi Y.

Related Articles, Links



Calcium-induced activation of the mitochondrial permeability transition in hippocampal neurons.

J Neurosci Res. 1998 Sep 15;53(6):728-41.

PMID: 9753200 [PubMed - indexed for MEDLINE]

175: Watanabe Y. Miura I, Ohgami Y, Fujiwara M.

Related Articles, Links



Extracellular presence of IL-8 in the astrocyte-rich cultured cerebellar granule cells under acidosis.

Life Sci. 1998;63(12):1037-46.

PMID: 9749826 [PubMed - indexed for MEDLINE]

176: Tatton WG, Chalmers-Redman RM.

Related Articles, Links



Mitochondria in neurodegenerative apoptosis: an opportunity for therapy? Ann Neurol. 1998 Sep;44(3 Suppl 1):S134-41. Review. PMID: 9749585 [PubMed - indexed for MEDLINE]

177: Akopian A, Gabriel R, Witkovsky P.

Related Articles, Links



Calcium released from intracellular stores inhibits GABAA-mediated currents in ganglion cells of the turtle retina.

J Neurophysiol. 1998 Sep;80(3):1105-15.

PMID: 9744925 [PubMed - indexed for MEDLINE]

178: Schuchmann S, Muller W, Heinemann U.

Related Articles, Links



Altered Ca2+ signaling and mitochondrial deficiencies in hippocampal neurons of trisomy 16 mice: a model of Down's syndrome.

J Neurosci. 1998 Sep 15;18(18):7216-31.

PMID: 9736644 [PubMed - indexed for MEDLINE]

179: Chin ER, Olson EN, Richardson JA, Yang Q, Humphries C, Shelton JM, Wu H, Zhu W, Bassel-Duby R, Williams RS.

Related Articles, Links



A calcineurin-dependent transcriptional pathway controls skeletal muscle fiber type.

Genes Dev. 1998 Aug 15;12(16):2499-509.

PMID: 9716403 [PubMed - indexed for MEDLINE]

180: Yardin C, Terro F, Lesort M, Esclaire F, Hugon J.

Related Articles, Links



FK 506 antagonizes apoptosis and c-jun protein expression in neuronal cultures.

Neuroreport. 1998 Jun 22;9(9):2077-80.

PMID: 9674596 [PubMed - indexed for MEDLINE]

181: Tauboll E, Gerdts R, Gjerstad L.

Related Articles, Links



Cyclosporin A and brain excitability studied in vitro.

Epilepsia. 1998 Jul;39(7):687-91.

PMID: 9670895 [PubMed - indexed for MEDLINE]

182: Tamura K.

Related Articles, Links




[Multiple actions of tacrolimus and cyclosporin A as specific inhibitors of calcineurin]

Tanpakushitsu Kakusan Koso. 1998 Jun;43(8 Suppl):1118-30. Review. Japanese. No abstract available.

PMID: 9655970 [PubMed - indexed for MEDLINE]

n cb hgeeefcg

e ch



b e

h cb hgeeefcg ech

cb

h

h g


е

fcg

Related Articles, Links 192: Kristian T. Siesjo BK. Calcium in ischemic cell death. Stroke. 1998 Mar; 29(3):705-18. Review. PMID: 9506616 [PubMed - indexed for MEDLINE] 193: Rana SS, Giuliani MJ, Oddis CV, Lacomis D. Related Articles, Links Acute onset of colchicine myoneuropathy in cardiac transplant recipients: case studies of three patients. Clin Neurol Neurosurg. 1997 Dec;99(4):266-70. PMID: 9491303 [PubMed - indexed for MEDLINE] 194: Shuto H, Kataoka Y, Kanaya A, Matsunaga K, Sucyasu M, Oishi Related Articles, Links Enhancement of serotonergic neural activity contributes to cyclosporineinduced tremors in mice. Eur J Pharmacol. 1998 Jan 2;341(1):33-7. PMID: 9489853 [PubMed - indexed for MEDLINE] Related Articles, Links 195: Gold BG. FK506 and the role of immunophilins in nerve regeneration. Mol Neurobiol. 1997 Dec;15(3):285-306. Review. PMID: 9457703 [PubMed - indexed for MEDLINE] Related Articles, Links 196: Little CW, Cox C, Wyatt J, del Cerro C, del Cerro M. Correlates of photoreceptor rescue by transplantation of human fetal RPE in the RCS rat. Exp Neurol. 1998 Jan;149(1):151-60. PMID: 9454624 [PubMed - indexed for MEDLINE] 197: Wood AM, Bristow DR. Related Articles, Links N-methyl-D-aspartate receptor desensitisation is neuroprotective by inhibiting glutamate-induced apoptotic-like death. J Neurochem. 1998 Feb;70(2):677-87. PMID: 9453562 [PubMed - indexed for MEDLINE] 198: Keller JN, Kindy MS, Holtsberg FW, St Clair DK, Yen HC, Related Articles, Links Germever A, Steiner SM, Bruce-Keller AJ, Hutchins JB, Mattson Mitochondrial manganese superoxide dismutase prevents neural apoptosis and reduces ischemic brain injury: suppression of peroxynitrite production, lipid peroxidation, and mitochondrial dysfunction. J Neurosci. 1998 Jan 15;18(2):687-97. PMID: 9425011 [PubMed - indexed for MEDLINE] 199: Jacoby DB, Lindberg C, Ratliff J, Wunderlich M, Bousquet J. Related Articles, Links Wetzel K, Beaulieu L, Dinsmore J. Fetal pig neural cells as a restorative therapy for neurodegenerative Artif Organs. 1997 Nov;21(11):1192-8. PMID: 9384325 [PubMed - indexed for MEDLINE] 200: Gunzel D, Durry S, Schlue WR. Related Articles, Links Intracellular alkalinization causes Mg2+ release from intracellular binding sites in leech Retzius neurones. Pflugers Arch. 1997 Dec;435(1):65-73. PMID: 9359904 [PubMed - indexed for MEDLINE] Related Articles, Links 201: Bauerfeind R. Takei K, De Camilli P.

e ch

Related Articles, Links



b e e ch cb h g e h fcg

Exp Neurol. 1997 Aug; 146(2):526-35.

210: Wang MS, Zeleny-Pooley M, Gold BG.

PMID: 9270064 [PubMed - indexed for MEDLINE]



Comparative dose-dependence study of FK506 and cyclosporin A on the rate of axonal regeneration in the rat sciatic nerve.

J Pharmacol Exp Ther. 1997 Aug;282(2):1084-93. PMID: 9262378 [PubMed - indexed for MEDLINE]

211: Sunio A, Bittner GD.

Related Articles, Links

 \equiv

Cyclosporin A retards the wallerian degeneration of peripheral mammalian axons.

Exp Neurol. 1997 Jul;146(1):46-56.

PMID: 9225737 [PubMed - indexed for MEDLINE]

212: Castillo BV Jr. del Cerro M. White RM, Cox C, Wyatt J, Nadiga Related Articles, Links G, del Cerro C

=

Efficacy of nonfetal human RPE for photoreceptor rescue: a study in dystrophic RCS rats.

Exp Neurol. 1997 Jul; 146(1):1-9.

PMID: 9225732 [PubMed - indexed for MEDLINE]

1213: McDonald JW, Behrens MI, Chung C, Bhattacharyya T, Choi Related Articles, Links DW.

Susceptibility to apoptosis is enhanced in immature cortical neurons.

Brain Res. 1997 Jun 13;759(2):228-32.

PMID: 9221941 [PubMed - indexed for MEDLINE]

214: Pintor J, Gualix J, Miras-Portugal MT.

Related Articles, Links

Dinucleotide receptor modulation by protein kinases (protein kinases A and C) and protein phosphatases in rat brain synaptic terminals.

J Neurochem. 1997 Jun;68(6):2552-7.

PMID: 9166752 [PubMed - indexed for MEDLINE]

215: Windebank AJ.

Related Articles, Links

The vehicle for cyclosporine is neurotoxic in vitro. Ann Neurol. 1997 Apr;41(4):563-4. No abstract available. PMID: 9124820 [PubMed - indexed for MEDLINE]

216: Midha R, Munro CA, Mackinnon SE, Ang LC.

Related Articles, Links

Motor and sensory specificity of host nerve axons influence nerve allograft rejection.

J Neuropathol Exp Neurol. 1997 Apr;56(4):421-34. PMID: 9100673 [PubMed - indexed for MEDLINE]

217: Steiner JP, Connolly MA, Valentine HL, Hamilton GS, Dawson Related Articles, Links TM, Hester L. Snyder SH.


=

Neurotrophic actions of nonimmunosuppressive analogues of immunosuppressive drugs FK506, rapamycin and cyclosporin A.

Nat Med. 1997 Apr;3(4):421-8.

PMID: 9095176 [PubMed - indexed for MEDLINE]

218: Rundqvist B, Casale R, Bergmann-Sverrisdottir Y, Friberg P. Related Articles, Links Mortara A, Elam M.



Rapid fall in sympathetic nerve hyperactivity in patients with heart failure after cardiac transplantation.

J Card Fail. 1997 Mar, 3(1):21-6.

PMID: 9110252 [PubMed - indexed for MEDLINE]

219: Nieminen AL, Petrie TG, Lemasters JJ, Selman WR.

Related Articles, Links



Cyclosporin A delays mitochondrial depolarization induced by N-methyl-D-aspartate in cortical neurons: evidence of the mitochondrial permeability transition.

e e e fcg cb h g

h

e ch

Neuroscience. 1996 Dec;75(4):993-7.

PMID: 8938735 [PubMed - indexed for MEDLINE]

220: McDonald JW, Goldberg MP, Gwag BJ, Chi SI, Choi DW.

Related Articles, Links

Cyclosporine induces neuronal apoptosis and selective oligodendrocyte death in cortical cultures.

Ann Neurol. 1996 Nov;40(5):750-8.

PMID: 8957016 [PubMed - indexed for MEDLINE]

221: Sasahara Y, Kobayashi T, Onodera H, Onoda M, Ohnishi M, Kato S, Kusuda K, Shima H, Nagao M, Abe H, Yanagawa Y, Himan A, Thomas S.

Related Articles, Links

Hiraga A, Tamura S.



Okadaic acid suppresses neural differentiation-dependent expression of the neurofilament-L gene in P19 embryonal carcinoma cells by posttranscriptional modification.

J Biol Chem. 1996 Oct 18;271(42):25950-7.

PMID: 8824230 [PubMed - indexed for MEDLINE]

222: Ankarcrona M, Dypbukt JM, Orrenius S, Nicotera P.

Related Articles, Links



Calcineurin and mitochondrial function in glutamate-induced neuronal cell death.

FEBS Lett. 1996 Oct 7;394(3):321-4.

PMID: 8830666 [PubMed - indexed for MEDLINE]

223: Schinder AF, Olson EC, Spitzer NC, Montal M.

Related Articles, Links



Mitochondrial dysfunction is a primary event in glutamate neurotoxicity. J Neurosci. 1996 Oct 1;16(19):6125-33.

PMID: 8815895 [PubMed - indexed for MEDLINE]

224: White RJ, Reynolds IJ.

Related Articles, Links



Mitochondrial depolarization in glutamate-stimulated neurons: an early signal specific to excitotoxin exposure.

J Neurosci. 1996 Sep 15;16(18):5688-97.

PMID: 8795624 [PubMed - indexed for MEDLINE]

225: Matsuura K, Kabuto H, Makino H, Ogawa N.

Related Articles, Links



Cyclosporin A attenuates degeneration of dopaminergic neurons induced by 6-hydroxydopamine in the mouse brain.

Brain Res. 1996 Sep 9;733(1):101-4.

PMID: 8891252 [PubMed - indexed for MEDLINE]

226: Martina M, Mozrzymas JW, Boddeke HW, Cherubini E.

Related Articles, Links



The calcineurin inhibitor cyclosporin A-cyclophilin A complex reduces desensitization of GABAA-mediated responses in acutely dissociated rat hippocampal neurons.

Neurosci Lett. 1996 Sep 6;215(2):95-8.

PMID: 8888004 [PubMed - indexed for MEDLINE]

227: Goldner FM, Patrick JW.

Related Articles, Links



Neuronal localization of the cyclophilin A protein in the adult rat brain. J Comp Neurol. 1996 Aug 19;372(2):283-93.

PMID: 8863131 [PubMed - indexed for MEDLINE]

228: Mata M, Merritt SE, Fan G, Yu GG, Holzman LB.

Related Articles, Links



Characterization of dual leucine zipper-bearing kinase, a mixed lineage kinase present in synaptic terminals whose phosphorylation state is regulated by membrane depolarization via calcineurin.

J Biol Chem. 1996 Jul 12;271(28):16888-96.

h cb hg e e e fcg e ch b e

Page 26 of 33 PMID: 8663324 [PubMed - indexed for MEDLINE] 229: Strasberg SR, Hertl MC, Mackinnon SE, Lee CK, Watanabe O, Related Articles, Links Tarasidis G, Hunter DA, Wong PY. Peripheral nerve allograft preservation improves regeneration and decreases systemic cyclosporin A requirements. Exp Neurol. 1996 Jun; 139(2): 306-16. PMID: 8654533 [PubMed - indexed for MEDLINE] 230: Chen XL, Roisen FJ, Gupta M. Related Articles, Links The effect of prior in vitro exposure of donor cells to trophic factors in neurotransplantation. Exp Neurol. 1996 Mar; 138(1):64-72. PMID: 8593897 [PubMed - indexed for MEDLINE] 231: Palladini G, Caronti B, Pozzessere G, Teichner A, Buttarelli FR. Related Articles, Links Morselli E, Valle E, Venturini G, Fortuna A, Pontieri FE. Treatment with cyclosporine A promotes axonal regeneration in rats = submitted to transverse section of the spinal cord--II--Recovery of function. J Hirnforsch. 1996;37(1):145-53. PMID: 8964973 [PubMed - indexed for MEDLINE] 232: Yagita Y, Kitagawa K, Matsushita K, Taguchi A, Mabuchi T. Related Articles, Links Ohtsuki T, Yanagihara T, Matsumoto M. Effect of immunosuppressant FK506 on ischemia-induced degeneration of hippocampal neurons in gerbils. Life Sci. 1996;59(19):1643-50. PMID: 8913329 [PubMed - indexed for MEDLINE] 233: Little CW, Castillo B, DiLoreto DA, Cox C, Wyatt J, del Cerro Related Articles, Links C, del Cerro M. Transplantation of human fetal retinal pigment epithelium rescues photoreceptor cells from degeneration in the Royal College of Surgeons Invest Ophthalmol Vis Sci. 1996 Jan;37(1):204-11. PMID: 8550325 [PubMed - indexed for MEDLINE] Related Articles, Links 234: Marcaida G, Kosenko E, Minana MD, Grisolia S, Felipo V. Glutamate induces a calcineurin-mediated dephosphorylation of Na+,K (+)-ATPase that results in its activation in cerebellar neurons in culture. J Neurochem. 1996 Jan;66(1):99-104. PMID: 8522995 [PubMed - indexed for MEDLINE] 235; Saito T, Ishiguro K, Uchida T, Miyamoto E, Kishimoto T, Related Articles, Links Hisanaga S. In situ dephosphorylation of tau by protein phosphatase 2A and 2B in fetal rat primary cultured neurons. FEBS Lett. 1995 Dec 4;376(3):238-42. PMID: 7498550 [PubMed - indexed for MEDLINE]

237: Anderson GW, Even C, Rowland RR, Palmer GA, Harty JT, Plagemann PG. C58 and AKR mice of all ages develop motor neuron disease after lactate dehydrogenase-elevating virus infection but only if antiviral immune

Retina-specifically expressed novel subtypes of bovine cyclophilin.

h

236: Ferreira PA, Hom JT, Pak WL.

J Biol Chem. 1995 Sep 29;270(39):23179-88. PMID: 7559465 [PubMed - indexed for MEDLINE] Related Articles, Links

Related Articles, Links

responses are blocked by chemical or genetic means or as a result of old J Neurovirol. 1995 Sep;1(3-4):244-52. PMID: 9222362 [PubMed - indexed for MEDLINE] 238: Garcia AR, Deacon TW, Dinsmore J, Isacson O. Related Articles, Links Extensive axonal and glial fiber growth from fetal porcine cortical xenografts in the adult rat cortex. Cell Transplant. 1995 Sep-Oct;4(5):515-27. PMID: 8520835 [PubMed - indexed for MEDLINE] 239: Chang HY, Takei K. Sydor AM, Born T, Rusnak F, Jay DG. Related Articles, Links Asymmetric retraction of growth cone filopodia following focal inactivation of calcineurin. Nature. 1995 Aug 24;376(6542):686-90. PMID: 7544441 [PubMed - indexed for MEDLINE] 240: Stark E, Wurster U, Patzold U, Sailer M, Haas J. Related Articles, Links Immunological and clinical response to immunosuppressive treatment in paraneoplastic cerebellar degeneration. Arch Neurol. 1995 Aug;52(8):814-8. PMID: 7639633 [PubMed - indexed for MEDLINE] 241: Victor RG. Thomas GD, Marban E, O'Rourke B. Related Articles, Links Presynaptic modulation of cortical synaptic activity by calcineurin. Proc Natl Acad Sci U S A. 1995 Jul 3;92(14):6269-73. PMID: 7541535 [PubMed - indexed for MEDLINE] Related Articles, Links 242: Zalewski AA, Azzam NA, Azzam RN. The loss of regenerated host axons in nerve allografts after stopping immunosuppression with cyclosporin A is related to immune effects on allogeneic Schwann cells. Exp Neurol. 1995 Jun;133(2):189-97. PMID: 7649224 [PubMed - indexed for MEDLINE] 243: Golowasch J, Paupardin-Tritsch D, Gerschenfeld HM. Related Articles, Links Enhancement by muscarinic agonists of a high voltage-activated Ca2+ current via phosphorylation in a snail neuron. J Physiol. 1995 May 15;485 (Pt 1):21-8. PMID: 7658375 [PubMed - indexed for MEDLINE] 1244: Perrot-Applanat M. Cibert C. Geraud G. Renoir JM. Baulieu EE. Related Articles, Links The 59 kDa FK506-binding protein, a 90 kDa heat shock protein binding immunophilin (FKBP59-HBI), is associated with the nucleus, the cytoskeleton and mitotic apparatus. J Cell Sci. 1995 May;108 (Pt 5):2037-51. PMID: 7544801 [PubMed - indexed for MEDLINE] 245: Bonfoco E, Ceccatelli S, Manzo L, Nicotera P. Related Articles, Links Colchicine induces apoptosis in cerebellar granule cells. Exp Cell Res. 1995 May;218(1):189-200. PMID: 7537689 [PubMed - indexed for MEDLINE] 246: Pakzaban P, Deacon TW, Burns LH, Dinsmore J, Isacson O. Related Articles, Links A novel mode of immunoprotection of neural xenotransplants: masking of donor major histocompatibility complex class I enhances transplant

h cb hg e e e fcg e ch b e

survival in the central nervous system.

Neuroscience. 1995 Apr;65(4):983-96. Erratum in: Neuroscience 1995 Jun;66(3):761. PMID: 7617173 [PubMed - indexed for MEDLINE] 247: Lyons WE, Steiner JP, Snyder SH, Dawson TM. Related Articles, Links Neuronal regeneration enhances the expression of the immunophilin FKBP-12. J Neurosci. 1995 Apr;15(4):2985-94. PMID: 7536825 [PubMed - indexed for MEDLINE] Related Articles, Links 248: Mulvanev JM, Parsons RL. Arachidonic acid may mediate the galanin-induced hyperpolarization in parasympathetic neurons from Necturus maculosus. Neurosci Lett. 1995 Mar 3;187(2):95-8. PMID: 7540273 [PubMed - indexed for MEDLINE] 249: Muller D, Hefft S, Figurov A. Related Articles, Links Heterosynaptic interactions between LTP and LTD in CA1 hippocampal Neuron. 1995 Mar;14(3):599-605. PMID: 7695906 [PubMed - indexed for MEDLINE] 250: Stapleton SR, Bell BA, Wootton JF, Scott RH. Related Articles, Links Modulation of Ca(2+)-dependent currents in metabolically stressed cultured sensory neurones by intracellular photorelease of ATP. Br J Pharmacol. 1995 Jan;114(2):544-50. PMID: 7881754 [PubMed - indexed for MEDLINE] Related Articles, Links 251: Wera S, Nevts J. Calcineurin as a possible new target for treatment of Parkinson's disease. Med Hypotheses. 1994 Sep;43(3):132-4. PMID: 7815962 [PubMed - indexed for MEDLINE] 252: Midha R. Mackinnon SE, Becker LE. Related Articles, Links The fate of Schwann cells in peripheral nerve allografts. J Neuropathol Exp Neurol. 1994 May;53(3):316-22. PMID: 8176414 [PubMed - indexed for MEDLINE] 253: Hodgkinson SJ, Westland KW, Pollard JD. Related Articles, Links Transfer of experimental allergic neuritis by intra neural injection of sensitized lymphocytes. J Neurol Sci. 1994 May;123(1-2):162-72. PMID: 8064309 [PubMed - indexed for MEDLINE] 254: Archer DR, Leven S, Duncan ID: Related Articles, Links Myelination by cryopreserved xenografts and allografts in the myelin-deficient rat. Exp Neurol. 1994 Feb;125(2):268-77. PMID: 8313941 [PubMed - indexed for MEDLINE] Related Articles, Links 255: Ferreira A, Kincaid R, Kosik KS. Calcineurin is associated with the cytoskeleton of cultured neurons and has a role in the acquisition of polarity. Mol Biol Cell. 1993 Dec;4(12):1225-38. PMID: 8167406 [PubMed - indexed for MEDLINE] 256: Rosenbluth J, Liu Z, Guo D, Schiff R. Related Articles, Links Myelin formation by mouse glia in myelin-deficient rats treated with

 $h \hspace{1.5cm} cb \hspace{1.5cm} h \hspace{1.5cm} g \hspace{1.5cm} e \hspace{1.5cm} e \hspace{1.5cm} fcg$

e ch

h

cb

h g

e e

cyclosporine. J Neurocytol. 1993 Nov;22(11):967-77. PMID: 8301327 [PubMed - indexed for MEDLINE] 257: Dawson TM, Steiner JP, Dawson VL, Dinerman JL, Uhl GR Related Articles, Links Snyder SH. Immunosuppressant FK506 enhances phosphorylation of nitric oxide synthase and protects against glutamate neurotoxicity. Proc Natl Acad Sci U S A. 1993 Nov 1;90(21):9808-12. PMID: 7694293 [PubMed - indexed for MEDLINE] 258: Ishida O, Daves J, Tsai TM, Breidenbach WC, Firrell J. Related Articles, Links Regeneration following rejection of peripheral nerve allografts of rats on withdrawal of cyclosporine. Plast Reconstr Surg. 1993 Oct;92(5):916-26. PMID: 8415974 [PubMed - indexed for MEDLINE] 259: Evans RJ, Surprenant A. Related Articles, Links Effects of phospholipase A2 inhibitors on coupling of alpha 2adrenoceptors to inwardly rectifying potassium currents in guinea-pig submucosal neurones. Br J Pharmacol. 1993 Oct;110(2):591-6. PMID: 7902174 [PubMed - indexed for MEDLINE] 1260: Trojanowski JQ, Mantione JR, Lee JH, Seid DP, You T, Inge LJ, Related Articles, Links Neurons derived from a human teratocarcinoma cell line establish molecular and structural polarity following transplantation into the rodent Exp Neurol. 1993 Aug;122(2):283-94. PMID: 8405265 [PubMed - indexed for MEDLINE] 261: Zalewski AA, Fahy GM, Azzam NA, Azzam RN. Related Articles, Links The fate of cryopreserved nerve isografts and allografts in normal and immunosuppressed rats. J Comp Neurol. 1993 May 1;331(1):134-47. PMID: 8320346 [PubMed - indexed for MEDLINE] 262: Midha R, Evans PJ, Mackinnon SE, Wade JA. Related Articles, Links Temporary immunosuppression for peripheral nerve allografts. Transplant Proc. 1993 Feb;25(1 Pt 1):532-6. No abstract available. PMID: 8438403 [PubMed - indexed for MEDLINE] **1 263:** Teichner A. Morselli E. Buttarelli FR. Caronti B. Pontieri FE. Venturini G. Palladini G. Related Articles, Links Treatment with cyclosporine A promotes axonal regeneration in rats submitted to transverse section of the spinal cord. J Hirnforsch. 1993;34(3):343-9. PMID: 8270787 [PubMed - indexed for MEDLINE] 1264: Bain JR, Mackinnon SE, Hudson AR, Wade J, Evans P, Makino Related Articles, Links A, Hunter D. The peripheral nerve allograft in the primate immunosuppressed with Cyclosporin A: I. Histologic and electrophysiologic assessment. Plast Reconstr Surg. 1992 Dec;90(6):1036-46. PMID: 1448498 [PubMed - indexed for MEDLINE] 265: Ansselin AD, Pollard JD, Davey DF. Related Articles, Links Immunosuppression in nerve allografting: is it desirable?

e ch

fcg

e

	J Neurol Sci. 1992 Oct;112(1-2):160-9. PMID: 1469428 [PubMed - indexed for MEDLINE]	
 	Wictorin K, Brundin P, Sauer H, Lindvall O, Bjorklund A.	Related Articles, Links
	Long distance directed axonal growth from human dop mesencephalic neuroblasts implanted along the nigrost hydroxydopamine lesioned adult rats. J Comp Neurol. 1992 Sep 22;323(4):475-94. PMID: 1358925 [PubMed - indexed for MEDLINE]	
□ 267:	Ortega JD, Sagen J, Pappas GD.	Related Articles, Links
	Survival and integration of bovine chromaffin cells tracentral nervous system without exogenous trophic fact J Comp Neurol. 1992 Sep 1;323(1):13-24. PMID: 1430313 [PubMed - indexed for MEDLINE]	-
268 :	Hougen HP, Thygesen P, Christensen HB, Rygaard J, Svendsen O, Juul P.	Related Articles, Links
	Effect of immunosuppressive agents on the guanethidi sympathectomy in athymic and euthymic rats. Int J Immunopharmacol. 1992 Aug;14(6):1113-23. PMID: 1385339 [PubMed - indexed for MEDLINE]	ne-induced
□ 269	Brat DJ, Windebank AJ, Brimijoin S.	Related Articles, Links
	Emulsifier for intravenous cyclosporin inhibits neurite deficits in rapid axonal transport and leads to structura differentiating N1E.115 neuroblastoma. J Pharmacol Exp Ther. 1992 May;261(2):803-10. PMID: 1578386 [PubMed - indexed for MEDLINE]	
	-	
□ 270	: McCombe PA, van der Kreek SA, Pender MP.	Related Articles, Links
□ 270 <u>□</u>	McCombe PA, van der Kreek SA, Pender MP. Neuropathological findings in chronic relapsing experineuritis induced in the Lewis rat by inoculation with in myelin and treatment with low dose cyclosporin A. Neuropathol Appl Neurobiol. 1992 Apr;18(2):171-87. PMID: 1620277 [PubMed - indexed for MEDLINE]	imental allergic
	Neuropathological findings in chronic relapsing experimentis induced in the Lewis rat by inoculation with in myelin and treatment with low dose cyclosporin A. Neuropathol Appl Neurobiol. 1992 Apr., 18(2):171-87.	imental allergic
	Neuropathological findings in chronic relapsing experimentis induced in the Lewis rat by inoculation with in myelin and treatment with low dose cyclosporin A. Neuropathol Appl Neurobiol. 1992 Apr,18(2):171-87. PMID: 1620277 [PubMed - indexed for MEDLINE] Kopyov OV, Polzik ES, Jacques DB, Kimble HJ, Rand RW.	imental allergic ntradural root Related Articles, Links
☐ 271	Neuropathological findings in chronic relapsing experimentis induced in the Lewis rat by inoculation with in myelin and treatment with low dose cyclosporin A. Neuropathol Appl Neurobiol. 1992 Apr,18(2):171-87. PMID: 1620277 [PubMed - indexed for MEDLINE] : Kopyov OV, Polzik ES, Jacques DB, Kimble HJ, Rand RW, Craft J. Effect of coherent blue light on fetal pig xenotransplar Transplant Proc. 1992 Apr;24(2):549-50. No abstract available.	imental allergic ntradural root Related Articles, Links
☐ 271	Neuropathological findings in chronic relapsing experimentis induced in the Lewis rat by inoculation with in myelin and treatment with low dose cyclosporin A. Neuropathol Appl Neurobiol. 1992 Apr,18(2):171-87. PMID: 1620277 [PubMed - indexed for MEDLINE] Kopyov OV, Polzik ES, Jacques DB, Kimble HJ, Rand RW, Craft J. Effect of coherent blue light on fetal pig xenotransplar Transplant Proc. 1992 Apr;24(2):549-50. No abstract available. PMID: 1566425 [PubMed - indexed for MEDLINE]	imental allergic ntradural root Related Articles, Links nts. Related Articles, Links allografts in rats
☐ 271 ☐ 272 ☐	Neuropathological findings in chronic relapsing experineuritis induced in the Lewis rat by inoculation with in myelin and treatment with low dose cyclosporin A. Neuropathol Appl Neurobiol. 1992 Apr;18(2):171-87. PMID: 1620277 [PubMed - indexed for MEDLINE] Kopyov OV, Polzik ES, Jacques DB, Kimble HJ, Rand RW, Craft J. Effect of coherent blue light on fetal pig xenotransplar Transplant Proc. 1992 Apr;24(2):549-50. No abstract available. PMID: 1566425 [PubMed - indexed for MEDLINE] Mackinnon SE, Midha R, Bain J, Hunter D, Wade J. An assessment of regeneration across peripheral nerve receiving short courses of cyclosporin A immunosupp Neuroscience. 1992;46(3):585-93.	imental allergic ntradural root Related Articles, Links nts. Related Articles, Links allografts in rats
☐ 271 ☐ 272 ☐	Neuropathological findings in chronic relapsing experineuritis induced in the Lewis rat by inoculation with in myelin and treatment with low dose cyclosporin A. Neuropathol Appl Neurobiol. 1992 Apr;18(2):171-87. PMID: 1620277 [PubMed - indexed for MEDLINE] Kopyov OV, Polzik ES, Jacques DB, Kimble HJ, Rand RW, Craft J. Effect of coherent blue light on fetal pig xenotransplant Transplant Proc. 1992 Apr;24(2):549-50. No abstract available. PMID: 1566425 [PubMed - indexed for MEDLINE] Mackinnon SE, Midha R, Bain J, Hunter D, Wade J. An assessment of regeneration across peripheral nerve receiving short courses of cyclosporin A immunosupp Neuroscience. 1992;46(3):585-93. PMID: 1545911 [PubMed - indexed for MEDLINE]	imental allergic intradural root Related Articles, Links ints. Related Articles, Links in rats ression. Related Articles, Links
☐ 271 ☐ 272 ☐ 273	Neuropathological findings in chronic relapsing experineuritis induced in the Lewis rat by inoculation with in myelin and treatment with low dose cyclosporin A. Neuropathol Appl Neurobiol. 1992 Apr;18(2):171-87. PMID: 1620277 [PubMed - indexed for MEDLINE] **Kopyov OV, Polzik ES, Jacques DB, Kimble HJ, Rand RW, Craft J. Effect of coherent blue light on fetal pig xenotransplant Transplant Proc. 1992 Apr;24(2):549-50. No abstract available. PMID: 1566425 [PubMed - indexed for MEDLINE] **Mackinnon SE, Midha R, Bain J, Hunter D, Wade J. An assessment of regeneration across peripheral nerve receiving short courses of cyclosporin A immunosupp Neuroscience. 1992;46(3):585-93. PMID: 1545911 [PubMed - indexed for MEDLINE] **Gouras P, Lopez R, Brittis M, Kjeldbye H. The ultrastructure of transplanted rabbit retinal epithel Graefes Arch Clin Exp Ophthalmol. 1992;230(5):468-75.	imental allergic intradural root Related Articles, Links ints. Related Articles, Links in rats ression. Related Articles, Links

 $h \hspace{1.5cm} cb \hspace{1.5cm} h \hspace{1.5cm} g \hspace{1.5cm} e \hspace{1.5cm} e \hspace{1.5cm} fcg$

e ch

PMID: 1936181 [PubMed - indexed for MEDLINE] Related Articles, Links 275: Maeda N, Ishiguro N, Inoue G, Miura T, Sugimura K. Nerve regeneration in rat composite-tissue allografts. J Reconstr Microsurg. 1991 Oct;7(4):297-301; discussion 303. PMID: 1753370 [PubMed - indexed for MEDLINE] 276: Stromberg I, van Horne C, Bygdeman M, Weiner N, Gerhardt Related Articles, Links Function of intraventricular human mesencephalic xenografts in immunosuppressed rats: an electrophysiological and neurochemical Exp Neurol. 1991 May;112(2):140-52. PMID: 1674693 [PubMed - indexed for MEDLINE] Related Articles, Links 277: Crang AJ. Blakemore WF. Remyelination of demyelinated rat axons by transplanted mouse oligodendrocytes. Glia. 1991;4(3):305-13. PMID: 1832658 [PubMed - indexed for MEDLINE] 278: Easterling KJ, Trumble TE. Related Articles, Links The treatment of peripheral nerve injuries using irradiated allografts and temporary host immunosuppression (in a rat model). J Reconstr Microsurg. 1990 Oct;6(4):301-7; discussion 309-10. PMID: 2269950 [PubMed - indexed for MEDLINE] Related Articles, Links 279: Becker M, Schaller E, Walter GF, Berger A. [Adverse effects of cyclosporin A with special reference to the peripheral nervous system] Handchir Mikrochir Plast Chir. 1990 Jul;22(4):196-202. German. PMID: 2391038 [PubMed - indexed for MEDLINE] 280: McCombe PA, van der Kreek SA, Pender MP. Related Articles, Links The effects of prophylactic cyclosporin A on experimental allergic neuritis (EAN) in the Lewis rat. Induction of relapsing EAN using low dose cyclosporin A. J Neuroimmunol. 1990 Jul;28(2):131-40. PMID: 2362014 [PubMed - indexed for MEDLINE] 281: Nakayasu H, Ota K, Tanaka H, Irie H, Takahashi K. Related Articles, Links Suppression of actively induced and passively transferred experimental allergic neuritis by cyclosporin A. J Neuroimmunol. 1990 Mar;26(3):219-27. PMID: 1689744 [PubMed - indexed for MEDLINE] 282: Pender MP, Stanley GP, Yoong G, Nguyen KB. Related Articles, Links The neuropathology of chronic relapsing experimental allergic encephalomyelitis induced in the Lewis rat by inoculation with whole spinal cord and treatment with cyclosporin A. Acta Neuropathol (Berl). 1990;80(2):172-83. PMID: 2389682 [PubMed - indexed for MEDLINE] 283: Shieh BH, Stamnes MA, Seavello S, Harris GL, Zuker CS. Related Articles, Links The ninaA gene required for visual transduction in Drosophila encodes a homologue of cyclosporin A-binding protein. Nature. 1989 Mar 2:338(6210):67-70.

h cb hg e e e fcg

e ch

PMID: 2493138 [PubMed - indexed for MEDLINE]

		84 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 -
□ 284:	Isacson O, Riche D, Hantraye P, Sofroniew MV, Maziere M.	Related Articles, Links
	A primate model of Huntington's disease: cross-species implantation of striatal precursor cells to the excitotoxically lesioned baboon caudate-	
	putamen. Exp Brain Res. 1989;75(1):213-20. PMID: 2523313 [PubMed - indexed for MEDLINE]	
□ 285:	Howard MA 3rd, Dacey RG Jr, Winn HR.	Related Articles, Links
	Brain xenografts: the effect of cyclosporin A on graft s J Neurosurg. 1988 Jul;69(1):121-6. PMID: 3379465 [PubMed - indexed for MEDLINE]	urvival.
□ 286:	Brundin P, Strecker RE, Widner H, Clarke DJ, Nilsson OG, Astedt B, Lindvall O, Bjorklund A.	Related Articles, Links
	Human fetal dopamine neurons grafted in a rat model of disease: immunological aspects, spontaneous and drugbehaviour, and dopamine release. Exp Brain Res. 1988;70(1):192-208. PMID: 3402564 [PubMed - indexed for MEDLINE]	
□ 287:	Finsen B, Poulsen PH, Zimmer J.	Related Articles, Links
	Xenografting of fetal mouse hippocampal tissue to the effects of cyclosporin A treatment. Exp Brain Res. 1988;70(1):117-33. PMID: 3402559 [PubMed - indexed for MEDLINE]	brain of adult rats:
□ 288	Nakayasu H, Ota K, Tanaka H, Irie H, Takahashi K.	Related Articles, Links
	Suppression of experimental allergic neuritis by cyclos Ann N Y Acad Sci. 1988;540:546-8. No abstract available. PMID: 3264681 [PubMed - indexed for MEDLINE]	sporin A.
□ 289	Schaller E, Mailander P, Becker M, Walter GF, Berger A.	Related Articles, Links
	[Nerve regeneration in autologous and allogeneic transnerve of the rat with and without immunosuppression Handchir Mikrochir Plast Chir. 1988 Jan;20(1):7-10. German. PMID: 3258265 [PubMed - indexed for MEDLINE]	
□ 290	Schneweis KE, Brado M, Ebers B, Friedrich A, Olbrich M, Schuler W	Related Articles, Links
	Immunological mechanisms giving rise to latency of h in the spinal ganglia of the mouse. Med Microbiol Immunol (Berl). 1988;177(1):1-8. PMID: 2828899 [PubMed - indexed for MEDLINE]	erpes simplex virus
□ 291	: Inoue H, Kohsaka S, Yoshida K, Otani M, Toya S, Tsukada Y.	Related Articles, Links
	Immunohistochemical studies on mouse cerebral corte third ventricle of rats treated with cyclosporin A. Neurosci Lett. 1985 Jun 24;57(3):289-94. PMID: 4034098 [PubMed - indexed for MEDLINE]	x grafted into the
□ 292	Zalewski AA, Gulati AK.	Related Articles, Links
	Rejection of nerve allografts after cessation of immune cyclosporin A. Transplantation. 1981 Jan;31(1):88-9. No abstract available. PMID: 7233527 [PubMed - indexed for MEDLINE]	osuppression with
□ 293	Zalewski AA, Gulati AK.	Related Articles, Links
	Survival of nerve and Schwann cells in allografts after	cyclosporin A

h

cb

treatment.
Exp Neurol. 1980 Nov;70(2):219-25. No abstract available.
PMID: 6968689 [PubMed - indexed for MEDLINE]

Display Summary

Show: 500 Sort Send to Text

Items 1-293 of 293


One page.

Write to the Help Desk
NCBi | NLM | NIH
Department of Health & Human Services
Freedom of Information Act | Disclaimer

Mar 11 2004 06:56:25







of Medicine PMC Structure OMIM Journals Sec. Protein PubMed Nucleotide Genome Search PubMed for rapamycin AND neuron Go Clear Details Preview/Index History Clipboard Limits About Entrez Display Show: |500 Sort Send to Summary Items 1-49 of 49 One page. Text Version 1: Si K, Giustetto M, Etkin A, Hsu R, Janisiewicz AM, Miniaci MC, Related Articles, Links Kim JH, Zhu H, Kandel ER. Entrez PubMed Overview A neuronal isoform of CPEB regulates local protein synthesis and stabilizes Help | FAQ synapse-specific long-term facilitation in aplysia. Tutoria! Cell. 2003 Dec 26;115(7):893-904. New/Noteworthy PMID: 14697206 [PubMed - indexed for MEDLINE] E-Utilities 2: Cammalleri M, Lutjens R, Berton F, King AR, Simpson C, Related Articles, Links PubMed Services Francesconi W, Sanna PP. Journals Database Time-restricted role for dendritic activation of the mTOR-p70S6K pathway MeSH Database Single Citation Matcher in the induction of late-phase long-term potentiation in the CA1. **Batch Citation Matcher** Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14368-73. Epub 2003 Nov 17. Clinical Queries PMID: 14623952 [PubMed - indexed for MEDLINE] LinkOut Cubby 3. Sun F, Li P, Ding Y, Wang L, Bartlam M, Shu C, Shen B, Jiang H. Related Articles, Links Li S, Rao Z. Related Resources Design and structure-based study of new potential FKBP12 inhibitors. Order Documents Biophys J. 2003 Nov;85(5):3194-201. **NLM Gateway** PMID: 14581219 [PubMed - in process] TOXNET Consumer Health 4. Kwon CH, Zhu X, Zhang J, Baker SJ. Related Articles, Links Clinical Alerts ClinicalTrials.gov mTor is required for hypertrophy of Pten-deficient neuronal soma in vivo. PubMed Central Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):12923-8. Epub 2003 Oct 08. PMID: 14534328 [PubMed - indexed for MEDLINE] Privacy Policy 5: An WL, Cowburn RF, Li L, Braak H, Alafuzoff I, Iqbal K, Iqbal IG. Related Articles, Links Winblad B, Pei JJ Up-regulation of phosphorylated/activated p70 S6 kinase and its relationship to neurofibrillary pathology in Alzheimer's disease. Am J Pathol. 2003 Aug;163(2):591-607. Erratum in: Am J Pathol. 2003 Dec;163(6):2645. PMID: 12875979 [PubMed - indexed for MEDLINE] Related Articles, Links 6: Avramut M, Achim CL. Immunophilins in nervous system degeneration and regeneration. Curr Top Med Chem. 2003;3(12):1376-82. Review. PMID: 12871169 [PubMed - indexed for MEDLINE] 7: Ryu JK, Choi HB, Hatori K, Heisel RL, Pelech SL, McLamon JG, Related Articles, Links Kim SU. Adenosine triphosphate induces proliferation of human neural stem cells: Role of calcium and p70 ribosomal protein S6 kinase. J Neurosci Res. 2003 May 1;72(3):352-62. PMID: 12692902 [PubMed - indexed for MEDLINE] Related Articles, Links 8: Avramut M. Achim CL.

Immunophilins and their ligands: insights into survival and growth of human


h cb hg e e e fcg e ch b

Physiol Behav. 2002 Dec;77(4-5):463-8. Review

h

cb

h g



b e

e ch

e fcg

Related Articles, Links 18: Witte MC, Montcouquiol M, Corwin JT. Regeneration in avian hair cell epithelia: identification of intracellular signals required for S-phase entry. Eur J Neurosci. 2001 Sep; 14(5):829-38. PMID: 11576187 [PubMed - indexed for MEDLINE] 19: Takei N, Kawamura M, Hara K, Yonezawa K, Nawa H. Related Articles, Links Brain-derived neurotrophic factor enhances neuronal translation by activating multiple initiation processes: comparison with the effects of J Biol Chem. 2001 Nov 16;276(46):42818-25. Epub 2001 Sep 10. PMID: 11551908 [PubMed - indexed for MEDLINE] 20: Yang H, Wang X, Raizada MK. Related Articles, Links Characterization of signal transduction pathway in neurotropic action of angiotensin II in brain neurons. Endocrinology. 2001 Aug;142(8):3502-11. PMID: 11459796 [PubMed - indexed for MEDLINE] Related Articles, Links 21: Khan A, Pepio AM, Sossin WS. Serotonin activates S6 kinase in a rapamycin-sensitive manner in Aplysia synaptosomes. J Neurosci. 2001 Jan 15;21(2):382-91. PMID: 11160419 [PubMed - indexed for MEDLINE] 22: Zheng WH, Kar S, Quirion R. Related Articles, Links Insulin-like growth factor-1-induced phosphorylation of the forkhead family transcription factor FKHRL1 is mediated by Akt kinase in PC12 cells. J Biol Chem. 2000 Dec 15;275(50):39152-8. PMID: 10995739 [PubMed - indexed for MEDLINE] 23: Bach LA, Leeding KS, Leng SL. Related Articles, Links Cyclic AMP agonists increase levels of insulin-like growth factor (IGF) binding protein-6 in PC12 rat phaeochromocytoma cells. Growth Horm IGF Res. 1998 Jun;8(3):265-71. PMID: 10984315 [PubMed - indexed for MEDLINE] 24: Zhang W, Victor RG. Related Articles, Links Calcineurin inhibitors cause renal afferent activation in rats: a novel mechanism of cyclosporine-induced hypertension. Am J Hypertens. 2000 Sep;13(9):999-1004. PMID: 10981550 [PubMed - indexed for MEDLINE] 125: Terashima A, Taniguchi T, Nakai M, Yasuda M, Kawamata T, Related Articles, Links Tanaka C. Rapamycin and FK506 induce long-term potentiation by pairing stimulation via an intracellular Ca(2+) signaling mechanism in rat hippocampal CA1 neurons. Neuropharmacology. 2000 Jul 24;39(10):1920-8. PMID: 10884573 [PubMed - indexed for MEDLINE] 26: Parker EM, Monopoli A, Ongini E, Lozza G, Babij CM. Related Articles, Links Rapamycin, but not FK506 and GPI-1046, increases neurite outgrowth in PC12 cells by inhibiting cell cycle progression. Neuropharmacology. 2000 Jul 24;39(10):1913-9. PMID: 10884572 [PubMed - indexed for MEDLINE]

b e

e ch

h cb hg e e e fcg

Related Articles, Links 27: Costantini LC, Isacson O. Immunophilin ligands and GDNF enhance neurite branching or elongation from developing dopamine neurons in culture. Exp Neurol. 2000 Jul; 164(1):60-70. PMID: 10877916 [PubMed - indexed for MEDLINE] 28: Li ST, Kato K, Mikoshiba K. Related Articles, Links High Ca(2+)/low Mg(2+) solution induces long-term depression in rat CA1 pyramidal neurons. Neurosci Lett. 2000 Apr 7;283(2):141-4. PMID: 10739895 [PubMed - indexed for MEDLINE] 29: Casadio A, Martin KC, Giustetto M, Zhu H, Chen M, Bartsch D, Related Articles, Links Bailey CH, Kandel ER. A transient, neuron-wide form of CREB-mediated long-term facilitation can be stabilized at specific synapses by local protein synthesis. Cell. 1999 Oct 15;99(2):221-37. PMID: 10535740 [PubMed - indexed for MEDLINE] 30: Alexanian AR, Bamburg JR. Related Articles, Links Neuronal survival activity of s100betabeta is enhanced by calcineurin inhibitors and requires activation of NF-kappaB. FASEB J. 1999 Sep;13(12):1611-20. PMID: 10463953 [PubMed - indexed for MEDLINE] 31: Williams EJ, Doherty P. Related Articles, Links Evidence for and against a pivotal role of PI 3-kinase in a neuronal cell survival pathway. Mol Cell Neurosci. 1999 Apr;13(4):272-80. Erratum in: Mol Cell Neurosci 2000 Mar;15 PMID: 10328886 [PubMed - indexed for MEDLINE] 132: Allen MP, Zeng C, Schneider K, Xiong X, Meintzer MK, Bellosta Related Articles, Links P. Basilico C, Varnum B, Heidenreich KA, Wierman ME. Growth arrest-specific gene 6 (Gas6)/adhesion related kinase (Ark) signaling promotes gonadotropin-releasing hormone neuronal survival via extracellular signal-regulated kinase (ERK) and Akt. Mol Endocrinol. 1999 Feb;13(2):191-201. PMID: 9973250 [PubMed - indexed for MEDLINE] 33: Bartlett SE, Reynolds AJ, Hendry IA. Related Articles, Links Retrograde axonal transport of neurotrophins: differences between neuronal populations and implications for motor neuron disease. Immunol Cell Biol. 1998 Oct;76(5):419-23. Review. PMID: 9797461 [PubMed - indexed for MEDLINE] 34: Ding JM, Buchanan GF, Tischkau SA, Chen D, Kuriashkina L, Related Articles, Links Faiman LE, Alster JM, McPherson PS, Campbell KP, Gillette MU A neuronal ryanodine receptor mediates light-induced phase delays of the circadian clock. Nature. 1998 Jul 23;394(6691):381-4. PMID: 9690474 [PubMed - indexed for MEDLINE] 135: Burnett PE, Blackshaw S, Lai MM, Qureshi IA, Burnett AF, Related Articles, Links Sabatini DM, Snyder SH. Neurabin is a synaptic protein linking p70 S6 kinase and the neuronal cytoskeleton. Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):8351-6.

h cb hg e e e fcg e ch b e

PMID: 9653190 [PubMed - indexed for MEDLINE]

□ 36:	Terashima A, Nakai M, Hashimoto T, Kawamata T, Taniguchi T, Yasuda M, Maeda K, Tanaka C.	Related Articles, Links
	Single-channel activity of the Ca2+-dependent K+ chan FK506 and rapamycin. Brain Res. 1998 Mar 9;786(1-2):255-8. PMID: 9555045 [PubMed - indexed for MEDLINE]	nel is modulated by
□ 37:	Kikuchi M, Kashii S, Mandai M, Yasuyoshi H, Honda Y, Kaneda K, Akaike A.	Related Articles, Links
	Protective effects of FK 506 against glutamate-induced retinal cell culture. Invest Ophthalmol Vis Sci. 1998 Jun;39(7):1227-32. PMID: 9620083 [PubMed - indexed for MEDLINE]	neurotoxicity in
□ 38	: Carreau A, Gueugnon J, Benavides J, Vige X.	Related Articles, Links
	Comparative effects of FK-506, rapamycin and cyclosperitro differentiation of dorsal root ganglia explants and eneurons. Neuropharmacology. 1997 Nov-Dec;36(11-12):1755-62. PMID: 9517448 [PubMed - indexed for MEDLINE]	
□ 39	Yanow SK, Manseau F, Hislop J, Castellucci VF, Sossin WS.	Related Articles, Links
	Biochemical pathways by which serotonin regulates transverses of Aplysia. J Neurochem. 1998 Feb;70(2):572-83. PMID: 9453551 [PubMed - indexed for MEDLINE]	
T 40	: Wang JH, Kelly PT.	Related Articles, Links
	Attenuation of paired-pulse facilitation associated with potentiation mediated by postsynaptic mechanisms. J Neurophysiol. 1997 Nov;78(5):2707-16. PMID: 9356420 [PubMed - indexed for MEDLINE]	synaptic
I 41	: Mark MD, Storm DR.	Related Articles, Links
	Coupling of epidermal growth factor (EGF) with the an activity of cAMP induces neuronal differentiation. J Biol Chem. 1997 Jul 4;272(27):17238-44. PMID: 9202048 [PubMed - indexed for MEDLINE]	tiproliferative
☐ 42	Gunn-Moore FJ, Williams AG, Toms NJ, Tavare JM.	Related Articles, Links
	Activation of mitogen-activated protein kinase and p70% correlated with cerebellar granule cell survival. Biochem J. 1997 Jun 1;324 (Pt 2):365-9. PMID: 9182692 [PubMed - indexed for MEDLINE]	S6 kinase is not
1 43	Steiner JP, Connolly MA, Valentine HL, Hamilton GS, Dawson TM, Hester L, Snyder SH.	Related Articles, Links
	Neurotrophic actions of nonimmunosuppressive analog immunosuppressive drugs FK506, rapamycin and cyclo Nat Med. 1997 Apr;3(4):421-8. PMID: 9095176 [PubMed - indexed for MEDLINE]	
□ 44	Lois AF, Cooper LT, Geng Y, Nobori T, Carson D.	Related Articles, Links
	Expression of the p16 and p15 cyclin-dependent kinase lymphocyte activation and neuronal differentiation. Cancer Res. 1995 Sep 15;55(18):4010-3. PMID: 7664273 [PubMed - indexed for MEDLINE]	inhibitors in

 $h \hspace{1cm} cb \hspace{1cm} h \hspace{1cm} g \hspace{1cm} e \hspace{1cm} e \hspace{1cm} e \hspace{1cm} ch \hspace{1cm} b \hspace{1cm} e$

□ 45:	Chang HY, Takei K, Sydor AM, Bom T, Rusnak F, Jay DG.	Related Articles, Links
	Asymmetric retraction of growth cone filopodia followinactivation of calcineurin. Nature. 1995 Aug 24;376(6542):686-90. PMID: 7544441 [PubMed - indexed for MEDLINE]	ng focal
□ 46:	Victor RG, Thomas GD, Marban E, O'Rourke B.	Related Articles, Links
	Presynaptic modulation of cortical synaptic activity by of Proc Natl Acad Sci U S A. 1995 Jul 3;92(14):6269-73. PMID: 7541535 [PubMed - indexed for MEDLINE]	calcineurin.
□ 47:	Perrot-Applanat M, Cibert C, Geraud G, Renoir JM, Baulieu EE.	Related Articles, Links
	The 59 kDa FK506-binding protein, a 90 kDa heat shoc immunophilin (FKBP59-HBI), is associated with the nu cytoskeleton and mitotic apparatus. J Cell Sci. 1995 May;108 (Pt 5):2037-51. PMID: 7544801 [PubMed - indexed for MEDLINE]	
□ 48:	Lyons WE, George EB, Dawson TM, Steiner JP, Snyder SH.	Related Articles, Links
	Immunosuppressant FK506 promotes neurite outgrowth PC12 cells and sensory ganglia. Proc Natl Acad Sci U S A. 1994 Apr 12;91(8):3191-5. PMID: 7512727 [PubMed - indexed for MEDLINE]	in cultures of
□ 49:	Dawson TM, Steiner JP, Dawson VI., Dinerman JL, Uhl GR, Snyder SH.	Related Articles, Links
	Immunosuppressant FK506 enhances phosphorylation of synthase and protects against glutamate neurotoxicity. Proc Natl Acad Sci U S A. 1993 Nov 1;90(21):9808-12. PMID: 7694293 [PubMed - indexed for MEDLINE]	of nitric oxide
Displa	y Summary ▼ _{Show:} 500 ▼ Sort ▼ S	end to Text 💌
	Items 1-49 of 49	One page

Write to the Help Desk
NCBI | NLM | NIH
Department of Health & Human Services
Freedom of Information Act | Disclaimer

Mar 11 2004 06:56:25

Page 6 of 6

FILE 'HOME' ENTERED AT 16:26:22 ON 16 MAR 2004

=> file BIOSCIENCE FILE 'ADISCTI' ENTERED AT 16:26:34 ON 16 MAR 2004 COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'ADISINSIGHT' ENTERED AT 16:26:34 ON 16 MAR 2004 COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'ADISNEWS' ENTERED AT 16:26:34 ON 16 MAR 2004 COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'AGRICOLA' ENTERED AT 16:26:34 ON 16 MAR 2004

FILE 'ANABSTR' ENTERED AT 16:26:34 ON 16 MAR 2004 COPYRIGHT (c) 2004 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'AQUASCI' ENTERED AT 16:26:34 ON 16 MAR 2004 COPYRIGHT 2004 FAO (On behalf of the ASFA Advisory Board). All rights reserved.

FILE 'BIOBUSINESS' ENTERED AT 16:26:34 ON 16 MAR 2004 COPYRIGHT (C) 2004 Biological Abstracts, Inc. (BIOSIS)

FILE 'BIOCOMMERCE' ENTERED AT 16:26:34 ON 16 MAR 2004
COPYRIGHT (C) 2004 BioCommerce Data Ltd. Richmond Surrey, United Kingdom. All rights reserved

FILE 'BIOSIS' ENTERED AT 16:26:34 ON 16 MAR 2004 COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED

FILE 'BIOTECHDS' ENTERED AT 16:26:34 ON 16 MAR 2004 COPYRIGHT (C) 2004 THOMSON DERWENT AND INSTITUTE FOR SCIENTIFIC INFORMATION

FILE 'BIOTECHNO' ENTERED AT 16:26:34 ON 16 MAR 2004 COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CABA' ENTERED AT 16:26:34 ON 16 MAR 2004 COPYRIGHT (C) 2004 CAB INTERNATIONAL (CABI)

FILE 'CANCERLIT' ENTERED AT 16:26:34 ON 16 MAR 2004

FILE 'CAPLUS' ENTERED AT 16:26:34 ON 16 MAR 2004 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CEABA-VTB' ENTERED AT 16:26:34 ON 16 MAR 2004 COPYRIGHT (c) 2004 DECHEMA eV

FILE 'CEN' ENTERED AT 16:26:34 ON 16 MAR 2004 COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE 'CIN' ENTERED AT 16:26:34 ON 16 MAR 2004 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE 'CONFSCI' ENTERED AT 16:26:34 ON 16 MAR 2004 COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'CROPB' ENTERED AT 16:26:34 ON 16 MAR 2004 COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'CROPU' ENTERED AT 16:26:34 ON 16 MAR 2004 COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'DISSABS' ENTERED AT 16:26:34 ON 16 MAR 2004 COPYRIGHT (C) 2004 Proquest Information and Learning Company; All Rights Reserved.

FILE 'DDFB' ACCESS NOT AUTHORIZED

FILE 'DDFU' ACCESS NOT AUTHORIZED

FILE 'DGENE' ENTERED AT 16:26:34 ON 16 MAR 2004 COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'DRUGB' ENTERED AT 16:26:34 ON 16 MAR 2004 COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'DRUGMONOG2' ENTERED AT 16:26:34 ON 16 MAR 2004 COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'IMSDRUGNEWS' ENTERED AT 16:26:34 ON 16 MAR 2004 COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'DRUGU' ENTERED AT 16:26:34 ON 16 MAR 2004 COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'IMSRESEARCH' ENTERED AT 16:26:34 ON 16 MAR 2004 COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'EMBAL' ENTERED AT 16:26:34 ON 16 MAR 2004 COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'EMBASE' ENTERED AT 16:26:34 ON 16 MAR 2004 COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 16:26:34 ON 16 MAR 2004 COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'FEDRIP' ENTERED AT 16:26:34 ON 16 MAR 2004

FILE 'FOMAD' ENTERED AT 16:26:34 ON 16 MAR 2004 COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FOREGE' ENTERED AT 16:26:34 ON 16 MAR 2004 COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FROSTI' ENTERED AT 16:26:34 ON 16 MAR 2004 COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FSTA' ENTERED AT 16:26:34 ON 16 MAR 2004 COPYRIGHT (C) 2004 International Food Information Service

FILE 'GENBANK' ENTERED AT 16:26:34 ON 16 MAR 2004

FILE 'HEALSAFE' ENTERED AT 16:26:34 ON 16 MAR 2004 COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'IFIPAT' ENTERED AT 16:26:34 ON 16 MAR 2004 COPYRIGHT (C) 2004 IFI CLAIMS(R) Patent Services (IFI)

FILE 'IMSPRODUCT' ENTERED AT 16:26:34 ON 16 MAR 2004 COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'JICST-EPLUS' ENTERED AT 16:26:34 ON 16 MAR 2004 COPYRIGHT (C) 2004 Japan Science and Technology Agency (JST)

FILE 'KOSMET' ENTERED AT 16:26:34 ON 16 MAR 2004 COPYRIGHT (C) 2004 International Federation of the Societies of Cosmetics Chemists

FILE 'LIFESCI' ENTERED AT 16:26:34 ON 16 MAR 2004 COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'MEDICONF' ENTERED AT 16:26:34 ON 16 MAR 2004 COPYRIGHT (c) 2004 FAIRBASE Datenbank GmbH, Hannover, Germany

FILE 'MEDLINE' ENTERED AT 16:26:34 ON 16 MAR 2004

FILE 'NIOSHTIC' ENTERED AT 16:26:34 ON 16 MAR 2004 COPYRIGHT (C) 2004 U.S. Secretary of Commerce on Behalf of the U.S. Government

FILE 'NTIS' ENTERED AT 16:26:34 ON 16 MAR 2004 Compiled and distributed by the NTIS, U.S. Department of Commerce. It contains copyrighted material.

```
All rights reserved. (2004)
FILE 'NUTRACEUT' ENTERED AT 16:26:34 ON 16 MAR 2004
Copyright 2004 (c) MARKETLETTER Publications Ltd. All rights reserved.
FILE 'OCEAN' ENTERED AT 16:26:34 ON 16 MAR 2004
COPYRIGHT (c) 2004 Cambridge Scientific Abstracts (CSA)
FILE 'PASCAL' ENTERED AT 16:26:34 ON 16 MAR 2004
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2004 INIST-CNRS. All rights reserved.
FILE 'PCTGEN' ENTERED AT 16:26:34 ON 16 MAR 2004
COPYRIGHT (C) 2004 WIPO
FILE 'PHAR' ENTERED AT 16:26:34 ON 16 MAR 2004
COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)
FILE 'PHARMAML' ENTERED AT 16:26:34 ON 16 MAR 2004
Copyright 2004 (c) MARKETLETTER Publications Ltd. All rights reserved.
FILE 'PHIC' ENTERED AT 16:26:34 ON 16 MAR 2004
COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)
FILE 'PHIN' ENTERED AT 16:26:34 ON 16 MAR 2004
COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)
FILE 'PROMT' ENTERED AT 16:26:34 ON 16 MAR 2004
COPYRIGHT (C) 2004 Gale Group. All rights reserved.
FILE 'RDISCLOSURE' ENTERED AT 16:26:34 ON 16 MAR 2004
COPYRIGHT (C) 2004 Kenneth Mason Publications Ltd.
FILE 'SCISEARCH' ENTERED AT 16:26:34 ON 16 MAR 2004
COPYRIGHT 2004 THOMSON ISI
FILE 'SYNTHLINE' ENTERED AT 16:26:34 ON 16 MAR 2004
COPYRIGHT (C) 2004 Prous Science
FILE 'TOXCENTER' ENTERED AT 16:26:34 ON 16 MAR 2004
COPYRIGHT (C) 2004 ACS
FILE 'USPATFULL' ENTERED AT 16:26:34 ON 16 MAR 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)
FILE 'USPAT2' ENTERED AT 16:26:34 ON 16 MAR 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)
FILE 'VETB' ENTERED AT 16:26:34 ON 16 MAR 2004
COPYRIGHT (C) 2004 THOMSON DERWENT
FILE 'VETU' ENTERED AT 16:26:34 ON 16 MAR 2004
COPYRIGHT (C) 2004 THOMSON DERWENT
FILE 'WPIDS' ENTERED AT 16:26:34 ON 16 MAR 2004
COPYRIGHT (C) 2004 THOMSON DERWENT
FILE 'WPINDEX' ACCESS NOT AUTHORIZED
=> s FK506 OR cyclosporin A OR rapamycin
  11 FILES SEARCHED...
  22 FILES SEARCHED...
  30 FILES SEARCHED...
  49 FILES SEARCHED...
  60 FILES SEARCHED...
        181235 FK506 OR CYCLOSPORIN A OR RAPAMYCIN
11
=> S Parkinson OR Huntington OR amyotrophic lateral sclerosis OR Alzheimer OR ischemic cerebra
  14 FILES SEARCHED...
  22 FILES SEARCHED...
  30 FILES SEARCHED...
  47 FILES SEARCHED...
  61 FILES SEARCHED...
       1064361 PARKINSON OR HUNTINGTON OR AMYOTROPHIC LATERAL SCLEROSIS OR
L2
```

```
=> S L1 AND L2
 46 FILES SEARCHED...
L3
          3244 L1 AND L2
=> DUP REM L3
DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, BIOCOMMERCE, DGENE,
DRUGMONOG2, IMSRESEARCH, FEDRIP, FOREGE, GENBANK, IMSPRODUCT, KOSMET,
MEDICONF, NUTRACEUT, PCTGEN, PHAR, PHARMAML, RDISCLOSURE, SYNTHLINE'
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING IS APPROXIMATELY 31% COMPLETE FOR L3
PROCESSING IS APPROXIMATELY 70% COMPLETE FOR L3
PROCESSING COMPLETED FOR L3
           2446 DUP REM L3 (798 DUPLICATES REMOVED)
=> S L4 AND PY<=2001
 2001' NOT A VALID FIELD CODE
   5 FILES SEARCHED...
   6 FILES SEARCHED...
   9 FILES SEARCHED...
  12 FILES SEARCHED...
  17 FILES SEARCHED..
'2001' NOT A VALID FIELD CODE
  23 FILES SEARCHED...
  29 FILES SEARCHED...
'2001' NOT A VALID FIELD CODE
2001' NOT A VALID FIELD CODE
  36 FILES SEARCHED...
  42 FILES SEARCHED...
'2001' NOT A VALID FIELD CODE
  46 FILES SEARCHED...
  49 FILES SEARCHED...
'2001' NOT A VALID FIELD CODE
  55 FILES SEARCHED...
  59 FILES SEARCHED...
           905 L4 AND PY<=2001
=> S L5 AND neuron?
  34 FILES SEARCHED...
           415 L5 AND NEURON?
=> S L6 AND transplant?
  30 FILES SEARCHED...
           228 L6 AND TRANSPLANT?
=> D L7 1-228
     ANSWER 1 OF 228 ADISCTI COPYRIGHT (C) 2004 Adis Data Information BV on
L7
AN
     1994:35376 ADISCTI
     807058827
DN
                                                    xxxAxxx
     No adverse effects of
                              ***cyclosporin***
                                                               on cellular and
TI
     functional development of foetal rat dopaminergic mesencephalic
                        grafted into the 6- hydroxydopamine rat model of
       ***neurones***
       ***Parkinson***
                         s disease.
     Earl C D; Frodl E M; Pupeter S C; et al.
ΑU
     CD Earl, Univ Munich, Klinikum Grosshadern, Dept Neurol, Marchioninistr
CS
     15, D-81377 Munich, Germany.
     Restorative Neurology and Neuroscience (Jul 1, 1994), Vol. 7, pp. 1-4
S<sub>0</sub>
DT
     Citation
     Transplant Rejection
FS
     Citation
ΙΔ
     English
     ANSWER 2 OF 228 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
L7
ΑN
     2002:24694 BIOSIS
     PREV200200024694
DN
     Porcine neural xenografts in rats and mice: Donor tissue development and
TT
     characteristics of rejection.
     Larsson, Lena C. [Reprint author]; Frielingsdorf, Helena; Mirza, Bilal;
     Hansson, Sophia J.dtr; Anderson, Per; Czech, Kimberly A.; Strandberg,
     Maria; Widner, Hakan
     Sedtion for Neuronal Survival, Department of Physiological Sciences,
CS
```

Wallenberg Neuroscience Center, Lund University, BMCA10, SE-221 84, Lund,

Sweden

```
Lena.Larsson@mphy.lu.se
     Experimental Neurology, (November, 2001) Vol. 172, No. 1, pp. 100-114.
SO
     print.
     CODEN: EXNEAC. ISSN: 0014-4886.
DT
     Article
     English
LA
     Entered STN: 26 Dec 2001
ED
     Last Updated on STN: 25 Feb 2002
     ANSWER 3 OF 228 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN 2001:519992 BIOSIS
L7
AN
     PREV200100519992
DN
     Embryonic stem cell ***transplantation*** in a rat model of ***Parkinson*** 's disease: II. Attenuation of levodopa-induced
ΤI
     dyskinesias and amphetamine-induced rotational behavior.
     McNaught, K. S. P. [Reprint author]; Bjorklund, L. [Reprint author];
ΑU
     Sanchez-Pernaute, S. [Reprint author]; Kim, K. S. [Reprint author];
     Isacson, O. [Reprint author]
     Neuroregeneration Laboratories and Udall Parkinson's Disease Center of
CS
     Excellence, McLean Hospital/Harvard Medical School, Belmont, MA, USA Society for Neuroscience Abstracts, (2001) Vol. 27, No. 1, pp. 970. print. Meeting Info.: 31st Annual Meeting of the Society for Neuroscience. San
S0
     Diego, California, USA. November 10-15, 2001. ISSN: 0190-5295.
      Conference; (Meeting)
DT
      Conference; Abstract; (Meeting Abstract)
LA
     English
     Entered STN: 7 Nov 2001
ED
      Last Updated on STN: 23 Feb 2002
      ANSWER 4 OF 228 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN 2001:519987 BIOSIS
L7
AN
      PREV200100519987
DN
      Grafting a human ventral mesencephalic immortalized cell line into a
TI
        ***Parkinson***
                           rat model.
ΑU
      Paul, G. [Reprint author]; Ahn, Y. H. [Reprint author]; Raymon, H.;
      Brundin, P. [Reprint author]; Schierle, G. Kaminski [Reprint author]
      Section for Neuronal Survival, Wallenberg Neuroscience Center, Lund,
CS
      Sweden
      Society for Neuroscience Abstracts, (2001) Vol. 27, No. 1, pp. 969. print.
SO
      Meeting Info.: 31st Annual Meeting of the Society for Neuroscience. San
      Diego, California, USA. November 10-15, 2001. ISSN: 0190-5295.
      Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
DT
      English
LA
      Entered STN: 7 Nov 2001
ED
      Last Updated on STN: 23 Feb 2002
      ANSWER 5 OF 228 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
L7
      2001:205545 BIOSIS
ΑN
      PREV200100205545
DN
      Intrathecal cyclosporin prolongs survival of late-stage ALS mice.
ΤI
            Marcus [Reprint author]; Elmer, Eskil; Fong, Keith S. K.; Csiszar,
ΑU
      Katalin
      Laboratory of Matrix Pathobiology, Pacific Biomedical Research Center,
CS
      University of Hawaii, 1960 East-West Road, Honolulu, HI, 96822, USA
      mkeep@aloha.net
      Brain Research, (16 March, 2001) Vol. 894, No. 2, pp. 327-331. print.
S0
      CODEN: BRREAP. ISSN: 0006-8993.
DT
      Article
      English
LA
      Entered STN: 25 Apr 2001
ED
      Last Updated on STN: 18 Feb 2002
      ANSWER 6 OF 228 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
L7
ΑN
      2001:98512
                  BIOSIS
      PREV200100098512
DN
      Survival of intrastriatal xenografts of ventral mesencephalic dopamine
TI
        ***neurons*** from MHC-deficient mice to adult rats.
      Duan, Wei-Ming; Westerman, Marcus; Flores, Tina; Low, Walter C. [Reprint
ΑU
      authorl
CS
      Department of Neurosurgery, University of Minnesota Medical School,
      Minneapolis, MN, 55455, USÁ
      lowwalt@tc.umn.edu
      Experimental Neurology, (January, 2001) Vol. 167, No. 1, pp. 108-117.
```

SO

```
print.
     CODEN: EXNEAC. ISSN: 0014-4886.
     Article
DT
     English
LA
     Entered STN: 21 Feb 2001
ED
     Last Updated on STN: 15 Feb 2002
     ANSWER 7 OF 228 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
L7
     1997:504051 BIOSIS
ΑN
     PREV199799803254
DN
     Implantation of xenogeneic transgenic neural plate tissues into
TI
     Parkinsonian rat brain.
     Hara, Koichi [Reprint author]; Uchida, Koichi; Fukunaga, Atsushi; Toya,
ΑU
     Shiqeo; Kawase, Takeshi
     Dep. Neurosurg., Keio Univ. Sch. Med., 35 Shinanomachi, Shinjuku-ku.
CS
     Tokyo, Japan
     Cell Transplantation, (1997) Vol. 6, No. 5, pp. 515-519.
SO
     ISSN: 0963-6897.
     Article
DT
     English
LA
ED
     Entered STN: 21 Nov 1997
     Last Updated on STN: 21 Nov 1997
     ANSWER 8 OF 228 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
L7
                BIOSIS
     1995:81335
ΑN
     PREV199598095635
DN
                                                          ***transplants***
     Long-term delayed vascularization of human neural
TI
                                                                               to
     the rat brain.
     Geny, Christian; Naimi-Sadaoui, Souad; Jeny, Roland; Belkadi, Abd El
ΑU
     Majid; Juliano, Sharon L.; Peschanski, Marc
     INSERM CJF 91-02, Faculte de Medecine, 8 Rue du General Sarrail, 94010
CS
     Creteil, France
     Journal of Neuroscience, (1994) Vol. 14, No. 12, pp. 7553-7562.
SO
     CODEN: JNRSDS. ISSN: 0270-6474.
     Article
DT
     English
ΙΑ
     Entered STN: 22 Feb 1995
ED
     Last Updated on STN: 22 Feb 1995
     ANSWER 9 OF 228 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
L7
     1992:526247
                 BIOSIS
AN
DN
     PREV199294134322; BA94:134322
     LONG DISTANCE DIRECTED AXONAL GROWTH FROM HUMAN DOPAMINERGIC MESENCEPHALIC
TI
     NEUROBLASTS IMPLANTED ALONG THE NIGROSTRIATAL PATHWAY IN 6 HYDROXYDOPAMINE
     LESIONED ADULT RATS.
     WICTORIN K [Reprint author]; BRUNDIN P; SAUER H; LINDVALL O; BJORKLUND A
ΑU
     DEP MED CELL RES, BISKOPSGATAN 5, S-223 62 LUND, SWED
CS
     Journal of Comparative Neurology, (1992) Vol. 323, No. 4, pp. 475-494.
SO
     CODEN: JCNEAM. ISSN: 0021-9967.
     Article
DT
     BA
FS
LA
     ENGLISH
ED
     Entered STN: 19 Nov 1992
     Last Updated on STN: 20 Nov 1992
     ANSWER 10 OF 228 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
L7
     1989:517057 BIOSIS
ΑN
DN
     PREV198988133200; BA88:133200
     XENOGRAFTING OF FETAL PIG VENTRAL MESENCEPHALON CORRECTS MOTOR ASYMMETRY
TI
     IN THE RAT MODEL OF
                            ***PARKINSON*** 'S DISEASE.
     HUFFAKER T K [Reprint author]; BOSS B D; MORGAN A S; NEFF N T; STRECKER R
AU
     E; SPENCE M S; MIAO R
HANA BIOL INC, 850 MARINA VILLAGE PKWY, ALAMEDA, CALIF 94501, USA
     Experimental Brain Research, (1989) Vol. 77, No. 2, pp. 329-336.
so
     CODEN: EXBRAP. ISSN: 0014-4819.
     Article
DT
FS
     BA
LA
     ENGLISH
ED
     Entered STN: 15 Nov 1989
     Last Updated on STN: 21 Nov 1989
L7
     ANSWER 11 OF 228 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
     1989:270921 BIOSIS
ΑN
     PREV198988007003; BA88:7003
DN
                           ***HUNTINGTON*** 'S DISEASE CROSS-SPECIES
```

IMPLANTATION OF STRIATAL PRECURSOR CELLS TO THE EXCITOTOXICALLY LESIONED

A PRIMATE MODEL OF

TT

```
BABOON CAUDATE-PUTAMEN.
     ISACSON O [Reprint author]; RICHE D; HANTRAYE P; SOFRONIEW M V; MAZIERE M MCLEAN HOSP, BELMONT, MASS 02178, USA Experimental Brain Research, (1989) Vol. 75, No. 1, pp. 213-220.
ΑU
CS
SO
     CODEN: EXBRAP. ISSN: 0014-4819.
DT
     Article
FS
     BA
LA
     ENGLISH
     Entered STN: 6 Jun 1989
ED
     Last Updated on STN: 6 Jun 1989
     ANSWER 12 OF 228 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN 1988:289677 BIOSIS
L7
ΑN
     PREV198886017944; BA86:17944
DN
     HUMAN FETAL DOPAMINE ***NEURONS*** GRAFTED IN A RAT MODEL OF
***PARKINSON*** 'S DISEASE IMMUNOLOGICAL ASPECTS SPONTANEOUS AND
TI
     DRUG-INDUCED BEHAVIOR AND DOPAMINE RELEASE.
     BRUNDIN P [Reprint author]; STRECKER R E; WIDNER H; CLARKE D J; NILSSON O
ΑU
     G; ASTEDT B; LINDVALL O; BJORKLUND A
     DEP MED CELL RES, UNIV LUND, BISKOPSGATAN 5, S-223 62 LUND, SWEDEN Experimental Brain Research, (1988) Vol. 70, No. 1, pp. 192-208.
CS
SO
     CODEN: EXBRAP. ISSN: 0014-4819.
DT
     Article
FS
     BA
LA
     ENGLISH
     Entered STN: 16 Jun 1988
ED
     Last Updated on STN: 16 Jun 1988
       ANSWER 13 OF 228 BIOTECHNO COPYRIGHT 2004 Elsevier Science B.V. on STN
L7
       2000:30058341
                         BIOTECHNO
ΑN
       Neuroprotective strategies for basal ganglia degeneration: ***Parkinson*** 's and ***Huntington*** 's diseases
TI
       ***Parkinson*** 's and ***Huntington*** 's diseases
Alexi T.; Borlongan C.V.; Faull R.L.M.; Williams C.E.; Clark R.G.;
ΑU
       Gluckman P.D.; Hughes P.E.
       T. Alexi, Research Centre, School of Medicine, University of Auckland,
CS
       Auckland, New Zealand.
       E-mail: t.alexi@auckland.ac.nz
       Progress in Neurobiology, ( ***2000*** ), 60/5 (409-470), 727
S0
       reference(s)
       CODEN: PGNBA5
                        ISSN: 0301-0082
       s0301008299000325
PUI
DT
       Journal; General Review
CY
       United Kingdom
       English
LA
       English
SL
L7
       ANSWER 14 OF 228 BIOTECHNO COPYRIGHT 2004 Elsevier Science B.V. on STN
ΑN
                         BIOTECHNO
TI
       CNS immunological modulation of neural graft rejection and survival
       Borlongan C.V.; Stahl C.E.; Cameron D.F.; Saporta S.; Freeman T.B.;
ΑU
       Cahill D.W.; Sanberg P.R.
       Division of Neurological Surgery, Department of Surgery, Univ. of South
CS
       Florida Coll. of Med., 12901 Bruce B. Downs Blvd, Tampa, FL 33612, United
       Neurological Research, ( ***1996*** ), 18/4 (297-304)
S0
       CODEN: NRESDZ ISSN: 0161-6412
DT
       Journal; General Review
CY
       United States
       English
LA
SL
       English
L7
      ANSWER 15 OF 228 CANCERLIT on STN
      2000081837
ΑN
                       CANCERLIT
DN
      20081837
                   PubMed ID: 10616091
      Reduced xenograft rejection in rat striatum after pretransplant
TI
      photodynamic therapy of murine neural xenografts.
      Honey C R; Obochi M O; Shen H; Margaron P; Yip S; Levy J G
ΑU
      Department of Immunology and Microbiology, University of British Columbia,
CS
      Vancouver, Canada.. choney@interchange.ubc.ca
      JOURNAL OF NEUROSURGERY, ***(2000 Jan)***
                                                          92 (1) 127-31.
SO
      Journal code: 0253357. ISSN: 0022-3085.
CY
      United States
DT
      Journal; Article; (JOURNAL ARTICLE)
LA
      English
      MEDLINE; Abridged Index Medicus Journals; Priority Journals MEDLINE 2000081837
FS
05
```

```
200001
EM
     Entered STN: 20000616
ED
     Last Updated on STN: 20000616
     ANSWER 16 OF 228 CANCERLIT ON STN
L7
     96173211
                   CANCERLIT
AN
                 PubMed ID: 8593897
DN
     96173211
     The effect of prior in vitro exposure of donor cells to trophic factors in
TI
     neurotransplantation.
     Chen X L; Roisen F J; Gupta M
ΑU
     Department of Anatomical Sciences & Neurobiology, University of Louisville
CS
     school of Medicine, Kentucky 40292, USA.
     NS24291 (NINDS)
NC
                                 ***(1996 Mar)***
                                                      138 (1) 64-72.
     EXPERIMENTAL NEUROLOGY,
S0
     Journal code: 0370712. ISSN: 0014-4886.
CY
     United States
     Journal; Article; (JOURNAL ARTICLE)
DT
LΑ
     English
     MEDLINE; Priority Journals
FS
     MEDLINE 96173211
os
EΜ
     199604
     Entered STN: 19960528
     Last Updated on STN: 19970509
     ANSWER 17 OF 228 CAPLUS COPYRIGHT 2004 ACS on STN
L7
     2001:499762 CAPLUS
AN
DN
     135:91542
     Porcine neural cells and their use in treatment of neurological deficits
TI
     due to neurodegenerative diseases
     Isacson, Ole; Dinsmore, Jonathan
IN
     Diacrin, Inc., USA
U.S., 68 pp., Cont.-in-part of U.S. Ser. No. 424,851.
PA
S0
     CODEN: USXXAM
DT
     Patent
     English
LA
FAN.CNT<sup>8</sup>
                        KIND DATE
                                              APPLICATION NO.
                                                                 DATE
     PATENT NO.
                        ----
                                              US 1995-554779
                                                                 19951107 <--
                         В1
                              20010710
     us 6258353
                                              US 1995-424851
                              20010925
                                                                 19950419 <--
     us 6294383
                         в1
     us 2002009461
                                              US 2001-847881
                                                                 20010502
                         Α1
                              20020124
PRAI US 1994-336856
US 1995-424851
                         в2
                              19941108
                         Α2
                              19950419
     us 1995-554779
                              19951107
                         Α3
RE.CNT 129
               THERE ARE 129 CITED REFERENCES AVAILABLE FOR THIS RECORD
               ALL CITATIONS AVAILABLE IN THE RE FORMAT
     ANSWER 18 OF 228 CAPLUS COPYRIGHT 2004 ACS on STN
L7
ΑN
      1992:529568 CAPLUS
DN
     117:129568
     Human neural graft function in rats treated with anti-interleukin II
TT
      receptor antibody
      Honey, Christopher R.; Clarke, Debbie J.; Dallman, Maggie J.; Charlton,
ΑU
      Harry M.
     Dep. Hum. Anat., Oxford Univ., Oxford, OX1 3QX, UK NeuroReport ( ***1990*** ), 1(3-4), 247-9
CS
S0
      CODEN: NERPEZ; ISSN: 0959-4965
DT
      Journal
      English
LA
L7
      ANSWER 19 OF 228 CAPLUS COPYRIGHT 2004 ACS on STN
      1988:466555 CAPLUS
ΑN
DN
      Brain xenografts: the effect of ***cyclosporin***
                                                                   ****
                                                                              on
TI
      graft survival
      Howard, Matthew A., III; Dacey, Ralph G., Jr.; Winn, H. Richard
ΑU
      Sch. Med., Univ. Washington, Seattle, WA, 98104, USA Journal of Neurosurgery ( ***1988*** ), 69(1), 121-6
CS
S0
      CODEN: JONSAC; ISSN: 0022-3085
DT
      Journal
LA
      English
      ANSWER 20 OF 228 DISSABS COPYRIGHT (C) 2004 ProQuest Information and
L7
      Learning Company; All Rights Reserved on STN
                         Order Number: AARCO49573 (not available for sale by
ΑN
      88:1749 DISSABS
```

UMI)

```
***TRANSPLANTATION***
                                                          ***PARKTNSON*** 'S
TT
     TOWARDS A
                                           THERAPY FOR
     DISEASE: AN EXPERIMENTAL STUDY ON INTRACEREBRAL GRAFTS OF FETAL DOPAMINE
       ***NEURONS***
ΑIJ
     BRUNDIN, PATRIK [MED.DR]
     LUNDS UNIVERSITET (SWEDEN) (0899)
CS
     Dissertation Abstracts International, ( ***1988*** ) Vol. 49, No. 4C, p.
SO
     601. Order No.: AARCO49573 (not available for sale by UMI). 224 pages.
     DEPARTMENT OF MEDICAL CELL RESEARCH, BISKOPSGATAN 5, S-223 62 LUND,
     SWEDEN.
     ISBN: 91-7900-492-X.
DT
     Dissertation
FS
     DAI
LA
     English
     Entered STN: 19921118
FD
     Last Updated on STN: 19921118
      ANSWER 21 OF 228 DGENE COPYRIGHT 2004 THOMSON DERWENT ON STN
L7
      ADF83693 peptide
                                DGENE
AN
      New 2-aminobenzamide derivatives are caspase and apoptic cell death
ΤI
      inhibitors used for treating neurodegenerative disorders, heart disease
      and autoimmune disorders.
      Cai S X; Wang Y; Weber E; Mills G B; Green D R
IN
                   CYTOVIA INC.
      (CYTO-N)
РΑ
        ***wo 2000055114 A1 20000921
                                                        55p***
PI
      wo 2000-us6398
                        20000315
ΑI
      US 1999-124675P
PRAI
                       19990316
      US 1999-158386P 19991012
DT
      Patent
      English
I A
os
      2000-638173 [61]
      Caspase 3 substrate peptide.
DESC
      ANSWER 22 OF 228 DGENE COPYRIGHT 2004 THOMSON DERWENT ON STN
L7
AN
      AAY84736 Peptide
                                DGENE
TI
      New isolated polyketide synthase nucleic acid and polyketide compounds,
      useful for treating e.g. ***transplane useful for cclerosis. ***Alzheimer*** 's disease,
                                                       rejection, uveitis,
                                                               ***Parkinson***
      disease, stroke, or peripheral neuropathy
IN
      Reeves C; Chu D; Khosla C; Santi D; Wu K
                   KOSAN BIOSCIENCES INC.
PA
       (KOSA-N)
PΙ
        ***WO 2000020601 A2 20000413
                                                      126p***
      wo 1999-US22886 19991001
ΑI
      US 1998-102748
                         19981002
PRAI
      us 1999-123810
                        19990311
      us 1999-139650
                        19990617
DT
      Patent
LA
      English
      2000-317716 [27]
05
      N-PSDB: AAA14672
CR
DESC
      Amino acid sequence of
                                ***rapamycin***
                                                    acyltransferase domain 12
       (AT12).
17
      ANSWER 23 OF 228 DGENE COPYRIGHT 2004 THOMSON DERWENT ON STN
AN
      AAY84735 Peptide
                               DGENE
      New isolated polyketide synthase nucleic acid and polyketide compounds,
TI
      New isolated polymer e.g. ***transplant useful for treating e.g. ***Alzheimer*** 's disease,
                                   ***transplant*** rejection, uveitis,
                                                               ***Parkinson*** 's
      disease, stroke, or peripheral neuropathy
Reeves C; Chu D; Khosla C; Santi D; Wu K
IN
PA
       (KOSA-N)
                   KOSAN BIOSCIENCES INC.
                                                      126p***
         ***WO 2000020601 A2 20000413
PΙ
      wo 1999-US22886 19991001
ΑI
PRAI
      us 1998-102748
                         19981002
      us 1999-123810
                         19990311
      us 1999-139650
                         19990617
DT
       Patent
      English
LA
os
       2000-317716 [27]
CR
      N-PSDB: AAA14671
                                                    acyltransferase domain 3
DESC
      Amino acid sequence of
                                 ***rapamycin***
       (AT3).
      ANSWER 24 OF 228 DGENE COPYRIGHT 2004 THOMSON DERWENT ON STN
L7
                                DGENE
AN
      AAY84733 Protein
      New isolated polyketide synthase nucleic acid and polyketide compounds,
TI
```

transplant rejection, uveitis,

useful for treating e.g.

```
***Parkinson***
                               ***Alzheimer*** 's disease,
       multiple sclerosis,
      disease, stroke, or peripheral neuropathy
       Reeves C; Chu D; Khosla C; Santi D; Wu K
IN
PA
                    KOSAN BIOSCIENCES INC.
                                                          126p***
         ***WO 2000020601 A2 20000413
PΙ
      wo 1999-us22886 19991001
ΑI
      US 1998-102748
                          19981002
PRAI
      us 1999-123810
                          19990311
       us 1999-139650
                          19990617
DT
       Patent
LA
       English
       2000-317716 [27]
os
      N-PSDB: AAA14669
CR
      Amino acid sequence of modified FK-520 PKS gene cluster module 8.
DESC
       ANSWER 25 OF 228 DGENE COPYRIGHT 2004 THOMSON DERWENT ON STN
L7
       AAY84732 Protein
                                  DGENE
AN
       New isolated polyketide synthase nucleic acid and polyketide compounds,
TI
       useful for treating e.g. ***transplant*** rejection multiple sclerosis, ***Alzheimer*** 's disease,
                                                           rejection, uveitis,
                                                                   ***Parkinson***
      multiple sclerosis, ***Alzheimer*** 's
disease, stroke, or peripheral neuropathy
Reeves C; Chu D; Khosla C; Santi D; Wu K
IN
                    KOSAN BIOSCIENCES INC.
       (KOSA-N)
PA
                                                          126p***
         ***WO 2000020601 A2 20000413
PΙ
       wo 1999-us22886 19991001
ΑI
PRAI
       US 1998-102748
                          19981002
                          19990311
       US 1999-123810
       US 1999-139650
                          19990617
DT
       Patent
       English
LA
       2000-317716 [27]
os
       N-PSDB: AAA14668
CR
       Amino acid sequence of modified FK-520 PKS gene cluster module 8.
DESC
L7
       ANSWER 26 OF 228 DGENE COPYRIGHT 2004 THOMSON DERWENT ON STN
AN
       AAY84731 Protein
                                  DGENE
       New isolated polyketide synthase nucleic acid and polyketide compounds,
TI
       useful for treating e.g. ***transplant*** reject
multiple sclerosis, ***Alzheimer*** 's disease,
                                                           rejection, uveitis,
                                                                    ***Parkinson*** 's
       multiple sclerosis,
       disease, stroke, or peripheral neuropathy
Reeves C; Chu D; Khosla C; Santi D; Wu K
IN
                    KOSAN BIOSCIENCES INC.
PA
         ***Wo 2000020601 A2 20000413
                                                          126p***
PΙ
       wo 1999-US22886 19991001
ΑI
       US 1998-102748
                          19981002
PRAI
       US 1999-123810
                          19990311
       us 1999-139650
                          19990617
DT
       Patent
       English
LA
       2000-317716 [27]
os
CR
       N-PSDB: AAA14667
       Amino aicd sequence of modified FK-520 PKS gene cluster module 8.
DESC
L7
       ANSWER 27 OF 228 DGENE COPYRIGHT 2004 THOMSON DERWENT ON STN
       AAY84730 Protein
                                  DGENE
AN
TI
       New isolated polyketide synthase nucleic acid and polyketide compounds,
       useful for treating e.g. ***transplant*** rejective multiple sclerosis, ***Alzheimer*** 's disease,
                                                            rejection, uveitis,
                                                                    ***Parkinson***
       disease, stroke, or peripheral neuropathy
Reeves C; Chu D; Khosla C; Santi D; Wu K
IN
                     KOSAN BIOSCIENCES INC.
PA
       (KOSA-N)
         ***WO 2000020601 A2 20000413
                                                           126p***
PΙ
       wo 1999-US22886 19991001
ΑI
PRAI
       US 1998-102748
                          19981002
       us 1999-123810
                          19990311
       us 1999-139650
                          19990617
DT
       Patent
       English
LA
os
       2000-317716 [27]
CR
       N-PSDB: AAA14666
       Amino acid sequence of modified FK-520 PKS gene cluster module 8.
DESC
       ANSWER 28 OF 228 DGENE COPYRIGHT 2004 THOMSON DERWENT ON STN
L7
ΑN
                                  DGENE
       AAY84728 Protein
       New isolated polyketide synthase nucleic acid and polyketide compounds.
TI
                                      ***transplant*** rejection, uveitis,
       useful for treating e.g.
```

```
***Alzheimer*** 's disease, ***Parkinson*** 's
       multiple sclerosis,
       disease, stroke, or peripheral neuropathy
Reeves C; Chu D; Khosla C; Santi D; Wu K
IN
PA
       (KOSA-N)
                     KOSAN BIOSCIENCES INC.
         ***WO 2000020601 A2 20000413
                                                              126p***
PΙ
                           19991001
       wo 1999-US22886
ΑI
       us 1998-102748
                            19981002
PRAI
       us 1999-123810
                            19990311
       us 1999-139650
                            19990617
       Patent
DT
LA
       English
       2000-317716 [27]
os
       N-PSDB: AAA14664
CR
       Amino acid sequence of a fragment of the FK-520 PKS gene cluster.
DESC
       ANSWER 29 OF 228 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
L7
       AAY84727 Protein
                                    DGENE
ΑN
       New isolated polyketide synthase nucleic acid and polyketide compounds, useful for treating e.g. ***transplant*** rejection, uveitis, multiple sclerosis, ***Alzheimer*** 's disease, ***Parkinson***
TI
       multiple sclerosis, ***Alzheimer*** 's
disease, stroke, or peripheral neuropathy
Reeves C; Chu D; Khosla C; Santi D; Wu K
ΙN
                      KOSAN BIOSCIENCES INC.
       (KOSA-N)
PA
                                                              126p***
          ***Wo 2000020601 A2 20000413
PΙ
       wo 1999-US22886
                           19991001
ΑI
PRAI
       US 1998-102748
                            19981002
       US 1999-123810
                            19990311
                            19990617
       us 1999-139650
DT
       Patent
       English
LA
       2000-317716 [27]
os
       N-PSDB: AAA14663
CR
       Amino acid sequence of a fragment of the FK-520 PKS gene cluster.
DESC
L7
       ANSWER 30 OF 228 DGENE COPYRIGHT 2004 THOMSON DERWENT ON STN
ΑN
       AAY84726 Protein
                                    DGENE
       New isolated polyketide synthase nucleic acid and polyketide compounds,
TI
       useful for treating e.g. ***transplant*** rejective multiple sclerosis, ***Alzheimer*** 's disease,
                                                               rejectión, uveitis,
ease, ***Parkinson***
       disease, stroke, or peripheral neuropathy
Reeves C; Chu D; Khosla C; Santi D; Wu K
IN
                      KOSAN BIOSCIENCES INC.
PA
          ***wo 2000020601 A2 20000413
                                                              126p***
PΙ
       wo 1999-us22886 19991001
ΑI
       US 1998-102748
                            19981002
PRAI
       us 1999-123810
                            19990311
       us 1999-139650
                            19990617
DT
       Patent
       English
LA
os
       2000-317716 [27]
CR
       N-PSDB: AAA14662
       Amino acid sequence of a fragment of the FK-520 PKS gene cluster.
DESC
       ANSWER 31 OF 228 DGENE COPYRIGHT 2004 THOMSON DERWENT ON STN
L7
AN
       AAY84725 Protein
                                    DGENE
       New isolated polyketide synthase nucleic acid and polyketide compounds,
TI
       useful for treating e.g. ***transplant*** rejective multiple sclerosis, ***Alzheimer*** 's disease,
                                                               rejection, uveitis,
                                                                        ***Parkinson***
       disease, stroke, or peripheral neuropathy
Reeves C; Chu D; Khosla C; Santi D; Wu K
IN
                      KOSAN BIOSCIENCES INC.
PA
       (KOSA-N)
                                                              126p***
          ***wo 2000020601 A2 20000413
PΙ
       wo 1999-US22886 19991001
ΑI
PRAI
       US 1998-102748
                            19981002
       US 1999-123810
                            19990311
       us 1999-139650
                            19990617
DT
       Patent
       English
LA
os
       2000-317716 [27]
CR
       N-PSDB: AAA14661
       Amino acid sequence of a fragment of the FK-520 PKS gene cluster.
DESC
       ANSWER 32 OF 228 DGENE COPYRIGHT 2004 THOMSON DERWENT ON STN
L7
                                DGENE
AN
       AAA14672 DNA
       New isolated polyketide synthase nucleic acid and polyketide compounds,
TI
                                        ***transplant*** rejection, uveitis,
```

useful for treating e.g.

```
multiple sclerosis,
                                                       ***Alzheimer*** 's disease, ***Parkinson*** 's
            disease, stroke, or peripheral neuropathy
            Reeves C; Chu D; Khosla C; Santi D; Wu K
IN
PA
                                    KOSAN BIOSCIENCES INC.
                                                                                                       126p***
                ***WO 2000020601 A2 20000413
PΙ
                                            19991001
            wo 1999-US22886
ΑI
           US 1998-102748
                                              19981002
PRAI
            us 1999-123810
                                              19990311
            us 1999-139650
                                              19990617
DT
            Patent
LA
            English
            2000-317716 [27]
os
            P-PSDB: AAY84736
CR
           Nucleotide sequence of ***rapamycin*** acyltransferase domain 12
DESC
            (AT12).
            ANSWER 33 OF 228 DGENE COPYRIGHT 2004 THOMSON DERWENT ON STN
L7
            AAA14671 DNA
                                                    DGENE
ΑN
            New isolated polyketide synthase nucleic acid and polyketide compounds,
TI
            useful for treating e.g. ***transplant*** rejection, uveitis, multiple sclerosis, ***Alzheimer*** 's disease, ***Parkinson***
            multiple sclerosis, ***Alzheimer*** 's
disease, stroke, or peripheral neuropathy
Reeves C; Chu D; Khosla C; Santi D; Wu K
TN
PA
            (KOSA-N)
                                    KOSAN BIOSCIENCES INC.
                ***Wo 2000020601 A2 20000413
                                                                                                       126p***
PΙ
ΑI
            wo 1999-us22886 19991001
                                              19981002
            us 1998-102748
PRAI
            US 1999-123810
                                              19990311
            us 1999-139650
                                               19990617
DT
            Patent
            English
LA
            2000-317716 [27]
OS
            P-PSDB: AAY84735
CR
            Nucleotide sequence of ***rapamycin***
                                                                                                   acyltransferase domain 3
DESC
             (AT3).
            ANSWER 34 OF 228 DGENE COPYRIGHT 2004 THOMSON DERWENT ON STN
L7
            AAA14669 DNA
                                                    DGENE
ΑN
            New isolated polyketide synthase nucleic acid and polyketide compounds,
TI
            useful for treating e.g. ***transplant*** rejective multiple sclerosis, ***Alzheimer*** 's disease,
                                                                                                         rejection, uveitis,
            multiple sclerosis, ***Alzheimer*** 's
disease, stroke, or peripheral neuropathy
Reeves C; Chu D; Khosla C; Santi D; Wu K
                                                                                                                       ***Parkinson***
IN
PA
                                    KOSAN BIOSCIENCES INC.
             (KOSA-N)
                 ***WO 2000020601 A2 20000413
                                                                                                       126p***
PΙ
            wo 1999-US22886 19991001
ΑI
PRAI
            US 1998-102748
                                               19981002
            US 1999-123810
                                               19990311
            us 1999-139650
                                              19990617
DT
             Patent
            English
 LA
 os
             2000-317716 [27]
             P-PSDB: AAY84733
CR
DESC
            Nucleotide sequence of modified FK-520 PKS gene cluster module 8.
L7
            ANSWER 35 OF 228 DGENE COPYRIGHT 2004 THOMSON DERWENT ON STN
             AAA14668 DNA
                                                    DGENE
 ΑN
            New isolated polyketide synthase nucleic acid and polyketide compounds,
TI
            useful for treating e.g. ***transplant*** rejective full process rej
                                                                                                         rejection, uveitis,
                                                                                                                        ***Parkinson*** 's
 IN
 PA
             (KOSA-N)
                                     KOSAN BIOSCIENCES INC.
                 ***WO 2000020601 A2 20000413
                                                                                                       126p***
 PΙ
            wo 1999-US22886 19991001
 ΑI
 PRAI
            US 1998-102748
                                               19981002
             US 1999-123810
                                               19990311
             US 1999-139650
                                               19990617
 DT
             Patent
             English
 LA
 os
             2000-317716 [27]
 CR
             P-PSDB: AAY84732
            Nucleotide sequence of modified FK-520 PKS gene cluster module 8.
DESC
             ANSWER 36 OF 228 DGENE COPYRIGHT 2004 THOMSON DERWENT ON STN
 L7
```

AAA14667 DNA

AN

DGENE

```
New isolated polyketide synthase nucleic acid and polyketide compounds,
ΤI
       useful for treating e.g. ***transplant*** rejection multiple sclerosis, ***Alzheimer*** 's disease,
                                                              rejection, uveitis,
                                                                       ***Parkinson***
       disease, stroke, or peripheral neuropathy
       Reeves C; Chu D; Khosla C; Santi D; Wu K
IN
       (KOSA-N)
                     KOSAN BIOSCIENCES INC.
PA
                                                              126p***
         ***WO 2000020601 A2 20000413
PΙ
       wo 1999-US22886 19991001
ΑI
       us 1998-102748
                           19981002
PRAI
       us 1999-123810
                           19990311
                           19990617
       us 1999-139650
DT
       Patent
       English
LA
       2000-317716 [27]
OS.
       P-PSDB: AAY84731
CR
       Nucleotide sequence of modified FK-520 PKS gene cluster module 8.
DESC
       ANSWER 37 OF 228 DGENE COPYRIGHT 2004 THOMSON DERWENT ON STN
L7
       AAA14666 DNA
                               DGFNF
AN
       New isolated polyketide synthase nucleic acid and polyketide compounds,
TI
       New isolated polyner useful for treating e.g. ***transplant useful for treating e.g. ***Alzheimer*** 's disease,
                                                              rejection, uveitis,
                                                                       ***Parkinson***
       multiple sclerosis, ***Alzheimer*** 's
disease, stroke, or peripheral neuropathy
Reeves C; Chu D; Khosla C; Santi D; Wu K
IN
                     KOSAN BIOSCIENCES INC.
       (KOSA-N)
PA
                                                              126p***
PΙ
          ***wo 2000020601 A2 20000413
       wo 1999-us22886 19991001
ΑI
                           19981002
       US 1998-102748
PRAI
       US 1999-123810
                           19990311
       us 1999-139650
                           19990617
DT
       Patent
       English
LA
os
       2000-317716 [27]
       P-PSDB: AAY84730
CR
DESC
       Nucleotide sequence of modified FK-520 PKS gene cluster module 8.
       ANSWER 38 OF 228 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
L7
       AAA14664 DNA
                               DGENE
ΑN
       New isolated polyketide synthase nucleic acid and polyketide compounds,
TI
       useful for treating e.g. ***transplant*** rejection multiple sclerosis, ***Alzheimer*** 's disease,
                                                               rejection, uveitis,
case, ***Parkinson***
       multiple sclerosis, ***Alzheimer*** 's
disease, stroke, or peripheral neuropathy
Reeves C; Chu D; Khosla C; Santi D; Wu K
IN
                      KOSAN BIOSCIENCES INC.
PA
       (KOSA-N)
          ***WO 2000020601 A2 20000413
                                                              126p***
PΙ
       wo 1999-us22886 19991001
ΑI
PRAI
       us 1998-102748
                            19981002
                            19990311
       us 1999-123810
       us 1999-139650
                            19990617
DT
       Patent
       English
LA
05
       2000-317716 [27]
CR
       P-PSDB: AAY84728
       Nucleotide sequence of a fragment of the FK-520 PKS gene cluster.
DESC
L7
       ANSWER 39 OF 228 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
                               DGENE
AN
       AAA14663 DNA
       New isolated polyketide synthase nucleic acid and polyketide compounds,
TI
       useful for treating e.g. ***transplant*** rejective multiple sclerosis, ***Alzheimer*** 's disease,
                                                               rejection, uveitis,
                                                                       ***Parkinson***
       disease, stroke, or peripheral neuropathy
Reeves C; Chu D; Khosla C; Santi D; Wu K
IN
                      KOSAN BIOSCIENCES INC.
PA
       (KOSA-N)
          ***WO 2000020601 A2 20000413
                                                              126p***
PΙ
       wo 1999-us22886 19991001
ΑI
PRAI
       US 1998-102748
                            19981002
       us 1999-123810
                            19990311
       us 1999-139650
                            19990617
DT
       Patent
       English
LA
os
       2000-317716 [27]
CR
       P-PSDB: AAY84727
       Nucleotide sequence of a fragment of the FK-520 PKS gene cluster.
DESC
L7
       ANSWER 40 OF 228 DGENE COPYRIGHT 2004 THOMSON DERWENT ON STN
```

AN

AAA14662 DNA

DGENE

```
New isolated polyketide synthase nucleic acid and polyketide compounds,
TI
      New isolated polymers useful for treating e.g. ***transplant useful for treating e.g. ***Alzheimer*** 's disease,
                                                        rejection, uveitis,
                                                                ***Parkinson*** 's
      disease, stroke, or peripheral neuropathy
      Reeves C; Chu D; Khosla C; Santi D; Wu K
IN
                   KOSAN BIOSCIENCES INC.
PA
                                                       126p***
         ***WO 2000020601 A2 20000413
PΙ
      wo 1999-US22886 19991001
ΑI
      US 1998-102748
                         19981002
PRAI
      us 1999-123810
                         19990311
      us 1999-139650
                         19990617
      Patent
DT
      English
LA
      2000-317716 [27]
os
      P-PSDB: AAY84726
CR
      Nucleotide sequence of a fragment of the FK-520 PKS gene cluster.
DESC
      ANSWER 41 OF 228 DGENE COPYRIGHT 2004 THOMSON DERWENT ON STN
L7
      AAA14661 DNA
                            DGENE
ΑN
      New isolated polyketide synthase nucleic acid and polyketide compounds,
TI
      New isolated polyner useful for treating e.g. ***transplant useful for treating e.g. ***Alzheimer*** 's disease,
                                                        rejection, uveitis,
                                                                ***Parkinson*** 's
      disease, stroke, or peripheral neuropathy
Reeves C; Chu D; Khosla C; Santi D; Wu K
IN
       (KOSA-N)
PΑ
                   KOSAN BIOSCIENCES INC.
                                                       126p***
         ***WO 2000020601 A2 20000413
PΙ
                        19991001
ΑI
      wo 1999-US22886
      US 1998-102748
                         19981002
PRAI
      US 1999-123810
                         19990311
                         19990617
      us 1999-139650
DT
      Patent
       English
LA
os
      2000-317716 [27]
      P-PSDB: AAY84725
CR
DESC Nucleotide sequence of a fragment of the FK-520 PKS gene cluster.
     ANSWER 42 OF 228 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS
L7
      RESERVED. on STN
      2000407300 EMBASE
AN
     No evidence for infection of human cells with porcine endogenous
TI
      retrovirus (PERV) after exposure to porcine fetal
                                                              ***neuronal***
      Dinsmore J.H.; Manhart C.; Raineri R.; Jacoby D.B.; Moore A.
      Dr. J.H. Dinsmore, Diacrin, Inc., Building 96, 13th Street, Charlestown,
CS
     MA 02129, United States
      Transplantation, (15 Nov 2000) 70/9 (1382-1389).
SO
      Refs: 38
      ISSN: 0041-1337 CODEN: TRPLAU
      United States
CY
      Journal; Article
DT
FS
      004
              Microbiology
              Neurology and Neurosurgery
      800
      026
              Immunology, Serology and Transplantation
              Drug Literature Index
      037
      English
LA
SL
      English
      ANSWER 43 OF 228 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS
L7
      RESERVED. on STN
      2000268854 EMBASE
AN
      Additive effects of caspase inhibitor and lazaroid on the survival of
TI
        ***transplanted*** rat and human embryonic dopamine ***neurons***
      Hansson O.; Castilho R.F.; Kaminski Schierle G.S.; Karlsson J.; Nicotera
ΑU
      P.; Leist M.; Brundin P.
      O. Hansson, Section for Neuronal Survival, Wallenberg Neuroscience Center.
CS
      Solvegatan 17, SE-22362 Lund, Sweden
50
      Experimental Neurology, (2000) 164/1 (102-111).
      Refs: 55
      ISSN: 0014-4886 CODEN: EXNEAC
CY
      United States
DT
      Journal; Article
FS
      800
              Neurology and Neurosurgery
      037
              Drug Literature Index
      English
LA
SL
      English
```

```
L7
     ANSWER 44 OF 228 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS
     RESERVED. on STN
     2000268853 EMBASE
AN
       ***FK506***
                                                  ****A***
                     and
                           ***cyclosporin***
                                                            enhance the survival
TI
                                                       ***neurons***
     of cultured and grafted rat embryonic dopamine
     Castilho R.F.; Hansson O.; Brundin P.
     R.F. Castilho, Section for Neuronal Survival, Wallenberg Neuroscience
CS
     Center, Solvegatan 17, SE-223 62 Lund, Sweden
     Experimental Neurology, (2000) 164/1 (94-101).
50
     Refs: 45
     ISSN: 0014-4886 CODEN: EXNEAC
     United States
     Journal; Article
DT
     800
             Neurology and Neurosurgery
FS
             Pharmacology
     030
     037
             Drug Literature Index
     English
LA
     English
SL
L7
     ANSWER 45 OF 228 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS
     RESERVED. on STN
     2000165796 EMBASE
     Intrastriatal ventral mesencephalic xenografts of porcine tissue in rats:
TI
     Immune responses and functional effects.
     Larsson L.C.; Czech K.A.; Brundin P.; Widner H.
ΑU
     L.C. Larsson, Section for Neuronal Survival, Department of Physiological
CS
     Sciences, Wallenberg Neuroscience Center, Solvegatan 17, SE-223 62 Lund,
     Sweden. Lena.Larsson@mphy.lu.se
SO
     Cell Transplantation, (2000) 9/2 (261-272).
     Refs: 55
     ISSN: 0963-6897 CODEN: CTRAE8
     United States
DT
     Journal; Article
     800
             Neurology and Neurosurgery
FS
     026
             Immunology, Serology and Transplantation
     037
             Drug Literature Index
     English
     English
SL
L7
     ANSWER 46 OF 228
                       EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS
     RESERVED. on STN
     1999304347 EMBASE
     Cyclosporine A-induced hyperactivity in rats: Is it mediated by
ΤI
     immunosuppression, neurotrophism, or both?.
     Borlongan C.V.; Stahl C.E.; Fujisaki T.; Sanberg P.R.; Watanabe S.
ΔU
     C.V. Borlongan, National Institutes of Health, National Institute on Drug
     Abuse, Intram. Res. Prog. Cell. Nuerobiol., 5500 Nathan Shock Drive,
     Baltimore, MD 21224, United States. cborlong@intra.nida.nih.gov
     Cell Transplantation, (1999) 8/1 (153-159).
50
     Refs: 30
ISSN: 0963-6897 CODEN: CTRAE8
     United States
DT
     Journal; Article
             Neurology and Neurosurgery
FS
     008
     026
             Immunology, Serology and Transplantation
     English
LA
     English
SL
L7
     ANSWER 47 OF 228
                       EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS
     RESERVED. on STN
     94105806 EMBASE
DN
     1994105806
       long term follow-up of fetal dopaminergic
                                                    ***neurons***
TT
       ***transplantation***
                               into the brain of three parkinsonian patients.
     Zabek M.; Mazurowski W.; Dymecki J.; Stelmachow J.; Zawada E.
AU
     Department of Neuropathology, Inst. of Psychiatry and Neurology,
CS
     Sobieskiego 1/9,02-957 Warsaw, Poland
S<sub>0</sub>
     Restorative Neurology and Neuroscience, (1994) 6/2 (97-106).
     ISSN: 0922-6028 CODEN: RNNEEL
     Ireland
     Journal; Article
DT
FS
     800
             Neurology and Neurosurgery
     037
             Drug Literature Index
     English
LA
SL
     English
```

```
ANSWER 48 OF 228 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS
L7
      RESERVED. on STN
      92350615 EMBASE
ΑN
      1992350615
DN
                                                  of human fetal mesencephalic tissue
                     ***transplantation***
TI
      Unilateral
      into the caudate nucleus of patients with
                                                          ***Parkinson*** 's disease.
      Spencer D.D.; Robbins R.J.; Naftolin F.; Marek K.L.; Vollmer T.; Leranth
ΑU
     C.; Roth R.H.; Price L.H.; Gjedde A.; Bunney B.S.; Sass K.J.; Elsworth J.D.; Kier E.L.; Makuch R.; Hoffer P.B.; Redmond Jr. D.E. Section of Neurosurgery, Yale University School of Medicine, P.O. Box 3333, New Haven, CT 06510, United States
CS
      New England Journal of Medicine, (1992) 327/22 (1541-1548).
S0
      ISSN: 0028-4793 CODEN: NEJMAG
      United States
CY
      Journal; Article
DT
               Neurology and Neurosurgery
FS
      800
      037
               Drug Literature Index
      English
LA
      English
SL
      ANSWER 49 OF 228 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS
L7
      RESERVED. on STN
ΑN
      87071513 EMBASE
      1987071513
DN
                                                             ***neurons***
                                                                                 grafted in a
      Behavioural effects of human fetal dopamine
TI
      rat model of ***Parkinson*** 's disease.
      Brundin P.; Nilsson O.G.; Strecker R.E.; et al. Department of Histology, University of Lund, S 223 62 Lund, Sweden Experimental Brain Research, (1987) 65/1 (235-240).
ΑU
CS
S0
      CODEN: EXBRAP
CY
      Germany
DT
      Journal
      037
               Drug Literature Index
FS
      002
               Physiology
      800
               Neurology and Neurosurgery
               Gerontology and Geriatrics
      020
      English
LA
L7
      ANSWER 50 OF 228 IFIPAT COPYRIGHT 2004 IFI on STN
                  IFIPAT;IFIUDB;IFICDB
       10051977
ΑN
TI
       COMPOSITIONS AND METHODS FOR PRODUCING AND USING HOMOGENOUS
                                      ***TRANSPLANTS*** ; TREATING DEFECTS OR
          ***NEURONAL***
                              CELL
       DISORDERS OF CENTRAL NERVOUS SYSTEM; IMPLANT GENEICALLY ENGINEERED SAMPLE
       OF CULTURED TISSUE INTO BRAIN OF HUMAN WITH NERVOUS SYSTEM DEFECT,
       MONITOR HUMAN FOR ADJUSTMENT IN CENTRAL NERVOUS SYSTEM RESPONSE
       Lee Virginia M Y; Trojanowski John Q
ΙN
       Unassigned Or Assigned To Individual (68000)
PA
       US 2001052136
PΙ
                          A1 20011213
                               20010522
ΑI
       US 2001-862204
PRAI
       WO 1994-US12899
                               19941109
       US 2001052136
                               20011213
FΙ
       Utility; Patent Application - First Publication
DT
FS
       CHEMICAL
       APPLICATION
CLMN
       24
GI
        3 Figure(s).
      FIG. 1A, FIG. 1B, FIG. 1C, FIG. 1D, FIG. 1E, FIG. 1F, FIG. 1G and FIG. 1H contain photomicrographs of NT2N graft in the hippocampus (dentate gyrus
       and polymorph layer) 4 weeks posttransplant probed with various
       monoclonal antibodies.
      FIG. 2A, FIG. 2B and FIG. 2D show photomicrographs of three different NT2N grafts in the subcortical white matter and the dorsal diencephalon (FIG. 2C) 2-4 weeks post- ***transplant*** stained with Cresyl Violet (FIG.
       2A, FIG. 2C and FIG. 2D) or the MAb (ED1) to macrophages (FIG. 2B).
      FIG. 3A, FIG. 3B, FIG. 3C, FIG. 3D, FIG. 3E, FIG. 3F, FIG. 3G and FIG. 3H
       contain photomicrographs of an NT2N graft in the subcortical white matter
                            ***transplant***
                                                   probed with MAbs and counterstained
       at 4 weeks post-
       with hematoxylin.
L7
      ANSWER 51 OF 228
                               MEDLINE on STN
ΑN
      86005269
                     MEDLINE
DN
      PubMed ID: 3930278
        ***Cyclosporin***
                                   ****A***
                                               increases survival of cross-species
TI
      intrastriatal grafts of embryonic dopamine-containing
                                                                         ***neurons***
ΑU
      Brundin P; Nilsson O G; Gage F H; Bjorklund A
NC
      AG-3766 (NIA)
```

```
NS-6705 (NINDS)
     Experimental brain research. Experimentelle Hirnforschung. Experimentation
SO
                  ***(1985)***
     cerebrale.
                                 60 (1) 204-8.
     Journal code: 0043312. ISSN: 0014-4819.
     GERMANY, WEST: Germany, Federal Republic of
CY
DT
     Journal; Article; (JOURNAL ARTICLE)
LA
     English
     Priority Journals
FS
     198511
EM
     Entered STN: 19900321
Last Updated on STN: 20000303
ED
     Entered Medline: 19851121
L7
      ANSWER 52 OF 228 PHARMAML COPYRIGHT 2004 MARKETLETTER on STN
      1636744
                PHARMAML
AN
      Guilford's Promising "Nerve Regenerators"
TI
SO
      Marketletter April 22, 1997
DT
      Newsletter
WC
      355
     ANSWER 53 OF 228 PROMT COPYRIGHT 2004 Gale Group on STN
17
                     2000:669286
ACCESSION NUMBER:
                                  PROMT
                     SCIENCE SCAN.
TITLE:
AUTHOR(S):
                     Leff, David N.
                     BIOWORLD Today, ( ***2 Aug 1999***
                                                            ) Vol. 10, No. 147.
SOURCE:
PUBLISHER:
                     American Health Consultants, Inc.
                     Newsletter
DOCUMENT TYPE:
LANGUAGE:
                     English
WORD COUNT:
                     723
                     *FULL TEXT IS AVAILABLE IN THE ALL FORMAT*
     ANSWER 54 OF 228 PROMT COPYRIGHT 2004 Gale Group on STN
L7
ACCESSION NUMBER:
                     2000:204926 PROMT
                     Cyclosporin Neuroprotection: Maas BiolAB's Canadian Patent.
TITLE:
                                       ***22 Mar 2000*** ) pp. 120.
SOURCE:
                     Business Wire, (
PUBLISHER:
                     Business Wire
DOCUMENT TYPE:
                     Newsletter
                     English
LANGUAGE:
WORD COUNT:
                     392
                     *FULL TEXT IS AVAILABLE IN THE ALL FORMAT*
L7
     ANSWER 55 OF 228 PROMT COPYRIGHT 2004 Gale Group on STN
ACCESSION NUMBER:
                     1999:208043 PROMT
                     Best PIPELINES.
TITLE:
AUTHOR(S):
                     Engel, Styli
                     Med Ad News, ( ***March 1999*** ) Vol. 18, No. 3, pp.
SOURCE:
                     1(1).
                     ISSN: 0745-0907.
PUBLISHER:
                     Engel Communications, Inc.
DOCUMENT TYPE:
                     Newsletter
                     English
LANGUAGE:
WORD COUNT:
                     41331
                     *FULL TEXT IS AVAILABLE IN THE ALL FORMAT*
L7
     ANSWER 56 OF 228
                       PROMT COPYRIGHT 2004 Gale Group on STN
                    <sup>→</sup>97:232738 PROMT
ACCESSION NUMBER:
                     Guilford's Promising "Nerve Regenerators"
Marketletter, ( ***28 Apr 1997*** ) pp. N/A.
TITLE:
SOURCE:
                     ISSN: 0951-3175.
                    _ English
LANGUAGE:
WORD COUNT:
                        354
                     *FULL TEXT IS AVAILABLE IN THE ALL FORMAT*
L7
     ANSWER 57 OF 228 PROMT COPYRIGHT 2004 Gale Group on STN
ACCESSION NUMBER:
                     96:643918 PROMT
TITLE:
                     Vertex compound accelerates nerve regeneration in rat
                     BIOTECH Patent News, ( ***1 Nov 1996*** ) pp. N/A.
SOURCE:
                     ISSN: 0898-2813.
LANGUAGE:
                     English
```

WORD COUNT:

605

```
"FULL TEXT IS AVAILABLE IN THE ALL FORMAT"
L7
     ANSWER 58 OF 228 PROMT COPYRIGHT 2004 Gale Group on STN
                    96:606025 PROMT
ACCESSION NUMBER:
                    Oral Compound Designed by Vertex Pharmaceuticals
TITLE:
                    Accelerates Nerve Regeneration in Rat Model
                     PR Newswire, ( ***18 Nov 1996*** ) pp. 1118NEM014.
SOURCE:
LANGUAGE:
                     English
                       679
WORD COUNT:
                     *FULL TEXT IS AVAILABLE IN THE ALL FORMAT*
     ANSWER 59 OF 228 PROMT COPYRIGHT 2004 Gale Group on STN
L7
ACCESSION NUMBER:
                    92:160979 PROMT
                                                           ***Transplantation***
                    Market Studies: Future Prospects of
TITLE:
                     - What Will Happen in the Next 20 Years?
                     Biomedical Market Newsletter, ( ***Jan 1992*** ) pp. N/A.
SOURCE:
LANGUAGE:
                     English
WORD COUNT:
                     2496
                     *FULL TEXT IS AVAILABLE IN THE ALL FORMAT*
L7
     ANSWER 60 OF 228 SCISEARCH COPYRIGHT 2004 THOMSON ISI ON STN
     2000:831671 SCISEARCH
AN
GΑ
     The Genuine Article (R) Number: 369JA
TI
     Neuroimmunophilin ligand enhances neurite outgrowth and effect of fetal
                ***transplants***
     Costantini L C; Isacson O (Reprint)
MCLEAN HOSP, MASSACHUSETTS GEN HOSP, DEPT NEUROL & PSYCHIAT, 115 MILL ST,
ΑU
CS
     BELMONT, MA 02178 (Reprint); MCLEAN HOSP, MASSACHUSETTS GEN HOSP, DEPT
     NEUROL & PSYCHIAT, BELMONT, MA 02178; HARVARD UNIV, MCLEAN HOSP, SCH MED, NEUROREGENERAT LAB, BELMONT, MA 02178
CYA
     NEUROSCIENCE, ( ***SEP 2000*** ) Vol. 100, No. 3, pp. 515-520.
S0
     Publisher: PERGAMON-ELSEVIER SCIENCE LTD, THE BOULEVARD, LANGFORD LANE,
     KIDLINGTON, OXFORD OX5 1GB, ENGLAND.
     ISSN: 0306-4522.
DT
     Article; Journal
FS
     LIFE
     English
LA
REC
     Reference Count: 50
     *ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS*
L7
     ANSWER 61 OF 228 SCISEARCH COPYRIGHT 2004 THOMSON ISI on STN
     1999:11963 SCISEARCH
ΑN
GΑ
     The Genuine Article (R) Number: 148QW
     Chronic cyclosporine-A injection in rats with damaged blood-brain barrier
TI
     does not impair retention of passive avoidance
     Borlongan C V (Reprint); Fujisaki T; Watanabe S
ΑU
     NIDA, DEPT CELLULAR NEUROPHYSIOL, INTRAMURAL RES PROGRAM, NIH, 5500 NATHAN
     SHOCK DR, BALTIMORE, MD 21224 (Reprint); KEIO UNIV, DEPT PSYCHOL, MINATO
     KU, TOKYÓ 108, JAPAŃ
     USA; JAPAN
CYA
     NEUROSCIENCE RESEARCH, ( ***NOV 1998*** ) Vol. 32, No. 3, pp. 195-200.
S0
     Publisher: ELSEVIER SCI IRELAND LTD, CUSTOMER RELATIONS MANAGER, BAY 15,
     SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND.
     ISSN: 0168-0102.
DT
     Article; Journal
FS
     LIFE
     English
LA
     Reference Count: 27
REC
     *ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS*
L7
     ANSWER 62 OF 228 SCISEARCH COPYRIGHT 2004 THOMSON ISI ON STN
     97:807435 SCISEARCH
AN
GΑ
     The Genuine Article (R) Number: YC965
     Fetal pig neural cells as a restorative therapy for neurodegenerative
TI
     disease
```

CYA USA SO ARTIFICIAL ORGANS, (***NOV 1997***) Vol. 21, No. 11, pp. 1192-1198. Publisher: BLACKWELL SCIENCE INC, 350 MAIN ST, MALDEN, MA 02148. ISSN: 0160-564X.

Beaulieu L; Dinsmore J (Reprint)

INC, CHARLESTOWN, MA 02129

ΑU

CS

Jacoby D B; Lindberg C; Ratliff J; Wunderlich M; Bousquet J; Wetzel K;

DIACRIN INC, BLDG 96, 13TH ST, CHARLESTOWN, MA 02129 (Reprint); DIACRIN

```
DT
      Article; Journal
      CLIN
FS
      English
LA
REC
      Reference Count: 34
      *ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS*
      ANSWER 63 OF 228 SCISEARCH COPYRIGHT 2004 THOMSON ISI on STN
L7
      97:376163 SCISEARCH
AN
      The Genuine Article (R) Number: WY073
GA
      Xenogeneic adrenal medulla graft rejection rather than survival leads to
TI
      increased rat striatal tyrosine hydroxylase immunoreactivity
      Bresjanac M (Reprint); Sagen J; Seigel G; Paino C L; Kordower J; Gash D M INST PATHOPHYSIOL, LAB NEURONAL PLAST & REGENERAT, ZALOSKA 4, LJUBLJANA
CS
      1000, SLOVENIA (Reprint)
CYA
      SLOVENIA
      JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, ( ***MAY 1997*** )
SO
      Vol. 56, No. 5, pp. 490-498.
      Publisher: AMER ASSN NEUROPATHOLOGISTS INC, 1041 NEW HAMPSHIRE ST,
      LAWRENCE, KS 66044.
      ISSN: 0022-3069.
      Article; Journal
DT
FS
      LIFE
      English
IΑ
REC
      Reference Count: 38
      *ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS*
L7
      ANSWER 64 OF 228 USPATFULL on STN
        2003:6968 USPATFULL
ΑN
TT
        GDNF receptor
        Klein, Robert D., South San Francisco, CA, United States
ΊN
        Moore, Mark W., San Francisco, CA, United States
Rosenthal, Arnon, Burlingham, CA, United States
Ryan, Anne M., Millbrae, CA, United States
        Genentech, Inc., South San Francisco, CA, United States (U.S.
PA
        corporation)
PΤ
        us 6504007
                                      20030107
        WO 9733912
                      19970918
                                                                                    <--
        US 1997-860370
                                      19970606 (8)
ΑI
        wo 1997-us4363
                                      19970313
                                      19970606 PCT 371 date
        Continuation-in-part of Ser. No. US 1996-618236, filed on 14 Mar 1996,
RLI
        now abandoned Continuation-in-part of Ser. No. US 1996-615902, filed on
        14 Mar 1996, now abandoned
DT
        Utility
        GRANTED
FS
LN.CNT 4881
INCL
        INCLM: 530/350.000
        INCLS: 930/010.000
        NCLM: 530/350.000
NCL
        NCLS: 930/010.000
IC
        [7]
        ICM: C07K014-71
        536/23.1; 536/23.4; 536/23.5; 435/69.1; 435/325; 435/320.1; 530/350;
EXF
        930/10
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L7
      ANSWER 65 OF 228 USPATFULL ON STN
        2002:160547 USPATFULL
ΑN
TT
        Tyrosine kinase receptors and ligands
        Valenzuela, David M., Yorktown Heights, NY, United States
Glass, David J., Cortlandt Manor, NY, United States
Bowen, David C., Washington, DC, United States
Yancopoulos, George D., Yorktown Heights, NY, United States
Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States (U.S.
IN
PΔ
        corporation)
PT
        US 6413740
                                      20020702
                                В1
        wo 9721811 19970619
                                                                                   <--
        US 1998-77955
ΑI
                                      19980910 (9)
                                      19961213
        WO 1996-US20695
                                      19980910
                                                 PCT 371 date
        Continuation-in-part of Ser. No. US 1996-644271, filed on 10 May 1996, now patented, Pat. No. US 5814478
RLI
        US 1995-8657P
PRAI
                                 19951215 (60)
        Utility
DT
FS
        GRANTED
LN.CNT 3819
```

```
INCL
          INCLM: 435/069.100
          INCLS: 435/070.100; 435/071.100; 435/071.200; 536/023.500; 530/350.000
NCL
                   435/069.100
                   435/070.100; 435/071.100; 435/071.200; 530/350.000; 536/023.500
IC
          [7]
          ICM: C12P021-06
ICS: C12P021-04; C07H021-04; C07K001-00; C12N015-74

EXF 514/2; 530/350; 530/300; 536/23.1; 536/23.5; 435/69.1; 435/70.1; 435/71.1; 435/71.2; 435/252.3; 435/320.1; 435/325; 435/471

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L7
       ANSWER 66 OF 228 USPATFULL on STN
ΑN
          2001:231277 USPATFULL
ΤI
          Carboxylic acids and carboxylic acid isosteres of N-heterocyclic
          compounds
IN
         Hamilton, Gregory S., Catonsville, MD, United States
          Norman, Mark H., Thousand Oaks, CA, United States
         Wu, Yong-Qian, Columbia, MD, United States
GPI Nil Holdings, Inc., Wilmington, DE, United States (U.S. corporation)
PA
PΙ
          us 6331537
                                   В1
                                          20011218
          US 1999-453571
                                           19991202 (9)
ΑI
RLI
          Continuation-in-part of Ser. No. US 1998-204237, filed on 3 Dec 1998,
          now abandoned
DT
          Utility
FS
          GRANTED
LN.CNT 3547
          INCLM: 514/215.000
INCL
          INCLS: 548/200.000;
                                     548/201.000; 548/123.000; 548/124.000; 548/127.000;
                                     548/131.000; 548/132.000;
548/143.000; 548/182.000;
548/255.000; 548/262.200;
                                                                        548/134.000;
                   548/128.000;
548/136.000;
                                                                                          548/135.000;
                                    548/143.000; 548/182.000; 548/206.000; 548/255.000; 548/262.200; 548/300.100; 548/364.100; 548/366.400; 548/540.000;
                                                                                          548/215.000;
                                                                                          548/311.100
                   548/240.000;
                                                                                          548/212.000
                   548/356.100;
                   548/326.000; 548/360.000; 548/361.000; 548/362.000;
                                                                                          548/363.000;
                   548/364.000; 548/365.000; 548/369.000; 548/371.000;
                                                                                          548/572.000;
                   548/374.000; 548/376.000; 548/378.000; 548/380.000; 548/383.000;
                   548/396.000; 548/401.000; 548/402.000; 548/406.000; 540/596.000;
                   540/597.000; 540/602.000; 540/603.000; 546/207.000; 546/208.000;
                   546/209.000; 546/210.000
                   514/215.000

540/596.000; 540/597.000; 540/602.000; 540/603.000; 546/207.000;

546/208.000; 546/209.000; 546/210.000; 548/123.000; 548/124.000;

546/208.000; 546/209.000; 546/210.000; 548/133.000; 548/134.000;
NCL
          NCLM:
          NCLS:
                                     548/128.000;
                                                      548/131.000; 548/132.000;
                                                                                          548/134.000
                   548/127.000;
                   548/135.000; 548/136.000;
                                                      548/143.000; 548/182.000;
                                                                                          548/200.000;
                   548/201.000; 548/206.000; 548/212.000; 548/215.000; 548/240.000;
                   548/255.000; 548/262.200; 548/300.100; 548/311.100; 548/356.100;
                   548/364.100; 548/366.400; 548/401.000; 548/402.000; 548/406.000; 548/540.000; 548/572.000
IC
          [7]
          ICM: A01N043-46
         ICS: A61K031-55; C07D403-12

548/200; 548/201; 548/540; 548/123; 548/124; 548/127; 548/128; 548/131;

548/132; 548/135; 548/136; 548/143; 548/182; 548/206; 548/215; 548/240;

548/250; 548/255; 548/262.2; 548/300.1; 548/311.1; 548/356.1; 548/364.1;
EXF
          548/366.4; 514/360; 514/361; 514/362; 514/363; 514/364; 514/365; 514/369; 514/371; 514/372; 514/374; 514/376; 514/378; 514/380; 514/383; 514/396; 514/401; 514/402; 514/406; 514/326; 514/212; 514/215
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L7
       ANSWER 67 OF 228 USPATFULL on STN
ΑN
          2001:231143 USPATFULL
          Arrays for identifying agents which mimic or inhibit the activity of
ΤI
          interferons
          Silverman, Robert H., Beachwood, OH, United States
IN
         Williams, Bryan R. G., Cleveland, OH, United States
Der, Sandy, Cleveland, OH, United States
          The Cleveland Clinic Foundation, Cleveland, OH, United States (U.S.
PΑ
          corporation)
PΙ
          us 6331396
                                          20011218
                                                                                             <--
          US 1999-405438
                                          19990923 (9)
ΑI
         US 1998-101497P
PRAI
                                    19980923 (60)
         Utility
DT
         GRANTED
FS
LN.CNT 9639
INCL
         INCLM: 435/006.000
          INCLS: 435/287.200; 536/023.100; 536/023.520; 536/024.300; 536/024.310
```

NCL

NCLM: 435/006.000

```
NCLS: 435/287.200; 536/023.100; 536/023.520; 536/024.300; 536/024.310
IC
       [7]
       ICM: C12Q001-68
       ICS: C12M001-36; C07H021-04
EXF
       435/6; 435/287.2; 536/23.1; 536/24.31; 536/23.52
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L7
     ANSWER 68 OF 228 USPATFULL on STN
       2001:226652 USPATFULL
ΑN
TI
       Hydroxy pipecolate hydroxamic acid derivatives
       McClure, Kim F., Mystic, CT, United States
IN
       Noe, Mark C., Mystic, CT, United States
       Letavic, Michael A., Mystic, CT, United States
       Chupak, Louis S., Old Saybrook, CT, United States
       Pfizer, New York, NY, United States (U.S. corporation)
PA
PΙ
       us 6329397
                            в1
                                 20011211
                                                                         <--
       us 1999-372946
                                 19990812 (9)
AΙ
       US 1998-96232P
                             19980812 (60)
PRAI
DT
       Utility
FS
       GRANTED
LN.CNT 3280
TNCL
       INCLM: 514/330.000
       INCLS: 514/354.000; 546/016.000; 546/225.000; 546/245.000; 546/323.000
NCL
               514/330.000
               514/354.000; 546/016.000; 546/225.000; 546/245.000; 546/323.000
       NCLS:
IC
       [7]
       ICM: A61K031-445
       ICS: C07D211-60
       546/16; 546/225; 546/245; 546/323; 514/330; 514/354
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L7
     ANSWER 69 OF 228 USPATFULL on STN
       2001:224608 USPATFULL
AN
TI
       METHOD FOR PROVIDING PATHOGEN-FREE PORCINE TISSUE SUITABLE FOR HUMAN
          ***TRANSPLANTATION***
       HUNTER, RICHARD, PRINCETON, NJ, United States
IN
       EGAN, E. MICHAEL, BROOKLINE, MA, United States
PA
       DIACRIN, INC. (U.S. corporation)
       us 2001049827
ΡI
                            Α1
                                 20011206
                                                                          <--
       us 1997-906009
                                 19970804 (8)
AΙ
                            Α1
RLI
       Continuation of Ser. No. US 1996-630282, filed on 10 Apr 1996, ABANDONED
       Utility
DT
       APPLICATION
FS
LN.CNT 1007
       INCLM: 800/008.000
INCL
       INCLS: 435/178.000; 424/093.100; 424/093.700; 424/093.210
               800/008.000
NCL
       NCLM:
       NCLS:
               435/178.000; 424/093.100; 424/093.700; 424/093.210
IC
        [7]
       ICM: A01K067-00
       ICS: A01K067-033; A61K048-00
L7
     ANSWER 70 OF 228 USPATFULL on STN
       2001:212419 USPATFULL
AN
TI
       Inhibition of apoptosis using interleukin-1B-converting enzyme
       (ICE)/CED-3 family inhibitors
IN
       Fritz, Lawrence C., Rancho Santa Fe, CA, United States
       Tomaselli, Kevin J., San Diego, CA, United States
Karanewski, Donald S., Escondido, CA, United States
       Linton, Steven D., San Diego, CA, United States
Bai, Xu, Carlsbad, CA, United States
US 2001044415 A1 20011122
PΙ
                                                                         --
ΑI
       us 2001-737169
                            Α1
                                 20010312 (9)
       Continuation of Ser. No. US 1997-979909, filed on 12 Sep 1997, GRANTED,
RLI
       Pat. No. US 6200969
PRAI
       US 1996-26011P
                             19960912 (60)
       Utility
DT
FS
       APPLICATION
LN.CNT 4242
INCL
       INCLM: 514/044.000
NCL
              514/044.000
       NCLM:
       [7]
IC
       ICM: A61K048-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
```

L7

ANSWER 71 OF 228 USPATFULL ON STN

```
2001:205917 USPATFULL
AN
       2-oxo-imidazolidine-4-carboxylic acid hydroxamide compounds that inhibit
TI
       matrix metalloproteinases
       Robinson, Ralph P., Gales Ferry, CT, United States
       Laird, Ellen R., Mystic, CT, United States
       US 2001041710
PΙ
                                20011115
                           Α1
                                                                        <--
       US 6458822
                                 20021001
                           В2
       US 2000-730302
US 2000-188892P
                                 20001205 (9)
ΑI
                           Α1
                            20000313 (60)
PRAI
DT
       Utility
       APPLICATION
FS
LN.CNT 1685
       INCLM: 514/278.000
INCL
       INCLS: 514/386.000; 514/387.000; 546/016.000; 546/216.000; 548/216.000;
               548/230.000
              514/401.000
NCL
       NCLM:
       NCLS:
              548/333.500
IC
       [7]
       ICM: A61K031-44
       ICS: A61K031-415
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L7
     ANSWER 72 OF 228 USPATFULL on STN
       2001:202682 USPATFULL
AN
       Therapeutic methods employing disulfide derivatives of dithiocarbonates
TI
       and compositions useful therefor
IN
       Lai, Ching-San, Encinitas, CA, United States
       Vassilev, Vassil, San Diego, CA, United States
       PA
PΙ
       us 2000-565666
                                 20000505 (9)
ΑI
       Division of Ser. No. US 1998-103639, filed on 23 Jun 1998, now patented,
RLI
       Pat. No. US 6093743
       Utility
DT
FS
       GRANTED
LN.CNT 2591
       INCLM: 514/599.000
INCL
       INCLS: 514/707.000; 514/825.000; 514/838.000; 514/851.000; 514/861.000;
               514/866.000; 514/885.000; 514/903.000; 514/912.000; 514/925.000
               514/599.000
NCL
       NCLM:
               514/707.000; 514/825.000; 514/838.000; 514/851.000; 514/861.000; 514/866.000; 514/885.000; 514/903.000; 514/912.000; 514/925.000
       NCLS:
       [7]
TC
       ICM: A01N037-18
       514/599; 514/707; 514/825; 514/838; 514/851; 514/861; 514/863; 514/885; 514/866; 514/903; 514/912; 514/925
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 73 OF 228 USPATFULL on STN
L7
       2001:200558 USPATFULL
ΑN
       Cloned ungulate embryos and animals, use of cells, tissues and organs thereof for ***transplantation*** therapies including
TI
         ***parkinson*** 's disease
       Stice, Steven L., Belchertown, MA, United States
IN
       Cibelli, Jose, Amherst, MA, United States
       Robl, James M., Belchertown, MA, United States
       University of Massachusetts, Amherst, MA, United States (U.S.
PA
       corporation)
PΙ
       us 2001039667
                           Α1
                                 20011108
                                                                         <--
ΑI
       us 2001-845352
                           Α1
                                 20010501 (9)
       Continuation of Ser. No. US 1998-66652, filed on 27 Apr 1998, PENDING
RLI
       Continuation-in-part of Ser. No. US 1998-4606, filed on 8 Jan 1998,
       GRANTED, Pat. No. US 6215041 Continuation-in-part of Ser. No. US
       1997-888057, filed on 3 Jul 1997, GRANTED, Pat. No. US 6235969
       Continuation-in-part of Ser. No. US 1997-781752, filed on 10 Jan 1997,
       GRANTED, Pat. No. US 5945577
DT
       Utility
       APPLICATION
FS
LN.CNT 3256
INCL
       INCLM: 800/015.000
       INCLS: 424/093.210; 435/325.000
NCL
       NCLM:
              800/015.000
              424/093.210; 435/325.000
       NCLS:
IC
       [7]
       ICM: A01K067-027
       ICS: A61K048-00; C12N005-06
```

```
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L7
     ANSWER 74 OF 228 USPATFULL on STN
       2001:194124 USPATFULL
AN
       Combinatorial enzymatic complexes
TI
       Nolan, Garry P., Menlo Park, CA, United States
Payan, Donald, Hillsborough, CA, United States
Rigel Pharmaceuticals, Inc. (U.S. corporation)
TN
PA
       us 2001036638
                                  20011101
PΙ
                            Α1
       us 2001-789652
                                  20010220 (9)
ΑI
                            Α1
       Division of Ser. No. US 1997-873601, filed on 12 Jun 1997, PENDING
RLI
       Utility
DT
       APPLICATION
FS
LN.CNT 2249
       INCLM: 435/007.100
INCL
       INCLS: 435/325.000
               435/007.100
NCL
       NCLM:
               435/325.000
       NCLS:
       [7]
IC
       ICM: G01N033-53
       ICS: C12N005-06; C12N005-08; C12N005-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L7
     ANSWER 75 OF 228 USPATFULL ON STN
       2001:188210 USPATFULL
AN
       Methods for inducing T cell tolerance to a tissue or organ graft
ΤI
       Noelle, Randolph J., Cornish, NH, United States
IN
       Durie, Fiona H., Seattle, WA, United States
Trustees of Dartmouth College, Hanover, NH, United States (U.S.
PA
       corporation)
PΙ
       us 2001033840
                                  20011025
                            Α1
       us 2001-888639
                            Α1
                                  20010626 (9)
AΙ
       Continuation of Ser. No. US 1999-227081, filed on 5 Jan 1999, PENDING
RLI
       Division of Ser. No. US 1997-906332, filed on 5 Aug 1997, GRANTED, Pat.
       No. US 5902585 Division of Ser. No. US 1994-234987, filed on 25 Apr
       1994, GRANTED, Pat. No. US 5683693
DT
       Utility
FS
       APPLICATION
LN.CNT 1061
        INCLM: 424/144.100
INCL
NCL
       NCLM: 424/144.100
IC
       ICM: A61K039-395
L7
     ANSWER 76 OF 228 USPATFULL on STN
        2001:185549
                     USPATFULL
ΑN
        Infection of human neural xenografts
TI
       Epstein, Leon G., 80 Council Rock Ave., Rochester, NY, United States
IN
       14610
       Del Cerro, Manuel, 13 Tall Acres Dr., Pittsford, NY, United States
       Blumberg, Benjamin M., 32 Calumet St., Rochester, NY, United States
       14610
PΙ
       US 6307122
                                  20011023
                            В1
ΑI
       us 1992-965901
                                  19921023 (7)
       Continuation-in-part of Ser. No. US 1991-786449, filed on 1 Nov 1991
RLI
DT
       Utility
        GRANTED
FS
LN.CNT
       829
INCL
        INCLM: 800/011.000
        INCLS: 800/003.000; 800/018.000; 424/009.000; 424/093.100
NCL
       NCLM:
               800/011.000
       NCLS:
               424/093.100; 800/003.000; 800/018.000
        [7]
IC
        ICM: A01N063-00
        424/9; 424/93; 424/570; 424/571; 424/520; 424/582; 424/578; 800/2;
EXF
        800/DIG.2; 800/DIG.5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 77 OF 228 USPATFULL on STN
L7
        2001:163053 USPATFULL
AN
       Porcine neural cells and their use in treatment of neurological deficits
TT
       due to neurodegenerative diseases
       Isacson, Ole, Cambridge, MA, United States
IN
       Dinsmore, Jonathan, Brookline, MA, United States
```

The McLean Hospital Corporation, Belmont, MA, United States (U.S.

PA

```
corporation)
         Diacrin, Inc., Charlestown, MA, United States (U.S. corporation)
                                          20010925
PΙ
         US 6294383
                                   В1
ΑI
         US 1995-424851
                                          19950419 (8)
         Continuation-in-part of Ser. No. US 1994-336856, filed on 8 Nov 1994,
RLI
         now abandoned
DT
         Utility
FS
         GRANTED
LN.CNT 4123
         INCLM: 435/379.000
INCL
         INCLS: 435/325.000
         NCLM: 435/379.000
NCL
         NCLS: 435/325.000
         [7]
IC
         ICM: C12N005-00
         ICS: C12N005-02
         435/240.1; 435/240.2; 435/325; 435/379
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
       ANSWER 78 OF 228 USPATFULL ON STN
L7
         2001:163016 USPATFULL
AN
         Use of multipotent neural stem cells and their progeny for the screening
TI
         of drugs and other biological agents
         Weiss, Samuel, Calgary, Canada
IN
         Reynolds, Brent, Calgary, Canada
         Hammang, Joseph P., Barrington, RI, United States
         Baetge, E. Edward, Barrington, RI, United States
         Neurospheres Holdings, Ltd., Alberta, Canada (non-U.S. corporation)
US 6294346 B1 20010925 <--
PA
PΙ
         US 1995-484406 19950607 (8)

Continuation-in-part of Ser. No. US 1995-385404, filed on 7 Feb 1995, now abandoned , said Ser. No. US 484406 And Ser. No. US 1995-376062, filed on 20 Jan 1995, now abandoned , said Ser. No. US 484406 And Ser. No. US 1994-359945, filed on 20 Dec 1994, now abandoned , said Ser. No. US 484406 And Ser. No. US 1994-338730, filed on 14 Nov 1994, now abandoned , said Ser. No. US 1994-311099 filed
ΑI
RLI
         abandoned, said Ser. No. US 484406 And Ser. No. US 1994-311099, filed
         on 23 Sep 1994, now abandoned , said Ser. No. US 484406 And Ser. No. US
         1994-270412, filed on 5 Jul 1994, now abandoned , said Ser. No. US
         484406 And Ser. No. US 1993-149508, filed on 9 Nov 1993, now abandoned Continuation-in-part of Ser. No. US 1991-726812, filed on 8 Jul 1991, now abandoned Continuation of Ser. No. US 1992-961813, filed on 16 Oct 1992, now abandoned Continuation-in-part of Ser. No. US 726812
         Continuation of Ser. No. US 1993-10829, filed on 29 Jan 1993, now abandoned Continuation-in-part of Ser. No. US 726812 Continuation of
         Ser. No. US 1994-221655, filed on 1 Apr 1994, now abandoned Continuation
         of Ser. No. US 1992-967622, filed on 28 Oct 1992, now abandoned
          Continuation-in-part of Ser. No. US 726812 , said Ser. No. US 338730
          Continuation-in-part of Ser. No. US 726812 , said Ser. No. US 311099
          Continuation-in-part of Ser. No. US 726812 , said Ser. No. US 270412
          Continuation-in-part of Ser. No. US 726812
DT
         Utility
          GRANTED
FS
LN.CNT 4153
          INCLM: 435/007.210
INCL
          INCLS: 435/368.000; 435/377.000; 435/375.000
                  435/007.210
NCL
                  435/368.000; 435/375.000; 435/377.000
         NCLS:
IC
          [7]
          ICM: G01N033-554
          ICS: C12N005-00
EXF 435/7.21; 435/368; 435/378; 435/377; 435/375 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
       ANSWER 79 OF 228 USPATFULL on STN
L7
          2001:152476 USPATFULL
AΝ
          Devices containing cells or tissue and an agent that inhibits damage by
TI
          a host cell molecule
          Lanza, Robert P., Clinton, MA, United States
ΙN
          Ecker, Dawn M., Shrewsbury, MA, United States
          Ringeling, John, Boston, MA, United States
         Marsh, Joanne P., Shrewsbury, MA, United States
Chick, William, Wellesley, MA, United States
BioHybrio Technologies LLC, Shrewsbury, MA, United States (U.S.
PA
          corporation)
PΤ
          US 6287558
                                    B1
                                          20010911
                                          19970801 (8)
AΤ
          US 1997-904808
```

```
DT
         Utility
         GRANTED
FS
LN.CNT 3319
         INCLM: 424/093.700
INCL
        INCLS: 424/130.100; 424/423.000; 435/177.000; 435/178.000; 435/182.000; 435/382.000; 435/395.000; 435/397.000; 436/528.000; 436/529.000; 436/535.000; 530/812.000; 530/813.000; 530/817.000
                  424/093.700
NCL
        NCLM:
                 424/130.100; 424/423.000; 435/177.000; 435/178.000; 435/182.000; 435/382.000; 435/395.000; 435/397.000; 436/528.000; 436/529.000; 436/535.000; 530/812.000; 530/813.000; 530/817.000
         NCLS:
IC
         [7]
         ICM: A61K035-12
         ICS: C12N011-00; C12N011-04; C12N005-00
         435/174; 435/177; 435/178; 435/182; 435/395; 435/397; 435/382; 424/93.7;
EXF
         424/423; 424/130.1; 436/528; 436/529; 436/535; 530/812; 530/813; 530/817
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 80 OF 228 USPATFULL ON STN
L7
AN
         2001:136181 USPATFULL
         Porcine neural cells and their use in treatment of neurological deficits
TI
         due to neurodegenerative diseases
         Fraser, Thomas, Newton, MA, United States
IN
         Dinsmore, Jonathan, Brookline, MA, United States
         Diacrin, Inc., Charlestown, MA, United States (U.S. corporation)
PA
                                       20010821
PΙ
         US 6277372
                                 В1
         US 1995-424855
                                       19950419 (8)
ΑI
         Continuation-in-part of Ser. No. US 1994-336856, filed on 8 Nov 1994,
RLI
         now abandoned
DT
         Utility
FS
         GRANTED
LN.CNT 4112
         INCLM: 424/093.700
INCL
         INCLS: 424/093.100; 435/325.000
NCL
                 424/093.700
                 424/093.100; 435/325.000
         NCLS:
         [7]
IC
         ICM: A01N063-00
ICS: C12N005-02; C12N005-06
EXF 435/325; 424/93.1; 424/93.7
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 81 OF 228 USPATFULL on STN
L7
         2001:131342 USPATFULL
AN
         Conjugates of dithiocarbamate disulfides with pharmacologically active
TT
         agents and uses therefor
         Lai, Ching-San, Encinitas, CA, United States
IN
         Vassilev, Vassil P., San Diego, CA, United States
         Wang, Tingmin, San Marcos, CA, United States
Medinox, Inc., San Diego, CA, United States (U.S. corporation)
PA
         US 6274627
                                       20010814
PΙ
                                 в1
         US 1999-416619
                                       19991012 (9)
ΑI
         Utility
DT
         GRANTED
FS
LN.CNT 2173
INCL
         INCLM: 514/599.000
         INCLS: 514/706.000; 514/707.000
                 514/599.000
NCL
         NCLM:
         NCLS:
                 514/706.000; 514/707.000
IC
         [7]
         ICM: A61K031-16
         ICS: A61K031-095; A61K031-105
514/599; 514/706; 514/707
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L7
      ANSWER 82 OF 228 USPATFULL on STN
         2001:126193 USPATFULL
ΑN
         Cells and methods for the generation of transgenic pigs
TI
         Piedrahita, Jorge A., College Station, TX, United States
Bazer, Fuller W., College Station, TX, United States
The Texas A & M University System, College Station, TX, United States
IN
PA
         (U.S. corporation)
US 6271436
                                       20010807
PT
                                                                                       <--
         US 1997-949155
                                       19971010 (8)
AΤ
                                  19961011 (60)
PRAI
         US 1996-27338P
                                  19970509 (60)
         US 1997-46094P
```

```
DT
         Utility
FS
         GRANTED
LN.CNT 8905
INCL
         INCLM: 800/021.000
        INCLS: 800/022.000; 800/024.000; 800/025.000; 800/014.000; 800/017.000; 800/018.000; 800/015.000; 800/016.000; 435/325.000; 435/383.000; 435/384.000; 435/455.000; 435/463.000; 435/461.000; 435/459.000;
                  435/462.000
         NCLM:
                  800/021.000
NCL
                  435/325.000; 435/383.000; 435/384.000; 435/455.000; 435/459.000; 435/461.000; 435/462.000; 435/463.000; 800/014.000; 800/015.000; 800/016.000; 800/017.000; 800/018.000; 800/022.000; 800/024.000;
         NCLS:
                  800/025.000
         [7]
IC
         ICM: C12N015-09
         ICS: C12N015-00; C12N015-63; C12N005-00
         435/325; 435/383; 435/384; 435/455; 435/463; 435/461; 435/459; 435/462;
EXF
         800/13; 800/14; 800/15; 800/16; 800/17; 800/21; 800/22; 800/24; 800/25;
         800/18
      ANSWER 83 OF 228 USPATFULL ON STN
L7
         2001:126109 USPATFULL
AN
         Tetracycline-inducible transcriptional inhibitor fusion proteins
ΤI
         Bujard, Hermann, Heidelberg, Germany, Federal Republic of
TN
         Gossen, Manfred, El Cerrito, CA, United States
         BASF Aktiengesellschaft, Ludwigshafen, Germany, Federal Republic of
PA
         (non-U.S. corporation)
         Knoll Aktiengesellschaft, Ludwigshafen, Germany, Federal Republic of
         (non-U.S. corporation)
                                         20010807
PΙ
         us 6271348
                                  В1
         us 2000-489777
                                         20000124 (9)
ΑI
         Division of Ser. No. US 1998-162184, filed on 28 Sep 1998, now patented, Pat. No. US 6136954 Continuation of Ser. No. US 1995-485978, filed on 7
RLI
         Jun 1995, now patented, Pat. No. US 5814618 Continuation-in-part of Ser.
         No. US 1995-383754, filed on 3 Feb 1995, now patented, Pat. No. US
         5789156 Continuation-in-part of Ser. No. US 1994-275876, filed on 15 Jul
         1994, now patented, Pat. No. US 5654168 Continuation-in-part of Ser. No.
         US 1994-270637, filed on 1 Jul 1994, now abandoned Continuation-in-part of Ser. No. US 1994-260452, filed on 14 Jun 1994, now patented, Pat. No. US 5650298 Continuation-in-part of Ser. No. US 1993-76327, filed on 19 Jun 1993, now abandoned Continuation-in-part of Ser. No. US 1993-76726,
         filed on 14 Jun 1993, now patented, Pat. No. US 5464758
DT
         Utility
         GRANTED
FS
LN.CNT 4009
INCL
         INCLM: 530/350.000
         INCLS: 435/006.000; 435/069.100; 536/023.400
NCL
                  530/350.000
                  435/006.000; 435/069.100; 536/023.400
         NCLS:
IC
         [7]
         ICM: C07K019-00
         ICS: C07K014-195
         530/350; 435/6; 435/69.1; 536/23.4
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
       ANSWER 84 OF 228 USPATFULL ON STN
L7
         2001:126102 USPATFULL
ΑN
         Transcriptional activators with graded transactivation potential
TI
         Baron, Udo, St. Ilgen, Germany, Federal Republic of
IN
         Gossen, Manfred, El Cerrito, CA, United States
Bujard, Hermann, Heidelberg, Germany, Federal Republic of
BASF Aktiengesellschaft, Ludwigshafen, Germany, Federal Republic of
PA
          (non-U.S. corporation)
         Udo Baron, St. Ilgen, Germany, Federal Republic of (non-U.S.
         corporation)
PΙ
         us 6271341
                                         20010807
                                                                                          <--
         US 2000-577027
                                         20000523 (9)
ΑI
         Division of Ser. No. US 1997-888080, filed on 3 Jul 1997, now patented,
RLI
         Pat. No. US 6087166
         Utility
DT
FS
         GRANTED
LN.CNT 1847
INCL
         INCLM: 530/300.000
         INCLS: 530/324.000; 530/350.000
NCL
         NCLM:
                   530/300.000
         NCLS:
                   530/324.000; 530/350.000
```

```
IC
        ICM: C07K019-00
        530/300; 530/324; 530/350
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 85 OF 228 USPATFULL on STN
L7
        2001:116980 USPATFULL
AN
        Peptide T and related peptides in the treatment of inflammation,
ΤI
        including multiple sclerosis
        Andersen, Anders Jorgen, Kokkedal, Denmark
Aston, Roger, Wiltshire, United Kingdom
Carlen, Peter Louis, Ontario, Canada
Doob, Penelope Reed, Ontario, Canada
IN
        MacFadden, Douglas Kevin, Ontario, Canada
        Phipps, David James, Ontario, Canada
        Rathjen, Deborah, New South Wales, Australia
        Widmer, Fred, New South Wales, Australia
        Advanced Immuni T, Inc., Stonybrook, NY, United States (U.S.
PA
        corporation)
        US 6265374
US 1999-421845
PΤ
                              В1
                                    20010724
                                                                                <--
                                     19991020 (9)
ΑI
        Continuation of Ser. No. US 1998-82837, filed on 21 May 1998, now
RLI
        patented, Pat. No. US 6011014 Continuation of Ser. No. US 1995-302829,
        filed on 24 Feb 1995, now patented, Pat. No. US 5756449 Continuation of
        Ser. No. WO 1993-GB649, filed on 29 Mar 1993 Continuation of Ser. No. US
        1992-987674, filed on 9 Dec 1992, now abandoned Continuation-in-part of
        Ser. No. US 1992-915118, filed on 17 Jul 1992, now abandoned
        Continuation-in-part of Ser. No. US 1992-858832, filed on 27 Mar 1992,
        now abandoned
DT
        Utility
        GRANTED
FS
        2172
LN.CNT
INCL
        INCLM: 514/008.000
        INCLS: 514/015.000; 514/016.000; 514/017.000; 530/300.000; 530/322.000;
                 530/328.000; 530/329.000; 424/185.100
NCL
                514/008.000
                424/185.100; 514/015.000; 514/016.000; 514/017.000; 530/300.000;
        NCLS:
                530/322.000; 530/328.000; 530/329.000
IC
        [7]
        ICM: A61K038-00
        ICS: A61K038-16; A61K038-04; C07K005-00; C07K007-00
514/8; 514/15; 514/16; 514/17; 514/18; 514/19; 530/300; 530/322;
530/328; 530/329; 530/330; 530/331; 424/185.1
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 86 OF 228 USPATFULL on STN
L7
        2001:98155 USPATFULL
ΑN
        Transgenic organisms having tetracycline-regulated transcriptional
TI
        regulatory systems
        Bujard, Hermann, Heidelberg, Germany, Federal Republic of
Gossen, Manfred, El Cerrito, CA, United States
Salfeld, Jochen G., North Grafton, MA, United States
ΙN
                            West Boylston, MA, United States
        Voss, Jeffrey W.
        BASF Aktiengesellschaft, Germany, Federal Republic of (non-U.S.
PA
        corporation)
        Knoll Aktiengesellschaft, Germany, Federal Republic of (non-U.S.
        corporation)
        US 6252136
                                     20010626
PI
                               В1
                                     19980929 (9)
        US 1998-163269
ΑI
RLI
        Continuation of Ser. No. US 1995-481970, filed on 7 Jun 1995, now
        patented, Pat. No. US 5859310 Continuation-in-part of Ser. No. US 1994-260452, filed on 14 Jun 1994, now patented, Pat. No. US 5650298
        Continuation-in-part of Ser. No. US 1993-76327, filed on 14 Jun 1993,
        now abandoned
        Utility
DT
        GRANTED
LN.CNT 3033
        INCLM: 800/278.000
INCL
        INCLS: 435/069.100; 435/069.700; 435/320.100; 435/468.000; 800/288.000;
                 800/298.000
                 800/278.000
NCL
        NCLM:
                 435/069.100; 435/069.700; 435/320.100; 435/468.000; 800/288.000;
        NCLS:
                 800/298.000
         [7]
IC
        ICM: C12N015-09
        ICS: C12N015-82: C12N015-87; C12N015-90; A01H005-00
```

```
435/69.1; 435/410; 435/419; 435/468; 435/69.7; 435/320.1; 800/278;
EXF
        800/288; 800/295; 800/298
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L7
     ANSWER 87 OF 228 USPATFULL on STN
ΑN
        2001:89522 USPATFULL
                                              using pluripotent neuroepithelial cells
                  ***transplantation***
TI
IN
        Sinden, John, London, Great Britain
        Gray, Jeffrey A., London, Great Britain
        Hodges, Helen, London, Great Britain
        Kershaw, Timothy, London, Great Britain
Rashid-Doubell, Fiza, Oxford, Great Britain
        us 2001001662
                              Α1
                                    20010524
PΙ
        us 2001-760274
                                   20010112 (9)
                              Α1
ΑI
        Continuation of Ser. No. US 2000-672606, filed on 28 Sep 2000, UNKNOWN
RLI
                               19950912
PRAI
        GB 1995-18606
DT
        Utility
        APPLICATION
FS
LN.CNT 1036
INCL
        INCLM: 424/093.210
        INCLS: 424/093.700
                424/093.210
NCL
        NCLM:
                424/093.700
        NCLS:
IC
        [7]
        ICM: A61K048-00
        ICS: A01N063-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L7
      ANSWER 88 OF 228 USPATFULL ON STN
        2001:82992 USPATFULL
AN
        Transgenic organisms having tetracycline-regulated transcriptional
TI
        regulatory systems
        Bujard, Hermann, Heidelberg, Germany, Federal Republic of
ΙN
        Gossen, Manfred, El Cerrito, CA, United States
        BASF Aktiengesellschaft, Germany, Federal Republic of (non-U.S.
PA
        corporation)
        Knoll Aktiengesekkscgaft, Germany, Federal Republic of (non-U.S.
        corporation)
        us 6242667
                                    20010605
PΙ
                              B1
                                    19980928 (9)
        us 1998-161902
AΤ
        Continuation of Ser. No. US 1995-487472, filed on 7 Jun 1995, now patented, Pat. No. US 5694426 Continuation-in-part of Ser. No. US 1995-383754, filed on 3 Feb 1995, now patented, Pat. No. US 5789156
RLI
        Continuation-in-part of Ser. No. US 1994-275876, filed on 15 Jul 1994,
        now patented, Pat. No. US 5654168 Continuation-in-part of Ser. No. US
        1994-270637, filed on 1 Jul 1994, now abandoned Continuation-in-part of
        Ser. No. US 1994-260452, filed on 14 Jun 1994, now patented, Pat. No. US
        5650298 Continuation-in-part of Ser. No. US 1993-76327, filed on 14 Jun 1993, now abandoned Continuation-in-part of Ser. No. US 1993-76726,
        filed on 14 Jun 1993, now patented, Pat. No. US 5464758
DT
        Utility
FS
        Granted
LN.CNT 4161
        INCLM: 800/278.000
INCL
        INCLS: 435/069.100; 435/069.700; 435/320.100; 435/468.000; 800/287.000;
                 800/288.000; 800/298.000
        NCLM:
                 800/278.000
NCL
                435/069.100; 435/069.700; 435/320.100; 435/468.000; 800/287.000;
        NCLS:
                 800/288.000; 800/298.000
         [7]
IC
        ICM: C12N015-09
        ICS: C12N015-82; C12N015-87; C12N015-90; A01H005-00 435/455; 435/69.1; 435/320.1; 435/468; 435/69.7; 800/8; 800/21; 800/278;
EXF
        800/288; 800/295; 800/298; 800/287
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L7
      ANSWER 89 OF 228 USPATFULL on STN
        2001:55995 USPATFULL
ΑN
        Aminoiminoquinone and aminoquinone alkaloid compounds and methods of use
TT
        Gunasekera, Sarath P., Vero Beach, FL, United States
IN
        McCarthy, Peter J., Vero Beach, FL, United States
Longley, Ross E., Vero Beach, FL, United States
Pomponi, Shirley A., Ft. Pierce, FL, United States
        Wright, Amy E., Ft. Pierce, FL, United States
        Harbor Branch Oceanographic Institution, Inc., Fort Pierce, FL, United
PA
        States (U.S. corporation)
```

```
PΙ
       us 6218419
                                 20010417
                                                                         <--
       us 1999-349070
                                 19990708 (9)
AΙ
       US 1998-92020P
PRAI
                             19980708 (60)
DT
       Utility
FS
       Granted
LN.CNT 2227
       INCLM: 514/415.000
INCL
       INCLS: 514/427.000; 548/469.000; 548/494.000; 548/511.000; 548/516.000
               514/415.000
NCL
       NCLM:
       NCLS:
               514/427.000; 548/469.000; 548/494.000; 548/511.000; 548/516.000
IC
        [7]
       ICM: A61K031-404
       ics: A61P035-00; A61P037-02; C07D209-04; C07D209-12
       514/415; 514/427; 548/469; 548/494; 548/511; 548/516
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 90 OF 228 USPATFULL on STN
L7
       2001:55464 USPATFULL
ΑN
       Materials and methods for making improved micelle compositions
TI
IN
       Onyuksel, Hayat, Western Springs, IL, United States
       Rubinstein, Ísrael, Highland Park, IL, United States
The Board of Trustees of the University of Illinois, Urbana, IL, United
PA
       States (U.S. corporation)
       US 6217886
PΙ
                            В1
                                 20010417
                                                                         <--
       us 1999-239069
                                 19990127 (9)
ΑI
       Continuation-in-part of Ser. No. Wo 1998-US14316, filed on 9 Jul 1998
RLI
       US 1997-52078P
                             19970714 (60)
PRAI
DT
       Utility
FS
       Granted
LN.CNT
       2282
        INCLM: 424/401.000
INCL
       INCLS: 424/450.000; 424/001.210; 424/009.321; 424/009.510; 514/002.000;
               514/021.000; 514/937.000; 264/004.100; 264/004.300; 264/004.600
NCL
       NCLM:
               424/401.000
       NCLS:
               264/004.100; 264/004.300; 264/004.600; 424/001.210; 424/009.321;
               424/009.510; 424/450.000; 514/002.000; 514/021.000; 514/937.000
        [7]
IC
       ICM: A61K009-10
       ICS: A61K009-127
       424/450; 424/1.21; 424/9.321; 424/9.51; 424/417; 424/96.3; 424/401; 514/2; 514/21; 514/937-943; 264/4.1; 264/4.3; 264/4.6
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L7
     ANSWER 91 OF 228 USPATFULL on STN
        2001:52094 USPATFULL
AN
TI
       Dioxocyclopentyl hydroxamic acids
IN
       McClure, Kim F., Mystic, CT, United States
       Robinson, Ralph P., Gales Ferry, CT, United States
        Pfizer Inc, New York, NY, United States (U.S. corporation)
PA
                                 20010410
PΙ
       us 6214870
                            в1
ΑI
       us 2000-536950
                                  20000328 (9)
       US 1999-127071P
                             19990331 (60)
PRAI
       Utility
DT
FS
        Granted
       2023
LN.CNT
        INCLM: 514/466.000
INCL
        INCLS: 514/464.000; 514/465.000; 549/229.000; 549/436.000; 549/439.000;
               549/441.000
               514/466.000
NCL
       NCLM:
               514/464.000; 514/465.000; 549/229.000; 549/436.000; 549/439.000;
       NCLS:
               549/441.000
        [7]
IC
        ICM: A61K031-36
        ICS: C07D317-44
        514/466; 514/464; 514/465; 549/229; 549/436; 549/439; 549/441
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L7
     ANSWER 92 OF 228 USPATFULL on STN
AN
        2001:40462 USPATFULL
        Pharmaceutical preparations of glutathione and methods of administration
TI
IN
       Demopoulos, Harry B., Scarsdale, NY, United States
        Seligman, Myron L., Fairfield, CT, United States
PA
       Antioxidant Pharmaceuticals Corp., Elmsford, NY, United States (U.S.
        corporation)
PI
        us 6204248
                            в1
                                 20010320
                                                                          <--
```

```
ΑI
       us 1999-457642
                                 19991209 (9)
       Continuation of Ser. No. US 331947 Continuation of Ser. No. US
RLI
       1997-2100, filed on 31 Dec 1997, now abandoned
PRAI
       US 1996-34101P
                            19961231 (60)
DT
       Utility
       Granted
FS
LN.CNT 5144
       INCLM: 514/021.000
INCL
       INCLS: 514/018.000
               514/021.000
NCL
       NCLM:
              514/018.000
       NCLS:
       [7]
IC
       ICM: A61K031-00
       514/21: 514/18
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 93 OF 228 USPATFULL on STN
L7
       2001:40268 USPATFULL
ΑN
       Porcine cortical cells and their use in treatment of neurological
TI
       deficits due to neurodegenerative diseases
       Dinsmore, Jonathan, Brookline, MA, United States
Diacrin, Inc., Charlestown, MA, United States (U.S. corporation)
IN
PA
       us 6204053
                                 20010320
PΙ
                            В1
ΑI
       us 1995-424856
                                 19950419 (8)
       Continuation-in-part of Ser. No. US 1994-336856, filed on 8 Nov 1994,
RLI
       now abandoned
DT
       Utility
       Granted
FS
LN.CNT 3891
       INCLM: 435/325.000
INCL
       INCLS: 424/093.700; 435/374.000
              435/325.000
NCL
       NCLM:
       NCLS: 424/093.700; 435/374.000
       [7]
IC
       ICM: C12N005-00
       435/240.2; 435/325; 435/374; 424/93.7
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L7
     ANSWER 94 OF 228 USPATFULL on STN
       2001:37011 USPATFULL
ΑN
       Transgenic animal models for cardiac hypertrophy and methods of use
ΤI
       Grant, Stephen R., Ft. Worth, TX, United States
ΙN
       Olson, Eric N., Dallas, TX, United States
       Board of Regents, University of Texas System, Austin, TX, United States
PA
        (U.S. corporation)
PΙ
       us 6201165
                            В1
                                 20010313
                                                                         <--
       us 1998-173798
                                 19981015 (9)
ΑI
       Continuation of Ser. No. US 1998-61417, filed on 16 Apr 1998
RLI
                             19971016 (60)
PRAI
       US 1997-62864P
       US 1997-65178P
                             19971110 (60)
       US 1998-81853P
                             19980415 (60)
       Utility
DT
       Granted
FS
       3166
LN.CNT
INCL
       INCLM: 800/003.000
       INCLS: 435/004.000; 435/006.000; 435/007.100; 435/008.000; 435/325.000;
               435/354.000; 435/366.000; 800/018.000
               800/003.000
NCL
       NCLM:
               435/004.000; 435/006.000; 435/007.100; 435/008.000; 435/325.000; 435/354.000; 435/366.000; 800/018.000
       NCLS:
IC
       ICM: C12N005-08
       ICS: C12N015-85; C12Q001-00; C12Q001-66; G01N033-00
       800/9; 800/13; 800/14; 800/18; 800/3; 435/325; 435/4
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L7
     ANSWER 95 OF 228 USPATFULL on STN
AN
       2001:36816 USPATFULL
       Inhibition of apoptosis using interleukin-1.beta.-converting enzyme
TI
        (ICE)/CED-3 family inhibitors
       Fritz, Lawrence C., Rancho Santa Fe, CA, United States
ΙN
       Tomaselli, Kevin J., San Diego, CA, United States
       Karanewski, Donald S., Escondido, CA, United States
       Linton, Steven D., San Diego, CA, United States
       Bai, Xu, Carlsbad, CA, United States
```

```
PA
       Idun Pharmaceuticals, Inc., La Jolla, CA, United States (U.S.
       corporation)
PΙ
       us 6200969
                                 20010313
                                                                          <--
       us 1997-979909
                                 19970912 (8)
ΑI
                             19960912 (60)
PRAI
       US 1996-26011P
       Utility
DT
FS
       Granted
LN.CNT 4190
       INCLM: 514/214.000
INCL
       INCLS: 514/419.000
               514/212.050
NCL
       NCLM:
               514/419.000
       NCLS:
IC
       [7]
       ICM: A61K031-55
       514/214; 514/419
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 96 OF 228 USPATFULL on STN
L7
       2001:33306 USPATFULL
AN
TI
       3-(arylsulfonylamino)-tetrahydropyran-3-carboxylic acid hydroxamides
       Reiter, Lawrence A., Mystic, CT, United States
Pfizer Inc, New York, NY, United States (U.S. corporation)
ΙN
PA
                                 20010306
       US 6197810
                            B1
                                                                          --
PΙ
ΑI
       us 2000-579059
                                  20000526 (9)
       US 1999-136530P
                             19990528 (60)
PRAI
DT
       Utility
FS
       Granted
LN.CNT 2190
INCL
       INCLM: 514/459.000
       INCLS: 549/419.000; 549/424.000
NCL
               514/459.000
       NCLM:
               549/419.000; 549/424.000
       NCLS:
       [7]
IC
       ICM: A01N043-16
EXF
       549/419; 549/424; 514/459
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 97 OF 228 USPATFULL on STN
L7
       2001:33078 USPATFULL
ΑN
TI
       Human adenylate cyclase and use therefor
       Antoni, Ferenc, Edinburgh, United Kingdom
TN
       Paterson, Janice M, Edinburgh, United Kingdom
       Medical Research Council, London, United Kingdom (non-U.S. corporation) US 6197581 B1 20010306 <--
PA
PΙ
       us 6197581
                                  19990917 (9)
ΑI
       us 1999-398193
       Continuation-in-part of Ser. No. US 894173, now patented, Pat. No. US
RLI
       6090612
PRAI
       GB 1995-2806
                             19950214
       GB 1995-16528
                             19950811
       Utility
DT
FS
       Granted
LN.CNT 2249
       INCLM: 435/325.000
INCL
       INCLS: 435/252.300; 435/252.330; 435/320.100; 435/369.000; 536/023.200
               435/325.000
NCL
       NCLM:
               435/252.300; 435/252.330; 435/320.100; 435/369.000; 536/023.200
       NCLS:
IC
       [7]
       ICM: C12N005-10
       ICS: C12N005-00; C12N001-20; C12N015-00; C07H021-04 435/320.1; 435/232; 435/369; 435/252.3; 435/252.33; 435/325; 536/23.2
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L7
     ANSWER 98 OF 228 USPATFULL on STN
       2001:25652 USPATFULL
AN
TI
       Expression of an exogenous gene in a mammalian cell by use of a
       non-mammalian DNA virus having an altered coat protein
ΙN
       Boyce, Frederick M., Belmont, MA, United States
       Barsoum, James G., Lexington, MA, United States
PA
       The General Hospital Corporation, Boston, MA, United States (U.S.
       corporation)
       Biogen, Inc., Cambridge, MA, United States (U.S. corporation)
                                 20010220
PΙ
       us 6190887
                            в1
       US 2000-514953
                                  20000228 (9)
ΑI
       Division of Ser. No. US 1997-927317, filed on 11 Sep 1997
RLI
DT
       Utility
FS
       Granted
```

```
LN.CNT 2998
        INCLM: 435/069.700
INCL
        INCLS: 435/007.230; 435/069.100; 435/320.100; 514/012.000; 424/246.100
NCL
                435/069.700
                424/246.100; 435/007.230; 435/069.100; 435/320.100; 514/012.000
        NCLS:
        [7]
IC
        ICM: C12P021-04
        ICS: C12P021-06; G01N033-574; C12N015-70; A61K039-07 435/69.7; 435/7.23; 435/920.1; 435/69.1; 435/230.1
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 99 OF 228 USPATFULL on STN
L7
        2001:25458 USPATFULL
ΑN
        Methods for treating inflammatory conditions
TT
        Mak, Vivien H. W., Menlo Park, CA, United States
IN
        Adolor Corporation, Malvern, PA, United States (U.S. corporation)
PA
                                      20010220
        us 6190691
                               в1
PΙ
        US 1998-97440 19980615 (9)
Continuation of Ser. No. US 1995-463819, filed on 5 Jun 1995, now abandoned Continuation-in-part of Ser. No. US 1995-400234, filed on 3 Mar 1995, now abandoned Continuation-in-part of Ser. No. US 1994-271287,
ΑI
RLI
        filed on 6 Jul 1994, now abandoned Continuation-in-part of Ser. No. US
        1994-225991, filed on 12 Apr 1994, now abandoned
        Utility
DT
        Granted
FS
LN.CNT 5240
        INCLM: 424/449.000
INCL
        INCLS: 514/859.000; 514/861.000; 514/863.000; 514/886.000; 514/887.000;
                 604/020.000
                 424/449.000
NCL
        NCLM:
                 514/859.000; 514/861.000; 514/863.000; 514/886.000; 514/887.000;
        NCLS:
                 604/020.000
         [7]
IC
        ICM: A61F013-00
EXF
         424/449; 514/859; 514/861; 514/863; 514/886; 514/887; 604/20
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L7
      ANSWER 100 OF 228 USPATFULL ON STN
        2001:18240 USPATFULL
ΑN
         Complement-resistant non-mammalian DNA viruses and uses thereof
ΤI
ΙN
        Boyce, Frederick M., Belmont, MA, United States
Barsoum, James G., Lexington, MA, United States
        The General Hospital Corporation, Boston, MA, United States (U.S.
PA
        corporation)
        Biogen, Inc., Cambridge, MA, United States (U.S. corporation)
        US 6183993
                                      20010206
PΙ
                                B1
        US 1999-329368
                                      19990610 (9)
ΑI
RLI
        Continuation-in-part of Ser. No. US 1997-927317, filed on 11 Sep 1997
        Utility
DT
         Granted
FS
        3502
LN.CNT
         INCLM: 435/069.700
INCL
         INCLS: 435/069.100; 435/172.300; 424/246.100; 536/023.400; 536/023.710
NCL
         NCLM:
                 435/069.700
                 424/246.100; 435/069.100; 435/235.100; 435/456.000; 536/023.400;
        NCLS:
                 536/023.710
IC
         [7]
         ICM: C12P021-04
        ICS: C12P021-06; C12N013-00; A61K039-07; C07H021-04 435/69.7; 435/69.1; 435/172.3; 424/246.1; 536/23.4; 536/23.71
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L7
      ANSWER 101 OF 228 USPATFULL on STN
         2001:14493 USPATFULL
ΑN
         1,2,5-trisubstituted 1,2-dihydroindazol-3-ones having anti-asthmatic,
TI
         anti-allergic, anti-inflammatory, immunomodulating and neuroprotective
         action, process for their preparation and their use as medicaments
        Schindler, Rudolf, Dresden, Germany, Federal Republic of
IN
        Hofgen, Norbert, Medingen, Germany, Federal Republic of Poppe, Hildegard, Dresden, Germany, Federal Republic of Brune, Kay, Marloffstein, Germany, Federal Republic of Arzneimittelwerk Dresden GmbH, Germany, Federal Republic of (non-U.S.
PA
         corporation)
        us 6180637
PΙ
                                      20010130
                                                                                   <--
ΑI
         us 1999-305602
                                      19990505 (9)
        DE 1998-19821003
                                 19980511
PRAI
```

```
DT
         Utility
         Granted
FS
LN.CNT 962
INCL
         INCLM: 514/259.000
         INCLS: 514/259.000; 514/254.090; 514/365.000; 514/405.000; 546/275.700; 546/153.000; 544/235.000; 544/144.000; 544/284.000; 544/298.000; 544/333.000; 544/371.000; 548/131.000; 548/159.000; 548/181.000; 548/266.200; 548/305.100; 548/306.700; 548/361.500
NCL
         NCLM:
                    514/266.230
                   514/254.090; 514/365.000; 514/405.000; 544/144.000; 544/235.000; 544/284.000; 544/298.000; 544/333.000; 544/371.000; 546/153.000; 546/275.700; 548/131.000; 548/159.000; 548/181.000; 548/240.000; 548/305.100; 548/306.700; 548/361.500
         NCLS:
IC
          [7]
          ICM: A61K031-513
          ICS: A61K031-4152; C07D231-56
          548/361.5; 548/131; 548/159; 548/181; 548/240; 548/305.1; 548/306.7; 514/405; 514/259; 514/245.06; 514/365; 546/275.7; 546/153; 544/235; 544/371; 544/298; 544/284; 544/144; 544/333
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
       ANSWER 102 OF 228 USPATFULL on STN
L7
          2001:14260 USPATFULL
ΑN
          Method for inhibiting apoptosis induced by photodynamic therapy using a
TI
          cysteine or serine protease inhibitor
          Granville, David J., Vancouver, Canada
IN
          Levy, Julia G., Vancouver, Canada
Hunt, David W. C., Vancouver, Canada
          QLT Inc., Victoria, Canada (non-U.S. corporation)
University of British Columbia, Vancouver, Canada (non-U.S. corporation)
US 6180402
B1 20010130

<--
PA
          US 6180402
US 1996-754491
PI
                                            19961120 (8)
ΑI
          Utility
DT
          Granted
FS
LN.CNT 1095
INCL
          INCLM: 435/375.000
NCL
          NCLM: 435/375.000
          [7]
IC
          ICM: C12N005-00
          435/1.1; 435/375; 514/2
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L7
       ANSWER 103 OF 228 USPATFULL ON STN
          2000:174649 USPATFULL
AN
          1,5- and 3-0-substituted 1H-indazoles having anti-asthmatic.
ΤI
          anti-allergic, anti-inflammatory, immunomodulating and neuroprotective
          action, process for their preparation and their use as medicaments
          Schindler, Rudolf, Dresden, Germany, Federal Republic of
ΙN
          Hofgen, Norbert, Medingen, Germany, Federal Republic of Poppe, Hildegard, Dresden, Germany, Federal Republic of Brune, Kay, Marloffstein, Germany, Federal Republic of
          Arzneimittelwerk Dresden GmbH, Germany, Federal Republic of (non-U.S.
PA
          corporation)
PΙ
          us 6166023
                                            20001226
                                                                                                <--
                                            19990505 (9)
          us 1999-305601
ΑI
          DE 1998-19821002
                                      19980511
PRAI
          Utility
DT
FS
          Granted
LN.CNT 1239
          INCLM: 514/258.000
INCL
          INCLS: 514/312.000; 514/364.000; 514/365.000; 514/418.000; 544/270.000; 546/158.000; 548/131.000; 548/204.000; 548/361.500
NCL
          NCLM:
                    514/234.500
          NCLS:
                    514/266.230; 514/312.000; 514/364.000; 514/365.000; 514/418.000;
                    544/270.000; 546/158.000; 548/131.000; 548/204.000; 548/361.500
IC
          [7]
          ICM: A61K031-513
          ICS: A61K031-4709; C07D231-56
          548/361.5; 548/131; 548/204; 514/418; 514/364; 514/365; 514/312; 514/258; 544/270; 546/158
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L7
       ANSWER 104 OF 228 USPATFULL ON STN
AN
          2000:164554 USPATFULL
          Cyclobutyl-aryloxyarylsulfonylamino hydroxamic acid derivatives
TI
```

Reiter, Lawrence A., Mystic, CT, United States

IN

```
Pfizer Inc, New York, NY, United States (U.S. corporation)
PA
PΙ
       US 6156798
                                  20001205
       us 1999-290023
                                  19990409 (9)
ΑI
PRAI
       US 1998-81392P
                             19980410 (60)
       US 1997-55208P
                             19970808 (60)
                             19970808 (60)
       US 1997-55207P
       US 1997-62766P
                             19971024 (60)
       US 1997-68261P
                             19971219 (60)
DT
       Utility
       Granted
FS
LN.CNT
       1142
       INCLM: 514/562.000
INCL
       INCLS: 560/013.000; 560/312.000; 562/427.000; 562/430.000
               514/562.000
NCL
       NCLM:
               560/013.000; 560/312.000; 562/427.000; 562/430.000
       NCLS:
IC
       [7]
       ICM: C07C031-195
       ICS: C07C317-14
       560/13; 560/312; 562/427; 562/430; 514/562
FXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 105 OF 228 USPATFULL on STN
L7
       2000:160777 USPATFULL
AN
       Methods for screening for transdominant intracellular effector peptides
TT
       and RNA molecules
IN
       Nolan, Garry P., Palo Alto, CA, United States
       Rothenberg, S. Michael, Palo Alto, CA, United States
       Rigel Pharmaceuticals, Inc., Sunnyvale, CA, United States (U.S.
PA
       corporation)
       The Board of Trustees for the Leland Stanford Junior University, Palo
       Alto, CA, United States (U.S. corporation)
       US 6153380
PΙ
                                  20001128
       us 1997-789333
                                  19970123 (8)
ΑI
       Continuation of Ser. No. US 1996-589108, filed on 23 Jan 1996, now
RLI
       abandoned And a continuation of Ser. No. US 1996-589911, filed on 23
       Jan 1996, now abandoned
DT
       Utility
       Granted
FS
LN.CNT 4104
        INCLM: 435/006.000
INCL
       INCLS: 435/069.100; 435/070.100; 435/091.100; 435/325.000; 536/023.100; 536/024.300; 536/024.310; 536/024.500
NCL
       NCLM:
               435/006.000
       NCLS:
               435/069.100; 435/070.100; 435/091.100; 435/325.000; 536/023.100;
               536/024.300; 536/024.310; 536/024.500
IC
        [7]
        ICM: C12Q001-68
       ICS: C12P019-34; C12N005-00; C07H021-04
435/6; 435/70.1; 435/325; 435/69.1; 435/91.1; 536/23.1; 536/24.3;
EXF
        536/24.31; 536/24.5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
17
     ANSWER 106 OF 228 USPATFULL on STN
       2000:142520 USPATFULL
AN
       Tetracycline-inducible transcriptional activator fusion proteins
TI
        Bujard, Hermann, Heidelberg, Germany, Federal Republic of
ΙN
        Gossen, Manfred, El Cerrito, CA, United States
        BASF_Aktiengesellschaft, Worcester, MA, United States (U.S. corporation)
PA
        Knoll Aktiengesellschaft, Germany, Federal Republic of (non-U.S.
        corporation)
PΙ
        us 6136954
                                  20001024
        us 1998-162184
                                  19980928 (9)
ΑI
       Continuation of Ser. No. US 1995-485978, filed on 7 Jun 1995, now
RLI
        patented, Pat. No. US 5814618 which is a continuation-in-part of Ser.
        No. US 1995-383754, filed on 3 Feb 1995, now patented, Pat. No. US
        5789156 which is a continuation-in-part of Ser. No. US 1994-275876,
        filed on 15 Jul 1994, now patented, Pat. No. US 5654168 which is a
        continuation-in-part of Ser. No. US 1994-270637, filed on 1 Jul 1994,
       now abandoned And a continuation-in-part of Ser. No. US 1994-260452, filed on 14 Jun 1994, now patented, Pat. No. US 5650298 which is a continuation-in-part of Ser. No. US 1993-76327, filed on 14 Jun 1993,
        now abandoned And a continuation-in-part of Ser. No. US 1993-76726,
        filed on 14 Jun 1993, now patented, Pat. No. US 5464758
DT
        Utility
FS
        Granted
```

LN.CNT 4871

```
INCL
       INCLM: 530/350.000
       INCLS: 536/023.400
       NCLM:
               530/350.000
NCL
       NCLS:
               536/023.400
       [7]
IC
       ICM: C07K014-00
       ICS: C12N015-11
       530/350; 536/23.4
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 107 OF 228 USPATFULL ON STN
L7
       2000:138360 USPATFULL
AN
       Hydroxyl-containing bicyclic compounds
TI
       Underiner, Gail E., Brier, WA, United States
IN
       Porubek, David, Seattle, WA, United States
       Klein, J. Peter, Vashon Island, WA, United States
       woodson, Paul, Edmonds, WA, United States
       Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PA
                                  20001017
PΙ
       us 6133274
                                 19961126 (8)
       us 1996-756703
AΤ
       Continuation of Ser. No. US 1993-153256, filed on 16 Nov 1993, now
RLI
        abandoned which is a continuation-in-part of Ser. No. US 1992-976353,
        filed on 16 Nov 1992, now patented, Pat. No. US 5473070
       Utility
DT
       Granted
FS
LN.CNT 1646
        INCLM: 514/263.000
INCL
        INCLS: 544/267.000
       NCLM:
               514/263.360
NCL
       NĊLS:
               544/267.000
        [7]
IC
        ICM: C07D473-04
        ICS: A61K031-52
        544/267; 514/263
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 108 OF 228 USPATFULL on STN
L7
        2000:131410 USPATFULL
AN
        Microcapsules and composite microreactors for immunoisolation of cells
TI
        Lanza, Robert P., Clinton, MA, United States
IN
        Kuhtréiber, Willém M., Shrewsbury, MA, United States
Chick, William L., Wellesley, MA, United States
        BioHybrid Technologies LLC, Shrewsbury, MA, United States (U.S.
PA
        corporation)
PΙ
        US 6126936
                                  20001003
                                                                          <--
        us 1995-402209
                                  19950310 (8)
ΑI
        Utility
DT
FS
        Granted
LN.CNT 4433
        INCLM: 424/093.700
INCL
        INCLS: 424/423.000; 435/177.000; 435/178.000; 435/182.000; 435/395.000; 435/397.000
NCL
        NCLM:
               424/093.700
        NCLS:
               424/423.000; 435/177.000; 435/178.000; 435/182.000; 435/382.000;
               435/395.000; 435/397.000
        [7]
IC
        ICM: A61K035-12
        ICS: C12N011-10; C12N011-04; C12N005-00
        435/174; 435/177; 435/178; 435/180; 435/182; 435/240.2; 435/240.23; 435/382; 435/395; 435/397; 424/93.7
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L7
      ANSWER 109 OF 228 USPATFULL ON STN
        2000:125047 USPATFULL
AN
TI
        Epoxide-containing compounds
        Underiner, Gail, Brier, WA, United States
IN
        Klein, J. Peter, Vashon, WA, United States
        Michnick, John, Seattle, WA, United States
        Leigh, Alistair, Brier, WA, United States
        Kumar, Anil, Seattle, WA, United States
        Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation) US 6121270 20000919 <--
PA
PΙ
        US 1998-98473
                                  19980617 (9)
AΙ
        Division of Ser. No. US 1997-778563, filed on 3 Jan 1997 which is a
RLI
        continuation of Ser. No. US 1993-167600, filed on 13 Dec 1993, now
        abandoned And a continuation-in-part of Ser. No. US 1992-991655, filed
```

```
on 16 Dec 1992, now abandoned
DT
       Utility
FS
       Granted
LN.CNT 3145
        INCLM: 514/263.000
INCL
       INCLS: 544/263.000
       NCLM: 514/263.230
NCL
              544/263.000
        NCLS:
IC
        [7]
       ICM: A61K031-52
       ICS: C07D473-04
544/267; 514/263
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 110 OF 228 USPATFULL ON STN
L7
        2000:121632 USPATFULL
ΑN
TI
        Human calcium-binding proteins
        Bandman, Olga, Mountain View, CA, United States
IN
        Hillman, Jennifer L., Mountain View, CA, United States
        Corley, Neil C., Mountain View, CA, United States
       Guegler, Karl J., Menlo Park, CA, United States
Lal, Preeti, Santa Clara, CA, United States
Patterson, Chandra, Mountain View, CA, United States
        Incyte Pharmaceuticals, Inc., Palo Alto, CA, United States (U.S.
PA
        corporation)
        us 6117989
                                  20000912
                                                                            <--
PΙ
                                  19980326 (9)
ΑI
        us 1998-48889
        Utility
DT
        Granted
FS
LN.CNT 2871
        INCLM: 536/023.100
INCL
        INCLS: 435/006.000; 435/069.100; 435/320.100; 435/252.300; 536/023.500;
                536/024.310
                536/023.100
        NCLM:
NCL
                435/006.000; 435/069.100; 435/252.300; 435/320.100; 536/023.500;
        NCLS:
                536/024.310
        [7]
IC
        ICM: C07H021-04
        ICS: C12N015-11; C12N015-63; C12N001-21; C12Q001-68
        536/23.1; 536/23.5; 536/24.31; 536/6; 435/69.1; 435/320.1; 435/252.3
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 111 OF 228 USPATFULL ON STN
L7
        2000:117742 USPATFULL
AN
        5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives
TI
        Robinson, Ralph P., Gales Ferry, CT, United States
IN
        Laird, Ellen R., Mystic, CT, United States
        Pfizer Inc., New York, NY, United States (U.S. corporation)
PΑ
                                  20000905
PΙ
        US 6114361
        us 1999-429937
                                   19991029 (9)
ΑI
        Utility
DT
FS
        Granted
LN.CNT
        1761
        INCLM: 514/340.000
INCL
                514/343.000; 514/423.000; 514/424.000; 546/278.400; 546/279.100;
        INCLS:
                548/537.000; 548/543.000; 548/550.000; 548/551.000
                514/340.000
NCL
                514/343.000; 514/423.000; 514/424.000; 546/278.400; 546/279.100;
        NCLS:
                548/537.000; 548/543.000; 548/550.000; 548/551.000
        [7]
TC
        ICM: A61K031-4015
        ICS: A61K031-4439; C07D207-12; C07D207-16; C07D401-04 514/423; 514/424; 514/340; 514/343; 548/537; 548/543; 548/550; 548/551;
        546/278.4; 546/279.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L7
      ANSWER 112 OF 228 USPATFULL ON STN
        2000:113991 USPATFULL
AN
        Bicyclic hydroxamic acid derivatives
TI
        Robinson, Ralph Pelton, Gales Ferry, CT, United States
ΙN
        Pfizer Inc., New York, NY, United States (U.S. corporation)
PA
                                   20000829
                                                                            <--
        us 6110964
PΙ
        wo 9952910
                     19991021
        US 1999-402259
                                   19990930 (9)
ΑI
        WO 1999-IB503
                                   19990324
                                   19990930 PCT 371 date
```

```
19990930 PCT 102(e) date
PRAI
       US 1998-81309P
                             19980410 (60)
       US 1997-55208P
                             19970808 (60)
       US 1997-55207P
                             19970808 (60)
       US 1997-62766P
                             19971024 (60)
       US 1997-68261P
                             19971219 (60)
       Utility
DT
FS
       Granted
LN.CNT 1851
       INCLM: 514/456.000
INCL
               549/397.000
       INCLS:
               514/456.000
       NCLM:
NCL
               549/397.000
       NCLS:
        [7]
TC
       ICM: A61K031-35
        ICS: C07D311-00
        549/397; 514/456
FXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L7
     ANSWER 113 OF 228 USPATFULL ON STN
ΑN
        2000:109610
                     USPATFULL
       Modulators of anchoring protein function
ΤI
       Lockerbie, Robert Owen, Kirkland, WA, United States
TN
       Howard, Monique L., Seattle, WA, United States
       Gallatin, W. Michael, Mercer Island, WA, United States
       Lai, Yvonne, Seattle, WA, United States
        ICOS Corporation, Bothell, WA, United States (U.S. corporation)
PA
PΙ
                                  20000822
       US 6107104
                                  19960927 (8)
ΑI
       us 1996-721458
       Continuation-in-part of Ser. No. US 1995-503226, filed on 17 Jul 1995
RLI
       which is a continuation-in-part of Ser. No. US 1995-404731, filed on 15
       Mar 1995, now patented, Pat. No. US 5744354 which is a continuation-in-part of Ser. No. US 1994-344227, filed on 23 Nov 1994,
        now patented, Pat. No. US 5807693
DT
        Utility
FS
        Granted
LN.CNT 3568
        INCLM: 436/578.000
INCL
        INCLS: 435/004.000; 435/007.100; 435/007.200; 435/007.930
NCL
        NCLM:
               436/518.000
        NCLS:
               435/004.000; 435/007.100; 435/007.200; 435/007.930
IC
        [7]
        ICM: G01N033-543
        435/4; 435/7.1; 435/7.2; 435/7.93; 436/501; 530/350; 530/780; 536/23.1;
FXF
        536/23.5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L7
     ANSWER 114 OF 228 USPATFULL ON STN
        2000:105913 USPATFULL
ΑN
ΤI
        Amine substituted compounds
        Klein, J. Peter, Vashon, WA, United States
Underiner, Gail E., Brier, WA, United States
IN
       Kumar, Anil M., Seattle, WA, United States
Ridgers, Lance H., Bothell, WA, United States
        Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PA
PΙ
        us 6103730
                                  20000815
ΑI
        us 1995-486264
                                  19950607 (8)
RLI
        Continuation of Ser. No. US 1994-217051, filed on 24 Mar 1994, now
        abandoned
DT
        Utility
FS
        Granted
LN.CNT 1702
INCL
        INCLM: 514/263.000
        INCLS:
               514/265.000; 544/268.000; 544/269.000; 544/270.000; 544/271.000;
               544/272.000
NCL
        NCLM:
               514/263.200
               514/151.000; 514/210.210; 514/263.210; 514/263.220; 514/263.230;
        NCLS:
               514/263.240; 514/263.350; 544/268.000; 544/269.000; 544/270.000;
               544/271.000; 544/272.000
IC
        [7]
        ICM: A61K031-522
        ICS: C07D473-10
        544/268; 544/269; 544/220; 544/271; 544/272; 514/263; 514/265
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
```

L7

ANSWER 115 OF 228 USPATFULL ON STN

```
AN
       2000:105417 USPATFULL
ΤI
       Neurite growth regulatory factors
       Schwab, Martin E., Zurich, Switzerland
IN
       Caroni, Pierenrico W., Zurich, Switzerland
       Paganetti, Paolo A., Zurich, Switzerland
       Erziehungsdirektion of the Canton Zurich, Zurich, Switzerland (non-U.S.
PA
       corporation)
       us 6103232
us 1995-464509
                                  20000815
PΙ
                                  19950605 (8)
ΑI
       Continuation of Ser. No. US 1989-401212, filed on 30 Aug 1989, now
RLI
       patented, Pat. No. US 5684133 which is a continuation-in-part of Ser.
       No. US 1988-267941, filed on 4 Nov 1988, now abandoned
DT
       Utility
       Granted
FS
       4223
LN.CNT
       INCLM: 424/130.100
INCL
       INCLS: 530/387.100; 530/350.000
               424/130.100
NCL
       NCLM:
               530/350.000; 530/387.100
       NCLS:
IC
        [7]
        ICM: C07K016-00
EXF
       424/130.1; 530/350; 530/387.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L7
     ANSWER 116 OF 228 USPATFULL on STN
ΑN
       2000:102304 USPATFULL
TI
       Therapeutic compounds containing xanthinyl
       Klein, J. Peter, Vashon, WA, United States
Leigh, Alistair J., Brier, WA, United States
Underiner, Gail E., Brier, WA, United States
Kumar, Anil M., Seattle, WA, United States
IN
       Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PA
       US 6100271
                                  20000808
PΙ
       US 1995-483871
ΑI
                                  19950607 (8)
       Continuation-in-part of Ser. No. US 1994-199368, filed on 18 Feb 1994,
RLI
       now abandoned
DT
       Utility
FS
        Granted
LN.CNT 1986
INCL
        INCLM: 514/263.000
        INCLS: 514/265.000; 544/268.000; 544/269.000; 544/271.000
               514/263.200
NCL
       NCLM:
       NCLS:
               514/210.210; 514/234.200; 514/263.220; 514/263.230; 514/263.240;
               514/263.350; 544/268.000; 544/269.000; 544/271.000
IC
        [7]
        ICM: A61K031-522
        ICS: C07D473-10
EXF
        544/271; 544/268; 544/269; 514/263; 514/265
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L7
     ANSWER 117 OF 228 USPATFULL on STN
       2000:98222 USPATFULL
AN
TI
       Cells with multiple altered epitopes on a surface antigen for use in
          ***transplantation***
       Chappel, Scott C., Milton, MA, United States
IN
PA
       Diacrin, Inc., Charlestown, MA, United States (U.S. corporation)
PΙ
       us 6096537
                                  20000801
ΑI
       US 1997-946637
                                  19971007 (8)
RLI
       Continuation of Ser. No. US 1994-240150, filed on 10 May 1994, now
       patented, Pat. No. US 5679340 which is a continuation-in-part of Ser.
       No. US 1994-220741, filed on 31 Mar 1994, now abandoned
DT
       Utility
FS
       Granted
LN.CNT 940
INCL
       INCLM: 435/325.000
       INCLS: 424/422.000; 424/133.100; 424/143.100; 424/093.700; 435/007.100;
               435/007.200; 435/007.210; 530/388.220
NCL
       NCLM:
               435/325.000
               424/093.700; 424/133.100; 424/143.100; 424/422.000; 435/007.100; 435/007.200; 435/007.210; 530/388.220
       NCLS:
IC
       ICM: C12N005-00
       ICS: A61F013-00; G01N033-53; C07K016-00
       424/93.7; 424/422; 424/133.1; 424/143.1; 435/325; 435/7.1; 435/7.2;
EXF
       435/7.21; 530/388.22
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
```

```
ANSWER 118 OF 228 USPATFULL on STN
L7
ΑN
        2000:95042 USPATFULL
        Therapeutic methods employing disulfide derivatives of dithiocarbamates
TI
        and compositions useful therefor
        Lai, Ching-San, Encinitas, CA, United States
IN
       Vassilev, Vassil, San Diego, CA, United States
Medinox Inc., San Diego, CA, United States (U.S. corporation)
PA
        us 6093743
                                   20000725
PΙ
        us 1998-103639
                                   19980623 (9)
ΑI
        Utility
DT
        Granted
FS
LN.CNT 2691
        INCLM: 514/599.000
INCL
        INCLS: 514/706.000; 514/707.000; 514/851.000; 514/861.000; 514/863.000;
                514/866.000; 514/909.000; 514/912.000
NCL
        NCLM:
                514/599.000
                514/706.000; 514/707.000; 514/851.000; 514/861.000; 514/863.000; 514/866.000; 514/909.000; 514/912.000
        NCLS:
        [7]
IC
        ICM: A61K031-16
        ICS: A61K031-095; A61K031-105
        514/599; 514/706; 514/707; 514/851; 514/861; 514/863; 514/866; 514/909;
EXF
        514/912
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 119 OF 228 USPATFULL on STN
L7
        2000:94864 USPATFULL
AN
TI
        Protein phosphatase regulatory subunit
        Hillman, Jennifer L., San Jose, CA, United States
Goli, Surya K., Sunnyvale, CA, United States
IN
        Incyte Pharmaceuticals, Inc., Palo Alto, CA, United States (U.S.
PA
        corporation)
        us 6093565
                                   20000725
PT
ΑI
        us 1996-764563
                                   19961212 (8)
        Utility
DT
        Granted
FS
LN.CNT 2093
        INCLM: 435/252.300
INCL
        INCLS: 536/023.100; 536/023.500; 536/023.200; 435/069.100; 435/069.200; 435/440.000; 435/196.000; 435/006.000; 435/325.000; 435/320.100
NCL
        NCLM:
                435/252.300
               435/006.000; 435/069.100; 435/069.200; 435/196.000; 435/320.100;
        NCLS:
                435/325.000; 435/440.000; 536/023.100; 536/023.200; 536/023.500
IC
        [7]
        ICM: C12N001-21
        ICS: C12N015-12; C12N015-63
        536/23.1; 536/23.5; 536/23.2; 435/69.1; 435/69.2; 435/172.3; 435/196.6; 435/252.3; 435/325; 435/320.1
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 120 OF 228 USPATFULL on STN
L7
AN
        2000:91767 USPATFULL
TI
        Calcineurin regulatable adenylate cyclase
ΙN
        Antoni, Ferenc, Edinburgh, United Kingdom
        Paterson, Janice MacKenzie, Edinburgh, United Kingdom
       Medical Research Council, London, United Kingdom (non-U.S. corporation) US 6090612 20000718 <--
PA
PΙ
        wo 9625502
                     19960822
        US 1997-894173
                                   19970813 (8)
ΑI
        WO 1996-GB312
                                   19960214
                                   19970813
                                               PCT 371 date
                                              PCT 102(e) date
                                   19970813
                              19950214
PRAI
        GB 1995-2806
        GB 1995-16528
                              19950811
DT
        Utility
FS
        Granted
LN.CNT 2856
INCL
        INCLM: 435/252.330
        INCLS: 435/320.100; 435/325.000; 435/369.000; 536/023.200
NCL
               435/252.330
        NCLM:
               435/320.100; 435/325.000; 435/369.000; 536/023.200
        NCLS:
        [7]
IC
        ICM: C12N001-20
        ICS: C12N015-00; C12N005-00; C07H021-04
        435/325; 435/369; 435/320.1; 435/252.33; 536/23.2
EXF
```

20000620

19961127 (60)

19971126 (8)

<--

us 6077680

US 1997-980858

US 1996-59126P

PT

ΑI

PRAI

```
Utility
DT
FS
          Granted
LN.CNT 5831
          INCLM: 435/007.240
INCL
          INCLS: 514/012.000; 514/009.000; 514/002.000; 424/185.100; 530/300.000;
                    530/324.000; 530/855.000
                    435/007.240
          NCLM:
NCL
                    424/185.100; 514/002.000; 514/009.000; 514/012.000; 530/300.000; 530/324.000; 530/855.000
          NCLS:
          [7]
IC
          ICM: G01N033-566
          ICS: A61K038-17; C07K014-435; A01N037-20 514/12; 514/2; 514/9; 530/300; 530/324; 530/855; 424/185.1; 435/7.24
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
       ANSWER 124 OF 228 USPATFULL ON STN
L7
          2000:70818 USPATFULL
AN
          In vivo genetic modification of growth factor-responsive neural
TI
          precursor cells
          Weiss, Samuel, Alberta, Canada
IN
          Reynolds, Brent, Alberta, Canada
Hammang, Joseph P., Barrington, RI, United States
Baetge, E. Edward, Barrington, RI, United States
          NeuroSpheres Holdings Ltd., Calgary, Canada (non-U.S. corporation)
PA
                                             20000606
          us 6071889
PΙ
          us 1995-479795
                                             19950607 (8)
ΑI
          Continuation-in-part of Ser. No. US 1994-270412, filed on 5 Jul 1994,
RLI
          now abandoned And a continuation-in-part of Ser. No. US 1995-385404,
          filed on 7 Feb 1995, now abandoned And a continuation-in-part of Ser. No. US 1994-359945, filed on 20 Dec 1994, now abandoned And a continuation-in-part of Ser. No. US 1995-376062, filed on 20 Jan 1995, now abandoned And a continuation-in-part of Ser. No. US 1993-149508,
          filed on 9 Nov 1993, now abandoned And a continuation-in-part of Ser. No. US 1994-311099, filed on 23 Sep 1994, now abandoned And a
          continuation-in-part of Ser. No. US 1994-338730, filed on 14 Nov 1994,
          now abandoned which is a continuation of Ser. No. US 1991-726812, filed
          on 8 Jul 1991, now abandoned , said Ser. No. US 1994-270412, filed on 5
          Jul 1994, now abandoned which is a continuation of Ser. No. US
          1991-726812, filed on 8 Jul 1991, now abandoned , said Ser. No. US 1995-385404, filed on 7 Feb 1995, now abandoned which is a continuation
          of Ser. No. US 1992-961813, filed on 16 Oct 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-726812, filed on 8 Jul 1991, now abandoned, said Ser. No. US 1994-359945, filed on 20 Dec 1994, now abandoned which is a continuation of Ser. No. US 1994-221655, filed on 1
          Apr 1994, now abandoned which is a continuation of Ser. No. US
          1992-967622, filed on 28 Oct 1992, now abandoned which is a
          continuation-in-part of Ser. No. US 1991-726812, filed on 8 Jul 1991,
          now abandoned, said Ser. No. US 1995-376062, filed on 20 Jan 1995, now abandoned which is a continuation of Ser. No. US 1993-10829, filed on 29
          Jan 1993, now abandoned which is a continuation-in-part of Ser. No. US
          1991-726812, filed on 8 Jul 1991, now abandoned , said Ser. No. US 1993-149508, filed on 9 Nov 1993, now abandoned which is a continuation-in-part of Ser. No. US 1991-726812, filed on 8 Jul 1991, now abandoned , said Ser. No. US 1994-311099, filed on 23 Sep 1994, now abandoned which is a continuation-in-part of Ser. No. US 1991-726812,
          filed on 8 Jul 1991, now abandoned
DT
          Utility
FS
           Granted
LN.CNT 4261
INCL
          INCLM: 514/044.000
          INCLS: 424/093.100; 424/093.200; 424/093.210; 435/440.000; 435/455.000
NCL
                     514/044.000
          NCLM:
                    424/093.100; 424/093.200; 424/093.210; 435/440.000; 435/455.000
          NCLS:
           [7]
IC
           ICM: A61K035-00
           ICS: A61K048-00
EXF
           514/44; 514/2; 536/23.1; 424/93.1; 424/93.2; 424/93.21; 435/455; 435/440
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
       ANSWER 125 OF 228 USPATFULL ON STN
L7
                          USPATFULL
          2000:57345
ΑN
           Surrogate tolerogenesis for the development of tolerance to xenografts
TI
          Beschorner, William E., Baldwin, MD, United States
Ximerex, Inc., Omaha, NE, United States (U.S. corporation)
IN
PA
                                              20000509
          US 6060049
PI
          wo 9427622 19931208
                                                                                                    <--
```

```
us 1995-295899
ΑI
                                   19950606 (8)
       wo 1994-US5844
                                   19940524
                                   19950606
                                              PCT 371 date
                                   19950606 PCT 102(e) date
        Continuation of Ser. No. US 1993-65370, filed on 24 May 1993
RLI
       Utility
DT
        Granted
FS
LN.CNT 3065
        INCLM: 424/093.210
INCL
        INCLS: 424/093.300; 424/577.000; 800/008.000; 435/001.100
               424/093.210
NCL
        NCLM:
               424/093.300; 424/577.000; 435/001.100; 800/008.000
        NCLS:
        [7]
IC
        ICM: A61K048-00
        ICS: C12N015-00; A01N001-02
        424/529; 424/577; 424/93.7; 424/93.21; 424/93.71; 424/2; 424/9; 424/93.3; 435/1; 435/240.2; 435/375; 435/377; 800/DIG.5; 800/2; 800/8
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 126 OF 228 USPATFULL ON STN
L7
        2000:54116 USPATFULL
ΑN
        Discorhabdin compounds and methods of use
ΤI
        Gunaskera, Sarath P., Vero Beach, FL, United States
ΙN
        McCarthy, Peter J., Vero Beach, FL, United States
        Pomponi, Shirley A., Fort Pierce, FL, United States
        Wright, Amy E., Fort Pierce, FL, United States
        Longley, Ross E., Vero Beach, FL, United States
        Harbor Branch Oceanographic Institution, Inc., Ft. Pierce, FL, United
PA
        States (U.S. corporation)
                                   20000502
        us 6057333
                                                                             <--
PΙ
                                   19980724 (9)
        us 1998-122572
ΑI
        US 1997-53752P
                              19970725 (60)
PRAI
        Utility
DT
        Granted
FS
LN.CNT 606
INCL
        INCLM: 514/278.000
        INCLS: 546/018.000; 424/573.000; 435/240.200
                514/278.000
        NCLM:
NCL
                424/573.000; 435/375.000; 546/018.000
        NCLS:
IC
        [7]
        ICM: A61K031-44
        ICS: C07D401-14
        514/278; 546/18; 424/573; 435/240.2
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L7
     ANSWER 127 OF 228 USPATFULL on STN
AN
        2000:37806 USPATFULL
        Methods for using therapeutic compounds containing xanthinyl
TI
        Klein, J. Peter, Vashon, WA, United States
Leigh, Alistair J., Brier, WA, United States
Underiner, Gail E., Brier, WA, United States
Kumar, Anil M., Seattle, WA, United States
Rice, Glenn C., Seattle, WA, United States
IN
        Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PA
        US 6043250
                                   20000328
PΙ
        US 1995-472296
                                   19950607 (8)
ΑI
        Continuation-in-part of Ser. No. US 1994-199368, filed on 18 Feb 1994,
RLI
        now abandoned
DT
        Utility
FS
        Granted
LN.CNT 2052
        INCLM: 514/263.000
INCL
                514/234.200
NCL
        NCLM:
               514/210.210; 514/263.200; 514/263.220; 514/263.230; 514/263.350
        NCLS:
        [7]
IC
        ICM: A61K003-52
        514/263
EXF
      ANSWER 128 OF 228 USPATFULL ON STN
L7
        2000:18418 USPATFULL
AN
        Treatment of CNS tumors with metalloprotease inhibitors
ΤI
        Schwab, Martin E., Zurich, Switzerland
ΙN
        Caroni, Pierenrico W., Zurich, Switzerland
        Paganetti, Paolo A., Birmensdorferstr., Switzerland
        Erziehungsdirektion of the Canton Zurich, Zurich, Switzerland (non-U.S.
PΑ
        corporation)
```

```
PΙ
       us 6025333
                                  20000215
       US 1995-462312
                                 19950605 (8)
ΑI
       Division of Ser. No. US 1989-401212, filed on 30 Aug 1989 which is a
RLI
       continuation-in-part of Ser. No. US 1988-267941, filed on 4 Nov 1988,
       now abandoned
DT
       Utility
       Granted
FS
LN.CNT 4299
       INCLM: 514/018.000
INCL
               514/019.000; 514/292.000; 424/DIG.006; 424/094.670
       INCLS:
               514/217.090
NCL
       NCLM:
               424/094.670; 424/DIG.006; 514/019.000; 514/292.000
       NCLS:
IC
        [7]
       ICM: A61K038-06
       ICS: A61K038-05; A61K038-55
        514/2; 514/18; 514/19; 514/292; 514/566; 514/738; 424/DIG.6; 424/94.67
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 129 OF 228 USPATFULL ON STN
L7
AN
       2000:18243 USPATFULL
TI
       Neurturin receptor
       Klein, Robert D., Palo Alto, CA, United States
IN
       Rosenthal, Arnon, Burlingame, CA, United States
       Hynes, Mary A., San Mateo, CA, United States
       Genentech, Inc., United States (U.S. corporation)
PA
                                  20000215
                                                                           <--
PΙ
        us 6025157
        us 1997-957063
                                  19971024 (8)
ΑI
       US 1997-38839P
                             19970218 (60)
PRAI
       US 1997-49818P
                             19970609 (60)
        Utility
DT
        Granted
FS
       5116
LN.CNT
        INCLM: 435/069.100
INCL
        INCLS: 435/069.100; 435/320.100; 435/325.000; 536/023.100; 536/023.500
NCL
               435/069.100
               435/320.100; 435/325.000; 536/023.100; 536/023.500
        NCLS:
        [7]
IC
        ICM: C12P021-06
        ICS: C12N015-00; C07H021-02; C07H021-04
536/23.5; 536/23.1; 435/325; 435/320.1; 435/69.1; 800/8
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 130 OF 228 USPATFULL on STN
L7
        2000:15639 USPATFULL
ΑN
        Regulation of gene expression
TI
        Peyman, John A., Cheshire, CT, United States
IN
        Yale University, New Haven, CT, United States (U.S. corporation)
PA
                                  20000208
PΙ
        us 6022863
        us 1996-646789
                                  19960521 (8)
ΑI
        Utility
DT
FS
        Granted
LN.CNT 4750
        INCLM: 514/044.000
INCL
        INCLS: 536/024.100; 435/325.000; 435/001.100; 435/091.100; 800/013.000;
                800/025.000
NCL
        NCLM:
                514/044.000
               435/001.100; 435/091.100; 435/325.000; 536/024.100; 800/013.000;
        NCLS:
                800/025.000
        [6]
IC
        ICM: C12N015-11
        536/23.1; 536/24.1; 536/24.33; 435/325; 435/1.1; 435/91.1; 514/44;
EXF
        800/13; 800/25
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L7
     ANSWER 131 OF 228 USPATFULL ON STN
ΑN
        2000:1857 USPATFULL
        Peptide T and related peptides in the treatment of inflammation.
ΤI
        including multiple sclerosis
        Andersen, Anders Jorgen, Kokkedal, Denmark
Aston, Roger, Wiltshire, United Kingdom
Carlen, Peter Louis, Ontario, Canada
Doob, Penelope Reed, Ontario, Canada
IN
        MacFadden, Douglas Kevin, Ontario, Canada
        Phipps, David James, Ontario, Canada
        Rathjen, Deborah, New South Wales, Australia
        Widmer, Fred, New South Wales, Australia
```

```
Advanced Immunit, Inc., Stony Brook, NY, United States (U.S.
PA
        corporation)
PΙ
        us 6011014
                                     20000104
                                                                                  <--
        US 1998-82837
                                     19980521 (9)
ΑI
        Continuation of Ser. No. US 302829
RLI
DT
        Utility
FS
        Granted
LN.CNT 2387
        INCLM: 514/015.000
INCL
                 514/016.000; 514/017.000; 514/018.000; 530/328.000; 530/329.000;
        INCLS:
                 530/330.000
                 514/015.000
        NCLM:
NCL
        NCLS:
                 514/016.000; 514/017.000; 514/018.000; 530/328.000; 530/329.000;
                 530/330.000
        [6]
IC
        ICM: A61K038-00
ICS: C07K005-00; C07K007-00

EXF 514/16; 514/15; 514/17; 514/18; 530/328; 530/330

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L7
      ANSWER 132 OF 228 USPATFULL on STN
ΑN
        2000:1692 USPATFULL
TI
        Sequence-directed DNA binding molecules compositions and methods
        Edwards, Cynthia A., Menlo Park, CA, United States
IN
        Cantor, Charles R., Boston, MA, United States
        Andrews, Beth M., Maynard, MA, United States
        Turin, Lisa M., Redwood City, CA, United States
Fry, Kirk E., Palo Alto, CA, United States
        Genelabs Technologies, Inc., Redwood, CA, United States (U.S.
PA
        corporation)
PΙ
        us 6010849
                                     20000104
                                                                                   <--
                                      19950607 (8)
        us 1995-482080
AΙ
        Division of Ser. No. US 1993-171389, filed on 20 Dec 1993, now patented,
RLI
        Pat. No. US 5578444 which is a continuation-in-part of Ser. No. US
        1993-123936, filed on 17 Sep 1993, now patented, Pat. No. US 5726014 which is a continuation-in-part of Ser. No. US 1992-996783, filed on 23
        Dec 1992, now patented, Pat. No. US 5693463 which is a continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991,
        now abandoned
        Utility
DT
FS
        Granted
LN.CNT 10022
INCL
        INCLM: 435/006.000
        INCLS: 435/007.100
                435/006.000
NCL
        NCLM:
        NCLS:
                435/007.100
         [6]
IC
        ICM: C12Q001-68
         ICS: G01N033-53
        435/6; 435/7.1; 436/501; 536/23.1; 536/24.1
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L7
      ANSWER 133 OF 228 USPATFULL on STN
ΑN
        1999:166981 USPATFULL
ΤI
        Methods for regulating gene expression
IN
        Bujard, Hermann, Heidelberg, Germany, Federal Republic of
        Gossen, Manfred, El Cerrito, CA, United States
PA
        BASF Aktiengesellschaft, Germany, Federal Republic of (non-U.S.
        corporation)
        BASF Bioresearch Corporation, Worcester, MA, United States (U.S.
        corporation)
        Knoll Aktiengelellschaft, Germany, Federal Republic of (non-U.S.
        corporation)
PΙ
        US 6004941
                                      19991221
                                                                                   <--
                                      19950607 (8)
        US 1995-485740
ΑI
RLI
        Continuation-in-part of Ser. No. US 1995-383754, filed on 3 Feb 1995,
        now patented, Pat. No. US 5789156 And a continuation-in-part of Ser. No.
        US 1994-275876, filed on 15 Jul 1994, now patented, Pat. No. US 5654168 which is a continuation-in-part of Ser. No. US 1994-270637, filed on 1 Jul 1994, now abandoned And a continuation-in-part of Ser. No. US
        1994-260452, filed on 14 Jun 1994, now patented, Pat. No. US 5650298 which is a continuation-in-part of Ser. No. US 1993-76327, filed on 14
        Jun 1993, now abandoned And a continuation-in-part of Ser. No. US
        1993-76726, filed on 14 Jun 1993, now patented, Pat. No. US 5464758
        Utility
```

Granted

FS

```
LN.CNT 4771
       INCLM: 514/044.000
INCL
       INCLS: 435/069.100; 435/070.100; 435/320.100; 435/325.000; 435/455.000;
               536/023.400; 536/024.100; 424/093.210
               514/044.000
NCL
       NCLM:
               424/093.210; 435/069.100; 435/070.100; 435/320.100; 435/325.000; 435/455.000; 536/023.400; 536/024.100
       NCLS:
       [6]
IC
       ĪCM: A61K048-00
       435/69.1; 435/70.1; 435/172.3; 435/325; 435/320.1; 435/455; 435/6;
EXF
       536/23.4; 536/24.1; 514/44; 935/22; 935/23; 935/33; 935/34; 935/59;
       935/66: 424/93.21
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 134 OF 228 USPATFULL on STN 1999:155687 USPATFULL
L7
ΑN
       PKA-binding proteins and uses thereof
TI
       Lockerbie, Robert Owen, Kirkland, WA, United States
Kashishian, Adam, Mountlake Terrace, WA, United States
IN
       ICOS Corporation, Bothell, WA, United States (U.S. corporation)
PA
PΙ
       us 5994304
                                 19991130
                                 19980817 (9)
ΑI
       us 1998-135211
       Division of Ser. No. US 1995-503172, filed on 17 Jul 1995, now patented,
RLI
       Pat. No. US 5795735
DT
       Utility
       Granted
FS
LN.CNT 1298
INCL
       INCLM: 514/012.000
               514/002.000; 530/350.000
       INCLS:
               514/012.000
NCL
       NCLM:
               514/002.000; 530/350.000
       NCLS:
       [6]
IC
       ICM: C07K014-435
EXF
       514/2; 514/12; 530/350
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L7
     ANSWER 135 OF 228 USPATFULL ON STN
       1999:155184 USPATFULL
ΑN
       Methods for prolonging the expression of a heterologous gene of interest
TI
       using soluble CTLA4 molecules and an antiCD40 ligand
       Linsley, Peter S., Seattle, WA, United States
ΤN
       Kay, Mark A., Seattle, WA, United States
       Wilson, Christopher B., Seattle, WA, United States
       Ledbetter, Jeffrey, Seattle, WA, United States
       Aruffo, Alejandro A., Seattle, WA, United States
       Hollenbaugh, Diane L., Seattle, WA, United States
       Bristol-Myers Squibb Company, Princeton, NJ, United States (U.S.
PA
       corporation)
       us 5993800
                                 19991130
PΙ
       us 1995-474210
                                 19950606 (8)
ΑI
       Continuation-in-part of Ser. No. US 1995-468407, filed on 5 Jun 1995,
RLI
       now abandoned
DT
       Utility
FS
       Granted
LN.CNT 1336
       INCLM: 424/093.210
INCL
       INCLS: 435/069.100; 435/320.100; 435/325.000; 514/044.000; 424/093.100
NCL
               424/093.210
       NCLM:
       NCLS:
               424/093.100; 435/069.100; 435/320.100; 435/325.000; 514/044.000
        [6]
IC
       ICM: A61K048-00
EXF
       424/93.1; 424/93.21; 514/2; 514/2.1; 514/44; 536/22.1; 436/85-87;
       435/325; 435/320.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 136 OF 228 USPATFULL ON STN
L7
       1999:146625 USPATFULL
AN
TI
       Method for inhibiting intracellular viral replication
       Leung, David W., Mercer Island, WA, United States
IN
       Underiner, Gail E., Malvern, PA, United States
       Singer, Jack W., Seattle, WA, United States
       Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PA
                                 19991116
PΙ
       us 5985926
ΑI
       us 1997-797326
                                 19970210 (8)
       Continuation of Ser. No. US 1993-147255, filed on 1 Nov 1993, now
RLI
       abandoned And a continuation of Ser. No. US 1994-333575, filed on 1 Nov
```

```
1994, now abandoned
          Utility
DT
          Granted
FS
LN.CNT 1916
          INCLM: 514/558.000
INCL
          INCLS: 514/258.000; 514/262.000; 514/274.000; 514/299.000; 514/315.000; 514/418.000; 514/425.000; 514/529.000; 514/552.000; 514/561.000; 514/613.000; 514/617.000; 514/626.000; 514/629.000; 514/669.000
                     514/558.000
NCL
          NCLM:
                     514/211.030; 514/217.120; 514/222.200; 514/241.000; 514/243.000;
          NCLS:
                     514/249.000; 514/250.000; 514/260.100; 514/261.100; 514/262.100; 514/266.100; 514/274.000; 514/299.000; 514/315.000; 514/418.000; 514/425.000; 514/529.000; 514/561.000; 514/613.000; 514/617.000; 514/626.000; 514/629.000; 514/669.000
           [6]
IC
           ICM: A61K031-20
          514/558; 514/258; 514/262; 514/274; 514/299; 514/315; 514/418; 514/425; 514/529; 514/552; 514/561; 514/613; 514/617; 514/626; 514/629; 514/669
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
        ANSWER 137 OF 228 USPATFULL on STN
L7
           1999:141292 USPATFULL
AN
           Growth factor-induced proliferation of neural precursor cells in vivo
TI
           Weiss, Samuel, Alberta, Canada
IN
           Reynolds, Brent, Alberta, Canada
           NeuroSpheres Holdings Ltd., Calgary, Canada (non-U.S. corporation)
PΑ
                                               19991109
           us 5980885
PΙ
           us 1995-486307
                                               19950607 (8)
ΑI
          Continuation-in-part of Ser. No. US 1994-270412, filed on 5 Jul 1994, now abandoned Ser. No. Ser. No. US 1995-385404, filed on 7 Feb 1995, now
RLI
           abandoned Ser. No. Ser. No. US 1994-359945, filed on 20 Dec 1994, now abandoned Ser. No. Ser. No. US 1995-376062, filed on 20 Jan 1995, now
           abandoned Ser. No. Ser. No. US 1993-149508, filed on 9 Nov 1993, now
           abandoned Ser. No. Ser. No. US 1994-311099, filed on 23 Sep 1994, now
           abandoned And Ser. No. US 1994-338730, filed on 14 Nov 1994, now
           abandoned which is a continuation-in-part of Ser. No. US 1991-726812,
          filed on 8 Jul 1991, now abandoned, said Ser. No. US 270412 which is a continuation of Ser. No. US 726812, said Ser. No. US 385404 which is a continuation of Ser. No. US 1992-961813, filed on 16 Oct 1992, now abandoned which is a continuation-in-part of Ser. No. US 726812, said Ser. No. US 359945 which is a continuation of Ser. No. US 1994-221655,
           filed on 1 Apr 1994, now abandoned which is a continuation of Ser. No.
           US 1992-967622, filed on 28 Oct 1992, now abandoned which is a
           continuation-in-part of Ser. No. US 726812, said Ser. No. US 376062 which is a continuation of Ser. No. US 1993-10829, filed on 29 Jan 1993,
           now abandoned which is a continuation-in-part of Ser. No. US 726812
           said Ser. No. US 149508 which is a continuation-in-part of Ser. No. US
           726812 ,
                        said Ser. No. US 311099 which is a continuation-in-part of Ser.
           No. US 726812
Utility
DT
FS
           Granted
LN.CNT 4215
INCL
           INCLM: 424/093.210
           INCLS: 424/093.100; 424/093.200; 435/325.000; 435/360.000; 435/366.000; 435/368.000; 435/377.000; 435/383.000; 435/384.000; 435/440.000; 435/455.000; 435/456.000; 435/457.000; 514/002.000; 514/044.000
                     424/093.210
NCL
           NCLM:
                     424/093.100; 424/093.200; 435/325.000; 435/360.000; 435/366.000; 435/368.000; 435/377.000; 435/383.000; 435/384.000; 435/440.000; 435/455.000; 435/456.000; 435/457.000; 514/002.000; 514/044.000
           NCLS:
IC
           ICM: A01N063-00
           ICS: A01N043-04; C12N005-00; C12N005-08
           435/240.2; 435/325; 435/360; 435/366; 435/368; 435/377; 435/383; 435/455; 435/456; 435/457; 514/2; 514/44; 424/93.1; 424/93.2; 424/93.21
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L7
        ANSWER 138 OF 228 USPATFULL on STN
           1999:132808 USPATFULL
AN
           Treatment of cerebral ischemia and cerebral damage with neuroprotective
TI
           Keep, Marcus Floyd, Honolulu, HI, United States
ΙN
           Elmer, Eskil Mats, Lund, Sweden
           Kokaia, Merab, Lund, Sweden
           Uchino, Hiroyuki, Tokyo, Japan
```

Kokaia, Zaal, Lund, Sweden

```
Widner, Hakan, Lund, Sweden
        Zhao, Qi, Sunnyvale, CA, United States
        Uchino, Keiko, Tokyo, Japan
PA
        Maas BiolAB, LLC, Honolulu, HI, United States (U.S. corporation)
        us 5972924
                                    19991026
PΙ
        wo 9622104 19960725
                                                                               <--
        us 1997-860898
                                    19970711 (8)
ΑI
                                    19960118
        wo 1996-SE36
                                    19970711 PCT 371 date
19970711 PCT 102(e) date
        SE 1995-209
                               19950120
PRAI
        Utility
DT
        Granted
FS
LN.CNT 719
        INCLM: 514/183.000
INCL
        NCLM: 514/183.000
NCL
IC
        [6]
        ICM: A61K031-33
EXF
        514/183
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 139 OF 228 USPATFULL on STN
L7
        1999:124900 USPATFULL
AN
        Enantiomerically pure hydroxylated xanthine compounds
TI
        Bianco, James A., Seattle, WA, United States
IN
        Woodson, Paul, Bothell, WA, United States
        Porubek, David, Edmonds, WA, United States
        Singer, Jack, Seattle, WA, United States
        Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PA
                                    19991012
        us 5965564
PΙ
        us 1998-44976
                                    19980320 (9)
ΑI
        Continuation of Ser. No. US 1995-457703, filed on 1 Jun 1995, now
RLI
        patented, Pat. No. US 5739138 which is a division of Ser. No. US
        1994-343810, filed on 22 Nov 1994, now patented, Pat. No. US 5652243
        which is a division of Ser. No. US 1994-307554, filed on 16 Sep 1994,
        now patented, Pat. No. US 5648357 which is a continuation of Ser. No. US
        1993-13977, filed on 4 Feb 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-926665, filed on 7 Aug 1992, now abandoned which is a continuation-in-part of Ser. No. US
        1992-846354, filed on 4 Mar 1992, now abandoned
DT
        Utility
FS
        Granted
LN.CNT 1770
        INCLM: 514/263.000
INCL
        INCLS: 514/267.000; 514/270.000; 514/271.000
NCL
                514/263.360
                514/265.100; 514/267.000; 514/270.000; 514/271.000
        NCLS:
IC
        [6]
        ICM: A61K031-52
        514/263; 514/262; 514/265
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 140 OF 228 USPATFULL on STN
L7
        1999:121379 USPATFULL
ΑN
        Screening methods for cytokine inhibitors
TI
        Mak, Vivian, Menlo Park, CA, United States
ΙN
        Adolor Corporation, Malvern, PA, United States (U.S. corporation)
PA
                                    19991005
PΙ
        us 5962477
        US 1998-97441 19980615 (9)
Continuation-in-part of Ser. No. WO 1995-US4677, filed on 11 Apr 1995
which is a continuation-in-part of Ser. No. US 1995-400234, filed on 3
Mar 1995, now abandoned which is a continuation-in-part of Ser. No. US
ΑI
RLI
        1994-271287, filed on 6 Jul 1994, now abandoned which is a
        continuation-in-part of Ser. No. US 1994-225991, filed on 12 Apr 1994,
        now abandoned
DT
        Utility
FS
        Granted
LN.CNT 5138
INCL
        INCLM: 514/327.000
        INCLS: 424/078.050
                514/327.000
NCL
        NCLM:
                424/078.050
        NCLS:
IC
        [6]
        ICM: A61K031-445
EXF
        514/327: 424/78.05
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
```

```
L7
     ANSWER 141 OF 228 USPATFULL ON STN
       1999:92325 USPATFULL
AN
TI
       Reversing excitotoxic CNS damage by cellular implantation
       Sagen, Jaqueline, 2509 W. Farwell, Chicago, IL, United States 60645
IN
       us 5935606
                                 19990810
ΡI
       us 1995-509522
                                 19950731 (8)
ΑI
       Utility
DT
       Granted
FS
LN.CNT 1140
       INCLM: 424/562.000
INCL
       INCLS: 424/093.700
               424/562.000
NCL
       NCLM:
              424/093.700
       NCLS:
IC
       [6]
       ICM: A61K035-55
       435/240.2; 424/93.1; 424/93.7; 424/562; 424/523
EXF
     ANSWER 142 OF 228 USPATFULL on STN
L7
       1999:85380 USPATFULL
ΑN
       Human calcium-binding phosphoprotein
TI
       Bandman, Olga, Mountain View, CA, United States
Corley, Neil C., Mountain View, CA, United States
IN
       Shah, Purvi, Sunnyvale, CA, United States
       Incyte Pharmaceuticals, Inc., Palo Alto, CA, United States (U.S.
PA
       corporation)
       us 5929029
                                  19990727
PΙ
       US 1998-96082
                                  19980611 (9)
ΑI
       Division of Ser. No. US 1997-884682, filed on 27 Jun 1997, now patented,
RLI
       Pat. No. US 5804419
DT
       Utility
FS
        Granted
LN.CNT 2124
        INCLM: 514/002.000
INCL
       INCLS: 514/012.000; 530/350.000
NCL
       NCLM:
               514/002.000
               514/012.000; 530/350.000
       NCLS:
        [6]
IC
        ICM: A61K038-17
        ICS: C07K014-435
EXF 530/350; 514/2; 514/12
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 143 OF 228 USPATFULL on STN
17
AN
        1999:81832 USPATFULL
       Apoptosis regulating composition
TI
IN
        Nakai, Satoru, Tokushima-ken, Japan
       Aihara, Koutoku, Tokushima-ken, Japan
       Mori, Hitomi, Tokushima, Japan
        Tominaga, Michiaki, Tokushima-ken, Japan
       Adachi, Masakazu, Takasaki, Japan
Ichikawa, Hiroyuki, Tokushima, Japan
        Akamatsu, Seiji, Naruto, Japan
        Saito, Fumio, Takasaki, Japan
        Otsuka Pharmaceutical Co. Ltd., Tokyo, Japan (non-U.S. corporation)
PA
PΙ
        us 5925640
                                  19990720
ΑI
        us 1997-853745
                                  19970509 (8)
        Division of Ser. No. US 1995-466449, filed on 6 Jun 1995, now patented,
RLI
        Pat. No. US 5672603 which is a continuation of Ser. No. US 989028
PRAI
        JP 1991-162587
                              19910703
        JP 1991-162587
                              19910703
        JP 1992-33469
                              19920220
        JP 1992-45178
                              19920303
        Utility
DT
FS
        Granted
LN.CNT 1240
INCL
        INCLM: 514/255.000
        NCLM: 514/253.070
NCL
IC
        [6]
        ICM: A61K031-495
514/255
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 144 OF 228 USPATFULL ON STN
L7
        1999:72582 USPATFULL
AN
TI
        Apoptosis regulating composition
```

```
ΙN
        Nakai, Satoru, Tokushima, Japan
        Aihara, Koutoku, Tokushima, Japan
        Mori, Hitomi, Tokushima, Japan
        Tominaga, Michiaki, Tokushima, Japan
        Adachi, Masakazu, Gunma, Japan
Ichikawa, Hiroyuki, Tokushima, Japan
        Akamatsu, Seiji, Tokushima, Japan
        Saito, Fumio, Gunma, Japan
        Otsuka Pharmaceutical Co., Ltd.
                                                Tokyo, Japan (non-U.S. corporation)
PA
                                      19990629
        us 5916890
PΙ
        us 1997-854073
                                      19970509 (8)
ΑI
        Division of Ser. No. US 1995-466449, filed on 6 Jun 1995, now patented,
RLI
        Pat. No. US 5672603 which is a continuation of Ser. No. US 1993-989028,
        filed on 30 Apr 1993, now abandoned which is a continuation of Ser. No.
        wo 1992-JP841, filed on 2 Jul 1992
                                 19910703
PRAI
        JP 1991-162587
                                 19920220
        JP 1992-33469
        JP 1992-45178
                                 19920303
        JP 1992-585
                                 19920325
DT
        Utility
        Granted
FS
LN.CNT 1244
        INCLM: 514/255.000
INCL
        NCLM: 514/253.070
NCL
IC
         [6]
         ICM: A61K031-495
        514/255
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L7
      ANSWER 145 OF 228 USPATFULL ON STN
        1999:67430 USPATFULL
AN
        Mice transgenic for a tetracycline-inducible transcriptional activator
ΤI
        Bujard, Hermann, Heidelberg, Germany, Federal Republic of
ΙN
        Gossen, Manfred, El Cerrito, CA, United States
PA
        University of Heidelberg, Heidelberg, Germany, Federal Republic of
         (non-U.S. corporation)
         us 5912411
                                      19990615
PΙ
                                                                                     <--
        us 1995-487472
                                      19950607 (8)
ΑI
        Continuation-in-part of Ser. No. US 1995-383754, filed on 3 Feb 1995 And
RLI
        a continuation-in-part of Ser. No. US 1994-275876, filed on 15 Jul 1994, now patented, Pat. No. US 5654168 which is a continuation-in-part of Ser. No. US 1994-270637, filed on 1 Jul 1994, now abandoned, said Ser. No. US 487472 which is a continuation-in-part of Ser. No. US
        1994-260452, filed on 14 Jun 1994, now patented, Pat. No. US 5650298 which is a continuation-in-part of Ser. No. US 1993-76327, filed on 14 Jun 1993, now abandoned, said Ser. No. US 1995-487472, filed on 7 Jun
         1995 which is a continuation-in-part of Ser. No. US 1993-76726, filed on
         14 Jun 1993, now patented, Pat. No. US 5464758
DT
        Utility
         Granted
FS
LN.CNT 4690
INCL
         INCLM: 800/002.000
         INCLS: 435/172.300; 435/069.100; 435/070.100; 435/325.000; 536/023.400;
                 536/024.100; 424/009.210
NCL
        NCLM:
                 800/018.000
        NCLS:
                 435/069.100; 435/070.100; 435/325.000; 435/462.000; 435/463.000;
                 514/152.000; 536/023.400; 536/024.100
IC
         [6]
         ICM: C12N005-00
        ICS: C12N015-00; C12N015-09
800/2; 435/69.1; 435/70.1; 435/172.3; 435/240.2; 435/240.4; 435/320.1;
435/325; 536/23.4; 536/24.1; 424/9.21
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L7
      ANSWER 146 OF 228 USPATFULL ON STN
         1999:56260 USPATFULL
AN
         Methods of inducing T cell unresponsiveness to donor tissue or organ in
TI
         a recipient with GP39 antagonists
        Noelle, Randolph J., Cornish, NH, United States
Durie, Fiona H., Seattle, WA, United States
Parker, David C., Gafton, MA, United States
IN
        Appel, Michael C., Grafton, MA, United States
         Phillips, Nancy E., Shrewsbury, MA, United States
        Mordes, John P., Newton, MA, United States
         Grenier, Dale L., Hubbardston, MA, United States
```

Rossini, Aldo A., Sudbury, MA, United States

```
PA
        University of Massachusetts Medical Center, Worcester, MA, United States
        (U.S. corporation)
        The Trustees of Dartmouth College, Hanover, NH, United States (U.S.
        corporation)
PΙ
        US 5902585
                                   19990511
        US 1997-906332
                                   19970805 (8)
ΑI
        Division of Ser. No. US 1994-234987, filed on 25 Apr 1994, now patented,
RLI
        Pat. No. US 5683693
DT
        Utility
FS
        Granted
LN.CNT
       1125
        INCLM: 424/144.100
INCL
        INCLS: 424/130.100; 424/133.100; 424/134.100; 424/141.100; 424/143.100;
                424/154.100; 424/173.100; 514/002.000; 514/008.000; 514/885.000; 530/387.100; 530/387.300; 530/388.100; 530/388.200; 530/388.220; 530/388.700; 530/388.730; 530/388.750; 530/350.000
                424/144.100
NCL
        NCLM:
                424/130.100; 424/133.100; 424/134.100; 424/141.100; 424/143.100; 424/154.100; 424/173.100; 514/002.000; 514/008.000; 514/885.000; 530/350.000; 530/387.100; 530/387.300; 530/388.100; 530/388.200; 530/388.200; 530/388.750
        NCLS:
IC
        [6]
        ICM: A61K039-395
        ICS: A61K035-26; C07K016-28; C07K014-435
        424/130.1; 424/133.1; 424/134.1; 424/143.1; 424/144.1; 424/173.1; 514/2;
EXF
        514/8; 514/885; 530/350; 530/387.1; 530/387.3; 530/388.2; 530/388.22;
        530/388.73; 530/388.75; 435/70.21; 435/452; 435/332; 435/334; 435/343.1;
        435/343.2
     ANSWER 147 OF 228 USPATFULL on STN 1999:43226 USPATFULL
L7
AN
        Non-steroidal anti-inflammatory agents inhibition of fibrotic response
TI
        to an implanted device
        Lanza, Robert P., Clinton, MA, United States
IN
        Chick, William L., Wellesley, MA, United States
        Biohybrid Technologies, Inc., Shrewsbury, MA, United States (U.S.
PA
        corporation)
        us 5891477
                                   19990406
                                                                              <--
PI
        US 1997-828327
                                   19970328 (8)
ΑI
DT
        Utility
        Granted
FS
LN.CNT
       1565
        INCLM: 424/501.000
INCL
        INCLS: 424/426.000; 424/502.000; 435/180.000; 435/182.000
                424/501.000
NCL
                424/426.000; 424/502.000; 435/180.000; 435/182.000
        NCLS:
IC
        [6]
        ICM: A61F002-02
        ICS: A61K009-50; C12N011-04; C12N011-08
        424/426; 424/501; 424/502; 435/180; 435/182
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 148 OF 228 USPATFULL on STN
L7
        1999:40428 USPATFULL
ΑN
        Substituted amino alkyl compounds
TI
        Klein, J. Peter, Vashon Island, WA, United States
IN
        Underiner, Gail E., Brier, WA, United States
        Leigh, Alistair J., Brier, WA, United States
        Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PA
        us 5889011
PΙ
                                    19990330
        us 1997-884037
                                    19970627 (8)
ΑI
        Continuation of Ser. No. US 1993-149681, filed on 9 Nov 1993, now
RLI
        abandoned which is a continuation-in-part of Ser. No. US 1992-973804,
        filed on 9 Nov 1992, now patented, Pat. No. US 5340813
DT
        Utility
        Granted
FS
LN.CNT 1351
        INCLM: 514/263.000
INCL
        INCLS: 514/261.000; 544/267.000; 544/264.000; 544/265.000
NCL
        NCLM:
                514/263.350
                544/264.000; 544/265.000; 544/267.000
        NCLS:
IC
        [6]
        ICM: C07D473-00
        ICS: A61K031-52
        544/257; 544/267; 544/263; 544/285; 544/287; 514/263; 514/261
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
```

```
ANSWER 149 OF 228 USPATFULL ON STN
L7
       1999:40399 USPATFULL
ΑN
TI
       Methods for regulating gene expression
       Bujard, Hermann, Heidelberg, Germany, Federal Republic of
IN
       Gossen, Manfred, El Cerrito, CA, United States
       Salfeld, Jochen G., North Grafton, MA, United States
       Voss, Jeffrey W., West Boylston, MA, United States
       BASF Aktiengesellschaft, Ludwigshafen, Germany, Federal Republic of
PA
       (non-U.S. corporation)
       Knoll Aktiengesellschaft, Ludwigshafen, Germany, Federal Republic of
       (non-U.S. corporation)
       ùs 5888981
PΤ
                                 19990330
       us 1995-479306
                                 19950607 (8)
ΑI
       Continuation-in-part of Ser. No. US 1994-260452, filed on 14 Jun 1994,
RLI
       now patented, Pat. No. US 5650298 which is a continuation-in-part of
       Ser. No. US 1993-76327, filed on 14 Jun 1993, now abandoned
DT
       Utility
       Granted
FS
       3270
LN.CNT
       INCLM: 514/044.000
INCL
       INCLS: 424/093.210; 435/172.300; 935/034.000; 935/062.000
NCL
              514/044.000
              424/093.210; 435/455.000; 435/463.000; 435/465.000
       NCLS:
IC
       [6]
       ICM: A61K048-00
       ICS: C12N015-00
EXF
       514/44; 435/69.1; 435/172.3; 435/240.2; 435/320.1; 536/24.1; 536/23.4;
       935/62; 935/34; 424/93.21
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 150 OF 228 USPATFULL on STN
L7
       1999:36949 USPATFULL
ΑN
       Engineering oral tissues
TI
       Mooney, David J., Ann Arbor, MI, United States
IN
       Rutherford, Robert B., Ann Arbor, MI, United States
       The Regents of the University of Michigan, Ann Arbor, MI, United States
PA
       (U.S. corporation)
       ùs 5885829
US 1997-864494
                                 19990323
PΙ
                                                                        <--
                                 19970528 (8)
ΑI
       US 1996-18450P
PRAI
                            19960528 (60)
       Utility
DT
       Granted
FS
LN.CNT 8001
       INCLM: 435/325.000
INCL
       INCLS: 424/049.000; 424/422.000; 424/435.000; 435/069.500; 435/374.000;
               435/378.000
       NCLM:
               435/325.000
NCL
               424/049.000; 424/422.000; 424/435.000; 435/069.100; 435/374.000;
       NCLS:
               435/378.000
IC
       ICM: C12N005-00
       ICS: C12N005-02; C12N005-08; C12N015-09
       435/69.1; 435/325; 435/69.4; 435/69.5; 435/69.6; 435/365; 435/393;
EXF
       435/366; 435/374; 435/378; 422/422; 422/423; 422/424; 422/435; 422/49;
       422/85.1; 422/93.7; 514/12; 514/21
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L7
     ANSWER 151 OF 228 USPATFULL on STN
ΑN
       1999:34025 USPATFULL
       Compositions and methods for treating and preventing pathologies
TI
       including cancer
IN
       Samid, Dvorit, Rockville, MD, United States
       The United States of America as represented by the Department of Health
PA
       and Human Services, Washington, DC, United States (U.S. government)
PΙ
       US 5883124
                                 19990316
       US 1995-484615
                                 19950607 (8)
ΑI
       Division of Ser. No. US 1994-207521, filed on 7 Mar 1994 which is a continuation-in-part of Ser. No. US 1993-135661, filed on 12 Oct 1993
RLI
       which is a continuation-in-part of Ser. No. US 1991-779744, filed on 21
       Oct 1991, now abandoned
       Utility
DT
       Granted
FS
LN.CNT 7729
INCL
       INCLM: 514/538.000
       INCLS: 514/557.000; 514/563.000; 514/567.000; 514/568.000; 514/570.000;
```

```
514/725.000
               514/538.000
NCL
       NCLM:
               514/557.000; 514/563.000; 514/567.000; 514/568.000; 514/570.000;
       NCLS:
               514/725.000
IC
       [6]
       ICM: A01N037-12
       ICS: A01N037-44; A61K031-24
514/538; 514/557; 514/563; 514/567; 514/568; 514/570; 514/725
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 152 OF 228 USPATFULL ON STN
L7
       1999:22101 USPATFULL
ΑN
       Apoptosis regulating composition
TI
       Nakai, Satoru, Tokushima, Japan
IN
       Aihara, Koutoku, Tokushima, Japan
       Mori, Hitomi, Tokushima, Japan
       Tominaga, Michiaki, Tokushima, Japan
       Adachi, Masakazu, Gunma, Japan
Ichikawa, Hiroyuki, Tokushima, Japan
       Akamatsu, Seiji, Tokushima, Japan
       Saito, Fumio, Gunma, Japan
PA
       Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan (non-U.S. corporation)
                                 19990216
PΙ
       US 5872120
       us 1997-854074
                                 19970509 (8)
ΑI
       Division of Ser. No. US 1995-466449, filed on 6 Jun 1995, now patented,
RLI
       Pat. No. US 5672603 which is a continuation of Ser. No. US 1993-989028,
       filed on 30 Apr 1993, now abandoned
PRAI
       JP 1991-162587
                             19910703
       JP 1992-33469
                             19920220
       JP 1992-45178
                             19920303
       JP 1992-100585
                             19920325
       WO 1992-JP841
                             19920702
DT
       Utility
       Granted
FS
LN.CNT 1240
       INCLM: 514/254.000
INCL
       NCLM: 514/253.070
NCL
IC
       [6]
       ICM: A61K031-495
       ICS: A61K031-50
       514/254
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L7
     ANSWER 153 OF 228 USPATFULL on STN
       1999:21928 USPATFULL
AN
       Modulators of anchoring protein function
TI
       Lockerbie, Robert Owen, Kirkland, WA, United States
IN
       Howard, Monique L., Seattle, WA, United States
Gallatin, W. Michael, Mercer Island, WA, United States
       ICOS Corporation, Bothell, WA, United States (U.S. corporation)
PA
                                 19990216
       us 5871945
ΡI
       US 1995-503226
                                 19950717 (8)
ΑI
RLI
       Continuation-in-part of Ser. No. US 1995-404731, filed on 15 Mar 1995,
       now patented, Pat. No. US 5744354 which is a continuation-in-part of
       Ser. No. US 1994-344227, filed on 23 Nov 1994, now patented, Pat. No. US
        5807693
DT
       Utility
        Granted
FS
LN.CNT
       2221
        INCLM: 435/007.930
INCL
        INCLS: 435/004.000; 435/007.100; 435/007.200
NCL
       NCLM:
               435/007.930
               435/004.000; 435/007.100; 435/007.200
       NCLS:
IC
        [6]
        ICM: C12Q001-00
        ICS: G01N033-53
        435/4; 435/7.1; 435/7.2; 435/7.93
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 154 OF 228 USPATFULL on STN
L7
        1999:18912 USPATFULL
AN
       Method of determining DNA sequence preference of a DNA-binding molecule
TI
       Edwards, Cynthia A., Menlo Park, CA, United States
IN
       Cantor, Charles R., Boston, MA, United States
       Andrews, Beth M., Maynard, MA, United States
       Turin, Lisa M., Redwood City, CA, United States
```

```
Fry, Kirk E., Palo Alto, CA, United States
        Genelabs Technologies, Inc., Redwood City, CA, United States (U.S.
        corporation)
        us 5869241
PΙ
                                   19990209
                                                                              <--
                                   19950607 (8)
        us 1995-475228
ΑI
RLI
        Division of Ser. No. US 1993-171389, filed on 20 Dec 1993, now patented,
        Pat. No. US 5578444 which is a continuation-in-part of Ser. No. US
       1993-123936, filed on 17 Sep 1993, now patented, Pat. No. US 5726014 which is a continuation-in-part of Ser. No. US 1992-996783, filed on 23 Dec 1992, now patented, Pat. No. US 5693463 which is a
        continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991,
        now abandoned
DT
        Utility
        Granted
FS
LN.CNT 9840
        INCLM: 435/006.000
INCL
        INCLS: 435/911.000; 435/912.000; 935/077.000; 935/078.000
               435/006.000
NCL
        NCLM:
               435/091.100; 435/091.200
        [6]
IC
        ICM: C12Q001-68
        ICS: C12P019-34
EXF
        435/6; 435/91.1; 435/91.2; 935/77; 935/78
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L7
     ANSWER 155 OF 228 USPATFULL on STN
        1999:16105 USPATFULL
ΑN
TI
        Animals transgenic for a tetracycline-regulated transcriptional
        inhibitor
        Bujard, Hermann, Heidelberg, Germany, Federal Republic of
IN
        Gossen, Manfred, El Cerrito, CA, United States
        BASF Aktiengellschaft, Germany, Federal Republic of (non-U.S.
PΑ
        corporation)
        Knoll Aktiengellschaft, Germany, Federal Republic of (non-U.S.
        corporation)
                                    19990202
PΙ
        us 5866755
        us 1995-486814
                                   19950607 (8)
ΑI
        Continuation-in-part of Ser. No. US 1995-383754, filed on 3 Feb 1995, now patented, Pat. No. US 5789156 Ser. No. Ser. No. US 1994-275876,
RLI
        filed on 15 Jul 1994, now patented, Pat. No. US 5654168 Ser. No. Ser. No. US 1994-260452, filed on 14 Jun 1994, now patented, Pat. No. US
        5650298 And Ser. No. US 1993-76726, filed on 14 Jun 1993, now patented,
        Pat. No. US 5464758 , said Ser. No. US 275876 which is a
        continuation-in-part of Ser. No. US 1994-270637, filed on 1 Jul 1994,
        now abandoned , said Ser. No. US 260452 which is a continuation-in-part
        of Ser. No. US 1993-76327, filed on 14 Jun 1993, now abandoned
        Utility
DT
        Granted
FS
LN.CNT 4493
INCL
        INCLM: 800/002.000
        INCLS: 435/172.300; 800/DIG.001
                800/009.000
NCL
        NCLM:
        NCLS:
               800/018.000
        [6]
IC
        ICM: C12N005-00
        ICS: C12N015-00
        800/2; 800/DIG.1-4; 536/23.1; 536/23.5; 530/350; 435/172.3
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L7
     ANSWER 156 OF 228 USPATFULL ON STN
AN
        1999:15930 USPATFULL
        Epoxide-containing compounds
TI
        Underiner, Gail, Brier, WA, United States
IN
        Klein, J. Peter, Vashon, WA, United States
        Michnick, John, Seattle, WA, United States
        Leigh, Alistair, Brier, WA, United States
       Kumar, Anil, Seattle, WA, United States
Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
US 5866576 19990202 <--
PA
PΙ
                                    19970103 (8)
        US 1997-778563
ΑI
        Continuation of Ser. No. US 1993-167600, filed on 13 Dec 1993, now
RLI
        abandoned which is a continuation-in-part of Ser. No. US 1992-991655,
        filed on 16 Dec 1992, now abandoned
DT
        Utility
FS
        Granted
```

LN.CNT 3141

```
INCL
        INCLM: 514/256.000
        INCLS: 514/396.000; 514/263.000; 544/242.000; 548/300.100; 548/311.100
NCL
                 514/256.000
                 514/262.100; 514/263.230; 514/396.000; 544/242.000; 548/300.100;
         NCLS:
                 548/311.100
IC
         [6]
         ICM: A61K031-505
         ICS: C07D239-02
        544/269; 544/266; 544/267; 544/268; 544/270; 544/272; 544/273; 544/271; 544/242; 514/263; 514/256; 548/300.1; 548/311.1
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L7
      ANSWER 157 OF 228 USPATFULL ON STN
         1999:4960 USPATFULL
AN
         Mice transgenic for a tetracycline-controlled transcriptional activator
ΤI
        Bujard, Hermann, Heidelberg, Germany, Federal Republic of
Gossen, Manfred, El Cerrito, CA, United States
Salfeld, Jochen G., Noth Graton, MA, United States
Voss, Jeffrey W., West Boylson, MA, United States
BASF Aktiengesellschaft, Heidelberg, Germany, Federal Republic of
IN
PA
         (non-U.S. corporation)
         us 5859310
PΙ
                                       19990112
                                                                                     <--
ΑI
         us 1995-481970
                                       19950607 (8)
         Continuation-in-part of Ser. No. US 1994-260452, filed on 14 Jun 1994,
RLI
         now patented, Pat. No. US 5650298 which is a continuation-in-part of
         Ser. No. US 1993-76327, filed on 14 Jun 1993, now abandoned
         Utility
DT
FS
         Granted
        3328
LN.CNT
         INCLM: 800/002.000
INCL
         INCLS: 435/172.300; 435/069.100; 435/070.100; 435/325.000; 435/320.100;
                  536/023.400; 536/024.100; 424/009.210
                 800/009.000
NCL
         NCLM:
                 435/069.100; 435/070.100; 435/320.100; 435/325.000; 514/152.000; 536/023.400; 536/024.100; 800/004.000; 800/018.000; 800/022.000;
         NCLS:
                  800/025.000
         [6]
IC
         ICM: C12N005-00
         ICS: C12N015-00; C12N015-09
800/2; 435/69.1; 435/70.1; 435/172.3; 435/240.2; 435/240.4; 435/320.1;
435/325; 536/23.4; 536/24.1; 424/9.21
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L7
      ANSWER 158 OF 228 USPATFULL on STN
         1998:159986 USPATFULL
ΑN
         Phenylacetate and derivatives alone or in combination with other
TI
         compounds against neoplastic conditions and other disorders
         Samid, Dvorit, Rockville, MD, United States
IN
         The United States of America as represented by the Department of Health
PA
         and Human Services, Washington, DC, United States (U.S. government)
         us 5852056
                                       19981222
PΙ
                                                                                      <--
         wo 9510271
                        19950420
                                                                                      <--
         us 1996-633833
                                       19960410 (8)
AΙ
         wo 1994-us11492
                                       19941012
                                       19960410
                                                   PCT 371 date
                                                  PCT 102(e) date
                                       19960410
         Continuation of Ser. No. US 1994-207521, filed on 7 Mar 1994, now
RLI
         patented, Pat. No. US 5605930 And Ser. No. US 1993-135661, filed on 12 oct 1993, now patented, Pat. No. US 5635532, each Ser. No. US - whi is a continuation-in-part of Ser. No. US 1991-779744, filed on 21 oct
         1991, now abandoned Utility
DT
FS
         Granted
LN.CNT 5051
         INCLM: 514/510.000
INCL
         INCLS: 514/513.000; 514/515.000; 514/529.000; 514/538.000; 514/563.000;
                  514/567.000
NCL
         NCLM:
                  514/510.000
                  514/513.000; 514/515.000; 514/529.000; 514/538.000; 514/563.000;
         NCLS:
                  514/567.000
IC
       . [6]
         ICM: A01N037-12
         ICS: A01N037-44; A61K031-195; A61K031-24
         514/510; 514/513; 514/515; 514/529; 514/538; 514/563; 514/567
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
```

```
L7
     ANSWER 159 OF 228 USPATFULL ON STN
        1998:159764 USPATFULL
AN
        In vitro growth and proliferation of multipotent neural stem cells and
TI
        their progeny
        Weiss, Samuel, Alberta, Canada
IN
        Reynolds, Brent, Alberta, Canada
        Hammang, Joseph P., Barrington, RI, United States
Baetge, E. Edward, Barrington, RI, United States
        Neurospheres, Ltd., Canada (non-U.S. corporation)
PA
        us 5851832
                                    19981222
PΙ
                                    19950607 (8)
ΑI
        us 1995-486648
        Continuation-in-part of Ser. No. US 1994-270412, filed on 5 Jul 1994
RLI
        now abandoned which is a continuation of Ser. No. US 1991-726812, filed
        on 8 Jul 1991, now abandoned And a continuation-in-part of Ser. No. US
        1995-385404, filed on 7 Feb 1995, now abandoned which is a continuation
        of Ser. No. US 1992-961813, filed on 16 Oct 1992, now abandoned which is
        a continuation-in-part of Ser. No. US 726812 And Ser. No. US
        1994-359945, filed on 20 Dec 1994, now abandoned which is a continuation of Ser. No. US 1994-221655, filed on 1 Apr 1994, now abandoned which is a continuation of Ser. No. US 1992-967622, filed on 28 Oct 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-726812,
        filed on 8 Jul 1991, now abandoned And Ser. No. US 1995-376062, filed on
        20 Jan 1995, now abandoned which is a continuation of Ser. No. US 1993-10829, filed on 29 Jan 1993, now abandoned which is a
        continuation-in-part of Ser. No. US 726812 And Ser. No. US 1993-149508,
        filed on 9 Nov 1993, now abandoned which is a continuation-in-part of
        Ser. No. US 726812 And Ser. No. US 1994-311099, filed on 23 Sep 1994,
        now abandoned which is a continuation-in-part of Ser. No. US 726812 And
        ser. No. US 1994-338730, filed on 14 Nov 1994, now abandoned which is a
        continuation-in-part of Ser. No. US 726812
DT
        Utility
FS
        Granted
LN.CNT 4487
        INCLM: 435/368.000
INCL
        INCLS: 435/325.000; 435/366.000; 435/383.000; 435/384.000
NCL
                435/368.000
                435/325.000; 435/366.000; 435/377.000; 435/383.000; 435/384.000
        NCLS:
IC
        [6]
        ICM: C12N005-06
        ICS: C12N005-08; C12N005-02
EXF
        435/240.2; 435/325; 435/366; 435/368; 435/377; 435/383; 435/384
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L7
      ANSWER 160 OF 228 USPATFULL ON STN
        1998:157347 USPATFULL
ΑN
TI
        N-benzylpiperazine compounds
        Wierzbicki, Michel, L'Etang la Ville, France
IN
        Boussard, Marie-Fran.cedilla.oise, Mareil Sur Mauldre, France
        Labidalle, Serge, Pinsaguel, France
        Guyot, Daniel, Montjoire, France
Rolland, Yves, Vanves, France
        Tillement, Jean-Paul, Bois le Roi, France
        Testa, Bernard, Lausanne, Switzerland
        Crevat, Aime, Marseilles, France
        ADIR et Compagnie, Courbevoie, France (non-U.S. corporation)
PA
        us 5849745
                                    19981215
PΙ
ΑI
        us 1997-990611
                                    19971215 (8)
PRAI
        FR 1996-15415
                               19961216
DT
        Utility
        Granted
FS
LN.CNT 904
INCL
        INCLM: 514/252.000
                514/255.000; 544/365.000; 544/372.000; 544/376.000; 544/394.000;
        INCLS:
                544/399.000; 544/374.000
                514/252.120
NCL
        NCLM:
                514/253.130; 514/254.010; 514/254.110; 544/365.000; 544/372.000;
        NCLS:
                544/374.000; 544/376.000; 544/394.000; 544/399.000
IC
        [6]
        ICM: A61K031-495
        ICS: C07D295-116; C07D401-12; C07D405-12
544/365; 544/372; 544/374; 544/376; 544/394; 544/399; 514/252; 514/255
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 161 OF 228 USPATFULL ON STN
L7
        1998:150994 USPATFULL
ΑN
        Compositions and methods for treating and preventing pathologies
```

TI

```
including cancer
         Samid, Dvorit, Rockville, MD, United States
IN
         The United States of America as representeed by the Department of Health
PA
         and Human Services, Washington, DC, United States (U.S. government)
         us 5843994
PΙ
                                        19981201
         us 1995-478264
ΑI
                                        19950607 (8)
         Division of Ser. No. US 1994-207521, filed on 7 Mar 1994, now patented,
RLI
         Pat. No. US 5605930 which is a continuation-in-part of Ser. No. US
         1993-135661, filed on 12 Oct 1993, now abandoned which is a
         continuation-in-part of Ser. No. US 1991-779744, filed on 21 Oct 1991,
         now abandoned
         Utility
DT
         Granted
FS
LN.CNT 7935
         INCLM: 514/510.000
INCL
         INCLS: 514/513.000; 514/515.000; 514/529.000; 514/538.000; 514/563.000;
                  514/567.000
                  514/510.000
NCL
         NCLM:
                  514/513.000; 514/515.000; 514/529.000; 514/538.000; 514/563.000;
         NCLS:
                  514/567.000
IC
         [6]
         ICM: A61K031-21
         ICS: A01N047-40
         514/510; 514/513; 514/515; 514/529; 514/538; 514/563; 514/567
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L7
      ANSWER 162 OF 228 USPATFULL on STN
         1998:144102 USPATFULL
ΑN
TI
         Amino-alcohol substituted cyclic compounds
        Kumar, Anil M., Seattle, WA, United States
Michnick, John, Seattle, WA, United States
Underiner, Gail E., Brier, WA, United States
Klein, J. Peter, Vastella States
IN
         Rice, Glenn C., Seattle, WA, United States
PA
         Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
                                        19981117
ΡI
         US 5837703
ΑI
         US 1993-152650
                                        19931112 (8)
         Continuation-in-part of Ser. No. US 1993-40820, filed on 31 Mar 1993,
RLI
         now abandoned
DT
         Utility
FS
         Granted
LN.CNT 2596
INCL
         INCLM: 514/183.000
         INCLS: 514/211.000; 514/228.800; 514/241.000; 514/242.000; 514/249.000;
                  514/256.000; 514/259.000; 514/263.000; 514/270.000; 514/274.000;
                  514/309.000; 514/312.000; 514/315.000; 514/348.000; 514/357.000;
                  514/374.000; 514/400.000; 514/425.000; 514/427.000; 540/467.000;
                  540/544.000; 544/216.000; 544/257.000; 544/272.000; 544/286.000;
                  544/301.000; 544/311.000; 544/335.000; 546/096.000; 546/141.000; 546/142.000; 546/157.000; 546/246.000; 546/296.000; 546/334.000; 548/215.000; 548/340.100; 548/485.000; 548/546.000; 548/561.000
                  514/183.000
NCL
         NCLM:
                  514/211.150; 514/228.800; 514/241.000; 514/242.000; 514/249.000;
         NCLS:
                                   514/266.200; 514/266.300; 514/270.000;
                                                                                     514/274.000;
                  514/256.000;
                  514/309.000; 514/312.000; 514/315.000; 514/348.000; 514/357.000;
                  514/374.000; 514/400.000; 514/425.000; 514/427.000; 540/467.000;
                  540/544.000; 544/216.000; 544/257.000; 544/272.000; 544/286.000;
                  544/301.000; 544/311.000; 544/335.000; 546/096.000; 546/141.000; 546/142.000; 546/157.000; 546/246.000; 546/296.000; 546/334.000; 548/215.000; 548/340.100; 548/485.000; 548/546.000; 548/561.000
IC
         [6]
         ICM: A61K031-55
         ICS: A61K031-515; A61K031-445; A61K031-52
         544/276; 544/272; 544/216; 544/257; 544/285; 544/286; 544/301; 544/311; 544/335; 514/263; 514/183; 514/211; 514/228.8; 514/241; 514/242; 514/249; 514/256; 514/259; 514/270; 514/274; 514/309; 514/312; 514/315; 514/348; 514/357; 514/374; 514/400; 514/418; 514/425; 514/427; 540/467; 540/544; 546/96; 546/141; 546/142; 546/157; 546/246; 546/296; 546/334; 548/215; 548/340.1; 548/485; 548/546; 548/561
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L7
      ANSWER 163 OF 228 USPATFULL ON STN
AN
         1998:128265
                        USPATFULL
TI
         Substituted amino alcohol compounds
IN
         Klein, J. Peter, Vashon, WA, United States
         Underiner, Gail E., Brier, WA, United States
```

```
Kumar, Anil M., Seattle, WA, United States
          Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PA
                                                19981020
ΡI
          us 5824677
          us 1995-474816
ΑI
                                                19950607 (8)
          Division of Ser. No. US 1994-303842, filed on 8 Sep 1994, now patented,
RLI
          Pat. No. US 5641783 which is a continuation-in-part of Sér. No. US
          1993-152650, filed on 12 Nov 1993, now patented, Pat. No. US 5801181 And Ser. No. US 1993-164081, filed on 8 Dec 1993, now patented, Pat. No. US 5470878, said Ser. No. US -152650 And Ser. No. US -164081, each
           5470878 , said Ser. No. US
                              - which is a continuation-in-part of Ser. No. US
          Ser. No. US
          1993-40820, filed on 31 Mar 1993, now abandoned
DT
          Utility
           Granted
FS
          3136
LN.CNT
           INCLM: 514/222.500
INCL
           INCLS: 514/223.500; 514/224.500; 514/226.800; 514/227.500; 514/228.800;
                                                             514/230.800; 514/237.800; 514/248.000;
514/258.000; 514/274.000; 514/301.000;
514/351.000; 514/360.000; 514/361.000;
514/364.000; 514/365.000; 514/367.000;
514/374.000; 514/375.000; 514/376.000;
                      514/229.200; 514/230.500;
514/249.000; 514/255.000;
                                         514/311.000;
514/363.000;
                      514/303.000;
                      514/362.000;
                      514/372.000;
                                         514/373.000;
                                                                                                     514/395.000
                      514/378.000;
                                         514/379.000;
                                                             514/380.000; 514/387.000;
                                                             514/424.000; 514/425.000; 514/433.000;
                      514/415.000; 514/418.000;
                      514/452.000; 514/432.000;
                                                             514/438.000; 346/113.000; 346/114.000;
                                                             549/014.000; 549/050.000; 549/075.000;
                      346/164.000; 346/300.000;
                                                             544/002.000; 544/003.000; 544/005.000;
                      549/367.000; 549/368.000;
                                                             544/063.000;
                      544/008.000; 544/053.000;
                                                                                 544/065.000; 544/066.000;
                      544/067.000;
                                          544/090.000;
                                                              544/091.000;
                                                                                 544/127.000; 544/128.000;
                                                                                  544/229.000;
544/311.000;
                                                                                                      544/235.000;
544/353.000;
                      544/162.000;
544/237.000;
                                          544/215.000;
544/255.000;
                                                              544/219.000;
544/278.000;
                      544/385.000;
                                          548/123.000;
                                                                                  548/131.000;
                                                                                                      548/134.000;
                                                              548/125.000;
                      548/143.000;
                                                                                                      548/207.000;
                                          548/146.000;
                                                              548/153.000;
                                                                                 548/174.000;
                                          548/215.000;
                                                              548/217.000; 548/221.000; 548/228.000;
                      548/214.000;
                                                              548/240.000; 548/241.000; 548/243.000;
                      548/229.000;
                                          548/237.000;
                      548/247.000; 548/267.200;
                                                             548/303.700; 548/307.100; 548/453.000;
                      548/486.000; 548/543.000; 548/546.000
                      514/222.500
NCL
           NCLM:
                      514/223.500;
           NCLS:
                                          514/224.500;
                                                             514/226.800; 514/227.500; 514/228.800;
                                         514/230.500;
514/255.020;
                                                              514/230.800; 514/237.800;
                                                                                                      514/248.000
                      514/229.200;
                                                                                 514/274.000;
                      514/249.000;
                                                              514/260.100;
                                                                                                      514/301.000;
                                                                                                      514/361.000;
514/367.000;
                                          514/311.000;
                                                                                 514/360.000;
                      514/303.000;
                                                              514/351.000;
                                          514/363.000;
                                                              514/364.000;
                                                                                 514/365.000;
                      514/362.000;
                      514/372.000;
                                          514/373.000;
                                                              514/374.000; 514/375.000;
                                                                                                      514/376.000
                                         514/379.000;
                      514/378.000;
                                                              514/380.000; 514/387.000;
                                                                                                      514/395.000:
                      514/415.000; 514/418.000;
                                                              514/424.000; 514/425.000; 514/432.000;
                      514/433.000; 514/438.000;
                                                              514/452.000; 544/002.000; 544/003.000;
                      544/005.000;
                                         544/008.000;
                                                              544/053.000; 544/063.000; 544/065.000;
                                                              544/090.000; 544/091.000;
                      544/066.000;
544/128.000;
                                          544/067.000;
                                                                                                      544/127.000;
                                         544/162.000;
544/237.000;
544/385.000;
                                                             544/215.000; 544/219.000;
544/255.000; 544/278.000;
546/113.000; 546/114.000;
                                                                                                      544/229.000;
                                                                                                      544/311.000;
546/164.000;
                      544/235.000;
                                                                                  546/114.000;
                      544/353.000;
                      546/300.000;
                                          548/123.000;
                                                              548/125.000;
                                                                                  548/131.000;
                                                                                                      548/134.000
                      548/143.000:
                                          548/146.000;
                                                              548/153.000; 548/174.000;
                                                                                                      548/207.000;
                                          548/215.000;
                                                              548/217.000; 548/221.000;
                      548/214.000;
                                                                                                      548/228.000;
                      548/229.000;
                                          548/237.000;
                                                              548/240.000; 548/241.000;
                                                                                                      548/243.000;
                                                             548/303.700; 548/307.100; 548/453.000; 548/546.000; 549/014.000; 549/050.000;
                      548/247.000; 548/267.200;
                      548/486.000; 548/543.000; 548/546.000
549/075.000; 549/367.000; 549/368.000
IC
           [6]
          ICM: A61K031-385
ICS: A61K031-445; A61K031-47; A61K031-505
549/75; 549/50; 549/14; 549/367; 549/368; 514/432; 514/438; 514/222.5;
514/223.5; 514/224.5; 514/226.8; 514/227.5; 514/228.8; 514/229.2;
514/230.5; 514/230.8; 514/237.8; 514/248; 514/249; 514/255; 514/258;
514/274; 514/301; 514/303; 514/311; 514/351; 514/360; 514/361; 514/362;
514/363; 514/364; 514/365; 514/367; 514/372; 514/373; 514/374; 514/375;
514/376; 514/378; 514/379; 514/380; 514/387; 514/395; 514/415; 514/418;
514/424; 514/425; 514/433; 514/452; 544/2; 544/3; 544/5; 544/8; 544/53;
544/63; 544/65; 544/66; 544/67; 544/90; 544/91; 544/127; 544/128;
544/162; 544/215; 544/219; 544/229; 544/235; 544/237; 544/255; 544/278;
544/311; 544/353; 544/385; 546/113; 546/114; 546/164; 546/300; 548/123;
548/125; 548/131; 548/134; 548/145; 548/146; 548/153; 548/174; 548/207;
548/214; 548/215; 548/217; 548/221; 548/228; 548/229; 548/237; 548/240;
548/241; 548/243; 548/247; 548/267.2; 548/303.7; 548/307.1; 548/453;
           ICM: A61K031-385
EXF
           548/241; 548/243; 548/247; 548/267.2; 548/303.7; 548/307.1; 548/453;
           548/486; 548/543; 548/546
```

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

```
ANSWER 164 OF 228 USPATFULL ON STN
L7
       1998:124453 USPATFULL
ΑN
TI
       Monoclonal antibody specific for novel PKA binding proteins
       Lockerbie, Robert Owen, Murray, UT, United States
IN
       Gallatin, W. Michael, Mercer Ísland, WA, United States
PA
       ICOS Corporation, Bothell, WA, United States (U.S. corporation)
       us 5821125
                                  19981013
PΙ
       us 1997-865422
                                  19970529 (8)
ΑI
       Continuation of Ser. No. US 1996-682265, filed on 17 Jul 1996, now
RLI
       abandoned
       US 1995-1043P
                             19950717 (60)
PRAI
       Utility
DT
       Granted
FS
LN.CNT 976
       INCLM: 435/346.000
INCL
       INCLS: 435/326.000; 435/334.000; 530/358.100; 530/388.220; 530/387.200
NCL
               435/346.000
       NCLS: 435/326.000; 435/334.000; 530/387.200; 530/388.100; 530/388.220
IC
        [6]
       ICM: C12N005-12
       ICS: C07K016-28; C12P021-08
       435/346; 435/326; 435/334; 530/388.1; 530/388.22; 530/387.2
FXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L7
     ANSWER 165 OF 228 USPATFULL ON STN
       1998:122413 USPATFULL
ΑN
       Substituted amino alkyl compounds
TI
IN
       Klein, J. Peter, Vashon Island, WA, United States
       Underiner, Gail E., Brier, WA, United States
Leigh, Alistair J., Brier, WA, United States
Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PA
       US 5817662
                                  19981006
PΙ
       us 1995-468656
                                  19950606 (8)
ΑI
RLI
       Division of Ser. No. US 1993-149681, filed on 9 Nov 1993, now abandoned
       which is a continuation-in-part of Ser. No. US 1992-973804, filed on 9
       Nov 1992, now patented, Pat. No. US 5340813
DT
       Utility
        Granted
FS
LN.CNT 1358
        INCLM: 514/263.000
INCL
        INCLS: 424/824.000; 424/825.000; 424/885.000; 424/921.000
               514/263.350
NCL
       NCLM:
       NCLS:
               424/824.000; 424/825.000
        [6]
TC
        ICM: A61K031-52
        514/397; 514/263; 424/824; 424/825; 424/885; 424/921
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 166 OF 228 USPATFULL on STN 1998:119134 USPATFULL
L7
ΑN
       Methods for regulating gene expression
Bujard, Hermann, Heidelberg, Germany, Federal Republic of
TI
IN
        Gossen, Manfred, El Cerrito, CA, United States
        BASF Aktiengesellschaft, Ludwigshafen, Germany, Federal Republic of
PA
        (non-U.S. corporation)
        Knoll Aktiengesellchaft, Ludwigshafen, Germany, Federal Republic of
        (non-U.S. corporation)
        us 5814618
PΙ
                                  19980929
        US 1995-485978 19950607 (8)
Continuation-in-part of Ser. No. US 1994-260452, filed on 14 Jun 1994
ΑI
RLI
        now patented, Pat. No. US 5650298 Ser. No. Ser. No. US 1993-76726, filed
        on 14 Jun 1993, now patented, Pat. No. US 5464758 Ser. No. Ser. No. US
        1995-383754, filed on 6 Feb 1995 And Ser. No. US 1994-275876, filed on
        15 Jul 1994, now patented, Pat. No. US 5654168 which is a
        continuation-in-part of Ser. No. US 1994-270637, filed on 1 Jul 1994,
        now abandoned , said Ser. No. US 260452 which is a continuation-in-part
        of Ser. No. US 1993-76327, filed on 14 Jun 1993, now abandoned
DT
        Utility
FS
        Granted
LN.CNT 4512
INCL
        INCLM: 514/044.000
        INCLS: 424/093.210; 435/172.300; 935/034.620
NCL
               514/044.000
        NCLM:
        NCLS:
               424/093.210
IC
        [6]
```

```
ICM: A61K048-00
        ICS: c12N015-00
EXF
        424/93.1; 424/93.21; 435/320.1; 435/240.2; 435/172.3; 435/69.1;
        536/24.1; 536/23.5; 536/23.4; 514/44; 935/6; 935/10; 935/36; 935/47;
        935/34; 935/62
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 167 OF 228 USPATFULL on STN 1998:111942 USPATFULL
L7
AN
        Therapeutic compounds containing pyrimidinyl moieties
ΤI
        Klein, J. Peter, Vashon, WA, United States
Leigh, Alistair J., Brier, WA, United States
Underiner, Gail E., Brier, WA, United States
IN
        Kumar, Anil M., Seattle, WA, United States
        Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PA
                                    19980915
        us 5807862
PΙ
                                    19950607 (8)
ΑI
        us 1995-478112
        Continuation-in-part of Ser. No. US 1994-199368, filed on 18 Feb 1994,
RLI
        now abandoned
DT
        Utility
FS
        Granted
LN.CNT 2190
        INCLM: 514/269.000
INCL
        INCLS: 544/309.000; 544/310.000; 544/311.000; 544/312.000
                514/269.000
NCL
        NCLS:
                544/309.000; 544/310.000; 544/311.000; 544/312.000
IC
        [6]
        ICM: A61K031-505
        ICS: C07D239-54
        514/269; 514/274; 544/309; 544/310; 544/311; 544/312
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 168 OF 228 USPATFULL on STN
L7
        1998:111941 USPATFULL
AN
TI
        Amine substituted xanthinyl compounds
IN
        Klein, J. Peter, Vashon, WA, United States
        Underiner, Gail E., Brier, WA, United States
        Kumar, Anil M., Seattle, WA, United States
        Ridgers, Lance H., Bothell, WA, United States
        Rice, Glenn C., Seattle, WA, United States
Leung, David W., Mercer Island, WA, United States
Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PA
                                    19980915
        us 5807861
PΙ
        US 1995-476911
                                    19950607 (8)
ΑI
        Continuation-in-part of Ser. No. US 1994-217051, filed on 24 Mar 1994,
RLI
        now abandoned
DT
        Utility
        Granted
FS
LN.CNT 1713
INCL
        INCLM: 514/263.000
NCL
        NCLM:
                514/263.350
                514/081.000; 514/151.000; 514/210.210; 514/263.200; 514/263.220;
        NCLS:
                514/263.230
IC
        [6]
        ICM: A61K031-52
        514/263
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L7
      ANSWER 169 OF 228 USPATFULL on STN
AN
        1998:108415 USPATFULL
TI
        Therapeutic compounds containing a monocyclic five- to six- membered
        ring structure having one to two nitrogen atoms
TN
        Underiner, Gail E., Brier, WA, United States
        Porubek, David, Seattle, WA, United States
        Klein, J. Peter, Vashon Island, WA, United States
        Woodson, Paul, Edmonds, WA, United States
        Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PA
                                    19980908
PΙ
        US 5804584
        US 1995-468659 19950606 (8)
Division of Ser. No. US 1993-153256, filed on 16 Nov 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-976353, filed on 16
ΑI
RLI
        Nov 1992, now patented, Pat. No. US 5473070
DT
        Utility
        Granted
FS
LN.CNT 1554
INCL
        INCLM: 514/269.000
```

```
INCLS: 544/298.000; 544/242.000; 544/301.000; 544/302.000; 514/256.000
               514/269.000
NCL
       NCLM:
              514/256.000; 544/242.000; 544/298.000; 544/301.000; 544/302.000
       NCLS:
IC
        [6]
        ICM: C07D239-54
        ICS: A61K031-52
        514/242; 514/243; 514/269; 544/298; 544/299
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 170 OF 228 USPATFULL ON STN 1998:108253 USPATFULL
L7
ΑN
        calcium-binding phosphoprotein
TI
        Bandman, Olga, Mountain View, CA, United States
IN
        Corley, Neil C., Mountain View, CA, United States
        Shah, Purvi, Sunnyvale, CA, United States
        Incyte Pharmaceuticles, Inc., Palo Alto, CA, United States (U.S.
PA
        corporation)
        us 5804419
                                  19980908
                                                                            <--
PΙ
                                  19970627 (8)
        us 1997-884682
AT
DT
        Utility
        Granted
FS
LN.CNT 2126
        INCLM: 435/069.100
INCL
        INCLS: 435/006.000; 435/252.300; 435/254.110; 435/320.100; 435/325.000;
                536/023.500; 536/024.310
NCL
        NCLM:
               435/069.100
               435/006.000; 435/252.300; 435/254.110; 435/320.100; 435/325.000;
        NCLS:
               536/023.500; 536/024.310
IC
        [6]
        ICM: C12N001-21
        ICS: C12N015-12; C12N015-63; C12P021-02 536/23.5; 514/44; 435/320.1; 435/325; 435/69.1; 435/6
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L7
      ANSWER 171 OF 228 USPATFULL on STN
        1998:104752 USPATFULL
AN
        Amine substituted compounds
TI
        Klein, J. Peter, Vashon, WA, United States
Underiner, Gail E., Brier, WA, United States
ΙN
        Kumar, Anil M., Seattle, WA, United States
Ridgers, Lance H., Bothell, WA, United States
Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PA
                                   19980901
        US 5801182
PΙ
        us 1995-485777
                                   19950607 (8)
ΑI
        Continuation-in-part of Ser. No. US 1994-217051, filed on 24 Mar 1994,
RLI
        now abandoned
DT
        Utility
FS
        Granted
LN.CNT 1706
INCL
        INCLM: 514/269.000
        INCLS: 514/274.000; 544/310.000; 544/311.000; 544/312.000
                514/269.000
NCL
        NCLM:
                514/274.000; 544/310.000; 544/311.000; 544/312.000
        NCLS:
IC
        [6]
        ICM: A61K031-505
        ICS: C07D239-02
EXF
        544/312; 514/269; 514/274; 514/310; 514/311
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 172 OF 228 USPATFULL ON STN
L7
        1998:101649 USPATFULL
AN
TI
        Apoptosis regulating composition
        Nakai, Satoru, Itano-gun, Japan
IN
        Aihara, Koutoku, Itano-gun, Japan
        Mori, Hitomi, Tokushima, Japan
        Tominaga, Michiaki, Itano-gun, Japan
        Adachi, Masakazu, Takasaki, Japan
        Ichikawa, Hiroyuki, Tokushima, Japan
        Akamatsu, Seiji, Naruto, Japan
                                  o., Ltd., Tokyo, Japan (non-U.S. corporation)
        Saito, Fumio, Takasaki, Japan
        Otsuka Pharmaceutical Co., Ltd.
PA
        us 5798358
PΙ
                                   19970509 (8)
        US 1997-853746
ΑI
        Division of Ser. No. US 1995-466449, filed on 6 Jun 1995, now patented,
RLI
        Pat. No. US 5672603 which is a continuation of Ser. No. US 1993-989028,
        filed on 30 Apr 1993, now abandoned
```

```
PRAI
       JP 1991-162587
                             19910703
                             19920220
       JP 1992-33469
       JP 1992-45178
                             19920303
       JP 1992-100585
                             19920325
DT
       Utility
FS
       Granted
LN.CNT 1241
       INCLM: 514/254.000
INCL
       NCLM: 514/253.070
NCL
IC
       [6]
       ICM: A61K031-495
       ICS: A61K031-50
       514/254
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 173 OF 228 USPATFULL on STN
L7
ΑN
       1998:98921 USPATFULL
       Oxohexyl methylxanthine compounds
TI
       Underiner, Gail, Brier, WA, United States
IN
       Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PA
       us 5795897
                                 19980818
PΙ
       us 1994-227295
                                 19940413 (8)
ΑI
       Continuation of Ser. No. US 1992-977993, filed on 18 Nov 1992
RLI
DT
       Utility
FS
       Granted
LN.CNT
       592
       INCLM: 514/261.000
INCL
       INCLS: 514/885.000; 514/886.000
NCL
       NCLM:
               514/211.070
               514/029.000; 514/171.000; 514/253.080; 514/254.070; 514/263.320; 514/885.000; 514/886.000
       NCLS:
IC
        ۲61
        ICM: A61K031-52
        514/261; 514/885
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 174 OF 228 USPATFULL ON STN
L7
        1998:98764 USPATFULL
AN
       Isolated polynucleotides encoding PKA-binding proteins and methods of
TT
       producing the proteins recombinantly
       Lockerbie, Robert Owen, Kirkland, WA, United States
Kashishian, Adam, Mountlake Terrace, WA, United States
IN
       ICOS Corporation, Bothell, WA, United States (U.S. corporation)
PΑ
       us 5795735
                                 19980818
PΙ
       us 1995-503172
                                 19950717 (8)
ΑI
       Utility
DT
FS
        Granted
LN.CNT 1284
        INCLM: 435/069.100
INCL
       INCLS: 536/023.100; 536/023.500; 536/024.300; 435/320.100; 435/326.000; 435/172.300; 435/252.300
               435/069.100
NCL
        NCLM:
               435/252.300; 435/320.100; 435/326.000; 536/023.100; 536/023.500;
       NCLS:
               536/024.300
        [6]
IC
        ICM: C07K014-435
        ICS: C12N001-21; C12N015-12
        536/23.1; 536/23.5; 536/24.3; 435/320.1; 435/326; 435/69.1; 435/172.3;
EXF
        435/252.3
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L7
     ANSWER 175 OF 228 USPATFULL on STN
        1998:95545 USPATFULL
ΑN
TI
        Enatiomerically pure hydroxylated xanthine compounds
        Bianco, James A., Seattle, WA, United States
IN
        Woodson, Paul, Bothell, WA, United States
        Porubek, David, Edmonds, WA, United States
        Singer, Jack, Seattle, WA, United States
        Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PA
       us 5792772 us 1995-458957
                                  19980811
PΙ
                                  19950601 (8)
ΑI
        Division of Ser. No. US 1994-343810, filed on 22 Nov 1994, now patented,
RLI
        Pat. No. US 5652243 which is a division of Ser. No. US 1994-307554,
        filed on 16 Sep 1994, now patented, Pat. No. US 5648357 which is a
        continuation of Ser. No. US 1993-13977, filed on 4 Feb 1993, now
        abandoned which is a continuation-in-part of Ser. No. US 1992-926665,
```

```
filed on 7 Aug 1992, now abandoned which is a continuation-in-part of
        Ser. No. US 1992-846354, filed on 4 Mar 1992, now abandoned
DT
        Utility
FS
        Granted
LN.CNT 1734
INCL
        INCLM: 514/263.000
        NCLM: 514/263.360
NCL
IC
        [6]
        ĬCM: A61K031-52
514/263
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L7
      ANSWER 176 OF 228 USPATFULL ON STN
        1998:82763 USPATFULL
AN
TI
        Hydroxyl-containing xanthine compounds
        Underiner, Gail E., Brier, WA, United States
IN
        Porubek, David, Seattle, WA, United States
Klein, J. Peter, Vashon Island, WA, United States
Woodson, Paul, Edmonds, WA, United States
        Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PA
                                      19980714
        us 5780476
PΙ
                                      19950606 (8)
        US 1995-468660
ΑI
RLI
        Division of Ser. No. US 1993-153256, filed on 16 Nov 1993, now abandoned
        which is a continuation-in-part of Ser. No. US 1992-976353, filed on 16
        Nov 1992, now patented, Pat. No. US 5473070
DT
        Utility
FS
        Granted
LN.CNT 1672
        INCLM: 514/263.000 INCLS: 544/267.000
INCL
        NCLM: 514/263.360
NCL
IC
        [6]
        ICM: A61K031-52
        ICS: C07D473-04
EXF
         514/263; 514/256; 514/257; 514/258; 514/259; 514/261; 514/269; 514/270
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L7
      ANSWER 177 OF 228 USPATFULL on STN
        1998:79344 USPATFULL
AN
TI
        Method for preparing substituted amino alcohol compounds
        Klein, J. Peter, Vashon, WA, United States
Underiner, Gail E., Brier, WA, United States
IN
        Kumar, Anil M., Seattle, WA, United States
        Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation) US 5777117 19980707 <--
PA
PΙ
ΑI
        us 1995-472569
                                      19950607 (8)
        Division of Ser. No. US 1994-303842, filed on 8 Sep 1994 which is a continuation-in-part of Ser. No. US 1993-152650, filed on 12 Nov 1993 And Ser. No. US 1993-164081, filed on 8 Dec 1993 which is a continuation-in-part of Ser. No. US 1993-60820, filed on 31 Mar 1993,
RLI
        now abandoned , said Ser. No. US -152650 which is a
        continuation-in-part of Ser. No. US
                                                       -40820
DT
        Utility
        Granted
FS
LN.CNT 3153
        INCLM: 544/267.000
INCL
        INCLS: 544/257.000; 544/285.000; 544/286.000; 544/287.000; 544/311.000;
                 546/141.000; 546/243.000; 546/246.000; 548/477.000; 548/546.000
NCL
        NCLM:
                 544/267.000
                 544/257.000; 544/285.000; 544/286.000; 544/287.000; 544/311.000; 546/141.000; 546/243.000; 546/246.000; 548/477.000; 548/546.000
        NCLS:
IC
         [6]
        ICM: C07D473-10
        ICS: C07D239-80; C07D211-94; C07D209-48
        544/267; 544/257; 544/285; 544/286; 544/287; 544/311; 546/141; 546/243; 546/246; 548/477; 548/546
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L7
      ANSWER 178 OF 228 USPATFULL on STN
        1998:79342 USPATFULL
AN
        Acetal-and ketal-substituted pyrimidine compounds
TI
        Leigh, Alistair, Brier, WA, United States
IN
        Underiner, Gail, Brier, WA, United States
        Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PΙ
        us 5777115
                                      19980707
                                      19940207 (8)
        US 1994-193331
ΑI
```

```
Continuation-in-part of Ser. No. US 1993-4353, filed on 14 Jan 1993, now
RLI
       abandoned
       Utility
DT
FS
       Granted
LN.CNT 1632
       INCLM: 544/242.000
INCL
       INCLS: 544/267.000; 514/269.000; 514/270.000; 514/256.000
       NCLM:
NCL
               544/242.000
       NCLS:
               544/267.000
       [6]
IC
       ICM: C07D239-26
       ICS: A61K031-505
       544/267; 544/242; 546/242; 546/243; 514/256; 514/269; 514/270
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 179 OF 228 USPATFULL on STN
L7
       1998:75151 USPATFULL
AN
       Hematopoietic facilitatory cells and their uses
TT
       Ildstad, Suzanne T., Pittsburgh, PA, United States
Simmons, Richard L., Pittsburgh, PA, United States
Ricordi, Camillo, Miami Beach, FL, United States
TN
       Wren, Sherry M., Pittsburgh, PA, United States
       Kaufman, Christina, Munhall, PA, United States
       The University of Pittsburgh, Pittsburgh, PA, United States (U.S.
PA
       corporation)
                                  19980630
PΙ
       us 5772994
                                  19950605 (8)
       US 1995-463908
ΑI
       Continuation of Ser. No. US 1993-69315, filed on 28 May 1993, now
RLI
        abandoned
DT
       Utility
FS
        Granted
LN.CNT 2333
       INCLM: 424/093.700
INCL
        INCLS: 424/093.710; 435/002.000; 435/724.000; 435/355.000; 435/372.000
NCL
               424/093.700
               424/093.710; 435/002.000; 435/007.240; 435/355.000; 435/372.000
        NCLS:
IC
        [6]
        ICM: A01N063-00
       ICS: C12N015-00 424/93.7; 424/529; 424/537; 435/2; 435/7.24; 435/240.1-240.2;
EXF
        435/352; 435/353; 435/354; 435/355; 435/363; 435/366; 435/372
     ANSWER 180 OF 228 USPATFULL on STN
L7
ΑN
        1998:72620 USPATFULL
        Oxime substituted therapeutic compounds
TI
        Klein, J. Peter, Vashon, WA, United States
IN
        Leigh, Alistair, Brier, WA, United States
        Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PA
        us 5770595
                                  19980623
PΙ
        us 1994-193344
                                  19940207 (8)
ΑI
        Continuation of Ser. No. US 1993-6083, filed on 19 Jan 1993, now
RLI
        abandoned
DT
        Utility
FS
        Granted
LN.CNT 2183
INCL
        INCLM: 514/263.000
        INCLS: 544/271.000; 544/273.000
NCL
        NCLM:
               514/263.350
               514/151.000; 544/271.000; 544/273.000
        NCLS:
IC
        [6]
        ICM: M61K031-52
        514/263; 544/271; 544/273
EXF
L7
     ANSWER 181 OF 228 USPATFULL ON STN
        1998:57873 USPATFULL
AN
        Peptide T and related peptides in the treatment of inflammation,
TI
        including inflammatory bowel disease
        Andersen, Anders Jorgen, Kokkedal, Denmark
IN
       Aston, Roger, Wiltshire, England
Carlen, Peter Louis, Ontario, Canada
Doob, Penelope Reed, Ontario, Canada
        MacFadden, Douglas Kevin, Ontario, Canada
        Phipps, David James, Ontario, Canada
        Rathjen, Deborah, New South Wales, Australia
        Widmer, Fred, New South Wales, Australia
        Peptide Technology Limited, Dee Why, Australia (non-U.S. corporation)
PA
```

```
Drug Royalty Corporation, New South Wales, Australia (non-U.S.
       corporation)
       us 5756449
PΙ
                                19980526
       wo 9320102 19931014
                                                                        <--
       us 1995-302829
                                19950224 (8)
AΙ
       wo 1993-GB649
                                19930329
                                19950224
                                           PCT 371 date
                                          PCT 102(e) date
                                19950224
                            19920514
PRAI
       DK 1992-645
DΤ
       Utility
FS
       Granted
LN.CNT 2365
       INCLM: 514/008.000
INCL
       NCLM: 514/008.000
NCL
       [6]
IC
       ICM: A61K037-10
EXF
       514/8
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 182 OF 228 USPATFULL on STN
L7
       1998:51651 USPATFULL
ΑN
       Substituted amino alcohol compounds
TI
       Klein, J. Peter, Vashon, WA, United States
IN
       Underiner, Gail E., Brier, WA, United States
       Kumar, Anil M., Seattle, WA, United States
       Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
US 5750575 19980512 <--
PA
PΙ
       US 1995-475721
                                19950607 (8)
ΑI
       Division of Ser. No. US 1994-303842, filed on 8 Sep 1994, now patented,
RLI
       Pat. No. US 5641783 which is a continuation-in-part of Ser. No. US
       1993-152650, filed on 12 Nov 1993 And a continuation-in-part of Ser.
       US 1993-164081, filed on 8 Dec 1993, now patented, Pat. No. US 5470878
       which is a continuation-in-part of Ser. No. US 1993-40820, filed on 31
       Mar 1993, now abandoned
DT
       Utility
FS
       Granted
LN.CNT 3115
       INCLM: 514/617.000
INCL
       INCLS: 514/653.000; 564/182.000; 564/355.000; 564/361.000
               514/617.000
NCL
       NCLM:
       NCLS:
               514/653.000; 564/182.000; 564/355.000; 564/361.000
TC
       [6]
       ICM: A61K031-165
       ICS: A61K031-135; C07C233-35; C07C215-20
       564/355; 564/182; 564/361; 514/617; 514/653
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L7
     ANSWER 183 OF 228 USPATFULL on STN
       1998:51605 USPATFULL
ΑN
TI
       Apoptosis regulating compostion
       Nakai, Satoru, Tokushima-ken, Japan
IN
       Aihara, Koutoku, Tokushima-ken, Japan
       Mori, Hitomi, Tokushima, Japan
       Tominaga, Michiaki, Tokushima-ken, Japan
       Adachi, Masakazu, Takasaki, Japan
       Ichikawa, Hiroyuki, Tokushima, Japan
       Akamatsu, Seiji, Naruto, Japan
       Saito, Fumio, Takasaki, Japan
       Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan (non-U.S. corporation)
US 5750529 19980512 <--
PA
       us 5750529
us 1995-469505
PΙ
                                 19950606 (8)
ΑI
       Division of Ser. No. US 1993-989028, filed on 30 Apr 1993, now abandoned
RLI
       JP 1991-162587
                            19910703
PRAI
       JP 1992-33469
                             19920220
       JP 1992-45718
                             19920303
       JP 1992-100585
                            19920325
DT
       Utility
FS
       Granted
LN.CNT 1233
       INCLM: 514/254.000
INCL
        INCLS: 514/255.000
       NCLM: 514/253.070
NCL
IC
        [6]
       ICM: A61K031-495
        ICS: A61K031-50
EXF
        514/254; 514/255
```

NCL

NCLM: 424/078.080

```
L7
       ANSWER 184 OF 228 USPATFULL ON STN
          1998:51459 USPATFULL
ΑN
          In vitro growth and proliferation of genetically modified multipotent
TI
          neural stem cells and their progeny
          Weiss, Samuel, Alberta, Canada
IN
          Reynolds, Brent, Alberta, Canada
Hammang, Joseph P., Barrington, RI, United States
Baetge, E. Edward, Barrington, RI, United States
NeuroSpheres Holdings Ltd., Callgary, Canada (non-U.S. corporation)
PA
          us 5750376
                                              19980512
PΙ
ΑI
          us 1995-483122
                                              19950607 (8)
          Continuation-in-part of Ser. No. US 1994-270412, filed on 5 Jul 1994, now abandoned Ser. No. Ser. No. US 1995-385404, filed on 7 Feb 1995, now abandoned Ser. No. Ser. No. US 1994-359945, filed on 20 Dec 1994, now
RLI
          abandoned Ser. No. Ser. No. US 1995-376062, filed on 20 Jan 1995, now abandoned Ser. No. Ser. No. US 1993-149508, filed on 9 Nov 1993, now abandoned Ser. No. Ser. No. US 1994-311099, filed on 23 Sep 1994, now abandoned And Ser. No. US 1994-338730, filed on 14 Nov 1994, now
          abandoned which is a continuation-in-part of Ser. No. US 1991-726812
          filed on 8 Jul 1991, now abandoned , said Ser. No. US 1995-385404, filed
          on 7 Feb 1995, now abandoned which is a continuation of Ser. No. US
          1992-961813, filed on 16 Oct 1992, now abandoned which is a
          continuation-in-part of Ser. No. US 1991-726812, filed on 8 Jul 1991, now abandoned, said Ser. No. US 1994-359345, filed on 20 Dec 1994, now abandoned which is a continuation of Ser. No. US 1994-221655, filed on 1
          Apr 1994, now abandoned which is a continuation of Ser. No. US 1992-967622, filed on 28 Oct 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-726812, filed on 8 Jul 1991, now abandoned, said Ser. No. US 1995-376062, filed on 20 Jan 1995, now
          abandoned which is a continuation of Ser. No. US 1993-10829, filed on 29
          Jan 1993, now abandoned which is a continuation-in-part of Ser. No. US
          1991-726812, filed on 8 Jul 1991, now abandoned , said Ser. No. US
          1994-270412, filed on 5 Jul 1994, now abandoned Ser. No. Ser. No. US
          1993-149508, filed on 9 Nov 1993, now abandoned And Ser. No. US 1994-311099, filed on 23 Sep 1994, now abandoned, each Ser. No. US which is a continuation-in-part of Ser. No. US 1991-726812, filed on 8
          Jul 1991, now abandoned
DT
          Utility
FS
          Granted
LN.CNT 4339
          INCLM: 435/069.520
INCL
          INCLS: 435/069.100; 435/172.300; 435/325.000; 435/368.000; 435/377.000;
                     435/384.000; 435/392.000; 435/395.000
                    435/069.520
NCL
          NCLM:
                    435/069.100; 435/325.000; 435/368.000; 435/377.000; 435/384.000; 435/392.000; 435/395.000; 435/455.000; 435/456.000; 435/458.000;
          NCLS:
                     435/461.000
IC
          [6]
          ICM: C12N005-00
          ICS: C12N005-08; C12N005-10; C12P001-00
EXF
          435/240.2; 435/172.3; 435/69.1; 435/69.52; 435/325; 435/368; 435/377;
          435/384; 435/392; 435/395
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L7
       ANSWER 185 OF 228 USPATFULL on STN
AN
          1998:44877 USPATFULL
TI
          Sequence-directed DNA-binding molecules compositions and methods
          Edwards, Cynthia A., Menlo Park, CA, United States
Fry, Kirk E., Palo Alto, CA, United States
ΙN
          Cantor, Charles R., Boston, MA, United States
          Andrews, Beth M., Maynard, MA, United States
PA
          Genelabs Technologies, Inc., Redwood City, CA, United States (U.S.
          corporation)
PΙ
          US 5744131
                                              19980428
                                                                                                      <--
                                              19950607 (8)
          US 1995-476876
ΑI
          Division of Ser. No. US 1992-996783, filed on 23 Dec 1992 which is a continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991,
RLI
          now abandoned
DT
          Utility
          Granted
FS
LN.CNT 5113
          INCLM: 424/078.080
INCL
          INCLS: 436/501.000; 514/001.000
```

```
NCLS: 436/501.000; 514/001.000
       [6]
IC
       ICM: A61K031-74
       ICS: G01N033-566; G01N033-558
EXF
       536/23.1; 536/27.1; 546/109; 436/501; 514/1; 424/78.08
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 186 OF 228 USPATFULL on STN
L7
       1998:39529 USPATFULL
ΑN
       Enantiomerically pure hydroxylated xanthine compounds to treat
TI
       autoimmune diabetes
       Bianco, James A., Seattle, WA, United States
TN
       Woodson, Paul, Bothell, WA, United States
       Porubek, David, Edmonds, WA, United States
       Singer, Jack, Seattle, WA, United States
       cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PA
       us 5739138
                                 19980414
PΙ
       us 1995-457703
                                 19950601 (8)
ΑI
RLI
       Division of Ser. No. US 1994-343810, filed on 22 Nov 1994, now abandoned
       which is a division of Ser. No. US 1994-307554, filed on 16 Sep 1994,
       now abandoned which is a continuation of Ser. No. US 1993-13977, filed
       on 4 Feb 1993, now abandoned which is a continuation-in-part of Ser. No.
       US 1992-926665, filed on 7 Aug 1992, now abandoned which is a
       continuation-in-part of Ser. No. US 1992-846354, filed on 4 Mar 1992,
       now abandoned
       Utility
DT
       Granted
FS
LN.CNT 1734
INCL
       INCLM: 514/263.000
       INCLS: 514/866.000
               514/263.360
NCL
       NCLM:
       NCLS:
              514/866.000
       [6]
IC
       ICM: A61K031-52
EXF
       514/263; 514/866
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L7
     ANSWER 187 OF 228 USPATFULL on STN
ΑN
       1998:39383 USPATFULL
TI
       Sequence-directed DNA-binding molecules compositions and methods
       Edwards, Cynthia A., Menlo Park, CA, United States
IN
       Fry, Kirk E., Palo Alto, CA, United States
       Cantor, Charles R., Boston, MA, United States
       Andrews, Beth M., Maynard, MA, United States
PA
       Genelabs Technologies, Inc., Redwood City, CA, United States (U.S.
       corporation)
PΙ
       us 5738990
                                 19980414
                                                                         <--
                                 19950607 (8)
       us 1995-475221
ΑI
       Division of Ser. No. US 1992-996783, filed on 23 Dec 1992 which is a continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991,
RLI
       now abandoned
       Utility
DT
FS
       Granted
LN.CNT 5040
       INCLM: 435/006.000
INCL
       INCLS: 435/691.000; 435/172.300; 435/320.100; 536/024.100; 935/036.000;
               935/039.000
NCL
       NCLM:
               435/006.000
       NCLS:
               435/069.100; 435/320.100; 536/024.100
IC
       [6]
       ICM: C12P021-02
       ICS: C12N015-67; C07H021-04
EXF
       435/172.1; 435/69.1; 435/6; 435/320.1; 435/172.3; 536/24.1; 935/36;
       935/39
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L7
     ANSWER 188 OF 228 USPATFULL on STN
ΑN
       1998:25075 USPATFULL
TI
       Screening assay for the detection of DNA-binding molecules
       Edwards, Cynthia A., Menlo Park, CA, United States Cantor, Charles R., Boston, MA, United States
ΙN
       Andrews, Beth M., Watertown, MA, United States
       Turin, Lisa M., Berkeley, CA, United States
       Genelabs Technologies, Inc., Redwood City, CA, United States (U.S.
PA
       corporation)
                                 19980310
       us 5726014
                                                                         <--
PΙ
```

```
ΑI
       us 1993-123936
                                  19930917 (8)
       Continuation-in-part of Ser. No. US 1992-996783, filed on 23 Dec 1992
RLI
       which is a continuation-in-part of Ser. No. US 1991-723618, filed on 27
        Jun 1991, now abandoned
DT
        Utility
        Granted
FS
LN.CNT 5659
        INCLM: 435/006.000
INCL
        INCLS: 435/091.200; 436/501.000
NCL
               435/006.000
        NCLM:
              435/091.200; 436/501.000
        NCLS:
        [6]
IC
        ICM: C12Q001-68
        ICS: C12P019-34; G01N033-566
        435/6; 435/235; 435/91.1; 435/91.2; 435/91.5; 536/23.1; 536/23.2;
EXF
        436/501
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 189 OF 228 USPATFULL ON STN
17
AN
        1998:14634 USPATFULL
        Method of constructing sequence-specific DNA-binding molecules
TI
       Edwards, Cynthia A., Menlo Park, CA, United States
Fry, Kirk E., Palo Alto, CA, United States
IN
        Cantor, Charles R., Boston, MA, United States
        Andrews, Beth M., Watertown, MA, United States
        Genelabs Technologies, Inc., Redwood City, CA, United States (U.S.
PA
        corporation)
ΡI
        us 5716780
                                  19980210
                                                                            <--
ΑI
        us 1995-484499
                                   19950607 (8)
        Division of Ser. No. US 1992-996783, filed on 23 Dec 1992 which is a continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991,
RLI
        now abandoned
DT
        Utility
FS
        Granted
LN.CNT 4929
        INCLM: 435/006.000
INCL
        INCLS: 436/501.000
NCL
        NCLM:
               435/006.000
        NCLS: 436/501.000
        [6]
        ICM: C12Q001-68
        ICS: G01N033-566
        435/6; 536/24.5; 935/33; 935/34; 935/36; 436/501
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L7
     ANSWER 190 OF 228 USPATFULL ON STN
        97:122850 USPATFULL
AN
                                                                  ***Parkinson*** 's
        Sertoli cells as neurorecovery inducing cells for
TI
        disease
        Sanberg, Paul R., Spring Hill, FL, United States Cameron, Don F., Lutz, FL, United States Borlongan, Cesario V., Lutz, FL, United States
IN
        University of South Florida, Tampa, FL, United States (U.S. corporation)
PA
        us 5702700
                                  19971230
PΙ
        us 1995-402389
                                  19950313 (8)
ΑI
DT
        Utility
F$
        Granted
LN.CNT 348
        INCLM: 424/093.100
INCL
        INCLS: 424/093.700; 424/562.000; 424/558.000
NCL
        NCLM:
               424/093.100
               424/093.700; 424/558.000; 424/562.000
        NCLS:
TC
        [6]
        ICM: A01N063-00
        ICS: A61K035-52; A61K038-22
        514/2; 514/44; 435/172.1; 435/172.2; 435/172.3; 435/240.1; 435/320.1;
EXF
        424/93.2; 424/93.21
L7
     ANSWER 191 OF 228 USPATFULL ON STN
        97:112300 USPATFULL
AN
        Method of ordering sequence binding preferences of a DNA-binding
TI
        molecule
IN
        Edwards, Cynthia A., Menlo Park, CA, United States
        Fry, Kirk E., Palo Alto, CA, United States
        Cantor, Charles R., Boston, MA, United States
        Andrews, Beth M., Maynard, MA, United States4)
```

```
Genelabs Technologies, Inc., Redwood City, CA, United States (U.S.
PA
       corporation)
PΙ
       us 5693463
                                  19971202
       us 1992-996783
                                  19921223 (7)
ΑI
       Continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991,
RLI
       now abandoned
DT
       Utility
       Granted
FS
LN.CNT 4908
INCL
       INCLM: 435/006.000
       INCLS: 435/007.230; 536/023.100; 935/076.000; 935/077.000
               435/006.000
NCL
       NCLS:
               435/007.230; 536/023.100
        [6]
IC
       ICM: C12Q001-68
       ICS: G01N033-574; C07H021-02; C12N015-00
       435/6; 435/235; 536/23.1; 536/23.2; 514/44; 530/350; 530/351
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 192 OF 228 USPATFULL on STN
L7
        97:109900 USPATFULL
ΑN
       Apoptosis regulating composition
ΤI
       Nakai, Satoru, Tokushima-ken, Japan
TN
       Aihara, Koutoku, Tokushima-ken, Japan
       Tanaka, Hideo, Tokushima, Japan
       Iba, Hitomi, Wakayama, Japan
       Kawai, Kazuyoshi, Tokushima-ken, Japan
Ichikawa, Hiroyuki, Tokushima, Japan
       Akamatsu, Seiji, Naruto, Japan
        Saito, Fumio, Takasaki, Japan
        Tominaga, Michiaki, Tokushima-ken, Japan
        Adachi, Masakazu, Takasaki, Japan
        Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan (non-U.S. corporation)
PA
        US 5691341
                                  19971125
PΙ
ΑI
       us 1995-520478
                                  19950829 (8)
       Division of Ser. No. US 1994-211818, filed on 19 Apr 1994, now patented,
RLI
        Pat. No. US 5464833
                              19920819
PRAI
        JP 1992-220373
        Utility
DT
FS
        Granted
LN.CNT 1599
        INCLM: 514/254.000
INCL
        INCLS: 514/249.000; 514/250.000; 514/251.000; 514/255.000
NCL
               514/253.070
        NCLS:
               514/249.000; 514/250.000; 514/251.000
IC
        [6]
        ICM: A61K031-495
        ICS: A61K031-50; A61K031-525
514/249; 514/250; 514/251; 514/255; 514/254
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 193 OF 228 USPATFULL ON STN
L7
        97:101884 USPATFULL
AN
        Neurite growth regulatory factors, antibodies thereto, and
TI
        pharmaceutical compositions
        Schwab, Martin E., Zurich, Switzerland
        Caroni, Pierenrico W., Zurich, Switzerland Erziehungsdirektion of the Canton Zurich, Zurich, Switzerland (non-U.S.
PΑ
        corporation)
US 5684133
                                   19971104
PΙ
        US 1989-401212
                                   19890830 (7)
ΑI
RLI
        Continuation-in-part of Ser. No. US 1988-267941, filed on 4 Nov 1988,
        now abandoned
DT
        Utility
FS
        Granted
LN.CNT 4086
INCL
        INCLM: 530/350.000
               530/399.000; 530/387.900; 530/388.240; 424/085.800; 514/002.000; 514/008.000; 514/012.000; 435/020.210; 436/548.000; 436/519.000
NCL
        NCLM:
                530/350.000
                435/070.210; 436/519.000; 436/548.000; 530/387.900; 530/388.240;
        NCLS:
                530/399.000
IC
        [6]
        ICM: C07K014-48
        ICS: C07K016-22
        530/350; 530/387; 530/399; 530/388.24; 530/387.9; 424/85.8; 435/70.2;
EXF
```

```
435/70.21; 514/8; 514/12; 436/548; 436/519
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 194 OF 228 USPATFULL on STN
L7
       97:101456 USPATFULL
ΑN
       Method for inducing T cell unresponsiveness to a tissue or organ graft
TI
       with anti-CD40 ligand antibody or soluble CD40
       Noelle, Randolph J., Cornish, NH, United States
Durie, Fiona H., Seattle, WA, United States
TN
       Parker, David C., Grafton, MA, United States
       Appel, Michael C., Grafton, MA, United States
       Phillips, Nancy E., Shrewsbury, MA, United States
       Mordes, John P., Newton, MA, United States
       Grenier, Dale L., Hubbardston, MA, United States
       Rossini, Aldo A., Sudbury, MA, United States
       Trustees of Dartmouth College, Hanover, NH, United States (U.S.
PA
       corporation)
       University of Massachusetts Medical Center, Worcester, MA, United States
       (U.S. corporation)
       us 5683693
                                 19971104
PΙ
                                                                          <--
       us 1994-234987
                                 19940425 (8)
ΑI
       Utility
DT
       Granted
FS
LN.CNT 1153
       INCLM: 424/144.100
INCL
       INCLS: 424/130.100; 424/133.100; 424/134.100; 424/141.100; 424/143.100;
               424/154.100; 424/193.100; 514/002.000; 514/008.000; 514/885.000
NCL
       NCLM:
               424/144.100
               424/130.100; 424/133.100; 424/134.100; 424/141.100; 424/143.100; 424/154.100; 424/173.100; 514/002.000; 514/008.000; 514/885.000
       NCLS:
       [6]
IC
       ICM: A61K039-395
       ICS: A61K038-17
       424/130.1; 424/133.1; 424/134.1; 424/141.1; 424/143.1; 424/144.1;
EXF
       424/154.1; 424/173.1; 514/2; 514/8; 514/885
     ANSWER 195 OF 228 USPATFULL on STN
L7
       97:96549 USPATFULL
AN
       Cells with multiple altered epitopes on a surface antigen for use in
TI
          ***transplantation***
IN
       Chappel, Scott C., Milton, MA, United States
       Diacrin, Inc., Charlestown, MA, United States (U.S. corporation)
PA
       us 5679340
                                 19971021
PΙ
ΑI
       us 1994-240150
                                 19940510 (8)
       Continuation-in-part of Ser. No. US 1994-220741, filed on 31 Mar 1994,
RLI
       now abandoned
DT
       Utility
       Granted
FS
LN.CNT 994
       INCLM: 424/093.100
INCL
       INCLS: 435/240.200
               424/093.100
NCL
       NCLM:
       NCLS:
               435/325.000; 435/366.000; 435/368.000; 435/370.000; 435/371.000;
               435/372.000
       [6]
IC
       ICM: C12N005-00
       ICS: A01N063-00
EXF
       424/93.1; 435/240.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L7
     ANSWER 196 OF 228 USPATFULL ON STN
       97:88984 USPATFULL
ΑN
TI
       Apoptosis regulating composition
       Nakai, Satorū, Tokushima-ken, Japan
IN
       Aihara, Koutoku, Tokushima-ken, Japan
       Mori, Hitomi, Tokushima, Japan
       Tominaga, Michiaki, Tokushima-ken, Japan
       Adachi, Masakazu, Takasaki, Japan
Ichikawa, Hiroyuki, Tokushima, Japan
       Akamatsu, Seiji, Naruto, Japan
       Saito, Fumio, Takasaki, Japan
PA
       Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan (non-U.S. corporation)
                                 19970930
PΙ
       us 5672603
ΑI
       us 1995-466449
                                 19950606 (8)
RLI
       Continuation of Ser. No. US 1993-989028, filed on 30 Apr 1993, now
       abandoned
```

```
JP 1991-162587
PRAI
                             19910703
       JP 1992-33469
                             19920220
       JP 1992-45178
                             19920303
       JP 1992-100585
                             19920325
       WO 1992-JP841
                             19920702
DT
       Utility
       Granted
FS
LN.CNT
       1262
       INCLM: 514/254.000
INCL
       NCLM: 514/253.070
NCL
       [6]
IC
       ICM: A61K031-499
       ICS: A61K031-50
       514/254
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 197 OF 228 USPATFULL on STN
L7
       97:86614 USPATFULL
AN
       Halogen, isothiocyanate or azide substituted xanthines
Leigh, Alistair, Brier, WA, United States
Michnick, John, Seattle, WA, United States
TI
IN
       Kumar, Anil, Seattle, WA, United States
       Underiner, Gail, Brier, WA, United States
       Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PA
                                 19970923
PΙ
       us 5670506
ΑI
       US 1993-42946
                                 19930405 (8)
       Utility
DT
FS
       Granted
       1994
LN.CNT
       INCLM: 514/258.000
INCL
       INCLS: 514/263.000; 544/267.000; 544/272.000; 544/277.000
NCL
       NCLM:
               514/141.000
       NCLS:
               544/267.000; 544/272.000; 544/277.000
IC
       [6]
       ICM: A61K031-52
       ICS: C07D473-00
EXF
       544/267; 544/276; 544/272; 544/277; 514/258
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L7
     ANSWER 198 OF 228 USPATFULL on STN
       97:86266 USPATFULL
AN
       Combined cellular and immunosuppressive therapies
TI
IN
       Sherwin, Stephen A., San Francisco, CA, United States
       Dubridge, Robert B., Belmont, CA, United States
PA
       Cell Genesys, Inc., Foster City,
                                           CA, United States (U.S. corporation)
PΙ
       US 5670148
                                  19970923
       US 1994-314452
                                  19940928 (8)
AΙ
       Continuation of Ser. No. US 1991-781075, filed on 21 Oct 1991, now
RLI
       abandoned
DT
       Utility
FS
       Granted
LN.CNT 700
INCL
       INCLM: 424/093.210
       INCLS: 435/192.300; 424/933.000; 424/937.000; 424/572.000
NCL
       NCLM:
               424/093.210
       NCLS:
               424/093.300; 424/093.700; 424/572.000
TC
       [6]
       ICM: C12N015-00
       ICS: A01N063-00; A61K035-12
       424/93.1
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L7
     ANSWER 199 OF 228 USPATFULL ON STN
AN
       97:73619 USPATFULL
TI
       Apoptosis regulating composition
TN
       Nakai, Satoru, Tokushima-ken, Japan
       Aihara, Koutoku, Tokushima-ken, Japan
       Mori, Hitomi, Tokushima, Japan
       Tominaga, Michiaki, Tokushima-ken, Japan
       Adachi, Masakazu, Takasaki, Japan
Ichikawa, Hiroyuki, Tokushima, Japan
       Akamatsu, Seiji, Naruto, Japan
       Saito, Fumio, Takasaki, Japan
PA
       Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan (non-U.S. corporation)
                                  19970819
PT
       us 5658912
                                  19950606 (8)
ΑI
       US 1995-469922
```

```
Division of Ser. No. US 1993-989028, filed on 30 Apr 1993, now abandoned
RLI
       JP 1991-162587
PRAI
                             19910703
        JP 1992-33469
                             19920220
        JP 1992-45718
                             19920303
        JP 1992-100585
                             19920325
DT
       Utility
        Granted
FS
LN.CNT 1242
        INCLM: 514/254.000
INCL
        INCLS: 514/255.000
               514/754.000
NCL
        NCLM:
               514/253.070
        NCLS:
IC
        [6]
        ICM: A61K031-495
        ICS: A61K031-50
        514/254; 514/255
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 200 OF 228 USPATFULL ON STN
L7
ΑN
        97:66130 USPATFULL
        Methods of using enantiomerically pure hydroxylated xanthine compounds
TI
        Bianco, James A., Seattle, WA, United States
IN
        Singer, Jack, Seattle, WA, United States
        Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PA
                                  19970729
PΙ
        us 5652243
                                  19941122 (8)
ΑI
        us 1994-343810
       Division of Ser. No. US 1994-307554, filed on 16 Sep 1994 which is a continuation-in-part of Ser. No. US 1992-926665, filed on 7 Aug 1992, now abandoned which is a continuation-in-part of Ser. No. US
RLI
        1992-846354, filed on 4 Mar 1992, now abandoned
DT
        Utility
        Granted
FS
LN.CNT 1731
INCL
        INCLM: 514/263.000
        INCLS: 514/262.000; 514/265.000; 514/814.000
               514/263.360
NCL
        NCLS: 514/814.000
IC
        [6]
        ICM: A61K031-52
EXF
        514/262; 514/263; 514/265
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 201 OF 228 USPATFULL ON STN
L7
AN
                  USPATFULL
TI
        Enatiomerically pure hydroxylated xanthine compounds
IN
        Bianco, James A., Seattle, WA, United States
        Woodson, Paul, Bothell, WA, United States
        Porubek, David, Edmonds, WA, United States
        Singer, Jack, Seattle, WA, United States
PA
        Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
                                  19970715
        us 5648357
PΙ
        us 1994-307554
                                  19940916 (8)
ΑI
        Continuation of Ser. No. US 1993-13977, filed on 4 Feb 1993, now
RLI
        abandoned which is a continuation-in-part of Ser. No. US 1992-926665
        filed on 7 Aug 1992, now abandoned which is a continuation-in-part of
        ser. No. US 1992-846354, filed on 4 Mar 1992, now abandoned
DT
        Utility
        Granted
FS
LN.CNT 1748
INCL
        INCLM: 514/263.000
               514/267.000; 514/270.000; 514/271.000
        INCLS:
               514/263.360
NCL
        NCLM:
        NCLS:
               514/267.000; 514/270.000; 514/271.000
IC
        [6]
        ICM: A61K031-52
EXF
        514/263; 514/267; 544/267; 544/270; 544/271
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 202 OF 228 USPATFULL ON STN
L7
AN
        97:54233 USPATFULL
        Substituted amino alcohol compounds
TI
        Klein, J. Peter, Vashon, WA, United States
TN
        Underiner, Gail E., Brier, WA, United States
        Kumar, Anil M., Seattle, WA, United States
        Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
US 5641783 19970624 <--
PΙ
        US 5641783
```

```
19940908 (8)
ΑI
        us 1994-303842
        Continuation-in-part of Ser. No. US 1993-152650, filed on 12 Nov 1993
RLI
        And Ser. No. US 1993-164081, filed on 8 Dec 1993, now patented, Pat. No.
        us 5470878
DT
        Utility
        Granted
FS
        3206
LN.CNT
                 514/263.000
INCL
        INCLM:
                 514/183.000;
        INCLS:
                                 514/222.500;
                                                 514/223.500; 514/224.200;
                                                                                 514/226.800;
                 514/227.500;
                                 514/228.800;
                                                 514/229.200;
                                                                 514/230.500;
                                                                                  514/230.800;
                                                 514/242.000;
                                                                                  514/246.000:
                 514/237.800;
                                 514/241.000;
                                                                 514/243.000;
                 514/247.000;
                                 514/248.000;
                                                 514/249.000; 514/255.000;
                                                                                 514/256.000;
                 514/258.000; 514/259.000;
                                                 514/261.000; 514/262.000;
                                                                                 514/263.000;
                                                 514/297.000; 514/300.000;
                                 514/274.000;
                                                                                 514/301.000;
                 514/270.000;
                                                 514/306.000; 514/307.000;
                 514/302.000; 514/303.000;
                                                                                 514/311.000;
                                                 514/345.000; 514/351.000;
514/361.000; 514/362.000;
514/367.000; 514/369.000;
514/375.000; 514/376.000;
                 514/312.000;
                                 514/315.000;
                                                                                 514/357.000;
                                                                 514/362.000;
514/369.000;
514/376.000;
514/383.000;
                 514/359.000; 514/360.000;
514/364.000; 514/365.000;
514/373.000; 514/374.000;
                                                                                 514/363.000;
514/372.000;
514/378.000;
                                 514/380.000;
514/395.000;
                 514/379.000;
                                                 514/381.000;
                                                                                  514/389.000
                 514/394.000;
                                                 514/398.000;
                                                                 514/399.000;
                                                                                  514/401.000
                                                                 514/415.000;
                                 514/406.000;
                                                 514/413.000;
                                                                                 514/416.000;
                 514/404.000;
                                                 514/424.000; 514/425.000;
                                                                                 514/427.000
                 514/418.000; 514/423.000;
                                 544/001.000;
                                                 544/002.000; 544/003.000;
                                                                                 544/008.000;
                 514/428.000;
                 544/053.000;
                                 544/063.000;
                                                 544/065.000; 544/066.000;
                                                                                 544/067.000;
                                                 544/162.000;
                                                                                 544/216.000;
                 544/090.000;
                                 544/091.000;
                                                                 544/215.000;
                                                                 544/235.000;
544/262.000;
544/283.000;
                 544/219.000;
                                                                                  544/239.000;
                                 544/220.000;
                                                 544/224.000;
                                 544/255.000;
544/278.000;
                 544/254.000;
                                                 544/257.000;
                                                                                  544/272.000
                                                                                  544/286.000
                 544/277.000;
                                                 544/280.000;
                                 544/311.000;
544/385.000;
                 544/301.000;
                                                 544/335.000;
                                                                 544/336.000;
                                                                                  544/350.000
                                                 544/401.000;
                                                                 546/102.000;
                                                                                  546/113.000
                 544/353.000;
                                 546/115.000;
                                                 546/117.000;
                                                                 546/118.000;
                                                                                  546/119.000
                 546/114.000;
                                 546/138.000;
                                                                                  546/153.000;
                 546/122.000;
                                                 546/139.000:
                                                                 546/150.000;
                 546/157.000;
                                 546/164.000;
                                                 546/176.000;
                                                                 546/178.000;
                                                                                  546/242.000;
                                 546/246.000;
                                                                                 546/334.000;
                                                 546/264.000;
                                                                 546/300.000;
                 546/243.000;
                                                                                 548/128.000;
                 548/100.000; 548/123.000;
                                                 548/125.000;
                                                                 548/127.000;
                 548/131.000;
                                 548/134.000;
                                                 548/146.000;
                                                                 548/153.000;
                                                                                  548/179.000;
                 548/186.000;
548/221.000;
548/237.000;
                                                                                 548/217.000;
548/235.000;
548/247.000;
                                 548/207.000;
                                                 548/214.000;
                                                                 548/215.000;
                                                                 548/229.000;
548/243.000;
548/303.700;
                                 548/225.000;
548/240.000;
                                                 548/228.000;
548/241.000;
548/267.800;
                                 548/267.200;
548/309.700;
                                                                                 548/306.400;
548/340.100;
                 548/252.000;
                                                 548/319.100;
                                                                  548/323.500;
                 548/307.100;
                 548/348.100;
                                 548/349.100;
                                                 548/356.100;
                                                                 548/370.100;
                                                                                  548/375.100;
                 548/379.400;
                                 548/452.000;
                                                                 548/470.000; 548/482.000;
                                                 548/453.000;
                                 548/486.000;
                                                                 548/503.000; 548/532.000;
                 548/485.000;
                                                 548/491.000;
                 548/543.000; 548/546.000;
                                                 548/550.000; 548/565.000; 548/566.000
NCL
        NCLM:
                 514/263.350
                 514/183.000;
514/227.500;
514/237.800;
                                                 514/223.500;
514/229.200;
                                                                 514/224.200; 514/226.800;
514/230.500; 514/230.800;
        NCLS:
                                 514/222.500;
                                 514/228.800;
514/241.000;
                                                 514/242.000;
514/249.000;
                                                                  514/243.000;
514/252.160;
                                                                                  514/246.000;
                 514/247.000;
                                 514/248.000;
                                                                                  514/256.000
                                 514/264.100;
                                                                 514/270.000;
                                                                                  514/274.000
                 514/259.500;
                                                 514/266.300;
                                                                 514/302.000;
                 514/297.000:
                                 514/300.000;
                                                 514/301.000;
                                                                                  514/303.000
                                 514/307.000;
                                                                                  514/315.000;
                 514/306.000;
                                                 514/311.000;
                                                                 514/312.000;
                                                 514/357.000; 514/359.000;
                 514/345.000; 514/351.000;
                                                                                  514/360.000;
                 514/361.000; 514/362.000;
                                                 514/363.000; 514/364.000;
                                                                                  514/365.000;
                 514/367.000; 514/369.000;
514/375.000; 514/376.000;
514/381.000; 514/383.000;
                                                 514/372.000; 514/373.000;
                                                                                  514/374.000;
                                 514/376.000;
514/383.000;
514/399.000;
                                                                 514/379.000;
514/394.000;
514/404.000;
                                                 514/378.000;
                                                                                  514/380.000;
                                                 514/389.000;
514/401.000;
                                                                                  514/395.000
                 514/398.000;
                                                                                  514/406.000
                                 514/415.000;
514/425.000;
                                                                                  514/423.000;
544/001.000;
                                                 514/416.000;
                                                                 514/418.000;
                 514/413.000;
                 514/424.000;
                                                 514/427.000;
                                                                 514/428.000;
                                                                 544/053.000;
                 544/002.000;
                                 544/003.000:
                                                 544/008.000;
                                                                                  544/063.000;
                                 544/066.000;
                                                                                  544/091.000;
                 544/065.000;
                                                 544/067.000;
                                                                 544/090.000;
                                 544/215.000;
                 544/162.000;
                                                                 544/219.000;
                                                                                  544/220.000;
                                                 544/216.000:
                 544/224.000; 544/235.000;
                                                                                  544/255.000;
                                                 544/239.000; 544/254.000;
                 544/257.000;
                                 544/262.000;
                                                 544/272.000;
                                                                                  544/278.000;
                                                                 544/277.000;
                                                                                  544/311.000;
544/385.000;
546/115.000;
                 544/280.000;
                                 544/283.000;
                                                 544/286.000;
                                                                 544/301.000;
                                 544/336.000;
546/102.000;
546/118.000;
                                                                 544/353.000;
546/114.000;
                 544/335.000;
                                                 544/350.000;
                                                 546/113.000;
546/119.000;
                 544/401.000;
                                                                  546/122.000;
                 546/117.000;
                                                                                  546/138.000
                                 546/150.000;
                                                 546/153.000;
                                                                 546/157.000;
                                                                                  546/164.000
                 546/139.000;
                                 546/178.000;
                                                 546/242.000;
                                                                 546/243.000;
                                                                                  546/246.000
                 546/176.000;
                                 546/300.000;
                                                 546/334.000; 548/100.000;
                                                                                  548/123.000;
                 546/264.000;
                 548/125.000; 548/127.000;
                                                 548/128.000; 548/131.000; 548/134.000;
                 548/146.000; 548/153.000; 548/179.000; 548/186.000; 548/207.000;
```

```
548/214.000; 548/215.000; 548/217.000; 548/221.000; 548/225.000;
                   548/228.000; 548/229.000;
                                                      548/235.000; 548/237.000;
                                                                                          548/240.000;
                   548/241.000; 548/243.000; 548/247.000; 548/252.000; 548/267.200;
                   548/267.800; 548/303.700; 548/306.400; 548/307.100; 548/309.700;
                   548/319.100; 548/323.500; 548/340.100; 548/348.100; 548/349.100; 548/356.100; 548/370.100; 548/375.100; 548/379.400; 548/452.000; 548/453.000; 548/470.000; 548/482.000; 548/485.000; 548/486.000; 548/491.000; 548/503.000; 548/532.000; 548/543.000; 548/546.000; 548/550.000; 548/565.000; 548/566.000
IC
         [6]
         ICM: A61K031-415
         ICS: A61K031-42; A61K031-425; A61K031-52
         544/272; 514/263
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 203 OF 228 USPATFULL on STN
L7
         97:40793 USPATFULL
AN
         Treatment of diseases using enantiomerically pure hydroxylated xanthine
TI
         compounds
         Bianco, James A., Seattle, WA, United States
Woodson, Paul, Bothell, WA, United States
Porubek, David, Edmonds, WA, United States
IN
         Singer, Jack, Seattle, WA, United States
         Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation) US 5629315 19970513 <--
PA
PΙ
ΑI
         us 1995-456900
                                          19950601 (8)
         Division of Ser. No. US 1994-343810, filed on 22 Nov 1994, now abandoned which is a division of Ser. No. US 1994-307554, filed on 16 Sep 1994,
RLI
         now abandoned which is a continuation of Ser. No. US 1993-13977, filed
         on 4 Feb 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-926665, filed on 7 Aug 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-846354, filed on 4 Mar 1992,
         now abandoned
DT
         Utility
FS
         Granted
LN.CNT 1736
         INCLM: 514/263.000
INCL
         INCLS: 514/866.000
                  514/263.360
NCL
         NCLM:
                  514/866.000
         NCLS:
IC
         [6]
         ICM: A61K031-52
         514/263
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L7
      ANSWER 204 OF 228 USPATFULL on STN
ΑN
         97:31820
                      USPATFULL
TI
         Process for preparing enantiomerically pure xanthine derivatives
IN
         Bianco, James A., Seattle, WA, United States
         Woodson, Paul, Bothell, WA, United States
Porubek, David, Edmonds, WA, United States
         Singer, Jack, Seattle, WA, United States
PA
         Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PΙ
                                          19970415
         us 5621102
                                          19950601 (8)
ΑI
         US 1995-456897
         Division of Ser. No. US 1994-343810, filed on 22 Nov 1994, now abandoned
RLI
         which is a division of Ser. No. US 1994-307554, filed on 16 Sep 1994,
         now abandoned which is a continuation of Ser. No. US 1993-13977, filed
         on 4 Feb 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-926665, filed on 7 Aug 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-846354, filed on 4 Mar 1992,
         now abandoned
         Utility
DT
         Granted
FS
LN.CNT 1763
INCL
         INCLM: 544/267.000
         INCLS: 514/340.000
NCL
         NCLM: 544/267.000
IC
         [6]
         ICM: C07D473-06
         ICS: C07D473-08; C07D473-12
         544/267
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L7
      ANSWER 205 OF 228 USPATFULL ON STN
AN
         97:31706 USPATFULL
```

```
Enatiomerically pure hydroxylated xanthine compounds to treat
TI
        inflammatory diseases
IN
       Bianco, James A., Seattle, WA, United States
       Woodson, Paul, Bothell, WA, United States
       Porubek, David, Edmonds, WA, United States
       Singer, Jack, Seattle, WA, United States
       Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation) US 5620984 19970415 <--
PA
PΙ
       us 5620984
       us 1995-456898
                                   19950601 (8)
ΑI
       Division of Ser. No. US 1994-343810, filed on 22 Nov 1994 which is a division of Ser. No. US 1994-307554, filed on 16 Sep 1994 which is a
RLI
       continuation of Ser. No. US 1993-13977, filed on 4 Feb 1993, now
       abandoned which is a continuation-in-part of Ser. No. US 1992-926665
       filed on 7 Aug 1992, now abandoned which is a continuation-in-part of
       Ser. No. US 1992-846354, filed on 4 Mar 1992, now abandoned
DT
       Utility
FS
        Granted
LN.CNT 1721
        INCLM: 514/263.000
INCL
NCL
       NCLM: 514/263.360
        [6]
IC
        ICM: A61K031-52
        514/263
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 206 OF 228 USPATFULL ON STN
L7
        97:22792 USPATFULL
ΑN
        Enantiomerically pure hydroxylated xanthine compounds to treat shock
TI
        symptoms
       Bianco, James A., Seattle, WA, United States
Woodson, Paul, Bothell, WA, United States
Porubek, David, Edmonds, WA, United States
IN
        Singer, Jack, Seattle, WA, United States
        PA
PΙ
                                   19950601 (8)
ΑI
        us 1995-457062
        Division of Ser. No. US 1994-343810, filed on 22 Nov 1994, now abandoned
RLI
        which is a division of Ser. No. US 1994-307554, filed on 16 Sep 1994,
        now abandoned which is a continuation of Ser. No. US 1993-13977, filed
       on 4 Feb 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-926665, filed on 7 Aug 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-846354, filed on 4 Mar 1992,
        now abandoned
DT
        Utility
        Granted
FS
LN.CNT 1725
        INCLM: 514/263.000
INCL
        INCLS: 514/921.000
NCL
        NCLM:
                514/263.360
               514/921.000
        NCLS:
IC
        [6]
        ICM: A61K031-52
        514/263
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L7
      ANSWER 207 OF 228 USPATFULL ON STN
ΑN
        97:16085 USPATFULL
TI
        Compositions and methods for treating and preventing pathologies
        including cancer
IN
        Samid, Dvorit, Rockville, MD, United States
        The United States of America as represented by the Department of Health
PA
        and Human Services, Washington, DC, United States (U.S. government)
                                   19970225
PΙ
        us 5605930
                                   19940307 (8)
        US 1994-207521
ΑI
        Continuation-in-part of Ser. No. US 1993-135661, filed on 12 Oct 1993
RLI
        which is a continuation-in-part of Ser. No. US 1991-779744, filed on 21
        Oct 1991
DT
        Utility
        Granted
FS
LN.CNT
       7722
INCL
        INCLM: 514/510.000
               514/513.000; 514/515.000; 514/529.000; 514/538.000; 514/563.000;
        INCLS:
                514/567.000
NCL
        NCLM:
                514/510.000
        NCLS:
                514/513.000; 514/515.000; 514/529.000; 514/538.000; 514/563.000;
```

514/567.000

```
IC
        [6]
        ICM: A61K031-21
        ICS: A01N037-00; A01N047-40; A01N047-46
        514/538; 514/563; 514/567; 514/510; 514/513; 514/515; 514/529
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L7
     ANSWER 208 OF 228 USPATFULL ON STN
        96:120774 USPATFULL
ΑN
        Tetracycline regulated transcriptional modulators with altered DNA
TI
        binding specificities
        Bujard, Hermann, Heidelberg, Germany, Federal Republic of
IN
       Gossen, Manfred, El Cerrito, Germany, Federal Republic of
       Hillen, Wolfgang, Erlangen, Germany, Federal Republic of
       Helbl, Vera, Fuerth, Germany, Federal Republic of
        Schnappinger, Dirk, Bad Driburg, Germany, Federal Republic of
        BASF Aktiengesellschaft, Ludwigshafen, Germany, Federal Republic of
PA
        (non-U.S. corporation)
        Knoll Aktiengesellschaft, Ludwigshafen, Germany, Federal Republic of
        (non-U.S. corporation)
        us 5589362
                                  19961231
PΙ
                                                                          <--
        US 1995-485971
                                  19950607 (8)
ΑI
        Continuation-in-part of Ser. No. US 1995-383754, filed on 3 Feb 1995 And
RLI
        a continuation-in-part of Ser. No. US 1994-275876, filed on 15 Jul 1994
        And a continuation-in-part of Ser. No. US 1994-260452, filed on 14 Jun
        1994 And a continuation-in-part of Ser. No. US 1993-76726, filed on 14
        Jun 1993, now patented, Pat. No. US 5464758 , said Ser. No. US
       which is a continuation-in-part of Ser. No. US 1994-270637, filed on 1 Jul 1994, now abandoned , said Ser. No. US -260452 which is a
        continuation-in-part of Ser. No. US 1993-76327, filed on 14 Jun 1993,
        now abandoned
DT
        Utility
        Granted
FS
LN.CNT 4415
INCL
        INCLM: 435/069.100
        INCLS: 435/172.300; 536/023.400; 536/024.100; 935/006.000; 935/010.000;
               935/034.000; 935/047.000; 935/036.000
NCL
        NCLM:
               435/069.100
        NCLS:
               435/320.100; 435/325.000; 435/358.000; 435/455.000; 536/023.400;
               536/024.100
IC
        ICM: C12P021-00
        ICS: C12N015-31; C07H021-04
        435/69.1; 435/172.3; 536/23.4; 536/24.1; 935/6; 935/10; 935/34; 935/36;
EXF
        935/47
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L7
     ANSWER 209 OF 228 USPATFULL on STN
        96:111463 USPATFULL
AN
TI
        Enatiomerically pure hydroxylated xanthine compounds
IN
        Bianco, James A., Seattle, WA, United States
        Woodson, Paul, Bothell, WA, United States
        Porubek, David, Edmonds, WA, United States
        Singer, Jack, Seattle, WA, United States
PA
        Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
                                  19961203
PΙ
        US 5580874
        US 1995-457685
ΑI
                                  19950601 (8)
        Division of Ser. No. US 1994-343810, filed on 22 Nov 1994, now abandoned
RLI
        which is a division of Ser. No. US 1994-307554, filed on 16 Sep 1994 which is a continuation of Ser. No. US 1993-13977, filed on 4 Feb 1993,
        now abandoned which is a continuation-in-part of Ser. No. US
        1992-926665, filed on 7 Aug 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-846354, filed on 4 Mar 1992,
        now abandoned
DT
        Utility
FS
        Granted
LN.CNT 1733
INCL
        INCLM: 514/263.000
NCL
        NCLM:
               514/263.360
IC
        [6]
        ICM: A61K031-52
514/263
FXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L7
     ANSWER 210 OF 228 USPATFULL ON STN
AN
        96:111462 USPATFULL
        Enatiomerically pure hydroxylated xanthine compounds to treat
TI
```

```
proliferative vascular diseases
IN
         Bianco, James A., Seattle, WA, United States
        Woodson, Paul, Bothell, WA, United States
         Porubek, David, Edmonds, WA, United States
         Singer, Jack, Seattle, WA, United States
        Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PA
        us 5580873
                                      19961203
PΙ
        US 1995-456899
                                      19950601 (8)
ΑI
        Division of Ser. No. US 1994-343810, filed on 22 Nov 1994 which is a division of Ser. No. US 1994-307554, filed on 16 Sep 1994 which is a
RLI
         continuation of Ser. No. US 1993-13977, filed on 4 Feb 1993, now
         abandoned which is a continuation-in-part of Ser. No. US 1992-926665.
         filed on 7 Aug 1992, now abandoned which is a continuation-in-part of
         Ser. No. US 1992-846354, filed on 4 Mar 1992, now abandoned
DT
        Utility
         Granted
FS
LN.CNT 1728
        INCLM: 514/263.000
NCLM: 514/263.360
INCL
NCL
         [6]
IC
         ICM: A61K031-52
         514/263
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L7
      ANSWER 211 OF 228 USPATFULL ON STN
         96:108816 USPATFULL
AN
TI
         Sequence-directed DNA-binding molecules compositions and methods
        Edwards, Cynthia A., Menlo Park, CA, United States
Cantor, Charles R., Boston, MA, United States
IN
        Andrews, Beth M., Maynard, MA, United States
        Turin, Lisa M., Redwood City, CA, United States
         Fry, Kirk E., Palo Alto, CA, United States
        Genelabs Technologies, Inc., Redwood City, CA, United States (U.S.
PA
         corporation)
                                      19961126
PΙ
        US 5578444
                                                                                    <--
        US 1993-171389 19931220 (8)
Continuation-in-part of Ser. No. US 1993-123936, filed on 17 Sep 1993
which is a continuation-in-part of Ser. No. US 1992-996783, filed on 23
Dec 1992 which is a continuation-in-part of Ser. No. US 1991-723618,
ΑI
RLI
        filed on 27 Jun 1991, now abandoned
DT
        Utility
FS
         Granted
LN.CNT 5845
INCL
         INCLM: 435/006.000
         INCLS: 435/007.230; 536/023.100; 935/076.000; 935/077.000
NCL
        NCLM: 435/006.000
        NCLS:
                435/007.230; 536/023.100
IC
         [6]
        ICM: C12Q001-68
        ICS: C12N015-00; G01N033-574; C07H021-02 435/6; 536/23.1; 536/23.2
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L7
      ANSWER 212 OF 228 USPATFULL on STN
ΑN
        96:97041 USPATFULL
TI
        R-enatiomerically pure hydroxylated xanthine compounds to treat baldness
        Bianco, James A., Seattle, WA, United States
Woodson, Paul, Bothell, WA, United States
Porubek, David, Edmonds, WA, United States
IN
        Singer, Jack, Seattle, WA, United States
        Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
US 5567704 19961022 <--
PA
PΙ
        US 1995-457683
ΑI
                                      19950601 (8)
RLI
        Division of Ser. No. US 1994-343810, filed on 22 Nov 1994 which is a
        division of Ser. No. US 1994-307554, filed on 16 Sep 1994 which is a
        continuation of Ser. No. US 1993-13977, filed on 4 Feb 1993, now
        abandoned which is a continuation-in-part of Ser. No. US 1992-926665, filed on 7 Aug 1992, now abandoned which is a continuation-in-part of
        Ser. No. US 1992-846354, filed on 4 Mar 1992, now abandoned
DT
        Utility
        Granted
FS
LN.CNT 1736
        INCLM: 514/263.000
INCL
        INCLS: 514/262.000
        NCLM: 514/263.360
NCL
        NCLS: 424/070.100
```

```
IC
        ICM: A61K031-52
EXF
        514/263; 514/262
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L7
      ANSWER 213 OF 228 USPATFULL ON STN
        96:70451 USPATFULL
ΑN
        Hepatitis treatment with carbostyril compounds
ΤI
        Nakai, Satoru, Tokushima-ken, Japan
IN
        Aihara, Koutoku, Tokushima-ken, Japan
        Mori, Hitomi, Tokushima, Japan
        Tominaga, Michiaki, Tokushima-ken, Japan
        Adachi, Masakazu, Takasaki, Japan
        Ichikawa, Hiroyuki, Tokushima, Japan
        Akamatsu, Seiji, Naruto, Japan
        Saito, Fumio, Takasaki, Japan
        Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan (non-U.S. corporation) US 5543412 19960806 <--
PA
PΙ
        US 1995-469893
                                     19950606 (8)
ΑI
        Division of Ser. No. US 1993-989028, filed on 30 Apr 1993, now abandoned
RLI
PRAI
        JP 1991-162587
                                19910703
        JP 1992-33469
                                19920220
        JP 1992-45178
                                19920303
        JP 1992-100585
                                19920325
        Utility
DT
FS
        Granted
LN.CNT 1245
INCL
        INCLM: 514/255.000
        NCLM: 514/253.070
NCL
        [6]
IC
        ICM: A61K031-495
        514/255
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L7
      ANSWER 214 OF 228 USPATFULL ON STN
        96:46169 USPATFULL
AN
        Olefin substituted long chain compounds
TI
        Underiner, Gail, Brier, WA, United States
Porubek, David, Seattle, WA, United States
Klein, J. Peter, Vashon, WA, United States
Eiseman, Elisa, Seattle, WA, United States
TN
        Leigh, Alistair, Brier, WA, United States
        Kumar, Anil, Seattle, WA, United States
Michnick, John, Seattle, WA, United States
        Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation) US 5521315 19960528 <--
PΑ
        us 5521315
PΙ
        US 1993-59697
ΑI
                                    19930510 (8)
        Continuation-in-part of Ser. No. US 1993-3372, filed on 12 Jan 1993, now
RLI
        patented, Pat. No. US 5354756
DT
        Utility
FS
        Granted
LN.CNT 2761
INCL
        INCLM: 546/243.000
        INCLS: 546/242.000; 544/285.000
                546/243.000
NCL
        NCLM:
        NCLS:
                544/285.000; 546/242.000
IC
        [6]
        ICM: C07D211-88
        ICS: C07D239-80
        548/545; 548/546; 548/547; 546/243; 544/285
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L7
      ANSWER 215 OF 228 USPATFULL ON STN
ΑN
        95:108287
                    USPATFULL
ΤI
        Substituted long chain alcohol xanthine compounds
IN
        Underiner, Gail, Brier, WA, United States
        Porubek, David, Edmonds, WA, United States
Klein, J. Peter, Vashon Island, WA, United States
Woodson, Paul, Bothell, WA, United States
PA
        Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
        us 5473070
PΙ
                                    19951205
        US 1992-976353
ΑI
                                    19921116 (7)
DT
        Utility
FS
        Granted
LN.CNT 890
INCL
        INCLM: 544/267.000
```

```
INCLs: 514/263.000
NCL
          NCLM: 544/267.000
IC
          [6]
          ICM: C07D473-04
          ICS: A61K031-52
EXF
          544/267; 514/263
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L7
       ANSWER 216 OF 228 USPATFULL on STN
          95:105868 USPATFULL
ΑN
TT
          Cell signaling inhibitors
          Michnick, John, Seattle, WA, United States
IN
          Underiner, Gail E., Brier, WA, United States
          Klein, J. Peter, Vashon Island, WA, United States
          Rice, Glenn C., Seattle, WA, United States
Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PA
                                             19951128
          us 5470878
PΙ
          us 1993-164081
                                            19931208 (8)
ΑI
          Continuation-in-part of Ser. No. US 1993-40820, filed on 31 Mar 1993.
RLI
          now abandoned
DT
          Utility
FS
          Granted
LN.CNT 2665
INCL
          INCLM: 514/558.000
          INCLS: 514/258.000; 514/262.000; 514/274.000; 514/299.000; 514/315.000;
                    514/238.000; 514/262.000; 514/274.000; 514/299.000; 514/315.000; 514/418.000; 514/425.000; 514/529.000; 514/552.000; 514/561.000; 514/613.000; 514/617.000; 514/626.000; 514/629.000; 514/669.000; 544/254.000; 544/285.000; 544/301.000; 546/183.000; 546/243.000; 548/486.000; 548/556.000; 554/055.000; 554/061.000; 554/108.000; 554/213.000; 560/130.000; 560/145.000; 562/553.000; 562/567.000; 564/183.000; 564/197.000; 564/198.000; 564/201.000; 564/506.000
NCL
          NCLM:
                    514/558.000
          NCLS:
                    514/274.000; 514/299.000; 514/315.000; 514/418.000; 514/425.000;
                    514/529.000; 514/552.000; 514/561.000; 514/613.000; 514/617.000; 514/626.000; 514/629.000; 514/669.000; 544/254.000; 544/285.000; 544/301.000; 546/183.000; 546/243.000; 548/486.000; 548/556.000
IC
          ۲6٦
          ICM: A61K031-20
          ICS: C07C233-00
          554/51; 554/61; 554/55; 554/108; 554/213; 564/224; 564/506; 564/198; 564/215; 564/201; 564/197; 514/625; 514/629; 514/613; 514/558; 514/552; 514/529; 514/561; 514/626; 514/669; 560/130; 560/145; 562/553; 562/567
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
       ANSWER 217 OF 228 USPATFULL on STN
L7
ΑN
          95:99146 USPATFULL
TI
          Apoptosis regulating composition
          Nakai, Satoru, Itano, Japan
Aihara, Koutoku, Itano, Japan
IN
          Tanaka, Hideo, Tokushima, Japan
          Iba, Hitomi, Wakayama, Japan
          Kawai, Kazuyoshi, Itano, Japan
          Ichikawa, Hiroyuki, Tokushima, Japan
          Akamatsu, Seiji, Tokushima, Japan
          Saito, Fumio, Takasaki, Japan
          Tominaga, Michiaki, Tokushima, Japan
          Adachi, Masakazu, Takasaki, Japan
          Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan (non-U.S. corporation) US 5464833 19951107 <--
PI
          wo 9404504
                           19940303
                                                                                                 <--
          US 1994-211818
ΑI
                                            19940419 (8)
          WO 1993-JP1144
                                            19930812
                                            19940419
                                                          PCT 371 date
                                            19940419
                                                          PCT 102(e) date
PRAI
          JP 1992-220373
                                      19920819
DT
          Utility
          Granted
FS
LN.CNT
         1474
INCL
          INCLM: 514/251.000
          INCLS: 514/249.000; 514/250.000; 514/255.000
NCL
                    514/251.000
          NCLM:
          NCLS:
                    514/249.000; 514/250.000; 514/253.070
IC
          [6]
          ICM: A61K031-495
EXF
          514/249; 514/250; 514/251; 514/255
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
```

```
ANSWER 218 OF 228 USPATFULL on STN
L7
        95:71491 USPATFULL
AN
        Acetal or ketal substituted xanthine compounds
TI
        Leigh, Alistair, Edmonds, WA, United States
IN
        Underiner, Gail, Brier, WA, United States
        Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation) US 5440041 19950808 <--
PA
PΙ
        us 1994-194135
                                     19940208 (8)
ΑI
        Continuation of Ser. No. US 1993-4353, filed on 14 Jan 1993, now
RLI
        abandoned
DT
        Utility
FS
        Granted
LN.CNT 874
        INCLM: 544/267.000
INCL
        INCLS: 544/268.000
NCL
        NCLM:
                544/267.000
                544/268.000
        NCLS:
        [6]
        ICM: C07D473-06
        544/267; 544/268; 514/263
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 219 OF 228 USPATFULL on STN
L7
        94:88699 USPATFULL
AN
        Olefin-substituted long chain xanthine compounds
TI
        Underiner, Gail, Brier, WA, United States
Porubek, David, Edmonds, WA, United States
IN
        Klein, J. Peter, Vashon Island, WA, United States
Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PA
        us 5354756
                                     19941011
PΙ
        us 1993-3372
                                     19930112 (8)
ΑI
        Utility
DT
FS
        Granted
LN.CNT 846
        INCLM: 514/263.000
INCL
        INCLS: 544/267.000; 544/272.000; 544/273.000
NCL
        NCLM:
                514/263.340
        NCLS:
                 514/263.350; 514/263.360; 544/267.000; 544/272.000; 544/273.000
         [5]
        ICM: A61K031-52
        ICS: C07D473-02
         544/267; 544/272; 544/273; 514/263
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 220 OF 228 USPATFULL on STN
L7
ΑN
        94:73300 USPATFULL
        Substituted aminoalkyl xanthine compounds
TI
        Klein, J. Peter, Vashon, WA, United States
Underiner, Gail, Bothell, WA, United States
Leigh, Alistair, Edmonds, WA, United States
Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
IN
РΔ
                                     19940823
PΙ
        US 5340813
                                     19921109 (7)
ΑI
        US 1992-973804
DT
        Utility
FS
        Granted
LN.CNT 725
INCL
        INCLM: 514/263.000
        INCLS: 544/272.000
NCLM: 514/263.350
NCL
        NCLS: 544/272.000
IC
         [5]
        ICM: C07D473-04
         ICS: A61K031-52
EXF
         544/267; 544/272; 514/263
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L7
      ANSWER 221 OF 228 USPATFULL ON STN
AN
        94:15745 USPATFULL
        Substituted epoxyalkyl xanthines
TI
        Klein, J. Peter, Vashon, WA, United States
Porubek, David, Edmonds, WA, United States
IN
        Rice, Glenn C., Seattle, WA, United States
        Woodson, Paul, Bothell, WA, United States
        Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
US 5288721 19940222 <--
PA
PΙ
```

```
ΑI
       US 1992-949330
                                 19920922 (7)
DT
       Utility
FS
       Granted
LN.CNT 945
INCL
       INCLM: 514/263.000
       INCLS: 544/267.000
NCL
               514/263.230
       NCLM:
       NCLS:
               514/263.320; 544/267.000
IC
       [5]
       ICM: A61K031-52
       ICS: C07D473-04
EXF
       544/267; 514/263
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L7
     ANSWER 222 OF 228 USPATFULL on STN
AN
       93:82731 USPATFULL
       Diagnostic methods using neurite growth regulatory factors
TI
       Schwab, Martin E., Zurich, Switzerland
Caroni, Pierenrico W., Zurich, Switzerland
IN
       Paganetti, Paolo A., Zurich, Switzerland
PA
       Erziehungsdirektion of the Canton Zurich, Zurich, Switzerland (non-U.S.
       corporation)
PΙ
       us 5250414
                                 19931005
       US 1991-719692
ΑI
                                 19910624 (7)
RLI
       Continuation-in-part of Ser. No. US 1989-401212, filed on 30 Aug 1989
       which is a continuation-in-part of Ser. No. US 1988-267941, filed on 4
       Nov 1988, now abandoned
DT
       Utility
       Granted
FS
LN.CNT 5260
INCL
       INCLM: 435/007.720
       INCLS: 435/007.230; 530/350.000; 514/002.000; 514/021.000; 436/064.000;
               436/813.000
NCL
       NCLM:
               435/007.720
       NCLS:
               435/007.230; 436/064.000; 436/813.000; 514/002.000; 514/021.000;
               530/350.000
IÇ
       [5]
       ICM: C12N009-64
       530/350; 514/2; 514/21; 435/7.72; 435/7.23; 436/64; 436/813
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L7
     ANSWER 223 OF 228 WPIDS
                                COPYRIGHT 2004 THOMSON DERWENT on STN
ΑN
     2001-536475 [59]
                         WPIDS
DNC
     C2001-159715
     New azolo-pyridine carboxamide compounds, are poly adenosine
TT
     diphosphate-ribose polymerase inhibitors useful e.g. for treating
     neurodegenerative disease, epilepsy, cardiac ischemia, tumors, sepsis,
     inflammation and diabetes mellitus.
DC
     B02
IN
     GRANDEL, R; HOEGER, T; KOCK, M; LUBISCH, W; MUELLER, R; SCHULT
PA
     (BADI) BASF AG; (GRAN-I) GRANDEL R; (HOEG-I) HOEGER T; (KOCK-I) KOCK M;
     (LUBI-I) LUBISCH W; (MUEL-I) MUELLER R; (SCHU-I) SCHULT S
     95
CYC
     WO 2001057038 A1 20010809 (200159)* DE
PΙ
                                                 29p
                                                        C07D471-04
        RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ
             NL OA PT SD SE SL SZ TR TZ UG ZW
            AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM
             DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC
             LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE
             SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
     AU 2001040542 A
                      20010814 (200173)
                                                        C07D471-04
     EP 1257551
                    A1 20021120 (200301)
                                           DF
                                                        C07D471-04
         R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT
             RO SE SI TR
     US 2003134843 A1 20030717 (200348)
                                                        A61K031-551
ADT
     WO 2001057038 A1 WO 2001-EP790 20010125; AU 2001040542 A AU 2001-40542
     20010125; EP 1257551 A1 EP 2001-911528 20010125, WO 2001-EP790 20010125; US 2003134843 A1 WO 2001-EP790 20010125, US 2002-182532 20021118
FDT
     AU 2001040542 A Based on WO 2001057038; EP 1257551 A1 Based on WO
     2001057038
PRAI DE 2000-10004238 20000201
     ICM A61K031-551; C07D471-04
          A61K031-437; A61K031-4745; A61K031-496; A61K031-5377; A61K031-55;
          A61P025-00; C07D471-02
```

ANSWER 224 OF 228 WPIDS COPYRIGHT 2004 THOMSON DERWENT ON STN

L7

```
2001-335518 [35]
                                       WPIDS
AN
        2001-301276 [32]
CR
DNC
       C2001-103613
        Azepinoindole derivatives are PARP inhibitors and are useful for the
TI
        treatment of neurodegenerative diseases, ischemia, tumor, septic shock,
        inflammation, rheumatic diseases, ARDS and diabetes mellitus.
DC
        GRANDEL, R; HOEGER, T; KOCK, M; LUBISCH, W; MUELLER, R; SCHULT, S; HOGER,
IN
        T; MULLER, R
        (BADI) BASF AG
PA
        95
CYC
       WO 2001023390 A2 20010405 (200135)* DE
                                                                                       C07D487-06
                                                                           21p
PΙ
             RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ
                   NL OA PT SD SE SL SZ TZ UG ZW
              W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM
                   DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC
                   LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE
                   AU 2001012712 A
                                                                                       C07D487-06
        NO 2001002567 A
                                                  (200147)
                                                                                       C07D487-06
                                    20010625
                                                                                                                 <--
        BR 2000007174 A
                                    20010904 (200160)
                                                                                       C07D487-06
                                                                                                                 <--
        SK 2001000884 A3 20020107 (200213)
                                                                                       C07D487-06
        KR 2001087401 A 20010915 (200219)
                                                                                       C07D487-06
                                                                                                                 <--
                             A1 20020228 (200223)
        DE 10039610
                                                                                       C07D487-06
        EP 1183259
                               A2 20020306 (200224) DE
                                                                                       C07D487-06
              R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT
       RO SE SI
HU 2001004917 A2 20020429 (200238)
                                                                                       C07D487-06
                                                                                       C07D487-06
                                                                                       C07D487-06
        CN 1374961
                                    20021016 (200311)
        JP 2003510328 W
                                    20030318 (200321)
                                                                           28p
                                                                                       C07D487-06
        MX 2001005199 A1 20020301 (200362)
                                                                                       A61K031-55
        ZA 2002001494 A 20031231 (200408)#
                                                                                       C07D000-00
                                                                         105p
       WO 2001023390 A2 WO 2000-EP9024 20000915; AU 2001012712 A AU 2001-12712
ADT
        20000915; No 2001002567 A WO 2000-EP9024 20000915, No 2001-2567 20010525;
        BR 2000007174 A BR 2000-7174 20000915, WO 2000-EP9024 20000915; SK
       2001000884 A3 W0 2000-EP9024 20000915, SK 2001-884 20000915; KR 2001087401 A KR 2001-706614 20010526; DE 10039610 A1 DE 2000-10039610 20000809; EP 1183259 A2 EP 2000-974379 20000915, WO 2000-EP9024 20000915; HU 2001004917 A2 WO 2000-EP9024 20000915, HU 2001-4917 20000915; CZ 2001002373 A3 WO 2000-EP9024 20000915, CZ 20000915, CZ 20000915, CZ 20000915, CZ 2000-EP90
        20000915; JP 2003510328 W WO 2000-EP9024 20000915, JP 2001-526542 20000915; MX 2001005199 A1 WO 2000-EP9024 20000915, MX 2001-5199 20010524;
        ZA 2002001494 A ZA 2002-1494 20020222
FDT
       AU 2001012712 A Based on WO 2001023390; BR 2000007174 A Based on WO
        2001023390; SK 2001000884 A3 Based on WO 2001023390; EP 1183259 A2 Based
        on WO 2001023390; HU 2001004917 A2 Based on WO 2001023390; CZ 2001002373
        A3 Based on WO 2001023390; JP 2003510328 W Based on WO 2001023390; MX
        2001005199 A1 Based on WO 2001023390
PRAI DE 2000-10039610 20000809; DE 1999-19946289 19990928; ZA 2002-1494
        20020222
IC
        ICM A61K031-55; C07D000-00; C07D487-06
                A61K031-437; A61P003-10; A61P009-10; A61P011-00; A61P013-12;
                A61P019-02; A61P025-00; A61P025-08; A61P025-10; A61P025-14;
                A61P025-16; A61P025-28; A61P029-00; A61P035-00; C07D209-00;
                C07D223-00; C07D471-06
ICI
       C07D209:00; C07D209:00; C07D223:00; C07D487-06; C07D223:00, C07D487-06;
                C07D2Ó9:00; C07D223:00; C07D487-06; C07D2O9:00; C07D223:00;
                C07D487-06
L7
        ANSWER 225 OF 228 WPIDS COPYRIGHT 2004 THOMSON DERWENT ON STN
AN
        2000-638173 [61]
                                       WPIDS
DNC
        C2000-191901
TI
        New 2-aminobenzamide derivatives are caspase and apoptic cell death
        inhibitors used for treating neurodegenerative disorders, heart disease
        and autoimmune disorders.
DC
IN
        CAI, S X; GREEN, D R; MILLS, G B; WANG, Y; WEBER, E
PA
        (CYTO-N) CYTOVIA INC
        92
CYC
PΙ
       WO 2000055114 A1 20000921 (200061)* EN
                                                                                       C07C229-00
                                                                           55p
             RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL
                   OA PT SD SE SL SZ TZ UG ZW
                  AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE
                   ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR
```

LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK

```
SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW
          AU 2000038766 A 20001004 (200101)
                                                                                                             C07C229-00
                                       A1 20020102 (200209) EN
          EP 1165490
                                                                                                             C07C229-00
                  R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT
                         RO SE SI
                                            20011213 (200237)
20020424 (200251)
20021119 (200281)
          KR 2001110667 A
                                                                                                             C07D403-14
                                                                                                                                              <--
          CN 1346344
                                                                                                             C07C229-00
                                       Α
                                                                                               65p
                                                                                                             C07C271-24
          JP 2002539183 W
                                      B1 20030916 (200362)
          US 6620782
                                                                                                             A61K038-05
          US 2003181388 A1 20030925 (200364)
                                                                                                             A61K038-08
          wo 2000055114 A1 wo 2000-us6398 20000315; Au 2000038766 A AU 2000-38766
ADT
          20000315; EP 1165490 A1 EP 2000-917859 20000315, WO 2000-US6398 20000315;
          KR 2001110667 A KR 2001-711734 20010915; CN 1346344 A CN 2000-805049 20000315; JP 2002539183 W JP 2000-605545 20000315, WO 2000-US6398 20000315; US 6620782 B1 Provisional US 1999-124675P 19990316, Provisional
          US 1999-158386P 19991012, US 2000-527225 20000316; US 2003181388 A1 Provisional US 1999-124675P 19990316, Provisional US 1999-158386P 19991012, Div ex US 2000-527225 20000316, US 2003-434335 20030509 AU 2000038766 A Based on WO 2000055114; EP 1165490 A1 Based on WO 2000055114; IP 2002539183 W Based on WO 2000055114
FDT
PRAI US 1999-158386P 19991012; US 1999-124675P 19990316; US 2000-527225
          20000316; US 2003-434335
                                                                 20030509
          ICM A61K038-05; A61K038-08; C07C229-00; C07C271-24; C07D403-14
                  A01N037-00; A01N037-10; A01N037-12; A61K009-02; A61K009-06
                    A01N037-10; A01N037-12; A61R009-02; A61R009-06; A61K009-08; A61K009-22; A61K031-27; A61K031-381; A61K038-00; A61K038-06; A61P001-00; A61P001-02; A61P001-04; A61P001-16; A61P001-18; A61P003-10; A61P007-00; A61P007-06; A61P007-06; A61P013-10; A61P013-12; A61P015-08; A61P017-06; A61P017-14; A61P017-16; A61P019-02; A61P025-00; A61P025-32; A61P027-02; A61P029-00; A61P037-00; A61P0
                    A61P039-00; A61P043-00; C07C069-74; C07C205-00; C07C271-28
                     C07D333-40; C07K005-023; C07K005-04; C07K005-06; C07K007-02;
                     C07K007-06; C12N005-00; C12N005-04; C12N005-06; C12N009-99
          ANSWER 226 OF 228 WPIDS COPYRIGHT 2004 THOMSON DERWENT ON STN
L7
          2000-317716 [27]
                                                 WPIDS
ΑN
          C2000-096144
DNC
          New isolated polyketide synthase nucleic acid and polyketide compounds
ΤI
          useful for treating e.g. ***transplant*** rejection, uveitis, multiple sclerosis, ***Alzheimer*** 's disease, ***Parkinson*** 's disease,
          stroke, or peripheral neuropathy.
          B02 B04 C02 C06 D16
DC
          CHU, D; KHOSLA, C; REEVES, C; SANTI, D; WU, K (KOSA-N) KOSAN BIOSCIENCES INC; (CHUD-I) CHU D; (KHOS-I) KHOSLA C;
ΙN
PA
           (REEV-I) REEVES C; (SANT-I) SANTI D; (WUKK-I) WU K
CYC
          WO 2000020601 A2 20000413 (200027)* EN 125p
PΙ
                                                                                                            C12N015-52
                 RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL
                         OA PT SD SE SL SZ TZ UG ZW
                   W: AL AM AU BA BB BG BR CA CN CR CU CZ DM EE GD GE HR HU IL IS JP KG
                         KP KR LC LK LR LT LV MD MG MK MN MX NO NZ PL RO SG SI SK TR TT UA
                         US UZ VN ZA
          AU 2000014415 A 20000426 (200036)
                                                                                                             C12N015-52
                                                                                                                                               <--
                                       A2 20010725 (200143) EN
          EP 1117801
                                                                                                             C12N015-52
                                                                                                                                               <--
                   R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT
                         RO SE SI
          US 2002010328 A1 20020124 (200210)
                                                                                                             C07D498-00
                                             20010907 (200218)
20020102 (200227)
                                                                                                             C12N015-62
C12N015-52
          KR 2001085877 A
                                                                                                                                               <--
          CN 1329668
          JP 2002526114 W
                                             20020820 (200258)
                                                                                             170p
                                                                                                             C12N015-09
          US 6503737
                                      B1 20030107 (200306)
                                                                                                             C12P019-62
          US 2003175901 A1 20030918 (200362)
                                                                                                             C12P019-62
          MX 2001003376 A1 20021101 (200376)
                                                                                                             C07D211-00
                                       B2 20031209 (200381)
          US 6660862
                                                                                                             C07D515-00
ADT
          WO 2000020601 A2 WO 1999-US22886 19991001; AU 2000014415 A AU 2000-14415
          19991001; EP 1117801 A2 EP 1999-970125 19991001, WO 1999-US22886 19991001;
          US 2002010328 A1 Provisional US 1998-102748P 19981002, Provisional US 1999-123810P 19990311, Provisional US 1999-139650P 19990617, Div ex US 1999-410551 19991001, US 2001-825621 20010403; KR 2001085877 A KR 2001-704222 20010402; CN 1329668 A CN 1999-813957 19991001; JP 2002526114 W WO 1999-US22886 19991001, JP 2000-574696 19991001; US 6503737 B1 Provisional US 1998-102748P 19981002, Provisional US 1999-123810P 19990311 Provisional US 1999-130650P 19990617 US 1999-410551 19991001;
           19990311, Provisional US 1999-139650P 19990617, US 1999-410551 19991001;
          US 2003175901 A1 Provisional US 1998-102748P 19981002, Provisional US
          1999-123810P 19990311, Provisional US 1999-139650P 19990617, Div ex US
```

1999-410551 19991001, US 2001-940316 20010827; MX 2001003376 A1 WO

```
1999-US22886 19991001, MX 2001-3376 20010330; US 6660862 B2 Provisional_US
     1998-102748P 19981002, Provisional US 1999-123810P 19990311, Provisional
     US 1999-139650P 19990617, Div ex US 1999-410551 19991001, US 2001-825621
     20010403
     AU 2000014415 A Based on WO 2000020601; EP 1117801 A2 Based on WO
FDT
     2000020601; JP 2002526114 W Based on WO 2000020601; US 2003175901 A1 Div
     ex US 6503737; MX 2001003376 A1 Based on WO 2000020601; US 6660862 B2 DIV
     ex US 6503737
PRAI US 1999-139650P 19990617; US 1998-102748P 19981002; US 1999-123810P
     19990311; US 2001-940316
                                    20010827
IC
           CO7D211-00; CO7D498-00; CO7D515-00; C12N015-09; C12N015-52;
           C12N015-62; C12P019-62
           A61P025-00; A61P037-06; C07D273-00; C07D311-00; C07D493-18; C07D498-18; C07H021-04; C12N001-15; C12N001-19; C12N001-21;
           C12N005-10; C12N009-00; C12N009-10; C12N009-16; C12N015-54;
           C12P017-18; C12P019-32; C12P021-02
     A61K031-436
TCA
     CO7D211:00; CO7D273:00, CO7D311:00, CO7D498-18; CO7D498-18; CO7D311:00;
ICI
           C07D273:00; C07D211:00
     ANSWER 227 OF 228 WPIDS COPYRIGHT 2004 THOMSON DERWENT ON STN
     2000-293478 [26]
                           WPIDS
ΑN
DNC
     C2000-088806
     Isolated precursor cells containing sensory receptors are useful for treating ***Parkinson*** 's disease, ***Alzheimer*** 's disease,
TI
                  ***Parkinson*** 's disease,
      treating
        ***Huntington*** 's disease, Multiple Sclerosis, stroke and spinal cord
      injury.
DC
     B04 D16
     GLOSTER, A; MILLER, F
IN
      (GLOS-I) GLOSTER A; (MILL-I) MILLER F; (UYMC-N) UNIV MCGILL
PΑ
CYC
                         19980226 (200026)*
                                                             C12N005-08
     CA 2213780
                                                     43p
PΙ
                     Α
     CA 2213780 A CA 1997-2213780 19970822
ADT
                                                        19960826
PRAI US 1996-24456P
                         19960827; US 1996-24590P
          C12N005-08
IC
     ICM
           A61K035-30; C12N005-06; C12N005-10; C12Q001-02; C12Q001-18
                          WPIDS COPYRIGHT 2004 THOMSON DERWENT ON STN
L7
     ANSWER 228 OF 228
     1999-312859 [26]
                           WPIDS
ΑN
     C1999-092323
DNC
     Stimulation of nerve cell growth to treat neurological conditions involving ***neuronal*** dysfunction.
TI
      B05 D16
DC
ΙN
      GOLD, B G
PA
      (UYOR-N) UNIV OREGON HEALTH SCI
CYC
     83
                     A1 19990506 (199926)* EN
                                                     52p
                                                             A61K031-395
PΙ
     wo 9921552
         RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL
              OA PT SD SE SZ UG ZW
          W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE
              GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK \mbox{LR} LS LT LU \mbox{LV} MD \mbox{MG}
              MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG
              US UZ VN YU ZW
      AU 9896783
                        19990517 (199939)
                     Α
                                                                               <--
                         19991019 (199950)
     US 5968921
                                                             A61K031-33
                                                                               <--
                     A1 20000809 (200039)
                                                             A61K031-395
      EP 1024806
                                               ΕN
                                                                                <--
          R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
                     B1 20010403 (200120)
                                                             G01N033-566
      US 6210974
                                                                               <--
      JP 2001520995 W 20011106 (200203)
                                                     70p
                                                             A61K031-395
                                                                               <--
      US 2002086015 A1 20020704 (200247)
                                                             A61K039-395
                     B 20030403 (200335)
B2 20031104 (200374)
      AU 759011
                                                             A61K031-395
      US 6641810
                                                             A61K039-395
     WO 9921552 A1 WO 1998-US20658 19981002; AU 9896783 A AU 1998-96783 19981002; US 5968921 A US 1997-956691 19971024; EP 1024806 A1 EP
ADT
      1998-950843 19981002, wo 1998-US20658 19981002; US 6210974 B1 Div ex US
      1997-956691 19971024, US 1999-288061 19990407; JP 2001520995 W WO
      1998-US20658 19981002, JP 2000-517710 19981002; US 2002086015 A1 Cont of
      US 1997-956691 19971024, Cont of US 1999-326728 19990607, US 2001-825243
      20010402; AU 759011 B AU 1998-96783 19981002; US 6641810 B2 Cont of US 1997-956691 19971024, Cont of US 1999-326728 19990607, US 2001-825243
      20010402
     AU 9896783 A Based on WO 9921552; EP 1024806 A1 Based on WO 9921552; US 6210974 B1 Div ex US 5968921; JP 2001520995 W Based on WO 9921552; AU
FDT
      759011 B Previous Publ. AU 9896783, Based on WO 9921552; US 6641810 B2
      Cont of US 5968921
```

19971024; US 1999-288061

19990407: US 1999-326728

L7

PRAI US 1997-956691

19990607; US 2001-825243 20010402
IC ICM A61K031-33; A61K031-395; A61K039-395; G01N033-566
ICS A01N043-30; A61K031-36; A61K031-40; A61K031-445; A61K031-704; A61K038-18; A61K045-00; A61P025-00; A61P043-00; G01N024-00;
STN INTERNATIONAL LOGOFF AT 17:16:39 ON 16 MAR 2004